2024


  1. Meyer HJ, Frille A (2024). [Pulmonary artery sling - case report and clinical review of a rare norm variant]. Rofo, 196(1), 74-76.
     
  2. Meyer HJ, Frille A (2024). [Pulmonary artery sling - case report and clinical review of a rare norm variant]. Rofo, 196(1), 74-76.
     
  3. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb), 45(1), 51-58.
     
  4. Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Möhler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2024). [Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. German version]. Pathologie (Heidelb), 45(1), 51-58.
     
  5. Frille A, Arends J, Abenavoli EM, Duke SA, Ferrara D, Gruenert S, Hacker M, Hesse S, Hofmann L, Holm SH, Lund TB, Rullmann M, Sandøe P, Sciagrà R, Shiyam Sundar LK, Tönjes A, Wirtz H, Yu J, Sabri O, Beyer T (2024). "Metabolic fingerprints" of cachexia in lung cancer patients. Eur J Nucl Med Mol Imaging, 51, folgt.
     
  6. Frille A, Broschewitz J, Metelmann IB, Steinert M, von Laffert M, Wirtz H, Wald A, Kraemer S (2024). Outcomes of oncological intended thoracic surgery after lung transplantation Journal of Thoracic Disease, 16(3), 1933-1946.
     
  7. Frille A, Boeschen M, Wirtz H, Stiller M, Bläker H, von Laffert M (2024). TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations Frontiers in Oncology, 14, 1357583.
     
  8. Holzhey M, Petroff D, Wirkner K, Engel C, Baber R, Tönjes A, Zeynalova S, Yahiaoui-Doktor M, Berg T, Karlas T, Wiegand J (2024). Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD. Eur J Gastroenterol Hepatol, 36(1), 107-112.
     
  9. Holzhey M, Petroff D, Wirkner K, Engel C, Baber R, Tönjes A, Zeynalova S, Yahiaoui-Doktor M, Berg T, Karlas T, Wiegand J (2024). Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Eur J Gastroenterol Hepatol, 36(1), 107-112.
     
  10. Holzhey M, Petroff D, Wirkner K, Engel C, Baber R, Tönjes A, Zeynalova S, Yahiaoui-Doktor M, Berg T, Karlas T, Wiegand J (2024). Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Eur J Gastroenterol Hepatol, 36(1), 107-112.
     
  11. Holzhey M, Petroff D, Wirkner K, Engel C, Baber R, Tönjes A, Zeynalova S, Yahiaoui-Doktor M, Berg T, Karlas T, Wiegand J (2024). Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD. Eur J Gastroenterol Hepatol, 36(1), 107-112.
     
  12. Tárnoki ÁD, Tárnoki DL, D?browska M, Knetki-Wróblewska M, Frille A, Stubbs H, Blyth KG, Juul AD (2024). New developments in the imaging of lung cancer. Breathe (Sheff), 20(1), 230176.
     


    13. 2023


  13. Ben-Aharon I, van Laarhoven HWM, Fontana E, Obermannova R, Nilsson M, Lordick F (2023). Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer Discov, 13(3), 538-551.
     
  14. Vu Trung K, Abou-Ali E, Caillol F, Paik WH, Napoleon B, Masaryk V, van der Wiel SE, Pérez-Cuadrado-Robles E, Musquer N, Halimi A, Soares K, Souche FR, Seyfried S, Petrone MC, Crippa S, Kleemann T, Albers D, Weismüller TJ, Dugic A, Meier B, Wedi E, Schiemer M, Regner S, Gaujoux S, Hollenbach M (2023). Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohort. Endoscopy, (), 110-115.
     
  15. Topf V, Kheifetz Y, Daum S, Ballhausen A, Schwarzer A, Trung KV, Stocker G, Aigner A, Lordick F, Scholz M, Knödler M (2023). Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors. J Cancer Res Clin Oncol, 149(10), 6989-6998.
     
  16. Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö (2023). Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol, 149(9), 5937-5950.
     
  17. Stocker G, Lorenzen S, Ettrich T, Herz AL, Longo F, Kiani A, Venerito M, Trojan J, Mahlberg R, Moosmann N, Chibaudel B, Kubicka S, Greil R, Daum S, Geissler M, Larcher-Senn J, Keller G, Lordick F, Haag GM (2023). S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial. ESMO Open, 8(3), 101572.
     
  18. Schnabel A, Lordick F, Oberth P, Neuschulz M, Lehmann-Laue A, Mehnert-Theuerkauf A, Hinz A (2023). Supportive care needs and health-related quality of life in cancer patients receiving palliative care. Front Psychol, 14(), 1166801.
     
  19. Lordick F, Merz M, Büch E, Aigner A (2023). Antibody-Drug Conjugates as a Targeted Therapeutic Approach Across Entities in Oncology. Dtsch Arztebl Int, 120(19), 329-336.
     
  20. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2023). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, 149(3), 1231-1240.
     
  21. Lordick F, Wörmann B (2023). National guidelines for gastric cancer: redundant or needed? Gastric Cancer, (), 1 - 9 .
     
  22. Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, Köberle D, Lorenzen S, Möhler M, Pritzkuleit R, Stahl M, Thuss-Patience P, Wöll E, Zander T, Maschmeyer G (2023). German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer, (), 1 - 39.
     
  23. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2023). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, 149(3), 1319-1329.
     
  24. Fischer J, Koukoulioti E, Müller T, Heyne R, Eslam M, George J, Finkelmeier F, Waidmann O, Berg T, van Bömmel F (2023). Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatol Res, 53(12), 1156-1168.
     
  25. Berg T, Krag A (2023). The future of hepatology - "The best way to predict the future is to create it". J Hepatol, 79(2), 253-260.
     
  26. van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T (2023). A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol, 78(5), 926-936.
     
  27. Engelmann C, Berg T (2023). Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global consensus? Hepatobiliary Surg Nutr, 12(2), 239-243.
     
  28. Petroff D, Wolffram I, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2023). Confirmation of guideline-defined hepatitis C screening strategies within the 'Check-Up35+' examination in the primary care setting. Liver Int, 43(4), 785-793.
     
  29. Lieb S, Ebel S, Seehofer D, Berg T, van Bömmel F (2023). The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab. Hepatobiliary Surg Nutr, 12(1), 148-150.
     
  30. Boettler T, Krag A, Berg T (2023). Reply to: "Depiction of alcohol-related liver disease in the EASL International Liver Congress". J Hepatol, 78(1), e38-e39.
     
  31. Petroff D, Berg T, Wiegand J (2023). Reply. Clin Gastroenterol Hepatol, 21(1), 240.
     
  32. Fischer J, Koukoulioti E, Müller T, Heyne R, Eslam M, George J, Finkelmeier F, Waidmann O, Berg T, van Bömmel F (2023). Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatol Res, 53(12), 1156-1168.
     
  33. Lieb S, Heni M, Rauschenberg S, Lange K, Feisthammel J, Bläker H, Wiegand J (2023). Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis. Z Gastroenterol, 61(11), 1500-1503.
     
  34. Hayn A, Fischer T, Mierke CT (2023). The role of ADAM8 in the mechanophenotype of MDA-MB-231 breast cancer cells in 3D extracellular matrices. Front Cell Dev Biol, 11(), 1148162.
     
  35. Gerhardt F, Blank V, Prasse G, Wiegand J, Rademacher S, von Laffert M, Karlas T (2023). Contrast-enhanced ultrasound characteristics for the diagnosis of biliary adenofibroma. Ultraschall Med, 1, 1-10.
     
  36. Yu X, Pfefferkorn M, van Bömmel F, Zhang X, Berg T (2023). Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity. Gut, (), 1-10.
     
  37. van Bömmel F, Berg T (2023). Response to: A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.". J Hepatol, (), 1-10.
     
  38. Hahn M, Herber A, Berg T, Seehofer D, van Bömmel F (2023). Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score. J Hepatol, (), 1-10.
     
  39. Hayn A, Fischer T, Mierke CT (2023). The role of ADAM8 in the mechanophenotype of MDA-MB-231 breast cancer cells in 3D extracellular matrices. Front Cell Dev Biol, 11(), 1148162.
     
  40. Vu Trung K, Hollenbach M, Hoffmeister A (2023). [Endoscopic treatment for obesity and diabetes]. Dtsch Med Wochenschr, 148(3), 102-111.
     
  41. Hollenbach M, Decker A, Schmidt A, Möschler O, Jung C, Blasberg T, Seif AAH, Vu Trung K, Hoffmeister A, Hochberger J, Ellenrieder V, Wedi E (2023). Comparison between traumatic and atraumatic over-the-scope clips in patients with duodenal ulcer bleeding: a retrospective analysis with propensity score-based matching. Gastrointest Endosc, 98(1), 51-58.e2.
     
  42. Hollenbach M, Vu Trung K, Hoffmeister A (2023). [Interventional endoscopy in gastroenterology]. Inn Med (Heidelb), 64(8), 766-778.
     
  43. Vu Trung K, Heise C, Abou-Ali E, Auriemma F, Karam E, van der Wiel SE, Bruno MJ, Caillol F, Giovannini M, Masaryk V, Will U, Anderloni A, Pérez-Cuadrado-Robles E, Dugic A, Meier B, Paik WH, Petrone MC, Wichmann D, Dinis-Ribeiro M, Gonçalves TC, Wedi E, Schmidt A, Gulla A, Hoffmeister A, Rosendahl J, Ratone JP, Saadeh R, Repici A, Deprez P, Sauvanet A, Souche FR, Fabre JM, Muehldorfer S, Caca K, Löhr M, Michl P, Krug S, Regner S, Gaujoux S, Hollenbach M (2023). Endoscopic Papillectomy for Ampullary Lesions of minor papilla. Gastrointest Endosc, (), -.
     
  44. Gerhardt F, Blank V, Prasse G, Wiegand J, Rademacher S, von Laffert M, Karlas T (2023). Contrast-enhanced ultrasound characteristics for the diagnosis of biliary adenofibroma. Ultraschall Med, (), -.
     
  45. Schumacher J, Böhlig A, Herber A, Karlas T (2023). Contrast-Enhanced Ultrasound in a Case of an Intrahepatic Mycotic Aneurysm. Ultraschall Med, 44(6), 647-649.
     
  46. Heinitz S, Müller J, Jenderka KV, Schlögl H, Stumvoll M, Blüher M, Blank V, Karlas T (2023). The application of high-performance ultrasound probes increases anatomic depiction in obese patients. Sci Rep, 13(1), 16297.
     
  47. Beer S, Babel J, Martin N, Blank V, Wiegand J, Karlas T (2023). Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease. PLoS One, 18(9), e0286882.
     
  48. Karlas T, Blank V, Trenker C, Ignee A, Dietrich CF (2023). [Ultrasound systems for abdominal diagnostics - current methods, clinical applications and new technologies]. Z Gastroenterol, 61(9), 1235-1245.
     
  49. Petroff D, Wiegand J, Karlas T (2023). Editorial: Let your muscles do the talking-what can muscle quality tell us about hepatic fibrosis? Aliment Pharmacol Ther, 58(3), 372-373.
     
  50. Blank V, Heni M, Karlas T (2023). Quantification of Portal Vein Vascularization Using an Automated Post-Processing Video Analysis Tool. Ultrasound Int Open, 9(1), E2-E10.
     
  51. Beer S, Babel J, Martin N, Blank V, Wiegand J, Karlas T (2023). Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease. PLoS One, 18(9), e0286882.
     
  52. Pauleck S, Sinnott JA, Zheng YL, Gadalla SM, Viskochil R, Haaland B, Cawthon RM, Hoffmeister A, Hardikar S (2023). Association of Telomere Length with Colorectal Cancer Risk and Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel), 15(4), -.
     
  53. Hollenbach M, Wedi E (2023). Response. Gastrointest Endosc, 98(2), 269-270.
     
  54. Höppner J, Krohn S, van den Munckhof EHA, Kallies R, Herber A, Zeller K, Tünnemann J, Matz-Soja M, Chatzinotas A, Böhm S, Hoffmeister A, Berg T, Engelmann C (2023). Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites. Sci Rep, 13(1), 23001.
     
  55. Wiegand J, Franke A, Stein K, Trautwein C, Berg T (2023). Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis. Hepatology, (), 1-10.
     
  56. Yu X, Pfefferkorn M, van Bömmel F, Zhang X, Berg T (2023). Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity. Gut, (), 1-10.
     
  57. Herta T, Dröge C, Herber A, Keitel V, Berg T (2023). Odevixibat treatment in an adult patient with advanced icteric progressive cholestatic liver disease J Hep Reports, (), 1-10.
     
  58. Hacker UT (2023). On the way to developing AAV-based vaccines as novel tools for cancer immunotherapy. Mol Ther Methods Clin Dev, 28(), 394-395.
     
  59. Potthoff K, Dechow T, Lorenzen S, Reinacher-Schick A, Binninger A, Matillon C, Siebenbach HU, Haffner I, Hacker U, Bläker H, Lordick F (2023). SAPHIR: real-world clinical research platform for molecular testing, treatment, and clinical and patient-reported outcomes in patients with gastroesophageal cancer in Germany ESMO Real World Data and Digital Oncology, Volume 2, 6.
     
  60. Lordick F, Merz M, Aigner A (2023). In Reply. Dtsch Arztebl Int, 120(38), 643.
     
  61. Bräunlich J, Köhler M, Wirtz H (2023). Nasal High-Flow (NHF) Improves Ventilation in Patients with Interstitial Lung Disease (ILD)-A Physiological Study. J Clin Med, 12(18), 1-11.
     
  62. Bräunlich J, Wirtz H (2023). Decreased COPD Exacerbation Rates During the COVID-19 Pandemic. Dtsch Arztebl Int, 120(7), 115-116.
     
  63. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2023). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, 149(3), 1319-1329.
     
  64. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Correction: Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 1-2.
     
  65. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 150-157.
     
  66. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Correction: Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 25-31.
     
  67. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 150-157.
     
  68. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 150-157.
     
  69. Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshof MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs CT, Slingerland M, Voncken FEM, Hartgrink H (2023). Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer, 185(), 28-39.
     
  70. Hönemann M, Thiem S, Bergs S, Berthold T, Propach C, Siekmeyer M, Frille A, Wallborn T, Maier M, Pietsch C (2023). In-depth analysis of the re-emergence of respiratory syncytial virus in the summer of 2021 after the alleviation of non-pharmaceutical interventions due to the SARS-CoV-2 pandemic Viruses, 15, 877.
     
  71. Schürfeld R, Sandner B, Hoffmann A, Klöting N, Baratashvili E, Nowicki M, Paeschke S, Kosacka J, Kralisch S, Bachmann A, Frille A, Dietel A, Stolzenburg JU, Blüher M, Zhang MZ, Harris RC, Isermann B, Stumvoll M, Tönjes A, Ebert T (2023). Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor Frontiers in Endocrinology, 14, 1152444.
     
  72. Boeschen M, Kuhn CK, Wirtz H, Seyfarth HJ, Frille A, Lordick F, Hacker UT, Obeck U, Stiller M, Bläker H, von Laffert M (2023). Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-) mutations in non-small cell lung cancer with a special focus on KRAS G12C. Lung Cancer, 184, 107361.
     
  73. Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler M, Schwarz C, Sieber S, Naehrig S, Naehrlich L (2023). Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur, 32, 100690.
     
  74. Boeschen M, Kuhn CK, Wirtz H, Seyfarth HJ, Frille A, Lordick F, Hacker UT, Obeck U, Stiller M, Bläker H, von Laffert M (2023). Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C. Lung Cancer, 184(), 107361.
     
  75. Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Shapiro J, Vernerey D, Smithers BM, Walsh T, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, de Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Roth J, Gebski V, Burmeister B, Paoletti X, van Sandick J, Fu J, Pignon JP, Ducreux M, Michiels S (2023). Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol, 41(28), 4535-4547.
     
  76. Kogel A, Machatschek M, Scharschmidt R, Wollny C, Lordick F, Ghanem M, Laufs U, Fikenzer S (2023). Physical exercise as a treatment for persisting symptoms post-COVID infection: review of ongoing studies and prospective randomized controlled training study. Clin Res Cardiol, (), 1-11.
     
  77. Falz R, Bischoff C, Thieme R, Tegtbur U, Hillemanns P, Stolzenburg JU, Aktas B, Bork U, Weitz J, Lässing J, Leps C, Voß J, Lordick F, Schulze A, Gockel I, Busse M (2023). Effect of home-based online training and activity feedback on oxygen uptake in patients after surgical cancer therapy: a randomized controlled trial. BMC Med, 21(1), 293.
     
  78. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med, 29(8), 2133-2141.
     
  79. Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, (2023). Corrigendum to "Dissecting the genetic heterogeneity of gastric cancer". EBioMedicine, 94(), 104709.
     
  80. Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J (2023). The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med, 29(6), 1298-1301.
     
  81. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E (2023). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open, 8(3), 101567.
     
  82. Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, (2023). Dissecting the genetic heterogeneity of gastric cancer. EBioMedicine, 92(), 104616.
     
  83. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet, 401(10389), 1655-1668.
     
  84. Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Knorrenschild JR, Illerhaus G, Dechow T, Moehler M, Moulin JC, Pink D, Stahl M, Schaaf M, Goetze TO, Al-Batran SE (2023). Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer, 23(1), 561.
     
  85. Baretton GB, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, Moehler M, Röcken C, Schirmacher P, Stahl M, Thuss-Patience P, Tiemann K (2023). Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J Cancer Res Clin Oncol, 149(17), 16231-16238.
     
  86. Alberti A, Stocker G, Lordick F, Hacker UT, Kobitzsch B, Haffner I, Baiocchi GL, Zamparini M, Tiberio GAM, Baronchelli C, Caruso A, Bossi P, Berruti A (2023). Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study). Front Oncol, 13(), 1276138.
     
  87. Franke AC, Hardet R, Prager L, Bentler M, Demeules M, John-Neek P, Jäschke NM, Ha TC, Hacker UT, Adriouch S, Büning H (2023). Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. Mol Ther Methods Clin Dev, 29(), 238-253.
     
  88. Bentler M, Hardet R, Ertelt M, Rudolf D, Kaniowska D, Schneider A, Vondran FWR, Schoeder CT, Delphin M, Lucifora J, Ott M, Hacker UT, Adriouch S, Büning H (2023). Modifying immune responses to adeno-associated virus vectors by capsid engineering. Mol Ther Methods Clin Dev, 30(), 576-592.
     
  89. Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A (2023). Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun, 14(1), 6761.
     
  90. Wiegand S, Wichmann G, Vogt J, Vogel K, Franke A, Kuhnt T, Lordick F, Scheuble AM, Hambsch P, Brossart P, Bauernfeind FG, Kaftan H, Maschmeyer G, Paland M, Münter M, Lewitzki V, Rotter N, Stromberger C, Beck M, Dommerich S, Gauler TC, Hapke G, Guntinas-Lichius O, Schröder U, Görner M, Hautmann MG, Steger F, Tamaskovics B, Schmiedeknecht A, Dietz A (2023). Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. Front Oncol, 13(), 1128176.
     
  91. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS (2023). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 24(11), 1181-1195.
     
  92. Lordick F, Merz M, Aigner A (2023). In Reply. Dtsch Arztebl Int, 120(38), 643.
     
  93. Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J, De Toni EN, Kudo M, Eiblmaier A, Klein HG, Hegel JK, Madin K, Kroeniger K, Sharma A, Chan HLY (2023). Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatol Commun, 7(11), 1-10.
     
  94. Mehta G, Riva A, Ballester MP, Uson E, Pujadas M, Carvalho-Gomes Â, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vazquez DM, Sharma R, Tsou HLP, Harris N, Broekhoven A, Kikkert M, Morales SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García D, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, di Benedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Canas-Per (2023). Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant. Hepatol Commun, 7(11), 1-10.
     
  95. Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, Zech CJ, van Delden O, Ümütlü MR, Deniz S, Khaled NB, De Toni EN, Hoang TPT, Seidensticker R, Aghdassi A, Pech M, Ricke J, Seidensticker M (2023). Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma. Eur J Radiol, 168(), 111120.
     
  96. Di Martino V, Questiaux J, Lemagoarou T, Weil D, Vendeville S, Engelmann C, Hu J, Singh V, Newsome PN, Lal SB, Sarin SK, Berg T, Thevenot T (2023). Granulocyte colony stimulating factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: A comprehensive meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol, 47(9), 102207.
     
  97. Roade L, Riveiro-Barciela M, Pfefferkorn M, Sopena S, Palom A, Bes M, Rando-Segura A, Casillas R, Tabernero D, Rodríguez-Frías F, Berg T, Esteban R, van Bömmel F, Buti M (2023). HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers. JHEP Rep, 5(10), 100842.
     
  98. Saalfeld S, Kreher R, Hille G, Niemann U, Hinnerichs M, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Preim B, Ricke J, Seidensticker M, Pech M, Surov A (2023). Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients. J Cachexia Sarcopenia Muscle, 14(5), 2301-2309.
     
  99. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Janssen HL, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B (2023). HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology, (), 1-10.
     
  100. Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, Dalekos GN, Goulis J, Berg T, Buti M, Kim SU, Kim YJ (2023). PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. J Hepatol, (), 1-10.
     
  101. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM (2023). A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol, 79(3), 618-634.
     
  102. Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O (2023). Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes. Clin Infect Dis, (), 1-10.
     
  103. Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM (2023). A global action agenda for turning the tide on fatty liver disease. Hepatology, (), 1-10.
     
  104. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B (2023). Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study. JHEP Rep, 5(8), 100790.
     
  105. Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Aleman S, Alghamdi AS, Alghamdi S, Al-Hamoudi WK, Aljumah AA, Altraif IH, Asselah T, Ben-Ari Z, Berg T, Biondi MJ, Blach S, Braga WSM, Brandão-Mello CE, Brunetto MR, Cabezas J, Cheinquer H, Chen PJ, Cheon ME, Chuang WL, Coffin CS, Coppola N, Craxi A, Crespo J, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Gaeta GB, Gamkrelidze I, García-Samaniego J, (2023). Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol, 79(2), 576-580.
     
  106. Weiss E, de la Peña-Ramirez C, Aguilar F, Lozano JJ, Sánchez-Garrido C, Sierra P, Martin PI, Diaz JM, Fenaille F, Castelli FA, Gustot T, Laleman W, Albillos A, Alessandria C, Domenicali M, Caraceni P, Piano S, Saliba F, Zeuzem S, Gerbes AL, Wendon JA, Jansen C, Gu W, Papp M, Mookerjee R, Gambino CG, Jiménez C, Giovo I, Zaccherini G, Merli M, Putignano A, Uschner FE, Berg T, Bruns T, Trautwein C, Zipprich A, Bañares R, Presa J, Genesca J, Vargas V, Fernández J, Bernardi M, Angeli P, Jalan R, Clar (2023). Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET). Gut, 72(8), 1581-1591.
     
  107. Stindt J, Dröge C, Lainka E, Kathemann S, Pfister ED, Baumann U, Stalke A, Grabhorn E, Shagrani MA, Mozer-Glassberg Y, Hartley J, Wammers M, Klindt C, Philippski P, Liebe R, Herebian D, Mayatepek E, Berg T, Schmidt-Choudhury A, Wiek C, Hanenberg H, Luedde T, Keitel V (2023). Cell-based BSEP trans-inhibition: A novel, non-invasive test for diagnosis of antibody-induced BSEP deficiency. JHEP Rep, 5(7), 100690.
     
  108. Walter Costa MB, Gärtner C, Schmidt M, Berg T, Seehofer D, Kaiser T (2023). Revising the MELD Score to Address Sex-Bias in Liver Transplant Prioritization for a German Cohort. J Pers Med, 13(6), 1-10.
     
  109. Surov A, Thormann M, Hinnerichs M, Seidensticker M, Seidensticker R, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Omari J, Wienke A, Ricke J, Pech M (2023). Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial. Hepatol Commun, 7(6), 1-10.
     
  110. Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J (2023). Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. JHEP Rep, 5(5), 100699.
     
  111. Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K (2023). Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep, 5(4), 100686.
     
  112. Schmalz F, Fischer J, Innes H, Buch S, Möller C, Matz-Soja M, von Schönfels W, Krämer B, Langhans B, Klüners A, Soyka M, Stickel F, Nattermann J, Strassburg CP, Berg T, Lutz P, Nischalke HD (2023). High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. JHEP Rep, 5(4), 100684.
     
  113. Salvo NM, Andersen JD, Janssen K, Meyer OL, Berg T, Børsting C, Olsen GH (2023). Association between Variants in the OCA2-HERC2 Region and Blue Eye Colour in HERC2 rs12913832 AA and AG Individuals. Genes (Basel), 14(3), 1-10.
     
  114. Brakenhoff SM, de Knegt RJ, van Campenhout MJH, van der Eijk AA, Brouwer WP, van Bömmel F, Boonstra A, Hansen BE, Berg T, Janssen HLA, de Man RA, Sonneveld MJ (2023). End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. J Microbiol Immunol Infect, 56(1), 31-39.
     
  115. Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, Weiss KH, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson SR, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi VR, Brosch M, Lackner C, Stauber RE, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving WL, Morling JR, Guha IN, Barnes E, Ansari MA, (2023). Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 72(2), 381-391.
     
  116. Geier A, Rau M, Pathil-Warth A, von der Ohe M, Schattenberg J, Dikopoulos N, Stein K, Serfert Y, Berg T, Buggisch P, Demir M, Roeb E, Wiebner B, Wedemeyer H, Zeuzem S, Hofmann WP (2023). Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry. Z Gastroenterol, 61(1), 60-70.
     
  117. Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C (2023). Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. J Hepatol, 78(1), 57-66.
     
  118. Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M (2023). Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol, 33(1), 493-500.
     
  119. Schmalz F, Fischer J, Innes H, Buch S, Möller C, Matz-Soja M, von Schönfels W, Krämer B, Langhans B, Klüners A, Soyka M, Stickel F, Nattermann J, Strassburg CP, Berg T, Lutz P, Nischalke HD (2023). High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. JHEP Rep, 5(4), 100684.
     
  120. Roade L, Riveiro-Barciela M, Pfefferkorn M, Sopena S, Palom A, Bes M, Rando-Segura A, Casillas R, Tabernero D, Rodríguez-Frías F, Berg T, Esteban R, van Bömmel F, Buti M (2023). HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers. JHEP Rep, 5(10), 100842.
     
  121. Beer S, Babel J, Martin N, Blank V, Wiegand J, Karlas T (2023). Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease. PLoS One, 18(9), 0286882.
     
  122. Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk AM, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lup?or-Platon M, Wong VW, Li G, Wong GL, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan WK, Mahadeva S, Rajaram R, Zheng MH, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee (2023). Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol, 8(8), 704-713.
     
  123. Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, Boursier J, Cassinotto C, de Lédinghen V, Chan WK, Mahadeva S, Eddowes P, Newsome P, Karlas T, Wiegand J, Wong VW, Schattenberg JM, Labenz C, Kim W, Lee MS, Lupsor-Platon M, Cobbold JFL, Fan JG, Shen F, Staufer K, Trauner M, Stauber R, Nakajima A, Yoneda M, Bugianesi E, Younes R, Gaia S, Zheng MH, Cammà C, Anstee QM, Mózes FE, Pavlides M, Petta S (2023). Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology, 78(1), 195-211.
     
  124. Struck MF, Werdehausen R, Kirsten H, Gössmann H, Veelken R, van Bömmel F, Stehr S, Denecke T, Ebel S (2023). Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan. Cancers (Basel), 15(15), 1-10.
     
  125. Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K (2023). Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep, 5(4), 100686.
     
  126. Kliem P, Ebel S, Werdehausen R, Girrbach F, Bösemann D, van Bömmel F, Denecke T, Stehr S, Struck MF (2023). [Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]. Anaesthesiologie, 72(2), 113-120.
     
  127. Kersten R, Trampert DC, Herta T, Hubers LM, Maillette de Buy Wenniger LJ, Verheij J, van de Graaf SFJ, Beuers U (2023). IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies. J Hepatol, 79(6), 1502-1523.
     
  128. Recknagel S, Rademacher S, Höhne C, Lederer AA, Lange UG, Herta T, Seehofer D, Sucher R, Scheuermann U (2023). Prediction of the Postoperative Outcome in Liver Resection Using Perioperative Serum Lactate Levels. J Clin Med, 12(6), 1-10.
     
  129. Schumacher J, Böhlig A, Herber A, Karlas T (2023). Contrast-Enhanced Ultrasound in a Case of an Intrahepatic Mycotic Aneurysm. Ultraschall Med, 44(6), 647-649.
     
  130. Fuhrmann V, Koscielny J, Vasilakis T, Andus T, Herber A, Fusco S, Roeb E, Schiefke I, Rosendahl J, Dollinger M, Caca K, Tacke F (2023). [Use of specific antidotes in DOAC-associated severe gastrointestinal bleeding - an expert consensus - Antagonozation of direct oral anticoagulants in gastrointestinal hemorrhages]. Z Gastroenterol, (), 1-10.
     
  131. Sauer F, Grosser S, Shahryari M, Hayn A, Guo J, Braun J, Briest S, Wolf B, Aktas B, Horn LC, Sack I, Käs JA (2023). Changes in Tissue Fluidity Predict Tumor Aggressiveness In Vivo. Adv Sci (Weinh), 10(26), 2303523.
     
  132. Petroff D, Wiegand J, Karlas T (2023). Editorial: Let your muscles do the talking-what can muscle quality tell us about hepatic fibrosis? Aliment Pharmacol Ther, 58(3), 372-373.
     
  133. Schönauer R, Sierks D, Boerrigter M, Jawaid T, Caroff L, Audrezet MP, Friedrich A, Shaw M, Degenhardt J, Forberger M, de Fallois J, Bläker H, Bergmann C, Gödiker J, Schindler P, Schlevogt B, Müller RU, Berg T, Patterson I, Griffiths WJ, Sayer JA, Popp B, Torres VE, Hogan MC, Somlo S, Watnick TJ, Nevens F, Besse W, Cornec-Le Gall E, Harris PC, Drenth JPH, Halbritter J (2023). Sex, genotype, and liver volume progression as risk of hospitalization determinants in autosomal dominant polycystic liver disease. Gastroenterology, (), 1-10.
     
  134. Sauer F, Grosser S, Shahryari M, Hayn A, Guo J, Braun J, Briest S, Wolf B, Aktas B, Horn LC, Sack I, Käs JA (2023). Changes in Tissue Fluidity Predict Tumor Aggressiveness In Vivo. Adv Sci (Weinh), 10(26), 1-10.
     
  135. Kersten R, Trampert DC, Herta T, Hubers LM, Maillette de Buy Wenniger LJ, Verheij J, van de Graaf SFJ, Beuers U (2023). IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies. J Hepatol, 79(6), 1502-1523.
     
  136. Recknagel S, Rademacher S, Höhne C, Lederer AA, Lange UG, Herta T, Seehofer D, Sucher R, Scheuermann U (2023). Prediction of the Postoperative Outcome in Liver Resection Using Perioperative Serum Lactate Levels. J Clin Med, 12(6), 1-10.
     
  137. Schumacher J, Böhlig A, Herber A, Karlas T (2023). Contrast-Enhanced Ultrasound in a Case of an Intrahepatic Mycotic Aneurysm. Ultraschall Med, 44(6), 647-649.
     
  138. Fuhrmann V, Koscielny J, Vasilakis T, Andus T, Herber A, Fusco S, Roeb E, Schiefke I, Rosendahl J, Dollinger M, Caca K, Tacke F (2023). [Use of specific antidotes in DOAC-associated severe gastrointestinal bleeding - an expert consensus - Antagonozation of direct oral anticoagulants in gastrointestinal hemorrhages]. Z Gastroenterol, (), 1-10.
     
  139. Pienn M, Gertz RJ, Gerhardt F, Kröger JR, Zaytoun H, Reimer RP, Kaplan A, Wissmüller M, Kovacs G, Rosenkranz S, Olschewski H, Bunck AC (2023). CT-derived lung vessel morphology correlates with prognostic markers in precapillary pulmonary hypertension. J Heart Lung Transplant, 43(1), 54-65.
     
  140. Gertz RJ, Gerhardt F, Pienn M, Lennartz S, Kröger JR, Caldeira L, Pennig L, Schömig TH, Hokamp NG, Maintz D, Rosenkranz S, Bunck AC (2023). Dual-layer dual-energy CT-derived pulmonary perfusion for the differentiation of acute pulmonary embolism and chronic thromboembolic pulmonary hypertension. Eur Radiol, (), 1-10.
     
  141. Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M (2023). Addendum ?Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion? zur S3-Leitlinie ?Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion? der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol, 61(12), 1635-1653.
     
  142. Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M (2023). Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol, 61(12), 1-10.
     
  143. Höppner J, Krohn S, van den Munckhof EHA, Kallies R, Herber A, Zeller K, Tünnemann J, Matz-Soja M, Chatzinotas A, Böhm S, Hoffmeister A, Berg T, Engelmann C (2023). Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites. Sci Rep, 13(1), 23001.
     
  144. Ammer-Herrmenau C, Antweiler KL, Asendorf T, Beyer G, Buchholz SM, Cameron S, Capurso G, Damm M, Dang L, Frost F, Gomes A, Hamm J, Henker R, Hoffmeister A, Meinhardt C, Nawacki L, Nunes V, Panyko A, Pardo C, Phillip V, Pukitis A, Rasch S, Riekstina D, Rinja E, Ruiz-Rebollo ML, Sirtl S, Weingarten M, Sandru V, Woitalla J, Ellenrieder V, Neesse A (2023). Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis. Gut, (), -.
     
  145. Denzer U, Müller M, Kreuser N, Thieme R, Hoffmeister A, Feisthammel J, Niebisch S, Gockel I (2023). [Therapy of esophageal motility disorders]. Laryngorhinootologie, 102(11), 824-838.
     
  146. Müller M, Denzer UW, Kreuser N, Thieme R, Hoffmeister A, Feisthammel J, Niebisch S, Gockel I (2023). [Diagnosis of esophageal motility disorders - Significance of the new Chicago classification v4.0]. Laryngorhinootologie, 102(10), 742-753.
     
  147. Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshof MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs CT, Slingerland M, Voncken FEM, Hartgrink H (2023). Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer, 185(), 28-39.
     
  148. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2023). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, 149(3), 1231-1240.
     
  149. Nagy R, Ocskay K, Sipos Z, Szentesi A, Vincze Á, Czakó L, Izbéki F, Shirinskaya NV, Poluektov VL, Zolotov AN, Zhu Y, Xia L, He W, Sutton R, Szatmary P, Mukherjee R, Burridge IS, Wauchope E, Francisco E, Aparicio D, Pinto B, Gomes A, Nunes V, Tantau VM, Sagau ED, Tantau AI, Suceveanu AI, Tocia C, Dumitru A, Pando E, Alberti P, Cirera A, Molero X, Lee HS, Jung MK, Kim EJ, Lee S, Rebollo MLR, Nistal RB, Santervas SI, Lesko D, Soltes M, Radonak J, Zatorski H, Ma?ecka-Panas E, Fabisiak A, Yaroslav MS (2023). Discharge protocol in acute pancreatitis: an international survey and cohort analysis. Sci Rep, 13(1), 22109.
     
  150. Antonelli G, Voiosu AM, Pawlak KM, Gonçalves TC, Le N, Bronswijk M, Hollenbach M, Elshaarawy O, Beilenhoff U, Mascagni P, Voiosu T, Pellisé M, Dinis-Ribeiro M, Triantafyllou K, Arvanitakis M, Bisschops R, Hassan C, Messmann H, Gralnek IM (2023). Training in basic gastrointestinal endoscopic procedures: a European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Position Statement. Endoscopy, (), -.
     
  151. Pérez-Cuadrado-Robles E, Phillpotts S, Bronswijk M, Conrad CC, Binda C, Monino L, Basiliya K, Hollenbach M, Papaefthymiou A, Alric H, Quénéhervé L, Di Gaeta A, Pioche M, Khani A, Lorenzo D, Moreels TG, Rahmi G, Boeken T, Fabbri C, Prat F, Laleman W, Cellier C, Van der Merwe S, Webster G, Ellrichmann M (2023). PERcutaneous transhepatic CHOLangioscopy using a new single-operator short cholangioscope (PERCHOL): European feasibility study. Dig Endosc, (), -.
     
  152. Staudacher JJ, Backes M, Bettinger D, Blüthner E, Dietz-Fricke C, Dugic A, Fusco S, Garbe J, Goeser F, Guliyeva S, Hamesch K, Hollenbach M, Huber Y, Kasper P, Kocheise L, Langsch P, Leppkes M, Martens N, Mücke MM, Munker S, Murillo K, Nagl S, Sanoubara F, Sturm N, Stathopoulos P, Storck K, Sulzer S, Thiel-Bodenstaff A, Tran F, Wiessner JR, Willuweit K, Yaqubi K, Zeidler C, Schlosser S (2023). Positionspapier ?Universitäre Karrierewege?. Z Gastroenterol, 61(8), 997-999.
     
  153. Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari (2023). Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study. Neuroendocrinology, 113(10), 1024-1034.
     
  154. Bo?koski I, Pontecorvi V, Ibrahim M, Huberty V, Maselli R, Gölder SK, Kral J, Samanta J, Patai ÁV, Haidry R, Hollenbach M, Pérez-Cuadrado-Robles E, Silva M, Messmann H, Tham TC, Bisschops R (2023). Curriculum for bariatric endoscopy and endoscopic treatment of the complications of bariatric surgery: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 55(3), 276-293.
     
  155. Karam E, Hollenbach M, Ali EA, Auriemma F, Gulla A, Heise C, Regner S, Gaujoux S, Regimbeau JM, Kähler G, Seyfried S, Vaillant JC, De Ponthaud C, Sauvanet A, Birnbaum D, Regenet N, Truant S, Pérez-Cuadrado-Robles E, Bruzzi M, Lupinacci RM, Brunel M, Belfiori G, Barbier L, Salamé E, Souche FR, Schwarz L, Maggino L, Salvia R, Gagniére J, Del Chiaro M, Leung G, Hackert T, Kleemann T, Paik WH, Caca K, Dugic A, Muehldorfer S, Schumacher B, Albers D (2023). Outcomes of rescue procedures in the management of locally recurrent ampullary tumors: A Pancreas 2000/EPC study. Surgery, 173(5), 1254-1262.
     
  156. Gerges C, Albers D, Schmitz L, Goni E, Cappello A, Schirra J, Casper M, Dormann AJ, Hartmann D, Hollenbach M, Schneider M, Denzer UW, Dechene A, Dollhopf M, Mayerle J, Schumacher B, van Geenen EM, Neuhaus H, Siersema PD, Ellrichmann M, Beyna T (2023). Digital single-operator pancreatoscopy for the treatment of symptomatic pancreatic duct stones: a prospective multicenter cohort trial. Endoscopy, 55(2), 150-157.
     
  157. Topf V, Kheifetz Y, Daum S, Ballhausen A, Schwarzer A, Vu Trung K, Stocker G, Aigner A, Lordick F, Scholz M, Knödler M (2023). Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors. J Cancer Res Clin Oncol, 149(10), 6989-6998.
     
  158. Ehrengut C, Vogt J, Leonhardi J, Carabenciov E, Teske F, Boemmel FV, Berg T, Seehofer D, Lincke T, Sabri O, Gößmann H, Denecke T, Ebel S (2023). Analysis of Periprocedural X-ray Exposure in Transarterial Radioembolization with Glass or Resin Microspheres. Diagnostics (Basel), 13(24), 1-10.
     
  159. Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS (2023). Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol, 24(12), 1399-1410.
     
  160. Devin M Razavi-Shearer, Maria Buti, Frank Tacke, Norah A Terrault, Stefan Zeuzem, Zaigham Abbas, Alessio Aghemo, Ulus S Akarca, Nasser M Al Masri, Abduljaleel M Alalwan, Marianne Alanko Blomé, Soo Aleman, Abdullah S Alghamdi, Mohammed Alghamdi, Saad Alghamdi, Waleed K Al-Hamoudi, Ela Ali, Abdulrahman A Aljumah, Ibrahim H Altraif, Jazag Amarsanaa, Tarik Asselah, Oidov Baatarkhuu, Adriana Babameto, Ziv Ben-Ari, Thomas Berg, Mia J Biondi, Wornei S M Braga, Carlos E Brandão-Mello, Robert S Brown, Jr (2023). Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol, (), 1-10.
     
  161. Di Martino V, Questiaux J, Lemagoarou T, Weil D, Vendeville S, Engelmann C, Hu J, Singh V, Newsome PN, Lal SB, Sarin SK, Berg T, Thevenot T (2023). Granulocyte colony stimulating factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: A comprehensive meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol, 47(9), 102207.
     
  162. Gu W, Zeleke Y, Hortlik H, Schaaf L, Uschner FE, Schulz M, Tischendorf M, Peiffer KH, Brol MJ, Kimmann M, Vogl T, Köhler M, Meyer C, Gerbes A, Rössle M, Laleman W, Zipprich A, Steib C, Praktiknjo M, Trebicka J (2023). Use and outcome of TIPS in hospitalized patients in Germany: A Nationwide study (2007-2018). Hepatol Commun, 7(10), 1-10.
     
  163. Lampertico P, Degasperi E, Sandmann L, Wedemeyer H, Berg T (2023). Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022. JHEP Rep, 5(9), 100818.
     
  164. Devin M Razavi-Shearer, Maria Buti, Frank Tacke, Norah A Terrault, Stefan Zeuzem, Zaigham Abbas, Alessio Aghemo, Ulus S Akarca, Nasser M Al Masri, Abduljaleel M Alalwan, Marianne Alanko Blomé, Soo Aleman, Abdullah S Alghamdi, Mohammed Alghamdi, Saad Alghamdi, Waleed K Al-Hamoudi, Ela Ali, Abdulrahman A Aljumah, Ibrahim H Altraif, Jazag Amarsanaa, Tarik Asselah, Oidov Baatarkhuu, Adriana Babameto, Ziv Ben-Ari, Thomas Berg, Mia J Biondi, Wornei S M Braga, Carlos E Brandão-Mello, Robert S Brown, Jr (2023). Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol, (), 1-10.
     
  165. Devin M Razavi-Shearer, Maria Buti, Frank Tacke, Norah A Terrault, Stefan Zeuzem, Zaigham Abbas, Alessio Aghemo, Ulus S Akarca, Nasser M Al Masri, Abduljaleel M Alalwan, Marianne Alanko Blomé, Soo Aleman, Abdullah S Alghamdi, Mohammed Alghamdi, Saad Alghamdi, Waleed K Al-Hamoudi, Ela Ali, Abdulrahman A Aljumah, Ibrahim H Altraif, Jazag Amarsanaa, Tarik Asselah, Oidov Baatarkhuu, Adriana Babameto, Ziv Ben-Ari, Thomas Berg, Mia J Biondi, Wornei S M Braga, Carlos E Brandão-Mello, Robert S Brown, Jr (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol, 8(10), 879-907.
     
  166. Ghany MG, Buti M, Lampertico P, Lee HM, AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty (2023). Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. J Hepatol, 79(5), 1254-1269.
     
  167. Walter Costa MB, Gärtner C, Schmidt M, Berg T, Seehofer D, Kaiser T (2023). Revising the MELD Score to Address Sex-Bias in Liver Transplant Prioritization for a German Cohort. J Pers Med, 13(6), 1-10.
     
  168. Sebastian Gibb ORCID logo EMAIL logo , Thomas Berg , Adam Herber , Berend Isermann and Thorsten Kaiser (2023). A new machine-learning-based prediction of survival in patients with end-stage liver disease Journal of Laboratory Medicine, 47, 1-10.
     
  169. Geier A, Rau M, Pathil-Warth A, von der Ohe M, Schattenberg J, Dikopoulos N, Stein K, Serfert Y, Berg T, Buggisch P, Demir M, Roeb E, Wiebner B, Wedemeyer H, Zeuzem S, Hofmann WP (2023). Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry. Z Gastroenterol, 61(1), 60-70.
     
  170. Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D (2023). Development and characterization of NILK-2301, a novel CEACAM5xCD3 ?? bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol, 16(1), 117.
     
  171. Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart JE, Hoogenboom JD, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P (2023). Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Ann Oncol, (), 4.
     
  172. Freitag-Wolf S, Schupp JC, Frye BC, Fischer A, Anwar R, Kieszko R, Mihailovi?-Vu?ini? V, Milanowski J, Jovanovic D, Zissel G, Bargagli E, Rottoli P, Bumbacea D, Jonkers R, Ho LP, Gaede KI, Dubaniewicz A, Marshall BG, Günther A, Petrek M, Keane MP, Haraldsdottir SO, Bonella F, Grah C, Pero?-Golubi?i? T, Kadija Z, Pabst S, Grohé C, Strausz J, Safrankova M, Millar A, Homolka J, Wuyts WA, Spencer LG, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Dempfle A, Müller-Quernheim J (2023). Genetic and geographic influence on phenotypic variation in European sarcoidosis patients. Front Med (Lausanne), 10(), 1218106.
     
  173. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD (2023). Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med, 389(6), 491-503.
     
  174. Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS (2023). Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. JAMA, 329(18), 1567-1578.
     
  175. Behr J, Bonella F, Günther A, Koschel D, Prasse A, Pittrow D, Klotsche J, Kreuter M (2023). Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry. BMC Pulm Med, 23(1), 64.
     
  176. Guth S, Wilkens H, Halank M, Held M, Hobohm L, Konstantinides S, Omlor A, Seyfarth HJ, Schäfers HJ, Mayer E, Wiedenroth CB (2023). [Chronic thromboembolic pulmonary hypertension]. Pneumologie, 77(11), 937-946.
     
  177. Douschan P, Egenlauf B, Gall H, Grünig E, Hager A, Heberling M, Koehler T, Olschewski H, Seyfarth HJ, Yogeswaran A, Ulrich S, Kovacs G (2023). [New definition and classification of pulmonary hypertension]. Pneumologie, 77(11), 854-861.
     
  178. Ten Cate V, Rapp S, Schulz A, Pallares Robles A, Jurk K, Koeck T, Espinola-Klein C, Halank M, Seyfarth HJ, Beutel ME, Schuster AK, Marini F, Hobohm L, Lankeit M, Lackner KJ, Ruf W, Münzel T, Andrade-Navarro MA, Prochaska JH, Konstantinides SV, Wild PS (2023). Circulating microRNAs predict recurrence and death following venous thromboembolism. J Thromb Haemost, 21(10), 2797-2810.
     
  179. Theobald V, Grünig E, Benjamin N, Seyfarth HJ, Halank M, Schneider MA, Richtmann S, Kazdal D, Hinderhofer K, Xanthouli P, Egenlauf B, Harutyunova S, Hoeper MM, Jonigk D, Sparla R, Muckenthaler MU, Eichstaedt CA (2023). Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients? Pulm Circ, 13(2), 1-12.
     
  180. Rosenkranz S, Pausch C, Coghlan JG, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Delcroix M, Ghofrani HA, Ewert R, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Scelsi L, Neurohr C, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Lange TJ, Olsson KM, Hoeper MM, Opitz C (2023). Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transplant, 42(1), 102-114.
     
  181. Hardavella G, Charpidou A, Frille A, Panagiotou E, Catarata MJ, Caruana E, Blum TG (2023). Lung cancer and inequalities in access to multidisciplinary lung cancer services In: Sinha IP, Lee A, Katikireddi SV, Quint JK, Inequalities in Respiratory Health (S. 153-166), Sheffield: ERS Monograph, European Respiratory Society.
     
  182. Berg T, Koerfer P, Engelmann E, Benckert J, (2023). Leberzirrhose, Hepatozelluläres Karzinom, Lebertransplantation, Virale und nicht-virale Hepatitiden In: Malte Ludwig, Repetitorium Facharztprüfung Innere Medizin (S. 640), München: Urban & Fischer in Elsevier.
     
  183. Thomas Berg, Andrea May, Andreas Stallmach (2023). Hepatologie I In: Peter Layer, Update Gastroenterologie (S. 609), Wiesbaden: med update GmbH.
     
  184. Thomas Berg, Sven Jonas, Verena Keitel-Anselmino, Beat Müllhaupt (2023). Akute Hepatitiden, akutes Leberversagen und DILI In: Thomas Berg, Sven Jonas, Verena Keitel-Anselmino, Beat Müllhaupt., Hepato Update (S. 550), Wiesbaden: med update GmbH.
     


    185. 2022


  185. Li T, di Stefano G, Raza GS, Sommerer I, Riederer B, Römermann D, Tan X, Tan Q, Pallagi P, Hollenbach M, Herzig KH, Seidler U (2022). Hydrokinetic pancreatic function and insulin secretion are moduled by Cl- uniporter Slc26a9 in mice. Acta Physiol (Oxf), 234(1), e13729.
     
  186. Engelmann C, Aehling NF, Schob S, Nonnenmacher I, Handmann L, Macnaughtan J, Herber A, Surov A, Kaiser T, Denecke T, Jalan R, Seehofer D, Moche M, Berg T (2022). Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis. Hepatol Commun, (), 1-10.
     
  187. Tu T, van Boemmel F, Berg T (2022). Surrogate markers for hepatitis B Virus covalently closed circular DNA. Semin Liver Dis, (), 1-10.
     
  188. Seehofer D, Petrowsky H, Schneeberger S, Vibert E, Ricke J, Sapisochin G, Nault JC, Berg T (2022). Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds? Transpl Int, 35(), 10333.
     
  189. Kuhn H, Frille A, Petersen MA, Oberhuber-Kurth J, Hofmann L, Gläser A, Taubenheim S, Klagges S, Kraemer S, Broschewitz J, von Laffert M, Wirtz H (2022). IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients. Transl Oncol, 27(), 101566.
     
  190. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC (2022). Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 33(10), 1005-1020.
     
  191. Lordick F, Obermannová R, Smyth EC (2022). Targeting HER2 for localised oesophageal cancer. Lancet Oncol, 23(2), 188-190.
     
  192. Pfrepper C, Knödler M, Schorling RM, Seehofer D, Petros S, Lordick F (2022). Predictors for thromboembolism in patients with cholangiocarcinoma. J Cancer Res Clin Oncol, 148(9), 2415-2426.
     
  193. Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D, Lordick F (2022). Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol, 33(7), 685-692.
     
  194. Pavlakis N, Tincknell G, Lim LE, Muro K, Obermannova R, Lorenzen S, Chua YJ, Jackson C, Karapetis CS, Price T, Chantrill L, Segelov E, Lordick F (2022). European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Ther Adv Med Oncol, 14(), 17588359221118874.
     
  195. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2022). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, (), 7-15.
     
  196. Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, Hook S, Schmitz J, Bräsen JH, Franke AC, Olarewaju O, Brandenberger C, Talbot SR, Fangmann J, Hacker UT, Odenthal M, Ott M, Piiper A, Büning H (2022). Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers (Basel), 14(2), 14-27.
     
  197. Lordick F, Hacker U, Hoffmeister A, Bläker H, Gockel I (2022). [What is confirmed in the treatment of colon cancer?]. Inn Med (Heidelb), 63(12), 1250-1256.
     
  198. Meyer HJ, Schnarkowski B, Pappisch J, Kerkhoff T, Wirtz H, Höhn AK, Krämer S, Denecke T, Leonhardi J, Frille A (2022). CT texture analysis and node-RADS CT score of mediastinal lymph nodes - diagnostic performance in lung cancer patients. Cancer Imaging, 22(1), 75.
     
  199. Bräunlich J, Köppe-Bauernfeind N, Petroff D, Franke A, Wirtz H (2022). Nasal high-flow compared to non-invasive ventilation in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease-protocol for a randomized controlled noninferiority trial (ELVIS). Trials, 23(1), 28.
     
  200. Bräunlich J, Turba K, Wirtz H (2022). Reversibility of Hypercapnia after an Acute Exacerbation of COPD. Respiration, 101(9), 816-822.
     
  201. Tacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein WO, Berg T (2022). S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie ? AWMF-Registernummer: 021-031 ? Stand 15. Juni 2022. Z Gastroenterol, 60(11), 1678-1698.
     
  202. Boettler T, Krag A, Berg T (2022). Reply to: "Depiction of alcohol-related liver disease in the EASL International Liver Congress". J Hepatol, 78(1), e38-e39.
     
  203. Olbrich A, Gros O, Ebel S, Denecke T, Gößmann H, Linder N, Lordick F, Forstmeyer D, Seehofer D, Sucher R, Rademacher S, Niemeyer J, Matz-Soja M, Berg T, Bömmel FV (2022). Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas. Cancers (Basel), 14(19), 1-10.
     
  204. Engelmann C, Berg T (2022). G-CSF treatment in decompensated liver disease: a double-edged sword? Hepatol Int, 16(5), 979-982.
     
  205. Ott F, Körner C, Werner K, Gericke M, Liebscher I, Lobsien D, Radrezza S, Shevchenko A, Hofmann U, Kratzsch J, Gebhardt R, Berg T, Matz-Soja M (2022). Hepatic Hedgehog Signaling Participates in the Crosstalk between Liver and Adipose Tissue in Mice by Regulating FGF21. Cells, 11(10), 1-10.
     
  206. Herta T, Hahn M, Maier M, Fischer J, Niemeyer J, Hönemann M, Böhlig A, Gerhardt F, Schindler A, Schumacher J, Berg T, Wiegand J, van Bömmel F (2022). Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens, 11(5), 1-10.
     
  207. Seehofer D, Petrowsky H, Schneeberger S, Vibert E, Ricke J, Sapisochin G, Nault JC, Berg T (2022). Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds? Transpl Int, 35(), 10333.
     
  208. Tu T, Bömmel FV, Berg T (2022). Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA. Semin Liver Dis, 42(3), 327-340.
     
  209. Engelmann C, Aehling NF, Schob S, Nonnenmacher I, Handmann L, Macnaughtan J, Herber A, Surov A, Kaiser T, Denecke T, Jalan R, Seehofer D, Moche M, Berg T (2022). Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis. Hepatol Commun, 6(8), 2198-2209.
     
  210. Petroff D, Berg T, Wiegand J (2022). Reply. Clin Gastroenterol Hepatol, 21(1), 240.
     
  211. Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J (2022). Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines, 10(2), 10(2).
     
  212. Schumacher J, Herta T, Stindt J, Keitel V, Berg T (2022). Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation. JHEP Rep, 4(2), 100418.
     
  213. Petroff D, Berg T, Wiegand J (2022). Reply. Clin Gastroenterol Hepatol, 20(3), 716-717.
     
  214. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2022). Age Dependence of Liver Enzymes: An Analysis of Over 1,300,000 Consecutive Blood Samples. Clin Gastroenterol Hepatol, 20(3), 641-650.
     
  215. Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J (2022). Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol, 34(1), 76-83.
     
  216. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2022). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, 45(2), 218-222.
     
  217. Blank V, Petroff D, Boehlig A, Heinze A, Karlas T, Berg T, Wiegand J (2022). Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 34(6), 686-692.
     
  218. Engelmann C, Bruns T, Berg T (2022). Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!". J Hepatol, 76(2), 473-475.
     
  219. Herta T, Beuers U (2022). A historical review of jaundice: May the golden oriole live forever. Clin Liver Dis (Hoboken), 20(Suppl 1), 45-56.
     
  220. Herta T, Kersten R, Chang JC, Hubers L, Go S, Tolenaars D, Paulusma CC, Nathanson MH, Elferink RO, van de Graaf SFJ, Beuers U (2022). Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. J Hepatol, 76(2), 319-331.
     
  221. Schumacher J, Böhlig A, Herber A, Karlas T (2022). Contrast-Enhanced Ultrasound in a Case of an Intrahepatic Mycotic Aneurysm. Ultraschall Med, (1), 1-10.
     
  222. Karlas T, Petroff D, Feisthammel J, Beer S, Blüher M, Schütz T, Lichtinghagen R, Hoffmeister A, Wiegand J (2022). Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. Obes Surg, 32(8), 2495-2503.
     
  223. Fischer J, Wellhöner S, Ebel S, Lincke T, Böhlig A, Gerhardt F, Veelken R, Goessmann H, Steinhoff KG, Denecke T, Sabri O, Berg T, Bömmel FV (2022). The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. Cancers (Basel), 14(21), 1-10.
     
  224. Hoffmann M, Kiesewetter K, Hoffmann I, Herbarth O, Lübbert C (2022). Gram-Negative Bacteria With 3MRGN Resistance Phenotype in Hospital Wastewater, Receiving Water Channels, and Sewage Plant Outlets in the Leipzig Metropolitan Area. Dtsch Arztebl Int, 119(40), 679-680.
     
  225. Zimmer F, Kellner N, Nenoff P, Lübbert C (2022). Eumycetoma caused by Biatriospora mackinnonii in a young pregnant woman from Somalia. Int J Infect Dis, 128(), 1-2.
     
  226. Wendt S, Lippmann N, Lübbert C (2022). Diagnosis at a Glance: Tapeworm Infestation. Dtsch Arztebl Int, 119(29-30), 513.
     
  227. Geißler J, Isham E, Hickey G, Ballard C, Corbett A, Lubbert C (2022). Patient involvement in clinical trials. Commun Med (Lond), 2(), 94.
     
  228. Schneider A, Trawinski H (2022). [39-year-old patient with chronic skin ulcer at his left hand]. Dtsch Med Wochenschr, 147(13), 829-830.
     
  229. Marx K, Gon?arova K, Fedders D, Kalbitz S, Kellner N, Fedders M, Lübbert C (2022). Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany. Infection, (), 1-12.
     
  230. Paquet D, Jung L, Trawinski H, Wendt S, Lübbert C (2022). Fever in the Returning Traveler. Dtsch Arztebl Int, 119(22), 400-407.
     
  231. Lippmann N, Wendt S, Stîngu CS, Wiegand J, Lübbert C (2022). Comparison of the certified Copan eSwab system with commercially available cotton swabs for the detection of multidrug-resistant bacteria in rectal swabs. Am J Infect Control, 50(10), 1145-1149.
     
  232. Wendt S, Lübbert C, Begemann K, Prasa D, Franke H (2022). Poisoning by Plants. Dtsch Arztebl Int, 119(Forthcoming), 317-24.
     
  233. Tannhäuser R, Nickel O, Lindner M, Bethge A, Wolf J, Borte S, Lübbert C (2022). Bacterial contamination of the smartphones of healthcare workers in a German tertiary-care hospital before and during the COVID-19 pandemic. Am J Infect Control, 50(4), 414-419.
     
  234. Otieno MA, Moonga G, Nidens N, Magero NV, Jung L (2022). Adapting to a changing environment: inspiration for planetary health from east African communities. Lancet Planet Health, 6(10), e775-e776.
     
  235. Wendt S, Prasa D, Lübbert C, Begemann K, Franke H (2022). Food Poisoning From Fruits in Germany. Dtsch Arztebl Int, 119(18), 333-334.
     
  236. Dietze N, Trawinski H, Schönherr SG, Lippmann N, Ranft D, Fichtner F, Laudi S, Notov D, Höch A, Kleber C, Lübbert C (2022). Infektionsmedizinische und chirurgische Herausforderungen durch Carbapenem-resistente bakterielle Erreger bei der Versorgung Kriegsverletzter aus der Ukraine Epidemiologisches Bulletin , 36, 3-10.
     
  237. Bußler S, Kellner N, Paquet D, Ermisch J, Al Sheikh Othman S, Lübbert C (2022). Lastkraftwagenfahrer im Fokus von Infektionskrankheiten Flugmedizin Tropenmedizin Reisemedizin - FTR , 29 (1), 22-26.
     
  238. Kalbitz S, Kellner N, Macholz M, Ermisch J, Fechner J, Lübbert C (2022). Erkrankungen durch hochpathogene Erreger - Teil 1 Krankenhaushygiene up2date , 17 (4), 371-390.
     
  239. Schumacher J, Jung L, Schönherr SG, Trawinski H, Lübbert C (2022). Differenzialdiagnose: Diarrhoe als Symptom nach Tropenaufenthalt Coloproctology, 44 (6), 395-405.
     
  240. Brouwer WP, Hollenbach M (2022). Search engine optimization for scientific publications: How one can find your needle in the haystack. United European Gastroenterol J, 10(8), 906-908.
     
  241. Hollenbach M, Capurso G (2022). "Car body appearance and engine": The morphology-function correlation in chronic pancreatitis. United European Gastroenterol J, 10(4), 361-362.
     
  242. Hollenbach M, Capurso G (2022). "Car body appearance and engine": The morphology-function correlation in chronic pancreatitis. United European Gastroenterol J, 10(4), 361-362.
     
  243. Schlosser T, Fischer D, Büttner S, Blank V, Hoffmeister A (2022). Cystic fibrosis transmembrane conductance regulator function in patients with chronic pancreatitis. Medicine (Baltimore), 101(8), 28904.
     
  244. Blank V, Petroff D, Boehlig A, Heinze A, Karlas T, Berg T, Wiegand J (2022). Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 34(6), 686-692.
     
  245. Blank V, Petroff D, Wiegand J, Karlas T (2022). M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. Dig Liver Dis, 54(3), 358-364.
     
  246. Henker R, Beyer G, Lerch MM, Mayerle J, Hoffmeister A (2022). [Overview of relevant clinical recommendations from the new S3 guidelines on acute and chronic pancreatitis]. Chirurg, 93(4), 369-372.
     
  247. Henker R, Lincke T, Hoffmeister A (2022). Case report - Selective internal radiation therapy (SIRT) in a patient with hyperinsulinemic hypoglycemia due to a metastatic insulinoma with late onset of endocrine activity. Z Gastroenterol, 60(9), 1332-1334.
     
  248. Schumacher J, Böhlig A, Herber A, Karlas T (2022). Contrast-Enhanced Ultrasound in a Case of an Intrahepatic Mycotic Aneurysm. Ultraschall Med, (), 124.
     
  249. Karlas T, Petroff D, Feisthammel J, Beer S, Blüher M, Schütz T, Lichtinghagen R, Hoffmeister A, Wiegand J (2022). Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis. Obes Surg, 32(8), 2495-2503.
     
  250. Heni M, Karlas T (2022). [69-year-old patient with chronic epigastric swelling]. Dtsch Med Wochenschr, 147(10), 585-586.
     
  251. Beyer G, Hoffmeister A, Michl P, Gress TM, Huber W, Algül H, Neesse A, Meining A, Seufferlein TW, Rosendahl J, Kahl S, Keller J, Werner J, Friess H, Bufler P, Löhr MJ, Schneider A, Lynen Jansen P, Esposito I, Grenacher L, Mössner J, Lerch MM, Mayerle J (2022). S3-Leitlinie Pankreatitis ? Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) ? September 2021 ? AWMF Registernummer 021-003. Z Gastroenterol, 60(3), 419-521.
     
  252. Blank V, Strobel D, Karlas T (2022). Digital Training Formats in Ultrasound Diagnostics for physicians: What options are available and how can they be successfully integrated into current DEGUM certified course concepts? Ultraschall Med, 43(5), 428-434.
     
  253. Hollenbach M, Hoffmeister A (2022). Adverse events in endoscopic retrograde cholangiopancreaticography (ERCP): Focus on post-ERCP-pancreatitis. United European Gastroenterol J, 10(1), 10-11.
     
  254. Pauleck S, Gigic B, Cawthon RM, Ose J, Peoples AR, Warby CA, Sinnott JA, Lin T, Boehm J, Schrotz-King P, Li CI, Shibata D, Siegel EM, Figueiredo JC, Toriola AT, Schneider M, Ulrich AB, Hoffmeister A, Ulrich CM, Hardikar S (2022). Association of circulating leukocyte telomere length with survival in patients with colorectal cancer. J Geriatr Oncol, 13(4), 480-485.
     
  255. Beyer G, Hoffmeister A, Lorenz P, Lynen P, Lerch MM, Mayerle J (2022). Clinical Practice Guideline?Acute and Chronic Pancreatitis. Dtsch Arztebl Int, 119(29-30), 495-501.
     
  256. Fischer J, Long S, Koukoulioti E, Müller T, Fueloep B, Heyne R, Eslam M, George J, Finkelmeier F, Waidmann O, Berg T, van Bömmel F (2022). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens, 12(1), 1-10.
     
  257. Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J (2022). Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines, 10(2), 1-10.
     
  258. Li T, di Stefano G, Raza GS, Sommerer I, Riederer B, Römermann D, Tan X, Tan Q, Pallagi P, Hollenbach M, Herzig KH, Seidler U (2022). Hydrokinetic pancreatic function and insulin secretion are moduled by Cl- uniporter Slc26a9 in mice. Acta Physiol (Oxf), 234(1), 13729.
     
  259. Neurohr C, Kneidinger N, Ghiani A, Monforte V, Knoop C, Jaksch P, Parmar J, Ussetti P, Sole A, Müller-Quernheim J, Kessler R, Wirtz H, Boerner G, Denk O, Prante Fernandes S, Behr J (2022). A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation. Am J Transplant, 22(1), 222-229.
     
  260. Wang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A (2022). Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res, 28(13), 2865-2877.
     
  261. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E (2022). Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol, 40(26), 3065-3076.
     
  262. Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, D'Ugo D, Haustermans K, van Cutsem E, van Hillegersberg R, van Rossum PSN (2022). Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer, 166(), 254-269.
     
  263. Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkins MA, Smyth E, Markar S, Hanna GB, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns CJ, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick JW, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot LV, Kolodziejczyk P, Polkowski WP, Alsina M, Pera M, Kanonnikoff TF, Nils (2022). Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer, 164(), 18-29.
     
  264. Myer NM, Shitara K, Chung HC, Lordick F, Kelly RJ, Szabo Z, Cao ZA, Leong S, Ilson DH, Weichert W (2022). Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. J Cancer Res Clin Oncol, 148(8), 2023-2043.
     
  265. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC (2022). Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 33(10), 992-1004.
     
  266. Zimmermann T, Dreismann L, Ginger V, Wenzel M, Hornemann B, Dietzsch F, Sura C, Bornhäuser M, Mehnert-Theuerkauf A, Heyne S, Gockel I, Lordick F, Franzke A, Weitz J, Vogel A (2022). Study protocol: the OptiScreen-Study: optimized psycho-oncological care-from screening to intervention. J Cancer Res Clin Oncol, (), 1-12.
     
  267. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K (2022). T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol, (), 1124-1134.
     
  268. Olbrich A, Gros O, Ebel S, Denecke T, Gößmann H, Linder N, Lordick F, Forstmeyer D, Seehofer D, Sucher R, Rademacher S, Niemeyer J, Matz-Soja M, Berg T, Bömmel FV (2022). Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas. Cancers (Basel), 14(19), 4807-4807.
     
  269. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M (2022). Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. J Cancer Res Clin Oncol, (), 1-7.
     
  270. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D'Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R (2022). Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol, (), 748-798.
     
  271. Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, Bläker H, Wittekind C, Lordick F (2022). Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol, (), 39-51.
     
  272. Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks EM, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E (2022). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res, (), 1-9.
     
  273. Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, Stahl M, Reichardt P, Sökler M, Pink D, Probst S, Hinke A, Goetze TO, Al-Batran SE (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer, 165(), 48-57.
     
  274. Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC (2022). Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer, 150(8), 1341-1349.
     
  275. Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks E, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E (2022). Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res, (), 58-78.
     
  276. Unterrainer M, Deroose CM, Herrmann K, Moehler M, Blomqvist L, Cannella R, Caramella C, Caruso D, Chouhan MD, Denecke T, De la Pinta C, De Geus-Oei LF, Dulskas A, Eisenblätter M, Foley KG, Gourtsoyianni S, Lecouvet FE, Lopci E, Maas M, Obmann MM, Oprea-Lager DE, Verhoeff JJC, Santiago I, Terraz S, D'Anastasi M, Regge D, Laghi A, Beets-Tan RGH, Heinemann V, Lordick F, Smyth EC, Ricke J, Kunz WG (2022). Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. Eur J Cancer, 176(), 193-206.
     
  277. Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R (2022). Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol, 12(), 917-961.
     
  278. Sgambato S, Passariello N, Paolisso G, Marano A, Buoninconti R, Tesauro P (2022). Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion. Acta Diabetol Lat, 23(1), 13-22.
     
  279. Ebert K, Haffner I, Zwingenberger G, Keller S, Raimúndez E, Geffers R, Wirtz R, Barbaria E, Hollerieth V, Arnold R, Walch A, Hasenauer J, Maier D, Lordick F, Luber B (2022). Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF. BMC Cancer, 22(1), 254-254.
     
  280. Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messman (2022). GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut, (), 21-26.
     
  281. Kuon J, Blasi M, Unsöld L, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2022). Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. Support Care Cancer, 30(4), 3131-3140.
     
  282. Sivanathan V, Utz C, Thomaidis T, Förster F, Stahl M, Lordick F, Ibach S, Kanzler S, Adler A, Mönig SP, Schimanski CC, Ignee A, Dietrich CF, Galle PR, Moehler M (2022). Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial. Ultraschall Med, 43(5), 514-521.
     
  283. van Schooten TS, Derks S, Jiménez-Martí E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor JM, Esteso F, Farrés J, Mas JM, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T (2022). The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer, 22(1), 646.
     
  284. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2022). Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer, 162(), 245-246.
     
  285. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2022). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, 45(2), 218-222.
     
  286. Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messman (2022). GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut, (), 326-336.
     
  287. Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N (2022). Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Healthy Longev, 3(6), 417-427.
     
  288. Jansen-Winkeln B, Eberth J, Moulla Y, Mehdorn M, Niebisch S, Schierle K, Bläker H, Lordick F, Gockel I, Thieme R (2022). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study. J Cancer Res Clin Oncol, (), 1-11.
     
  289. Bernard M, Löbner M, Lordick F, Mehnert-Theuerkauf A, Riedel-Heller SG, Luck-Sikorski C (2022). Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour? BMC Womens Health, 22(1), 511.
     
  290. Kroese TE, Takahashi Y, Lordick F, van Rossum PSN, Ruurda JP, Lagarde SM, van Hillegersberg R, Verhoeven RHA, van Laarhoven HWM (2022). Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. Eur J Cancer, 179(), 65-75.
     
  291. Baum P, Do L, Deterding L, Lier J, Kunis I, Saur D, Classen J, Wirtz H, Laufs U (2022). Cardiac function in relation to functional status and fatigue in patients with post-COVID syndrome. Sci Rep, 12(1), 19575.
     
  292. Ewert R, Ittermann T, Schmitt D, Pfeuffer-Jovic E, Stucke J, Tausche K, Halank M, Winkler J, Hoheisel A, Stubbe B, Heine A, Seyfarth HJ, Opitz C, Habedank D, Wensel R, Held M (2022). Prognostic Relevance of Cardiopulmonary Exercise Testing for Patients with Chronic Thromboembolic Pulmonary Hypertension. J Cardiovasc Dev Dis, 9(10), 333.
     
  293. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Park DH, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Lange TJ, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Swift AJ, Thompson AAR, Elliot CA, Rosenkranz S, Condliffe R, Kiely DG, Halank M (2022). Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med, 10(10), 937-948.
     
  294. Lier J, Stoll K, Obrig H, Baum P, Deterding L, Bernsdorff N, Hermsdorf F, Kunis I, Bräsecke A, Herzig S, Schroeter ML, Thöne-Otto A, Riedel-Heller SG, Laufs U, Wirtz H, Classen J, Saur D (2022). Neuropsychiatric phenotype of post COVID-19 syndrome in non-hospitalized patients. Front Neurol, 13(), 988359.
     
  295. Valerio L, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, Ewert R, Faehling M, Fistera D, Gerhardt F, Ghofrani HA, Grgic A, Grünig E, Halank M, Held M, Hobohm L, Hoeper MM, Klok FA, Lankeit M, Leuchte HH, Martin N, Mayer E, Meyer FJ, Neurohr C, Opitz C, Schmidt KH, Seyfarth HJ, Wachter R, Wilkens H, Wild PS, Konstantinides SV, Rosenkranz S (2022). Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J, 43(36), 3387-3398.
     
  296. Kneidinger N, Hecker M, Bessa V, Hettich I, Wald A, Wege S, Nolde AB, Oldigs M, Syunyaeva Z, Wilkens H, Gottlieb J (2022). Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection, (), 1-9.
     
  297. Kneidinger N, Valtin C, Hettich I, Frye BC, Wald A, Wilkens H, Bessa V, Gottlieb J (2022). Five-year Outcome of an Early Everolimus-based Quadruple Immunosuppression in Lung Transplant Recipients: Follow-up of the 4EVERLUNG Study. Transplantation, 106(9), 1867-1874.
     
  298. Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Andreas S, Welte T, Rabe KF, Wouters EFM, Sassmann-Schweda A, Wirtz H, Ficker JH, Vogelmeier CF, Jörres RA (2022). Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis, 17(), 1703-1713.
     
  299. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S (2022). COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J, 60(1), 2102311.
     
  300. Stubbe B, Halank M, Seyfarth HJ, Obst A, Desole S, Opitz CF, Ewert R (2022). [Risk Stratification in Patients with Pulmonary Arterial Hypertension under Treatment - Results of Four German Centers]. Pneumologie, 76(5), 330-339.
     
  301. Theobald V, Benjamin N, Seyfarth HJ, Halank M, Schneider MA, Richtmann S, Hinderhofer K, Xanthouli P, Egenlauf B, Seeger R, Hoeper MM, Jonigk D, Grünig E, Eichstaedt CA (2022). Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Genes (Basel), 13(5), 759.
     
  302. Eichstaedt CA, Saßmannshausen Z, Shaukat M, Cao D, Xanthouli P, Gall H, Sommer N, Ghofrani HA, Seyfarth HJ, Lerche M, Halank M, Kleymann J, Benjamin N, Harutyunova S, Egenlauf B, Milger K, Rosenkranz S, Ewert R, Klose H, Hoeper MM, Olsson KM, Lankeit M, Lange TJ, Hinderhofer K, Grünig E (2022). Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respir Res, 23(1), 74.
     
  303. Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, Gläser S, Kruse JM, Zickler D, Peric A, Meisel C, Meyer T, Staudacher OL, Wittke K, Kedor C, Bauer S, Besher NA, Kalus U, Pruß A, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG (2022). SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Front Immunol, 13(), 840126.
     
  304. Roick J, Danker H, Kersting A, Dietrich A, Dietz A, Papsdorf K, Meixensberger J, Stolzenburg JU, Wirtz H, Singer S (2022). Predictors of psychiatric comorbidity in cancer patients at the time of their discharge from the hospital. Soc Psychiatry Psychiatr Epidemiol, 57(3), 553-561.
     
  305. Lommatzsch M, Rabe KF, Taube C, Joest M, Kreuter M, Wirtz H, Blum TG, Kolditz M, Geerdes-Fenge H, Otto-Knapp R, Häcker B, Schaberg T, Ringshausen FC, Vogelmeier CF, Reinmuth N, Reck M, Gottlieb J, Konstantinides S, Meyer J, Worth H, Windisch W, Welte T, Bauer T (2022). Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Respiration, 101(3), 307-320.
     
  306. Neurohr C, Kneidinger N, Ghiani A, Monforte V, Knoop C, Jaksch P, Parmar J, Ussetti P, Sole A, Müller-Quernheim J, Kessler R, Wirtz H, Boerner G, Denk O, Prante Fernandes S, Behr J (2022). A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation. Am J Transplant, 22(1), 222-229.
     
  307. Gottlieb J, Lepper PM, Berastegui C, Montull B, Wald A, Parmar J, Magnusson JM, Schönrath F, Laisaar T, Michel S, Larsson H, Vos R, Haneya A, Sandhaus T, Verschuuren E, le Pavec J, Tikkanen J, Hoetzenecker K (2022). Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study. Eur Respir J, 59(6), 2102078.
     
  308. Fischer J, Wellhöner S, Ebel S, Lincke T, Böhlig A, Gerhardt F, Veelken R, Goessmann H, Steinhoff KG, Denecke T, Sabri O, Berg T, Bömmel FV (2022). The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. Cancers (Basel), 14(21), 1-10.
     
  309. Ebel S, Struck MF, van Boemmel F, Beeskow AB, Gößmann H, Denecke T (2022). Chemosaturation of the Liver - an Update. Rofo, 1, 1858-3418.
     
  310. Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA (2022). A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol, 19(11), 727-745.
     
  311. Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P (2022). Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol, 76(2), 464-469.
     
  312. Sierks D, Schönauer R, Friedrich A, Hantmann E, de Fallois J, Linder N, Fischer J, Herber A, Bergmann C, Berg T, Halbritter J (2022). Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis. JHEP Rep, 4(11), 100579.
     
  313. Ebel S, Reinhardt M, Beeskow AB, Teske F, Struck MF, Veelken R, van Boemmel F, Berg T, Moche M, Gutberlet M, Gößmann H, Denecke T (2022). Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience. BMC Med Imaging, 22(1), 165.
     
  314. Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P (2022). Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol, 76(2), 464-469.
     
  315. Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C (2022). Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. J Hepatol, 78(1), 57-66.
     
  316. Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR (2022). Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol, 77(6), 1670-1689.
     
  317. Kondili LA, Buti M, Riveiro-Barciela M, Maticic M, Negro F, Berg T, Craxì A (2022). Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey. JHEP Rep, 4(9), 100531.
     
  318. Brakenhoff SM, de Knegt RJ, van Campenhout MJH, van der Eijk AA, Brouwer WP, van Bömmel F, Boonstra A, Hansen BE, Berg T, Janssen HLA, de Man RA, Sonneveld MJ (2022). End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. J Microbiol Immunol Infect, (22), 1684-1182.
     
  319. Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M (2022). Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol, 33(1), 493-500.
     
  320. Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M (2022). Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol, 77(4), 1161-1197.
     
  321. Engelmann C, Habtesion A, Hassan M, Kerbert AJ, Hammerich L, Novelli S, Fidaleo M, Philips A, Davies N, Ferreira-Gonzalez S, Forbes SJ, Berg T, Andreola F, Jalan R (2022). Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol, 77(5), 1325-1338.
     
  322. Rademacher S, Denecke T, Berg T, Seehofer D (2022). [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer]. Chirurgie (Heidelb), 93(7), 644-651.
     
  323. Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, Weiss KH, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson SR, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi VR, Brosch M, Lackner C, Stauber RE, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving WL, Morling JR, Guha IN, Barnes E, Ansari MA, (2022). Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, (1), -327196.
     
  324. Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S (2022). Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine, 40(32), 4348-4360.
     
  325. Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Engelmann C, Herber A, Trepte C, Capel J, De Gottardi A (2022). Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump. Liver Int, 42(10), 2247-2259.
     
  326. Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S (2022). Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun, 6(9), 2488-2495.
     
  327. Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V, Lisy MR, Piratvisuth T (2022). Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open, 6(5), 292-300.
     
  328. Metwally M, Berg T, Tsochatzis EA, Eslam M (2022). Translation Reprogramming as a Novel Therapeutic Target in MAFLD. Adv Biol (Weinh), 6(5), -2101298.
     
  329. Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH (2022). Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol, 20(6), 1343-1353.
     
  330. Innes H, Nischalke HD, Guha IN, Weiss KH, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari MA, Rosendahl J, Lin SK, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz PL, Hamill V, Mueller S, Morling JR, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt JU, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S (2022). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatol Commun, 6(5), 1213-1226.
     
  331. Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D'Alessio A, Pinato DJ, Bettinger D, Binder H, John Wherry E, Schultheiss M, Thimme R, Bengsch B (2022). T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol, 77(2), 397-409.
     
  332. Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V, Lisy MR, Piratvisuth T (2022). Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open, 6(5), 292-300.
     
  333. Tergast TL, Blach S, Tacke F, Berg T, Cornberg M, Kautz A, Manns M, Razavi H, Sarrazin C, Serfert Y, van Thiel I, Zeuzem S, Wedemeyer H (2022). Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. J Viral Hepat, 29(7), 536-542.
     
  334. Agarwal K, Lok J, Carey I, Shivkar Y, Biermer M, Berg T, Lonjon-Domanec I (2022). A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'. J Hepatol, 77(1), 245-248.
     
  335. Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F (2022). Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep, 4(5), 100462.
     
  336. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B (2022). Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol, 76(5), 1042-1050.
     
  337. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B (2022). Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol, 20(4), 784-793.
     
  338. Steinhoff KG, Petersen TO, Purz S, Veelken R, Van Boemmel F, Denecke T, Berg T, Sabri O (2022). Yttrium-90 radioembolization-induced abscopal effect on hepatocellular carcinoma. J Dig Dis, 23(4), 237-239.
     
  339. Metwally M, Berg T, Tsochatzis EA, Eslam M (2022). Translation Reprogramming as a Novel Therapeutic Target in MAFLD. Adv Biol (Weinh), 6(5), -2101298.
     
  340. Wilde AB, Greverath LM, Steinhagen LM, de Chamorro NW, Leicht E, Fischer J, Herta T, Berg T, Preuss B, Klein R, Tacke F, Müller T (2022). Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. J Clin Med, 11(3), 1-10.
     
  341. Seidensticker M, Steffen IG, Bargellini I, Berg T, Benito A, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Ricke J (2022). Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort. Curr Oncol, 29(2), 565-577.
     
  342. Lia M, Berg T, Weydandt LC, Stepan H (2022). Intrahepatic cholestasis of pregnancy resistant to both therapeutic plasma exchange and albumin dialysis. BMJ Case Rep, 15(2), -246318.
     
  343. Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M (2022). Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging, 22(1), 1.
     
  344. Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH (2022). An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol, 76(2), 311-318.
     
  345. Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, Engelmann C, Zhang P, Jeong JY, van Vugt JLA, Xiao H, Deng H, Gao X, Ye Q, Zhang J, Yang L, Cai Y, Liu Y, Liu N, Li Z, Han T, Kaido T, Sohn JH, Strassburg C, Berg T, Trebicka J, Hsu YC, IJzermans JNM, Wang J, Su GL, Ji F, Nguyen MH (2022). Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol, 76(3), 588-599.
     
  346. Russo FP, Izzy M, Rammohan A, Kirchner VA, Di Maira T, Belli LS, Berg T, Berenguer MC, Polak WG (2022). Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). J Hepatol, 76(2), 364-370.
     
  347. Öcal O, Schütte K, Kup?inskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M (2022). Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol, 148(2), 475-485.
     
  348. Kolano L, Knappe D, Berg A, Berg T, Hoffmann R (2022). Effect of Amino Acid Substitutions on 70S Ribosomal Binding, Cellular Uptake, and Antimicrobial Activity of Oncocin Onc112. Chembiochem, 23(5), -202100609.
     
  349. Nischalke HD, Schmalz F, Buch S, Fischer J, Möller C, Matz-Soja M, Krämer B, Langhans B, Klüners A, Soyka M, Stickel F, Nattermann J, Berg T, Strassburg CP, Lutz P (2022). Genetic Variation of SAMM50 Is Not an Independent Risk Factor for Alcoholic Hepatocellular Carcinoma in Caucasian Patients. Int J Mol Sci, 23(23), -15353.
     
  350. Wilharm N, Fischer T, Hayn A, Mayr SG (2022). Structural Breakdown of Collagen Type I Elastin Blend Polymerization. Polymers (Basel), 14(20), -4434.
     
  351. Martinez-Garcia FD, Fischer T, Hayn A, Mierke CT, Burgess JK, Harmsen MC (2022). A Beginner's Guide to the Characterization of Hydrogel Microarchitecture for Cellular Applications. Gels, 8(9), -535.
     
  352. Lippmann N, Wendt S, Stîngu CS, Wiegand J, Lübbert C (2022). Comparison of the certified Copan eSwab system with commercially available cotton swabs for the detection of multidrug-resistant bacteria in rectal swabs. Am J Infect Control, 50(10), 1145-1149.
     
  353. Farahat TM, Ungan M, Vilaseca J, Ponzo J, Gupta PP, Schreiner AD, Al Sharief W, Casler K, Abdelkader T, Abenavoli L, Alami FM, Ekstedt M, Jabir MS, Armstrong MJ, Osman MH, Wiegand J, Attia D, Verhoeven V, Amir AAQ, Hegazy NN, Tsochatzis EA, Fouad Y, Cortez-Pinto H (2022). The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint. Liver Int, 42(6), 1259-1267.
     
  354. Blank V, Petroff D, Wiegand J, Karlas T (2022). M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. Dig Liver Dis, 54(3), 358-364.
     
  355. Kliem P, Ebel S, Werdehausen R, Girrbach F, Bösemann D, van Bömmel F, Denecke T, Stehr S, Struck MF (2022). [Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]. Anaesthesiologie, (1), 1-10.
     
  356. Öcal O, Zech CJ, Fabritius MP, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Berg T, Sengel C, Bargellini I, Iezzi R, Benito A, Pech M, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J, Seidensticker M (2022). Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression. Eur Radiol, 33(1), 493-500.
     
  357. Alharthi J, Bayoumi A, Thabet K, Pan Z, Gloss BS, Latchoumanin O, Lundberg M, Twine NA, McLeod D, Alenizi S, Adams LA, Weltman M, Berg T, Liddle C, George J, Eslam M (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nat Commun, 13(1), 7430.
     
  358. Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Philipp A, Berg T, Klümpen HJ, Benckert J, Pech M, Gasbarrini A, Amthauer H, Bartenstein P, Sangro B, Malfertheiner P, Ricke J, Seidensticker M (2022). Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging, 49(13), 4716-4726.
     
  359. Stolze T, Franke S, Haybaeck J, Moehler M, Grimminger PP, Lang H, Roth W, Gockel I, Kreuser N, Bläker H, Wittekind C, Lordick F, Vieth M, Veits L, Waidmann O, Lingohr P, Peitz U, Schildberg C, Kruschewski M, Vassos N, Goni E, Bruns CJ, Ridwelski K, Wolff S, Lippert H, Schumacher J, Malfertheiner P, Venerito M (2022). Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. J Cancer Res Clin Oncol, (), 1-11.
     
  360. Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, Hook S, Schmitz J, Bräsen JH, Franke AC, Olarewaju O, Brandenberger C, Talbot SR, Fangmann J, Hacker UT, Odenthal M, Ott M, Piiper A, Büning H (2022). Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers (Basel), 14(2), 1-19.
     
  361. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC (2022). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 22(1), 39-51.
     
  362. Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M (2022). Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers (Basel), 14(23), 5966.
     
  363. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med, 387(3), 217-226.
     
  364. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol, 33(12), 1250-1268.
     
  365. Mücke VT, Fischer J, Mücke MM, Teumer A, Koch A, Vermehren J, Fromme M, Zeuzem S, Trautwein C, Sarrazin C, Berg T, Zhou B, Hamesch K (2022). Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts. J Clin Med, 12(1), 1-10.
     
  366. Neumann B, Lippmann N, Wendt S, Karlas T, Lübbert C, Werner G, Pfeifer Y, Schuster CF (2022). Recurrent bacteremia with a hypermucoviscous Escherichia coli isolated from a patient with perihilar cholangiocarcinoma: insights from a comprehensive genome-based analysis. Ann Clin Microbiol Antimicrob, 21(1), 28.
     
  367. van Daalen KR, Kallesøe SS, Davey F, Dada S, Jung L, Singh L, Issa R, Emilian CA, Kuhn I, Keygnaert I, Nilsson M (2022). Extreme events and gender-based violence: a mixed-methods systematic review. Lancet Planet Health, 6(6), 504-523.
     
  368. Stöhr M, Fest S, von Braun A, Quaeschling U, Schob S, Dietz A (2022). [Paranasal sinus mucormycosis with internal carotid artery bleeding]. Laryngorhinootologie, 101(9), 741-744.
     
  369. Nicoli F, Clave E, Wanke K, von Braun A, Bondet V, Alanio C, Douay C, Baque M, Lependu C, Marconi P, Stiasny K, Heinz FX, Muetsch M, Duffy D, Boddaert J, Sauce D, Toubert A, Karrer U, Appay V (2022). Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. EBioMedicine, 76(), 103852.
     
  370. Kannenberg J, Trawinski H, Henschler R, Buhmann R, Hönemann M, Jassoy C (2022). Antibody Course and Memory B-Cell Response in the First Year After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis, 226(4), 664-672.
     
  371. The ITAC (INSIGHT 013) Study Group (2022). Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, 399(10324), 530-540.
     
  372. Schiek S, Ranft D, Truckenbrod C, Dürrbeck A, Chaberny I, Rodloff A, Lübbert C, Bertsche T (2022). [Antibiotics Stewardship Team Recommendations - An Analysis under Routine Conditions in a University Hospital]. Gesundheitswesen, 84(6), 503-509.
     
  373. Heyde CE, Lübbert C, Wendt S, Rodloff A, Völker A, von der Höh NH (2022). Spinal Tuberculosis. Z Orthop Unfall, 160(1), 74-83.
     
  374. Nickel O, Rockstroh A, Wolf J, Landgraf S, Kalbitz S, Kellner N, Borte M, Pietsch C, Fertey J, Lübbert C, Ulbert S, Borte S (2022). Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS One, 17(10), 10.
     
  375. Arnold L, Kellermann L, Fischer F, Gepp S, Hommes F, Jung L, Mohsenpour A, Starke D, Stratil JM (2022). What Factors Influence the Interest in Working in the Public Health Service in Germany? Part I of the OeGD-Studisurvey. Int J Environ Res Public Health, 19(18), 11838.
     
  376. Arnold L, Kellermann L, Fischer F, Hommes F, Jung L, Mohsenpour A, Stratil JM (2022). How to Increase the Attractiveness of the Public Health Service in Germany as a Prospective Employer? Part II of the OeGD-Studisurvey. Int J Environ Res Public Health, 19(18), 11733.
     
  377. Staessen JA, Wendt R, Yu YL, Kalbitz S, Thijs L, Siwy J, Raad J, Metzger J, Neuhaus B, Papkalla A, von der Leyen H, Mebazaa A, Dudoignon E, Spasovski G, Milenkova M, Canevska-Taneska A, Salgueira Lazo M, Psichogiou M, Rajzer MW, Fu?awka ?, Dzitkowska-Zabielska M, Weiss G, Feldt T, Stegemann M, Normark J, Zoufaly A, Schmiedel S, Seilmaier M, Rumpf B, Banasik M, Krajewska M, Catanese L, Rupprecht HD, Czerwie?ska B, Peters B, Nilsson Å, Rothfuss K, Lübbert C, Mischak H, Beige J (2022). Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. Lancet Digit Health, 4(10), 727-737.
     
  378. van Daalen KR, Chowdhury M, Dada S, Khorsand P, El-Gamal S, Kaidarova G, Jung L, Othman R, O'Leary CA, Ashworth HC, Socha A, Olaniyan D, Azeezat FT, Abouhala S, Abdulkareem T, Dhatt R, Rajan D (2022). Does global health governance walk the talk? Gender representation in World Health Assemblies, 1948-2021. BMJ Glob Health, 7(8), 009312.
     
  379. Thomas Schleenvoigt B, Ankert J, Stocker H, Stoehr A, Lehmann C, Schulz C, Wesselmann H, Bickel M, Haberl A, Degen O, Pletz MW, Seybold U, Stephan C (2022). [HIV First Diagnoses in Germany in 2014 - A Regional Analysis]. Gesundheitswesen, 84(11), 45-52.
     
  380. Arndt V, Doege D, Fröhling S, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts C, Brossart P, Brucker SY, Brümmendorf TH, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, Lordick F, Peters C, Schadendorf D, Stilgenbauer S, Braun D, Seufferlein T, Nettekoven G, Baumann M (2022). Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie Forum, 37(5), 372-376.
     
  381. Schnabel I, Schneitler S, Schüttoff T, Trawinski H, Lübbert C, Jassoy C (2022). Diagnostic Specificity of Two Dengue Virus IgG ELISAs after Yellow Fever and Japanese Encephalitis Virus Vaccination. Trop Med Infect Dis, 8(1), 1-11.
     
  382. Hunyady P, Streller L, Rüther DF, Groba SR, Bettinger D, Fitting D, Hamesch K, Marquardt JU, Mücke VT, Finkelmeier F, Sekandarzad A, Wengenmayer T, Bounidane A, Weiss F, Peiffer KH, Schlevogt B, Zeuzem S, Waidmann O, Hollenbach M, Kirstein MM, Kluwe J, Kütting F, Mücke MM (2022). Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study. Clin Infect Dis, (), 1-2.
     
  383. Rodríguez-Lago I, Hollenbach M, Archibugi L, Ciocan D, Libânio D, Nuzzo A, Pawlak KM, Zanetto A, Melchior C (2022). Young GI angle: Challenges and opportunities as a trainee editor: The United European Gastroenterology journal experience. United European Gastroenterol J, 10(3), 348-353.
     
  384. Li T, di Stefano G, Raza GS, Sommerer I, Riederer B, Römermann D, Tan X, Tan Q, Pallagi P, Hollenbach M, Herzig KH, Seidler U (2022). Hydrokinetic pancreatic function and insulin secretion are moduled by Cl(-) uniporter Slc26a9 in mice. Acta Physiol (Oxf), 234(1), 13729.
     
  385. Müller M, Denzer UW, Kreuser N, Thieme R, Hoffmeister A, Feisthammel J, Niebisch S, Gockel I (2022). [Diagnosis of esophageal motility disorders - Significance of the new Chicago classification v4.0]. Z Gastroenterol, (), 141.
     
  386. Meier B, Wannhoff A, Denzer U, Stathopoulos P, Schumacher B, Albers D, Hoffmeister A, Feisthammel J, Walter B, Meining A, Wedi E, Zachäus M, Pickartz T, Küllmer A, Schmidt A, Caca K (2022). Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2). Gut, 71(7), 1251-1258.
     
  387. Moulla Y, Lyros O, Mehdorn M, Lange U, Hamade H, Thieme R, Hoffmeister A, Feisthammel J, Blüher M, Jansen-Winkeln B, Gockel I, Dietrich A (2022). Correction to: Preoperative Upper-GI Endoscopy Prior to Bariatric Surgery: Essential or Optional? Obes Surg, 32(1), 225.
     
  388. Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J (2022). Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines, 10(2), 143.
     
  389. Brunnert L, Puasa ID, Garten A, Penke M, Gaul S, Grafe N, Karlas T, Kiess W, Flemming G, Vogel M (2022). Pediatric percentiles for transient elastography measurements - effects of age, sex, weight status and pubertal stage. Front Endocrinol (Lausanne), 13(), 1030809.
     
  390. Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F (2022). Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) ? April 2022 ? AWMF-Registernummer: 021?025. Z Gastroenterol, 60(9), 1346-1421.
     
  391. Divers (2022). Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - April 2022 - AWMF Registration No.: 021-025. Z Gastroenterol, 60(9), 733-801.
     
  392. Neumann B, Lippmann N, Wendt S, Karlas T, Lübbert C, Werner G, Pfeifer Y, Schuster CF (2022). Recurrent bacteremia with a hypermucoviscous Escherichia coli isolated from a patient with perihilar cholangiocarcinoma: insights from a comprehensive genome-based analysis. Ann Clin Microbiol Antimicrob, 21(1), 28.
     
  393. Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J (2022). Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines, 10(2), 125.
     
  394. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lup?or-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Y?lmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geie (2022). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 71(5), 1006-1019.
     
  395. Lordick F, Hacker U, Hoffmeister A, Bläker H, Gockel I (2022). [What is confirmed in the treatment of colon cancer?]. Inn Med (Heidelb), 63(12), 1250-1256.
     
  396. Beyer G, Hoffmeister A, Lorenz P, Lynen P, Lerch MM, Mayerle J (2022). Clinical Practice Guideline?Acute and Chronic Pancreatitis. Dtsch Arztebl Int, 119, 495-501.
     
  397. Schröder J, Chegwidden L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messman (2022). GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut, (), 456.
     
  398. Trojan J, Hoffmeister A, Neu B, Kasper S, Dechêne A, Jürgensen C, Schirra J, Jakobs R, Palmer D, Selbo PK, Olivecrona H, Finnesand L, Høgset A, Walday P, Sturgess R (2022). Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma. Oncologist, 27(6), 430-433.
     
  399. Krause A, Stocker G, Gockel I, Seehofer D, Hoffmeister A, Bläker H, Denecke T, Kluge R, Lordick F, Knödler M (2022). Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. J Cancer Res Clin Oncol, (), 154.
     
  400. Mayerle J, Jansen PL, Lorenz P, Beyer G, Hoffmeister A, Lerch MM (2022). S3-Leitlinie Pankreatitis ? Editorial der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (September 2021 ? AWMF Registernummer 021-003) ? Neue Leitlinie zur akuten und chronischen Pankreatitis (New guideline for acute and chronic pancreatitis). Z Gastroenterol, 60, 297-298.
     
  401. Lorenz P, Lynen Jansen P, Beyer G, Hoffmeister A, Lerch MM, Mayerle J (2022). S3-Leitlinie Pankreatitis ? Leitlinienreport der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) ? September 2021 ? AWMF Registernummer 021-003. Z Gastroenterol, 60, 236-247.
     
  402. Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkins MA, Smyth E, Markar S, Hanna GB, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns CJ, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick JW, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot LV, Kolodziejczyk P, Polkowski WP, Alsina M, Pera M, Kanonnikoff TF, Nils (2022). Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer, 164(), 18-29.
     
  403. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M (2022). Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol, 7(5), 388-390.
     
  404. Arnold L, Kellermann L, Fischer F, Gepp S, Hommes F, Jung L, Mohsenpour A, Starke D, Stratil JM (2022). What Factors Influence the Interest in Working in the Public Health Service in Germany? Part I of the OeGD-Studisurvey. Int J Environ Res Public Health, 19(18), 11838.
     
  405. Mücke VT, Fischer J, Mücke MM, Teumer A, Koch A, Vermehren J, Fromme M, Zeuzem S, Trautwein C, Sarrazin C, Berg T, Zhou B, Hamesch K (2022). Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts. J Clin Med, 12(1), 1-10.
     
  406. Sucher E, Sucher R, Guice H, Schneeberger S, Brandacher G, Gockel I, Berg T, Seehofer D (2022). Hyperspectral Evaluation of the Human Liver During Major Resection. Ann Surg Open, 3(2), 1-10.
     
  407. Peter Layer, Thomas Berg, Andrea May, Andreas Stallmach (2022). Update Gastroenterologie 2022 In: Peter Layer, Thomas Berg, Andrea May, Andreas Stallmach, Update Gastroenterologie 2022 (S. 1), Wiesbaden: med update GmbH.
     
  408. Thomas Ber,g Sven Jonas, Verena Keitel-Anselmino, Beat Müllhaupt (2022). Update Hepatologie 2022 In: Thomas Ber,g Sven Jonas, Verena Keitel-Anselmino, Beat Müllhaupt, Update Hepatologie (S. 1), Wiesbaden: med update GmbH.
     
  409. Jung L (2022). Psychische und Physische Gesundheit in der Planetaren Krise In: van Bronswijk K, Hausmann CM, Climate Emotions Klimakrise und psychische Gesundheit (S. 23-31), Gießen: Psychosozial-Verlag.
     


    410. 2021


  410. Hacker U, Hoffmeister A, Lordick F (2021). [Gastric Cancer: diagnosis and current treatment strategies]. Dtsch Med Wochenschr, 146(23), 1533-1537.
     
  411. Frille A, Costantini A, Sreter KB (2021). Associations of aspirin, statins and metformin with lung cancer risk and related mortality Breathe (Sheff), 17(2), 200325.
     
  412. Vogt J, Beyer F, Sistermanns J, Kuon J, Kahl C, Alt-Epping B, Stevens S, Ahlborn M, George C, Heider A, Tienken M, Loquai C, Stahlhut K, Ruellan A, Kubin T, Dietz A, Oechsle K, Mehnert-Theuerkauf A, van Oorschot B, Thomas M, Ortmann O, Engel C, Lordick F (2021). Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist, 26(6), e1058-e1065.
     
  413. Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö (2021). Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+?gastroesophageal adenocarcinoma. Gastric Cancer, 24(3), 721-730.
     
  414. Jenke R, Reßing N, Hansen FK, Aigner A, Büch T (2021). Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel), 13(4), 634.
     
  415. Catanese S, Lordick F (2021). Targeted and immunotherapy in the era of personalised gastric cancer treatment. Best Pract Res Clin Gastroenterol, 50-51, 50-51.
     
  416. Körfer J, Lordick F, Hacker UT (2021). Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers (Basel), 13(20), 20-20.
     
  417. Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S, Decker T, Wittekind C, Lordick F (2021). HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol, 39(13), 1468-1478.
     
  418. Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, Ceglarek U, Hacker UT (2021). Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle, (), 18-21.
     
  419. Meyer H?J, Leonhardi J, Höhn AK, Pappisch J, Wirtz H, Denecke T, Frille A (2021). CT Texture Analysis of Pulmonary Neuroendocrine Tumors ? Associations with Tumor Grading and Proliferation Journal of Clinical Medicine, 10(23), 5571.
     
  420. Engelmann C, Herber A, Franke A, Bruns T, Reuken P, Schiefke I, Zipprich A, Zeuzem S, Goeser T, Canbay A, Berg C, Trebicka J, Uschner FE, Chang J, Mueller T, Aehling N, Schmelzle M, Splith K, Lammert F, Lange CM, Sarrazin C, Trautwein C, Manns M, Häussinger D, Pfeiffenberger J, Galle PR, Schmiedeknecht A, Berg T (2021). Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). J Hepatol, 75(6), 1346-1354.
     
  421. van Bömmel F, Berg T (2021). Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun, 5(10), 1632-1648.
     
  422. van Bömmel F, Berg T (2021). Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine. Lancet Infect Dis, 21(9), 1197-1198.
     
  423. Buggisch P, Heiken H, Mauss S, Weber B, Jung MC, Görne H, Heyne R, Hinrichsen H, Hidde D, König B, Pires Dos Santos AG, Niederau C, Berg T (2021). Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study. PLoS One, 16(5), e0250833.
     
  424. Tacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein WO, Berg T (2021). S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie ? AWMF-Register Nr. 021-031 ? Stand: 07.01.21. Z Gastroenterol, 59(4), 345-359.
     
  425. Herta T, Berg T (2021). COVID-19 and the liver - Lessons learned. Liver Int, 41 Suppl 1(), 1-8.
     
  426. Wiegand J, Berg T (2021). Hepatitis C-committing the world to an eradication of the infection. Hepatobiliary Surg Nutr, 10(1), 96-99.
     
  427. Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J (2021). Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol, 34(1), 76-83.
     
  428. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2021). The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings. Viruses, 13(11), 1-10.
     
  429. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2021). Age Dependence of Liver Enzymes: An Analysis of Over 1,300,000 Consecutive Blood Samples. Clin Gastroenterol Hepatol, (), 1-10.
     
  430. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2021). Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut, 70(1), 219-221.
     
  431. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2021). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, (), 1-10.
     
  432. Hochmuth L, Körner C, Ott F, Volke D, Cokan KB, Juvan P, Brosch M, Hofmann U, Hoffmann R, Rozman D, Berg T, Matz-Soja M (2021). Sex-dependent dynamics of metabolism in primary mouse hepatocytes. Arch Toxicol, 95(9), 3001-3013.
     
  433. Berg T, Lampertico P (2021). The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol, 75(2), 474-480.
     
  434. Berndt N, Kolbe E, Gajowski R, Eckstein J, Ott F, Meierhofer D, Holzhütter HG, Matz-Soja M (2021). Functional Consequences of Metabolic Zonation in Murine Livers: Insights for an Old Story. Hepatology, 73(2), 795-810.
     
  435. Herta T, Kersten R, Chang JC, Hubers L, Go S, Tolenaars D, Paulusma CC, Nathanson MH, Elferink RO, van de Graaf SFJ, Beuers U (2021). Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. J Hepatol, (), 1-10.
     
  436. Karlas T, Blank V, Böhlig A (2021). Diagnostic Value of Ultrasound in Fatty Liver Disease. Ultraschall Med, 42(2), 128-153.
     
  437. Petroff D, Berg T, Wiegand J (2021). Reply. Clin Gastroenterol Hepatol, (), 1-10.
     
  438. Wiegand J, Berg T (2021). Hepatitis C-committing the world to an eradication of the infection. Hepatobiliary Surg Nutr, 10(1), 96-99.
     
  439. Herta T, Bhattacharyya A, Rosolowski M, Conrad C, Gurtner C, Gruber AD, Ahnert P, Gutbier B, Frey D, Suttorp N, Hippenstiel S, Zahlten J (2021). Krueppel-Like Factor 4 Expression in Phagocytes Regulates Early Inflammatory Response and Disease Severity in Pneumococcal Pneumonia. Front Immunol, 12(), 726135.
     
  440. Engelmann C, Bruns T, Berg T (2021). Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!" J Hepatol, (), 1-10.
     
  441. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2021). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, (), 1-10.
     
  442. van Bömmel F, Berg T (2021). Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun, 5(10), 1632-1648.
     
  443. Lampertico P, Berg T (2021). Reply to: Correspondence on 'the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.' J Hepatol, 75(6), 1499-1501.
     
  444. Engelmann C, Martino VD, Kerbert AJC, Weil-Verhoeven D, Aehling NF, Herber A, Thévenot T, Berg T (2021). The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure. Semin Liver Dis, 41(3), 298-307.
     
  445. Petroff D, Berg T, Wiegand J (2021). Reply. Clin Gastroenterol Hepatol, (), 1-10.
     
  446. Thomas Berg, Daniel Seehofer, Peter Schrimacher (2021). Hepatobiliäre Tumore Verdauungskrankheiten, 39/3, 125-126.
     
  447. Pfrepper C, Knödler M, Schorling RM, Seehofer D, Petros S, Lordick F (2021). Predictors for thromboembolism in patients with cholangiocarcinoma. J Cancer Res Clin Oncol, (), 432.
     
  448. Hacker U, Hoffmeister A, Lordick F (2021). [Gastric Cancer: diagnosis and current treatment strategies]. Dtsch Med Wochenschr, 146(23), 1533-1537.
     
  449. Leuchte HH, Halank M, Held M, Borst M, Ewert R, Klose H, Lange TJ, Meyer FJ, Skowasch D, Wilkens H, Seyfarth HJ (2021). [Differential Diagnosis of Pulmonary Hypertension Using the Example of Collagenosis-associated PAH in the Context of Chronic Lung and Left Heart Disease]. Pneumologie, 75(2), 122-137.
     
  450. Petroff D, Bätz O, Jedrysiak K, Lüllau A, Kramer J, Möller H, Heyne R, Jäger B, Berg T, Wiegand J (2021). From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. Pathogens, 10(12), 1-10.
     
  451. Sinn M, Wege H, van Bömmel F (2021). Zukünftige Entwicklungen in der Behandlung hepatobiliärer Karzinome Verdauungskrankheiten, 3/2021, 125-126.
     
  452. Schindler a, van Bömmel F, Lordick F, Berg T (2021). Therapiewandel beim Hepatozellulären Karzinom onkologie heute, 9, 1-10.
     
  453. Hollenbach M, Sonnenberg S, Sommerer I, Lorenz J, Hoffmeister A (2021). Glyoxalase-I Is Upregulated in Acute Cerulein-Induced Pancreatitis: A New Mechanism in Pancreatic Inflammation? Antioxidants (Basel), 10(10), 1574.
     
  454. Hollenbach M, Feisthammel J, Hoffmeister A (2021). [Interventional endoscopic treatment in acute pancreatitis]. Internist (Berl), 62(10), 1055-1064.
     
  455. Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K (2021). COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J, (), 750-765.
     
  456. Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE (2021). Correction: Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 53(8), C10.
     
  457. Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE (2021). Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 53(8), 850-868.
     
  458. Hollenbach M, Siersema PD (2021). Editorial: Cuff- and cap-assisted colonoscopy: More questions than answers. United European Gastroenterol J, 9(4), 425-426.
     
  459. Hollenbach M, Sonnenberg S, Sommerer I, Lorenz J, Hoffmeister A (2021). Pitfalls in AR42J-model of cerulein-induced acute pancreatitis. PLoS One, 16(1), e0242706.
     
  460. Hollenbach M, Feisthammel J, Hoffmeister A (2021). [Endoscopic diagnosis, treatment, and follow-up of polyps of the lower gastrointestinal tract]. Internist (Berl), 62(2), 151-162.
     
  461. de-Madaria E, Sánchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Márta K, Kamal A, Lauret-Braña E, Barbu ST, Nunes V, Ruiz-Rebollo ML, García-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ (2021). Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut, 70(1), 139-147.
     
  462. Schlosser T, Hoffmeister A, Feisthammel J, Niebisch S, Thieme R, Gockel I (2021). [Treatment recommendations for early esophageal cancer : Endoscopic and surgical options]. Chirurg, 92(12), 1077-1084.
     
  463. Schlosser T, Hoffmeister A, Feisthammel J, Niebisch S, Thieme R, Gockel I (2021). [Treatment recommendations for early esophageal cancer : Endoscopic and surgical options]. Chirurg, 92(12), 1077-1084.
     
  464. Schlosser T, Piechotta P, Karlas T (2021). A Life-Threatening Complication of Upper Endoscopy. Gastroenterology, 160(3), e1-e2.
     
  465. Bielow T, Blank V, Opitz S, Gößmann H, Hecker M, Seehofer D, Lübbert C, Karlas T (2021). Klebsiella Pneumoniae Liver Abscess Syndrome - A Challenge for Contrast-Enhanced Ultrasound. Ultrasound Int Open, 7(1), E2-E5.
     
  466. Blank V, Gößmann H, Karlas T (2021). [Imaging diagnostics of chronic pancreatitis]. Internist (Berl), 62(10), 1015-1024.
     
  467. Blank V, Petroff D, Wiegand J, Karlas T (2021). M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. Dig Liver Dis, (), 000438.
     
  468. Karlas T, Blank V, Böhlig A (2021). Diagnostic Value of Ultrasound in Fatty Liver Disease. Ultraschall Med, 42(2), 128-153.
     
  469. Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T (2021). Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol, 6(3), 185-198.
     
  470. Karlas T, Franke GN (2021). [Liver stiffness in allogeneic stem cell transplantation]. Z Gastroenterol, 59(9), 995-996.
     
  471. Zimmermann L, Wendt S, Lübbert C, Karlas T (2021). Epidemiology of pyogenic liver abscesses in Germany: Analysis of incidence, risk factors and mortality rate based on routine data from statutory health insurance. United European Gastroenterol J, 9(9), 1039-1047.
     
  472. Gora T, Kirsten H, Eder IB, Simon JC, Ziemer M, Trawinski H (2021). Persistierende pustulöse Plaque im Gesicht. J Dtsch Dermatol Ges, 19(12), 1790-1792.
     
  473. Wendt S, Trawinski H, Pietsch C, Borte M, Lübbert C (2021). [Vaccinations]. Internist (Berl), 62(12), 1295-1309.
     
  474. Tannhäuser R, Nickel O, Lindner M, Bethge A, Wolf J, Borte S, Lübbert C (2021). Bacterial contamination of the smartphones of healthcare workers in a German tertiary-care hospital before and during the COVID-19 pandemic. Am J Infect Control, (), ().
     
  475. Schönherr SG, Ranft D, Lippmann N, Lübbert C (2021). Changes in antibiotic consumption, AMR and Clostridioides difficile infections in a large tertiary-care center following the implementation of institution-specific guidelines for antimicrobial therapy: A nine-year interrupted time series study. PLoS One, 16(10), e0258690.
     
  476. Kalbitz S, Ermisch J, Schmidt JM, Wallstabe I, Lübbert C (2021). Unhappy Triad: Infection with Leptospira spp. Escherichia coli and Bacteroides uniformis Associated with an Unusual Manifestation of Portal Vein Thrombosis. Case Rep Gastroenterol, 15(2), 598-602.
     
  477. Gora T, Kirsten H, Eder IB, Simon JC, Ziemer M, Trawinski H (2021). Persistent facial pustular plaque on the face. J Dtsch Dermatol Ges, 19(12), 1790-1792.
     
  478. Viehweger A, Blumenscheit C, Lippmann N, Wyres KL, Brandt C, Hans JB, Hölzer M, Irber L, Gatermann S, Lübbert C, Pletz MW, Holt KE, König B (2021). Context-aware genomic surveillance reveals hidden transmission of a carbapenemase-producing Klebsiella pneumoniae. Microb Genom, 7(12), 000741.
     
  479. Sasse M, Reinhardt F, Lübbert C (2021). [Traveler's Diarrhea]. Dtsch Med Wochenschr, 146(19), 1258-1264.
     
  480. Lübbert C, Peukert W (2021). Characterization of Electrospray Drop Size Distributions by Mobility-Classified Mass Spectrometry: Implications for Ion Clustering in Solution and Ion Formation Pathways. Anal Chem, 93(38), 12862-12871.
     
  481. Schneider A, Wendt S, Lübbert C, Trawinski H (2021). Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art. Expert Opin Pharmacother, 22(17), 2337-2342.
     
  482. Trawinski H, Lübbert C, Bußler S (2021). Secondary Syphilis. Dtsch Arztebl Int, 118(14), 249.
     
  483. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Correction: Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(5), e0251623.
     
  484. Rodloff AC, Lübbert C (2021). Critical Review. Dtsch Arztebl Int, 118(6), 98.
     
  485. Wendt S, Beier D, Paquet D, Trawinski H, Fuchs A, Lübbert C (2021). Medical Advice for Travelers. Dtsch Arztebl Int, 118(21), 349–356.
     
  486. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(2), e0246312.
     
  487. Krämer S, Wirtz H (2021). [Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery]. Chirurg, (), 1.
     
  488. Tout I, Lampertico P, Berg T, Asselah T (2021). Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res, 185(), 104992.
     
  489. Falz R, Thieme R, Tegtbur U, Bischoff C, Leps C, Hillemanns P, Kohlhaw K, Klempnauer J, Lordick F, Stolzenburg JU, Aktas B, Weitz J, Bork U, Wimberger P, Thomas C, Biemann R, Jansen-Winkeln B, Schulze A, Gockel I, Busse M (2021). CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial. BMC Sports Sci Med Rehabil, 13(1), 15.
     
  490. Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon JC, Ziemer M, Kunz M (2021). Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int J Mol Sci, 22(15), 8017.
     
  491. Wichmann G, Willner M, Kuhnt T, Kluge R, Gradistanac T, Wald T, Fest S, Lordick F, Dietz A, Wiegand S, Zebralla V (2021). Standardized Diagnostics Including PET-CT Imaging, Bilateral Tonsillectomy and Neck Dissection Followed by Risk-Adapted Post-Operative Treatment Favoring Radio-Chemotherapy Improve Survival of Neck Squamous Cell Carcinoma of Unknown Primary Patients. Front Oncol, 11(), 682088.
     
  492. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Correction: Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(5), 623.
     
  493. Brückner L, Reinshagen A, Hoang NA, Höhn AK, Lordick F, Bechmann I, Aktas B, Nel I, Kallendrusch S (2021). FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo. Cancers (Basel), 13(5), 956.
     
  494. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A (2021). Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS One, 16(2), 312.
     
  495. Gutsch D, Jenke R, Büch T, Aigner A (2021). Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy. Cells, 10(2), 272.
     
  496. Schaudinn A, Hudak A, Linder N, Reinhardt M, Stocker G, Lordick F, Denecke T, Busse H (2021). Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. Obesity (Silver Spring), 29(2), 294-301.
     
  497. Gervaso L, Pellicori S, Cella CA, Bagnardi V, Lordick F, Fazio N (2021). Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. Ther Adv Med Oncol, 13, 17-21.
     
  498. Junk D, Krämer S, Broschewitz J, Laura H, Massa C, Moulla Y, Hoang NA, Monecke A, Eichfeld U, Bechmann I, Lordick F, Seliger B, Kallendrusch S (2021). Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition. Cell Death Discov, 7(1), 264.
     
  499. Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J (2021). PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology, 10(1), 1960729.
     
  500. Gervaso L, Lordick F, Fazio N (2021). Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? JAMA Oncol, (), 10-11.
     
  501. Kunzke T, Hölzl FT, Prade VM, Buck A, Huber K, Feuchtinger A, Ebert K, Zwingenberger G, Geffers R, Hauck SM, Haffner I, Luber B, Lordick F, Walch A (2021). Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer. Clin Transl Med, 11(9), 547.
     
  502. Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, Ceglarek U, Hacker UT (2021). Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle, (), 17-21.
     
  503. Sender A, Friedrich M, Leuteritz K, Stuckenberg E, Richter D, Stöbel-Richter Y, Lordick F, Geue K (2021). Psychosocial aftercare of adolescent and young adult cancer survivors in Germany: Awareness, utilisation, satisfaction and associated factors. Psychooncology, 30(8), 1311-1321.
     
  504. Scarpitta A, Hacker UT, Büning H, Boyer O, Adriouch S (2021). Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses. Front Oncol, 11(), 731598.
     
  505. Wuerstlein R, Harbeck N, Grischke EM, Forstmeyer D, von Schumann R, Krabisch P, Lüdtke-Heckenkamp K, Stefek A, Stoetzer O, Grafe A, Kaltenecker G, Forstbauer H, Augustin D, Schrader I, Tio J, Nitz U, Gluz O, Kates RE, Graeser MK (2021). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care (Basel), 16(1), 50-58.
     
  506. Jaeger J, Hammer J, Ehrengut C, Frille A, Krasselt M (2021). [Thoracolumbar back pain as the leading symptom of a marked COVID-19 pneumonia]. Dtsch Med Wochenschr, 146(23), 1571-1575.
     
  507. Blank V, Petroff D, Wiegand J, Karlas T (2021). M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. Dig Liver Dis, (), 1-10.
     
  508. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lup?or-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Y?lmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geie (2021). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, (), 1-10.
     
  509. Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T (2021). Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol, 6(3), 185-198.
     
  510. Nischalke HD, Klüners A, Nattermann J, Berg T, Strassburg CP, Lutz P (2021). Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link? Hepatol Commun, 5(12), 2151-2152.
     
  511. Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, Engelmann C, Zhang P, Jeong JY, van Vugt JLA, Xiao H, Deng H, Gao X, Ye Q, Zhang J, Yang L, Cai Y, Liu Y, Liu N, Li Z, Han T, Kaido T, Sohn JH, Strassburg C, Berg T, Trebicka J, Hsu YC, IJzermans JNM, Wang J, Su GL, Ji F, Nguyen MH (2021). Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis. J Hepatol, (), 1-10.
     
  512. Russo FP, Izzy M, Rammohan A, Kirchner VA, Di Maira T, Belli LS, Berg T, Berenguer MC, Polak WG (2021). Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). J Hepatol, (), 1-10.
     
  513. Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH (2021). An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol, (), 1-10.
     
  514. Öcal O, Rössler D, Gasbarrini A, Berg T, Klümpen HJ, Bargellini I, Peynircioglu B, van Delden O, Schulz C, Schütte K, Iezzi R, Pech M, Malfertheiner P, Sangro B, Ricke J, Seidensticker M (2021). Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol, (), 1-10.
     
  515. Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH (2021). Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol, (), 1-10.
     
  516. Sarkar S, Kemper J, Sarkar R, Brants L, Friebe A, Spengler U, Schläpfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Discher T, Zeuzem S, Berg T, Schaefer M (2021). Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-?-induced depression. J Affect Disord, 292(), 766-772.
     
  517. Nischalke HD, Fischer J, Klüners A, Matz-Soja M, Krämer B, Langhans B, Goeser F, Soyka M, Stickel F, Spengler U, Nattermann J, Strassburg CP, Berg T, Lutz P (2021). A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver Int, 41(9), 2139-2148.
     
  518. Hunold P, Berg T, Seehofer D, Sucher R, Herber A, Isermann B, Thiery J, Kaiser T (2021). Experiences from six years of quality assured Model of End Stage Liver Disease (MELD) diagnostics. PLoS One, 16(8), 1-10.
     
  519. Rademacher S, Aehling NF, Sucher R, Berg T, Seehofer D (2021). Current State and Future Possibilities in Liver Transplantation. Surg Technol Int, 39(), 1-10.
     
  520. Metwally M, Bayoumi A, Khan A, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Bugianesi E, Miele L, Anna A, Latchoumanin O, Han S, Alenizi S, Sharkawy RE, Elattar A, Gallego-Durán R, Fischer J, Berg T, Liddle C, Romero-Gomez M, George J, Eslam M (2021). Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 70(), 103521.
     
  521. Jüngst C, Justinger C, Fischer J, Berg T, Lammert F (2021). Common ABCB4 and ABCB11 genotypes are associated with idiopathic chronic cholestasis in adults. Dig Dis, (), 1-10.
     
  522. Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J (2021). S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion ? (AWMF-Register-Nr. 021-11). Z Gastroenterol, 59(7), 691-776.
     
  523. Klinker H, Naumann U, Rössle M, Berg T, Bondin M, Lohmann K, Koenig B, Zeuzem S, Cornberg M (2021). Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int, 41(7), 1518-1522.
     
  524. Bayoumi A, Elsayed A, Han S, Petta S, Adams LA, Aller R, Khan A, García-Monzón C, Arias-Loste MT, Miele L, Latchoumanin O, Alenizi S, Gallego-Durán R, Fischer J, Berg T, Craxì A, Metwally M, Qiao L, Liddle C, Yki-Järvinen H, Bugianesi E, Romero-Gomez M, George J, Eslam M (2021). Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Adv Sci (Weinh), 8(11), 2004168.
     
  525. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P (2021). Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep, 3(3), 100290.
     
  526. Soret PA, Lam L, Carrat F, Smets L, Berg T, Carbone M, Invernizzi P, Leroy V, Trivedi P, Cazzagon N, Weiler-Normann C, Alric L, Rosa-Hezode I, Heurgué A, Cervoni JP, Dumortier J, Potier P, Roux O, Silvain C, Bureau C, Anty R, Larrey D, Levy C, Pares A, Schramm C, Nevens F, Chazouillères O, Corpechot C (2021). Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther, 53(10), 1138-1146.
     
  527. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, (2021). PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol, 74(5), 1097-1108.
     
  528. Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, Hinz S, Hendricks A, Nati M, Herrmann A, Rekhade DR, Berg T, Matz-Soja M, Huse K, Klipp E, Pauling JK, Wodke JA, Miranda Ackerman J, Bonin MV, Aigner E, Datz C, von Schönfels W, Nehring S, Zeissig S, Röcken C, Dahl A, Chavakis T, Stickel F, Shevchenko A, Schafmayer C, Hampe J, Subramanian P (2021). Loss of hepatic Mboat7 leads to liver fibrosis. Gut, 70(5), 940-950.
     
  529. Öcal O, Schütte K, Kup?inskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M (2021). Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol, (), 1-10.
     
  530. Buch S, Sharma A, Ryan E, Datz C, Griffiths WJH, Way M, Buckley TWM, Ryan JD, Stewart S, Wright C, Dongiovanni P, Fracanzani A, Zwerina J, Merle U, Weiss KH, Aigner E, Krones E, Dejaco C, Fischer J, Berg T, Valenti L, Zoller H, McQuillin A, Hampe J, Stickel F, Morgan MY (2021). Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. Aliment Pharmacol Ther, 53(7), 830-843.
     
  531. Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L (2021). Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol, 74(4), 775-782.
     
  532. Efe C, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Onnerhag K, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, K?y?c? M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Beretta-Piccoli BT, Wahlin S (2021). Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol, 36(4), 936-942.
     
  533. Wilde AB, Lieb C, Leicht E, Greverath LM, Steinhagen LM, Wald de Chamorro N, Petersen J, Hofmann WP, Hinrichsen H, Heyne R, Berg T, Naumann U, Schwenzer J, Vermehren J, Geier A, Tacke F, Müller T (2021). Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany. J Clin Med, 10(5), 1-10.
     
  534. Schmidt J, Hübler C, Krohn S, Schmalz G, Schneider H, Berg T, Haak R, Ziebolz D (2021). Detection of Inflammatory and Homeostasis Biomarkers after Selective Removal of Carious Dentin-An In Vivo Feasibility Study. J Clin Med, 10(5), 1-10.
     
  535. Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro-Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M (2021). Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Aliment Pharmacol Ther, 53(6), 733-744.
     
  536. Pfrepper C, Herber A, Weimann A, Siegemund R, Engelmann C, Aehling N, Seehofer D, Berg T, Petros S (2021). Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int, 34(3), 423-435.
     
  537. Schmidt J, Krohn S, Kallies R, Schneider H, Zeller K, Ziebolz D, Berg T, Haak R (2021). Antibacterial effect of a brominated self-etch adhesive on carious dentin - An in vivo study. J Dent, 105(), 103555.
     
  538. Schuff-Werner P, Pönisch W, Berg T, Kaiser T (2021). Transient Howell-Jolly-body-like cytoplasmic inclusions in neutrophils after severe intoxication with alpha-lipoic acid. Scand J Clin Lab Invest, 81(1), 8-11.
     
  539. Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA (2021). Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clin Infect Dis, 72(2), 202-211.
     
  540. Tout I, Lampertico P, Berg T, Asselah T (2021). Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res, 185(), 104992.
     
  541. Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ (2021). Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther, 53(2), 314-320.
     
  542. Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Ida Chen YD, Chowdhury A, Daly AK, Datz C, de Gracia Hahn D, DiStefano JK, Dong J, Duret A, Emdin C, Fairey M, Gerhard GS, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, (2021). rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. J Hepatol, 74(1), 20-30.
     
  543. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C (2021). Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clin Gastroenterol Hepatol, 19(1), 195-198.
     
  544. Zimmermann A, Hänsel R, Gemünden K, Kegel-Hübner V, Babel J, Bläker H, Matz-Soja M, Seehofer D, Damm G (2021). In Vivo and In Vitro Characterization of Primary Human Liver Macrophages and Their Inflammatory State. Biomedicines, 9(4), 1-10.
     
  545. Kocher A, Papac L, Barquera R, Key FM, Spyrou MA, Hübler R, Rohrlach AB, Aron F, Stahl R, Wissgott A, van Bömmel F, Pfefferkorn M, Mittnik A, Villalba-Mouco V, Neumann GU, Rivollat M, van de Loosdrecht MS, Majander K, Tukhbatova RI, Musralina L, Ghalichi A, Penske S, Sabin S, Michel M, Gretzinger J, Nelson EA, Ferraz T, Nägele K, Parker C, Keller M, Guevara EK, Feldman M, Eisenmann S, Skourtanioti E, Giffin K, Gnecchi-Ruscone GA, Friederich S, Schimmenti V, Khartanovich V, Karapetian MK, Chaplyg (2021). Ten millennia of hepatitis B virus evolution. Science, 374(6564), 182-188.
     
  546. Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P (2021). Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol, (), 1-10.
     
  547. Struck MF, Kliem P, Ebel S, Bauer A, Gössmann H, Veelken R, van Bömmel F, Dennecke T, Stehr SN, Girrbach FF (2021). Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. PLoS One, 16(7), 1-10.
     
  548. Maisa A, Kollan C, An der Heiden M, van Bömmel F, Cornberg M, Mauss S, Wedemeyer H, Schmidt D, Dudareva S (2021). Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. Front Public Health, 9(), 667253.
     
  549. Ablefoni M, Surup H, Ehrengut C, Schindler A, Seehofer D, Denecke T, Meyer HJ (2021). Diagnostic Benefit of High b-Value Computed Diffusion-Weighted Imaging in Patients with Hepatic Metastasis. J Clin Med, 10(22), 1-10.
     
  550. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lup?or-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Y?lmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geie (2021). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, (), 1-10.
     
  551. Bhattacharyya A, Herta T, Conrad C, Frey D, García P, Suttorp N, Hippenstiel S, Zahlten J (2021). Induction of Krüppel-Like Factor 4 Mediates Polymorphonuclear Neutrophil Activation in Streptococcus pneumoniae Infection. Front Microbiol, 11(), 582070.
     
  552. Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, Engelmann C, Zhang P, Jeong JY, van Vugt JLA, Xiao H, Deng H, Gao X, Ye Q, Zhang J, Yang L, Cai Y, Liu Y, Liu N, Li Z, Han T, Kaido T, Sohn JH, Strassburg C, Berg T, Trebicka J, Hsu YC, IJzermans JNM, Wang J, Su GL, Ji F, Nguyen MH (2021). Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis. J Hepatol, (), 1-10.
     
  553. Öcal O, Rössler D, Gasbarrini A, Berg T, Klümpen HJ, Bargellini I, Peynircioglu B, van Delden O, Schulz C, Schütte K, Iezzi R, Pech M, Malfertheiner P, Sangro B, Ricke J, Seidensticker M (2021). Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol, (), 1-10.
     
  554. Hunold P, Berg T, Seehofer D, Sucher R, Herber A, Isermann B, Thiery J, Kaiser T (2021). Experiences from six years of quality assured Model of End Stage Liver Disease (MELD) diagnostics. PLoS One, 16(8), 1-10.
     
  555. Öcal O, Schütte K, Kup?inskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M (2021). Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol, (), 1-10.
     
  556. Kuscuoglu D, Bewersdorf L, Wenzel K, Gross A, Kobazi Ensari G, Luo Y, Kilic K, Hittatiya K, Golob-Schwarzl N, Leube RE, Preisinger C, George J, Metwally M, Eslam M, Lampertico P, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Loglio A, Sutton A, Nahon P, Schaefer B, Zoller H, Aigner E, Trautwein C, Haybaeck J, Strnad P (2021). Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. J Pathol, 254(1), 80-91.
     
  557. Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M (2021). Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers, 7(1), 91.
     
  558. Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K (2021). Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol, 18(8), 473-487.
     
  559. Shen J, Kong M, Yang H, Jin K, Chen Y, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Ma D, Ye M, Wang C, Wang Z, Brunelli A, Cerfolio RJ, D'Journo XB, Fernando HC, Lordick F, Fu J, Chen B, Zhu C (2021). Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010). Ann Transl Med, 9(20), 1516.
     
  560. Franck C, Zimmermann N, Goni E, Lippert H, Ridwelski K, Kruschewski M, Kreuser N, Lingohr P, Schildberg C, Vassos N, Waidmann O, Peitz U, Lang H, Grmminger PP, Bruns C, Veits L, Vieth M, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2021). Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. J Gastrointestin Liver Dis, 30(4), 431-437.
     
  561. Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC (2021). Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). Int J Cancer, (), 881.
     
  562. Rhode P, Mehdorn M, Lyros O, Kahlert C, Kurth T, Venus T, Schierle K, Estrela-Lopis I, Jansen-Winkeln B, Lordick F, Gockel I, Thieme R (2021). Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers (Basel), 13(23), 5975.
     
  563. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E, Georgoulias V, Ben-Aharon I, Shi Q (2021). Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. J Clin Oncol, 39(36), 4009-4019.
     
  564. Kuon J, Blasi M, Unsöld L, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2021). Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study. Support Care Cancer, (), 520-521.
     
  565. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC (2021). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, (), 1-13.
     
  566. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2021). Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer, (), 224-227.
     
  567. Veelken R, Maiwald B, Strocka S, Petersen TO, Moche M, Ebel S, Denecke T, Rehak M, Struck MF, Forstmeyer D, Rademacher S, Seehofer D, Berg T, van Bömmel F (2021). Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol, (), 1-5.
     
  568. Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, Franke C, Glöckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick RH (2021). [S1 Guideline Post-COVID/Long-COVID]. Pneumologie, 75(11), 869-900.
     
  569. Dohna M, Renz DM, Stehling F, Dohna-Schwake C, Sutharsan S, Neurohr C, Wirtz H, Eickmeier O, Grosse-Onnebrink J, Sauerbrey A, Soditt V, Poplawska K, Wacker F, Montag MJ (2021). Coil embolisation for massive haemoptysis in cystic fibrosis. BMJ Open Respir Res, 8(1), 000-985.
     
  570. Stubbe B, Seyfarth HJ, Kleymann J, Halank M, Al Ghorani H, Obst A, Desole S, Ewert R, Opitz CF (2021). Monotherapy in patients with pulmonary arterial hypertension at four German PH centres. BMC Pulm Med, 21(1), 130.
     
  571. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A (2021). Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med, 9(5), 476-486.
     
  572. Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grünig E, Halank M, Hoeper MM, Klok FA, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Schmidt KH, Seyfarth HJ, Trudzinski F, Wachter R, Wilkens H, Wild PS, Konstantinides SV (2021). Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study. Chest, 159(6), 2428-2438.
     
  573. Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, ?imková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoeper MM (2021). Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respir Med, 178(), 106220.
     
  574. Klose H, Chin KM, Ewert R, Gall H, Parambil J, Poch D, Seyfarth HJ, Axelsen LN, Hsu Schmitz SF, Stein C, Preston IR (2021). Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respir Res, 22(1), 34.
     
  575. Rashid H, Eichler M, Hechtner M, Gianicolo E, Wehler B, Buhl R, Schmidberger H, Stratmann JA, Gohrbandt B, Kortsik C, Nestle U, Wirtz H, Blettner M, Singer S (2021). Returning to work in lung cancer survivors-a multi-center cross-sectional study in Germany. Support Care Cancer, 29(7), 3753-3765.
     
  576. Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol, 32(5), 609-619.
     
  577. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, IJzerman M, Solomon BJ (2021). Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO Open, 6(5), 100224.
     
  578. Franck C, Zimmermann N, Goni E, Lippert H, Ridwelski K, Kruschewski M, Kreuser N, Lingohr P, Schildberg C, Vassos N, Waidmann O, Peitz U, Lang H, Grmminger PP, Bruns C, Veits L, Vieth M, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2021). Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. J Gastrointestin Liver Dis, 30(4), 431-437.
     
  579. Innes H, Nischalke HD, Guha IN, Weiss KH, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari MA, Rosendahl J, Lin SK, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz PL, Hamill V, Mueller S, Morling JR, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt JU, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S (2021). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatol Commun, (), 1-10.
     
  580. Zimmermann R, Külper-Schiek W, Steffen G, Gillesberg Lassen S, Bremer V, Dudareva S (2021). [How to assess the elimination of viral hepatitis B, C, and D in Germany? Outcomes of an interdisciplinary workshop]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 64(1), 77-90.
     
  581. Hacker U, Hoffmeister A, Lordick F (2021). [Gastric Cancer: diagnosis and current treatment strategies]. Dtsch Med Wochenschr, 146(23), 1533-1537.
     
  582. Jansen-Winkeln B, Takoh JP, Chalopin C, Maktabi M, Lyros O, Sucher R, Hoffmeister A, Teich N, Köhler H, Gockel I (2021). Hyperspectral Imaging: A New Intraoperative Tool for Pouch Assessment in Patients Undergoing Restorative Proctocolectomy. Visc Med, 37(5), 426-433.
     
  583. Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K (2021). COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J, (), 750-765.
     
  584. Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE (2021). Correction: Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 53(8), 1528-2092.
     
  585. Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE (2021). Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 53(8), 850-868.
     
  586. de-Madaria E, Sánchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Márta K, Kamal A, Lauret-Braña E, Barbu ST, Nunes V, Ruiz-Rebollo ML, García-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ (2021). Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut, 70(1), 139-147.
     
  587. Teich N, Ludewig C, Schmelz R, Bästlein EC, Geißler S, Nagl S, Walldorf J, Krause T, Maaser C, Mohl W, Wedemeyer HH, Bauer T, Büning C, Grunert P, Hasselblatt P, Hänschen M, Kahl M, Engelke O, Schubert S, Holler B, Streetz K, Arnim UV, Schmidt K, Stallmach A (2021). [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease]. Z Gastroenterol, 59(11), 1189-1196.
     
  588. Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lup?or-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Y?lmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geie (2021). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, (), 324243.
     
  589. Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J (2021). Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. Ultraschall Med, 42(2), 20.
     
  590. Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J (2021). Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. Ultraschall Med, 42(2), 178-186.
     
  591. Ammer-Herrmenau C, Asendorf T, Beyer G, Buchholz SM, Cameron S, Damm M, Frost F, Henker R, Jaster R, Phillip V, Placzek M, Ratei C, Sirtl S, van den Berg T, Weingarten MJ, Woitalla J, Mayerle J, Ellenrieder V, Neesse A (2021). Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis-a prospective multicentre translational study. BMC Gastroenterol, 21(1), 304.
     
  592. Berger C, Heyne HO, Heiland T, Dommel S, Höfling C, Guiu-Jurado E, Lorenz J, Roßner S, Dannemann M, Kelso J, Kovacs P, Blüher M, Klöting N (2021). A novel compound heterozygous leptin receptor mutation causes more severe obesity than in Leprdb/db mice. J Lipid Res, 62(), 100105.
     
  593. Wendt R, Lingitz MT, Laggner M, Mildner M, Traxler D, Graf A, Krotka P, Moser B, Hoetzenecker K, Kalbitz S, Lübbert C, Beige J, Ankersmit HJ (2021). Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19. Biology (Basel), 10(11), 1186.
     
  594. Kratzsch D, Nenoff P, Uhrlaß S, Wendt S, Simon JC, Treudler R (2021). Phäohyphomykose durch Cladosporium cladosporioides bei einem immunsupprimierten Jungen mit Ewing-Sarkom. J Dtsch Dermatol Ges, 19(8), 1204-1206.
     
  595. Siwy J, Wendt R, Albalat A, He T, Mischak H, Mullen W, Latosinska A, Lübbert C, Kalbitz S, Mebazaa A, Peters B, Stegmayr B, Spasovski G, Wiech T, Staessen JA, Wolf J, Beige J (2021). CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology? Proteomics, 21(20), 2100133.
     
  596. Zimmermann L, Wendt S, Lübbert C, Karlas T (2021). Epidemiology of pyogenic liver abscesses in Germany: Analysis of incidence, risk factors and mortality rate based on routine data from statutory health insurance. United European Gastroenterol J, 9(9), 1039-1047.
     
  597. Mehdorn M, Lübbert C, Chaberny IF, Gockel I, Jansen-Winkeln B (2021). Correction to: Mechanical plus oral bowel preparation with paromomycin and metronidazole reduces infectious complications in elective colorectal surgery: a matched case-control study. Int J Colorectal Dis, 36(9), 1851.
     
  598. Kratzsch D, Nenoff P, Uhrlaß S, Wendt S, Simon JC, Treudler R (2021). Phaeohyphomycosis caused by Cladosporium cladosporioides in an immunosuppressed boy with Ewing sarcoma. J Dtsch Dermatol Ges, 19(8), 1204-1206.
     
  599. Reiners N, Schnurra C, Trawinski H, Kannenberg J, Hermsdorf T, Aebischer A, Schöneberg T, Reiche S, Jassoy C (2021). Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain. Eur J Clin Microbiol Infect Dis, 40(12), 2645-2649.
     
  600. Wendt R, Thijs L, Kalbitz S, Mischak H, Siwy J, Raad J, Metzger J, Neuhaus B, Leyen HV, Dudoignon E, Mebazaa A, Spasovski G, Milenkova M, Canevska-Talevska A, Czerwie?ska B, Wiecek A, Peters B, Nilsson Å, Schwab M, Rothfuss K, Lübbert C, Staessen JA, Beige J (2021). A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine, 36(), 100883.
     
  601. Schiek S, Ranft D, Truckenbrod C, Dürrbeck A, Chaberny I, Rodloff A, Lübbert C, Bertsche T (2021). [Antibiotics Stewardship Team Recommendations - An Analysis under Routine Conditions in a University Hospital]. Gesundheitswesen, (), 0-0.
     
  602. Mehdorn M, Lübbert C, Chaberny IF, Gockel I, Jansen-Winkeln B (2021). Mechanical plus oral bowel preparation with paromomycin and metronidazole reduces infectious complications in elective colorectal surgery: a matched case-control study. Int J Colorectal Dis, 36(9), 1839-1849.
     
  603. Bielow T, Blank V, Opitz S, Gößmann H, Hecker M, Seehofer D, Lübbert C, Karlas T (2021). Klebsiella Pneumoniae Liver Abscess Syndrome - A Challenge for Contrast-Enhanced Ultrasound. Ultrasound Int Open, 7(1), 2-5.
     
  604. Kieserling H, Giefer P, Uttinger MJ, Lautenbach V, Nguyen T, Sevenich R, Lübbert C, Rauh C, Peukert W, Fritsching U, Drusch S, Maria Wagemans A (2021). Structure and adsorption behavior of high hydrostatic pressure-treated ?-lactoglobulin. J Colloid Interface Sci, 596(), 173-183.
     
  605. Rockstroh A, Wolf J, Fertey J, Kalbitz S, Schroth S, Lübbert C, Ulbert S, Borte S (2021). Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerg Microbes Infect, 10(1), 774-781.
     
  606. Wendt R, Tittelbach J, Schrick L, Kellner N, Kalbitz S, Ruehe B, Michel J, Schliemann S, Elsner P, Lübbert C, Nitsche A (2021). Generalized cowpox virus infection in an immunosuppressed patient. Int J Infect Dis, 106(), 276-278.
     
  607. Haberl L, Audebert F, Feiterna-Sperling C, Gillor D, Jakubowski P, Jonsson-Oldenbüttel C, Khaykin P, Kiener R, Reitter A, Rieke A, Rodríguez E, Rößler S, Rump JA, Schüttfort G, Stephan C, Ulmer A, von Braun A, von Weizsäcker K, Haberl A (2021). Not Recommended, But Done: Breastfeeding with HIV in Germany. AIDS Patient Care STDS, 35(2), 33-38.
     
  608. Uttinger MJ, Jung D, Dao N, Canziani H, Lübbert C, Vogel N, Peukert W, Harting J, Walter J (2021). Probing sedimentation non-ideality of particulate systems using analytical centrifugation. Soft Matter, 17(10), 2803-2814.
     
  609. Wendt R, Nickel O, Kalbitz S, Fertey J, Ulbert S, Wolf J, Lübbert C, Borte S (2021). Comparison of pre-analytical characteristics for molecular and serological diagnostics of COVID-19. GMS Hyg Infect Control, 16(), 03.
     
  610. Heyde CE, Lübbert C, Wendt S, Rodloff A, Völker A, von NHH (2021). Spinal Tuberculosis. Z Orthop Unfall, (), 0-0.
     
  611. Klaper K, Wendt S, Lübbert C, Lippmann N, Pfeifer Y, Werner G (2021). Hypervirulent Klebsiella pneumoniae of Lineage ST66-K2 Caused Tonsillopharyngitis in a German Patient. Microorganisms, 9(1), 133.
     
  612. Klaper K, Wendt S, Lübbert C, Lippmann N, Pfeifer Y, Werner G (2021). Hypervirulent Klebsiella pneumoniae of Lineage ST66-K2 Caused Tonsillopharyngitis in a German Patient. Microorganisms, 9(1), 133.
     
  613. Viehweger A, Blumenscheit C, Lippmann N, Wyres KL, Brandt C, Hans JB, Hölzer M, Irber L, Gatermann S, Lübbert C, Pletz MW, Holt KE, König B (2021). Context-aware genomic surveillance reveals hidden transmission of a carbapenemase-producing Klebsiella pneumoniae. Microb Genom, 7(12), 000741.
     
  614. Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, Franke C, Glöckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick RH (2021). [S1 Guideline Post-COVID/Long-COVID]. Pneumologie, 75(11), 869-900.
     
  615. Roick J, Danker H, Kersting A, Dietrich A, Dietz A, Papsdorf K, Meixensberger J, Stolzenburg JU, Wirtz H, Singer S (2021). Predictors of psychiatric comorbidity in cancer patients at the time of their discharge from the hospital. Soc Psychiatry Psychiatr Epidemiol, (), 1.
     
  616. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB (2021). Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med, 384(13), 1204-1215.
     
  617. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G (2021). Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med, 9(6), 573-584.
     
  618. Lommatzsch M, Rabe KF, Taube C, Joest M, Kreuter M, Wirtz H, Blum TG, Kolditz M, Geerdes-Fenge H, Otto-Knapp R, Häcker B, Schaberg T, Ringshausen FC, Vogelmeier CF, Reinmuth N, Reck M, Gottlieb J, Konstantinides S, Meyer FJ, Worth H, Windisch W, Welte T, Bauer T (2021). [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie, 75(1), 19-30.
     
  619. Gottlieb J, Lepper PM, Berastegui C, Montull B, Wald A, Parmar J, Magnusson JM, Schönrath F, Laisaar T, Michel S, Larsson H, Vos R, Haneya A, Sandhaus T, Verschuuren E, le Pavec J, Tikkanen J, Hoetzenecker K (2021). Lung transplantation for acute respiratory distress syndrome - a retrospective European Cohort Study. Eur Respir J, (), 1.
     
  620. Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S (2021). COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J, (), 1.
     
  621. Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Park DH, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H (2021). Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. Eur Respir J, (), 1.
     
  622. Hacker U, Hoffmeister A, Lordick F (2021). [Gastric Cancer: diagnosis and current treatment strategies]. Dtsch Med Wochenschr, 146(23), 1533-1537.
     
  623. Maisa A, Kollan C, An der Heiden M, van Bömmel F, Cornberg M, Mauss S, Wedemeyer H, Schmidt D, Dudareva S (2021). Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. Front Public Health, 9(), 667253.
     
  624. Wedemeyer H, Herzer K, Serfert Y, Taubert R, Trautwein C, Eurich D, Strassburg CP, Lang M, Weiss KH, Berg T, Galle PR, Heinzow H, Zeuzem S (2021). Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. Dtsch Arztebl Int, 118(46), 797-798.
     
  625. Ulrich Rosien, Thomas Berg, Peter Layer (2021). Facharztwissen Gastroenterologie und Hepatologie: Mit Zugang zum Elsevier-Portal In: Ulrich Rosien, Thomas Berg, Peter Layer, Facharztwissen Gastroenterologie und Hepatologie: Mit Zugang zum Elsevier-Portal (S. 0-978), München: Urban & Fischer Verlag/Elsevier GmbH.
     
  626. Heiner Wedemeyer, Christoph Sarrazin, Verena Keitel, Brigitte Schumacher, Peter Fickert, Beat Müllhaupt, Andrea Tannapfel, Jonel Trebicka, Jörg Trojan, Sven Jonas, Henrik Petrowsky, Thomas Berg (2021). Akute Hepatitiden und akutes Leberversagen In: Anette Hindermann, UPDATE Hepatologie 2021 (S. 1-10), Wiesbaden: med publico GmbH.
     
  627. Carsten Schmidt, Peter Layer, Andrea Tannapfel, Thomas Berg, Claas Lahmann, Andreas Stallmach, Andrea May, Viola Andresen, Christian Trautwein, Dietmar Lorenz, Rainer Porschen, Helmut Messmann, (2021). Hepatologie I und Hot Topic: Komplikationen/Kritische Fälle (CIRS) In: Anette Hindermann, UPDATE Gastro 2021 (S. 1-10), Wiesbaden: med publico GmbH.
     
  628. Lordick F, Schneider PM (2021). Ösophagus-Karzinom - Neoadjuvante Therapie In: Hölscher AH, Mönig SP, Meyer HJ, Oberer Gastrointestinaltrakt (S. 212-216), Stuttgart: Georg-Thieme-Verlag KG.
     
  629. Lordick F, Haustermanns K (2021). Gastrointestinal Tract Tumors In: Cervantes Andres, Essentials for Clinicians 2nd Edition (S. 23-29), Madrid: Oncology Pro.
     
  630. Ackmann C, Hollenbach M (2021). Akute Erkrankungen der Bauchspeicheldrüse In: Eckart Weigand Briegel, Intensivmedizin Kompendium und Repetitorium zur interdisziplinären Weiter- und Fortbildung (S. 1-12), Köln: Ecomed Medizin.
     
  631. Hollenbach M, Hoffmeister A (2021). Endoskopisches Management und interventionelle Therapie der Barrett-Metaplasie und der intraepithelialen Neoplasie des Ösophagus In: Gockel I, Benigne Ösophaguserkrankungen (S. 287-304), Berlin: Springer Verlag.
     
  632. Jung N, Lehmann C, Rieg S (2021). Amerikanische Trypanosomiasis (Chagas-Krankheit) In: Lehmann C, Klinikleitfaden Infektiologie 1. Auflage (S. 486-488), München: Elsevier.
     
  633. Jung N, Lehmann C, Rieg S (2021). Afrikanische Trypanosomiasis (Schlafkrankheit) In: Rieg S, Klinikleitfaden Infektiologie (S. 483-486), München: Elsevier.
     
  634. Jung N, Lehmann C, Rieg S (2021). Kutane, mukokutane und viszerale Leishmaniasis In: Rieg S, Klinikleitfaden Infektiologie (S. 468-474), München: Elsevier.
     
  635. Jung N, Lehmann C, Rieg S (2021). Amöbiasis In: Rieg S, Klinikleitfaden Infektiologie (S. 465-468), München: Elsevier.
     


    636. 2020


  636. Frille A, Hardavella G, Lee R (2020). Lung cancer incidence and mortality with extended follow-up in the National LungScreening Trial. Breathe (Sheff), 16(1), 190322.
     
  637. Frille A, Wirtz H (2020). Misleading Conclusion Dtsch Arztebl Int, 117(9), 145.
     
  638. Lordick F (2020). Hepatocellular carcinoma-united forces against a global killer. Ann Oncol, 31(4), 449-450.
     
  639. Smyth E, Knodler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F (2020). VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol, 9, 1320-.
     
  640. Lordick F (2020). Chemotherapy for resectable microsatellite instability-high gastric cancer? Lancet Oncol, 21(2), 203-.
     
  641. Lordick F, Herrmann K (2020). Metabolic response assessment and PET-guided treatment of esophageal cancer. Ann Oncol, 31(2), 163-164.
     
  642. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2020). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 11(1), 135-144.
     
  643. Spormann L, Rennert C, Kolbe E, Ott F, Lossius C, Lehmann R, Gebhardt R, Berg T, Matz-Soja M (2020). Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver. Cells, 9(8), E1817.
     
  644. Berndt N, Kolbe E, Gajowski R, Eckstein J, Ott F, Meierhofer D, Holzhütter HG, Matz-Soja M (2020). Functional consequences of metabolic zonation in murine livers: New insights for an old story. Hepatology, (x), x.
     
  645. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T (2020). Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep, 2(5), 100169.
     
  646. Aehling NF, Seehofer D, Berg T (2020). [Liver transplantation - current trends]. Dtsch Med Wochenschr, 145(16), 1124-1131.
     
  647. Boehlig A, Blank V, Karlas T, Trawinski H, Hau HM, Lederer AA, Berg T (2020). A young woman from an Echinococcus-endemic area with progressive abdominal distension: a case report. J Med Case Rep, 14(1), 65.
     
  648. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T (2020). Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep, 2(3), 100113.
     
  649. Aehling NF, Seehofer D, Berg T (2020). Liver transplantation - current trends Dtsch Med Wochenschr, 145(16), 1124-1131.
     
  650. Newsome PN, Berg T (2020). 2020 - A new decade of innovation for EASL. J Hepatol, 72(1), 8.
     
  651. Frille A, Rullmann M, Becker GA, Patt M, Luthardt J, Tiepolt S, Wirtz H, Sabri O, Hesse S, Seyfarth HJ (2020). Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension. Eur J Nucl Med Mol Imaging, (), 1-12.
     
  652. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T (2020). Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep, 2(5), 100169.
     
  653. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F (2020). Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol, x, x.
     
  654. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  655. Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J (2020). Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol, 55(6), 706-711.
     
  656. Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J (2020). Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol, 55(6), 706-711.
     
  657. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2020). Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut, 1, 1.
     
  658. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020). Gastric cancer. Lancet, 396(10251), 635-648.
     
  659. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G (2020). Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol, 31(10), 1320-1335.
     
  660. Lordick F, Ghadimi M, Gockel I, Graeven U, Westphalen CB (2020). Precision Medicine. Visc Med, 36(5), 407-410.
     
  661. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020). Gastric cancer. Lancet, 396(10251), 635-648.
     
  662. Lordick F, Ghadimi M, Gockel I, Graeven U, Westphalen CB (2020). Precision Medicine. Visc Med, 36(5), 407-410.
     
  663. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2020). Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut, 1, 1.
     
  664. Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J (2020). Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol, 1, 1.
     
  665. Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J (2020). Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol, 55(6), 706-711.
     
  666. Hollenbach M, Feisthammel J, Hoffmeister A (2020). Endoscopic diagnosis, treatment, and follow-up of polyps of the lower gastrointestinal tract. Internist (Berl), (), 1825-1830.
     
  667. Heise C, Abou Ali E, Hasenclever D, Auriemma F, Gulla A, Regner S, Gaujoux S, Hollenbach M (2020). Systematic Review with Meta-Analysis: Endoscopic and Surgical Resection for Ampullary Lesions. J Clin Med, 9(11), 3622-26.
     
  668. Hollenbach M, Feisthammel J, Hoffmeister A (2020). Interventional endoscopy in the gastrointestinal tract : Indications and limitations. Internist (Berl), 61(10), 1017-1030.
     
  669. Hollenbach M, Barresi L (2020). Shedding light on painless chronic pancreatitis. Dig Liver Dis, 52(11), 1331-1332.
     
  670. Hollenbach M, Ali EA, Auriemma F, Gulla A, Heise C, Regnér S, Gaujoux S (2020). Study Protocol of the ESAP Study: Endoscopic Papillectomy vs. Surgical Ampullectomy vs. Pancreaticoduodenectomy for Ampullary Neoplasm-A Pancreas2000/EPC Study. Front Med (Lausanne), 7(), 152.
     
  671. Hollenbach M, Stoll SJ, Jörgens K, Seufferlein T, Kroll J (2020). Correction: Different Regulation of Physiological and Tumor Angiogenesis in Zebrafish by Protein Kinase D1 (PKD1). PLoS One, 15(3), e0231153.
     
  672. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  673. Schlosser T, Piechotta P, Karlas T (2020). A life-threatening complication of upper endoscopy. Gastroenterology, 20, 16.
     
  674. Bielow T, Karlas T (2020). [39-years-old woman with chronic abdominal pain]. Dtsch Med Wochenschr, 145(2), 77-78.
     
  675. Pfrepper C, Herber A, Weimann A, Siegemund R, Engelmann C, Aehling N, Seehofer D, Berg T, Petros S (2020). Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int, 1, 1-10.
     
  676. Koukoulioti E, Ziagaki A, Weber SN, Lammert F, Berg T (2020). Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease. Hepatology, 1, 1-10.
     
  677. Berg T, Seehofer D, Aehling N (2020). Aktuelle Entwicklungen bei der Lebertransplantation ? Wo stehen wir? Deutsche medizinische Wochenschrift , 145, 1124-1131.
     
  678. Deterding L, Körner T, Borte G, Wirtz H, Seyfarth HJ (2020). Nocardiosis mimicking lung cancer in a heart transplant patient with end-stage renal disease. Respir Med Case Rep, 30, 101101.
     
  679. Gockel I, Lordick F (2020). [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?] Chirurg, 91(5), 384-390.
     
  680. Serra O, Smyth EC, Lordick F (2020). Progress and challenges in gastroesophageal cancer. Curr Probl Cancer, 44(6), 100590.
     
  681. Bräunlich J, Wirtz H (2020). [Differential Therapy NIV - NHF]. Pneumologie, 74(3), 137-148.
     
  682. Hacker UT, Bentler M, Kaniowska D, Morgan M, Büning H (2020). Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives. Cancers (Basel), 12(7), 12.
     
  683. Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 5(Suppl 3), 826-826.
     
  684. Catanese S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 5(Suppl 3), 804-804.
     
  685. Ben-Aharon I, Goshen-Lago T, Turgeman I, Fontana E, Smyth E, Lordick F (2020). Young patients with cancer and a digital social network: the voice beyond the clinic. ESMO Open, 5(3), 651-652.
     
  686. Jenke R, Holzhäuser-Rein M, Mueller-Wilke S, Lordick F, Aigner A, Büch T (2020). SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. Int J Mol Sci, 22(1), 82-83.
     
  687. Schorling RM, Pfrepper C, Golombek T, Cella CA, Muñoz-Unceta N, Siegemund R, Engel C, Petros S, Lordick F, Knödler M (2020). Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients. Oncol Res Treat, 43(9), 414-427.
     
  688. Lordick F, Hacker U, Gockel I, Bläker H (2020). Magenkarzinom. Neue molekulare Konzepte. Deutsches Ärzteblatt, 2, 4-6.
     
  689. Hacker UT (2020). Kachexie bei Tumorerkrankungen TumorDiagnostik & Therapie, 41, 89-92.
     
  690. Wendt R, Nagel S, Nickel O, Wolf J, Kalbitz S, Kaiser T, Borte S, Lübbert C (2020). Comprehensive investigation of an in-hospital transmission cluster of a symptomatic SARS-CoV-2-positive physician among patients and healthcare workers in Germany. Infect Control Hosp Epidemiol, 41(10), 1209-1211.
     
  691. Schönherr SG, Wendt S, Ranft D, Schock B, Lübbert C (2020). Assessing the impact of institution-specific guidelines for antimicrobials on doctors' prescribing behavior at a German tertiary-care center and the additional benefits of providing a mobile application. PLoS One, 15(11), e0241642.
     
  692. Trawinski H, Wendt S, Lippmann N, Heinitz S, von Braun A, Lübbert C (2020). [Typhoid and paratyphoid fever]. Z Gastroenterol, 58(2), 160-170.
     
  693. Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F (2020). ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 5(Suppl 3), 826.
     
  694. Catanese S, Lordick F (2020). Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind? Ann Transl Med, 8(24), 1701.
     
  695. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T (2020). Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep, 2(5), 100169.
     
  696. Westphal C, Gorlich D, Kampmeier S, Herzog S, Braun N, Hitschke C, Mellmann A, Peters G, Kahl BC, Staphylococcal CF Study Group (2020). Antibiotic Treatment and Age Are Associated With Staphylococcus aureus Carriage Profiles During Persistence in the Airways of Cystic Fibrosis Patients. Front Microbiol, 11, 230.
     
  697. Wiesener A, Knaup KX, Buttner-Herold M, Dieterle A, Stoeckert J, Riedl B, Morath C, Wald A, Vondran F, Braun F, Schodel J, Schueler M, Schiffer M, Amann K, Reis A, Kraus C, Wiesener MS (2020). Molecular diagnosis of kidney transplant failure based on urine. Am J Transplant, 00, 1-7.
     
  698. Weise F, Vieth M, Reinhold D, Haybaeck J, Goni E, Lippert H, Ridwelski K, Lingohr P, Schildberg C, Vassos N, Kruschewski M, Krasniuk I, Grimminger PP, Waidmann O, Peitz U, Veits L, Kreuser N, Lang H, Bruns C, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M (2020). Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J, 8(2), 175-184.
     
  699. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Erratum to: Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91(4), 318-.
     
  700. Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A, Hagen V, Gleiber W, Bohnet S, Kruggel L, Dille S, Nusch A, Dorfel S, Decker T, Janicke M (2020). Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer. JAMA Netw Open, 3(3), 1-13.
     
  701. Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, Hofheinz RD, Al-Batran SE, Vogel A, Mueller L, Lutz MP, Lordick F, Alsina M, Borchert K, Greil R, Eisterer W, Schad A, Slotta-Huspenina J, Van Cutsem E, Lorenzen S (2020). Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol, 31(2), 228-235.
     
  702. Wagner AD, Lordick F, Grabsch HI, Terashima M, Terada M, Yoshikawa T, Boku N, Kataoka K, Smyth EC, Mauer M, Haustermans K, Moehler MH (2020). Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. Eur J Cancer, 124, 67-76.
     
  703. Le B, Knoedler M, Roberge G (2020). Intraprostatic injection of tranexamic acid to control refractory bleeding while maintaining therapeutic anticoagulation. Urol Case Rep, 28, 100914-.
     
  704. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2020). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 11(1), 135-144.
     
  705. Richter MJ, Harutyunova S, Bollmann T, Classen S, Fuge J, Gall H, Gerhardt F, Ghofrani HA, Gunkel H, Grünig E, Halank M, Heine A, Klose H, Lange TJ, Neurohr C, Nickolaus K, Opitz CF, Rosenkranz S, Seyfarth HJ, Tello K, Ewert R, Olsson KM (2020). Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension. Pulmonary Circulation, 10(1), 2045894020910136-.
     
  706. Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M (2020). Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J, 56(2), 1902279.
     
  707. Efe C, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Onnerhag K, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, K?y?c? M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Beretta-Piccoli BT, Wahlin S (2020). Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol, (), 1-7.
     
  708. Busche M, Tomilova O, Schütte J, Werner S, Beer M, Groll N, Hagmeyer B, Pawlak M, Jones PD, Schmees C, Becker H, Schnabel J, Gall K, Hemmler R, Matz-Soja M, Damm G, Beuck S, Klaassen T, Moer J, Ullrich A, Runge D, Schenke-Layland K, Gebhardt R, Stelzle M (2020). HepaChip-MP - a twenty-four chamber microplate for a continuously perfused liver coculture model. Lab Chip, 20(16), 2911-2926.
     
  709. Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, Hinz S, Hendricks A, Nati M, Herrmann A, Rekhade DR, Berg T, Matz-Soja M, Huse K, Klipp E, Pauling JK, Wodke JA, Miranda Ackerman J, Bonin MV, Aigner E, Datz C, von Schönfels W, Nehring S, Zeissig S, Röcken C, Dahl A, Chavakis T, Stickel F, Shevchenko A, Schafmayer C, Hampe J, Subramanian P (2020). Loss of hepatic Mboat7 leads to liver fibrosis. Gut, (0), 1-11.
     
  710. Heinemann ML, Elsing L, Kaiser T, Boettcher M, Herber A, Seehofer D, Berg T, Ceglarek U (2020). Challenges of LC-MS/MS ethyl glucuronide analysis in abstinence monitoring of liver transplant candidates. Clin Chem Lab Med, 58(8), 1265-1270.
     
  711. Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen H, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol, (1), 1-20.
     
  712. Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Ida Chen YD, Chowdhury A, Daly AK, Datz C, de Gracia Hahn D, DiStefano JK, Dong J, Duret A, Emdin C, Fairey M, Gerhard GS, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, (2020). rs641738C>T near MBOAT7 is associated with liver fat, ALT, and fibrosis in NAFLD: a meta-analysis. J Hepatol, (1), 1-10.
     
  713. Efe C, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Onnerhag K, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, K?y?c? M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Beretta-Piccoli BT, Wahlin S (2020). Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol, (1), 1-10.
     
  714. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solè C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufo (2020). The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol, (1), 1-10.
     
  715. Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H (2020). Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther, 52(3), 500-512.
     
  716. Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, Irving W, Forrest E, Pedergnan V, Goldberg D, Aspinall E, Barclay S, Hayes P, Dillon J, Nischalke HD, Lutz P, Spengler U, Fischer J, Berg T, Brosch M, Eyer F, Datz C, Mueller S, Peccerella T, Deltenre P, Marot A, Soyka M, McQuillin A, Morgan MY, Hampe J, Stickel F (2020). Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology, (1), 1-10.
     
  717. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P (2020). Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol, (1), 1-10.
     
  718. Rössle M, Bettinger D, Trebicka J, Klinger C, Praktiknjo M, Sturm L, Caca K, Mücke VT, Radecke K, Engelmann C, Zipprich A, Heinzow H, Meyer C, Tappe U, Appenrodt B, Schmidt A, Lange C, Strassburg C, Zeuzem S, Grandt D, Schmidt H, Moessner J, Berg T, Lammert F, Thimme R, Schultheiß M (2020). A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. Aliment Pharmacol Ther, 52(2), 329-339.
     
  719. Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J (2020). Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol, 55(6), 706-711.
     
  720. Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley TWM, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber RE, Canbay A, Link A, Valenti L, Grove JI, Aithal GP, Marquardt JU, Fateen W, Zopf S, Dufour JF, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, M (2020). Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 72(1), 88-102.
     
  721. Dietz J, Kalinina OV, Vermehren J, Peiffer KH, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze Zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C (2020). Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat, (1), 1-10.
     
  722. Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J (2020). Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut, (1), 1-10.
     
  723. van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA (2020). Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat, 27(6), 610-619.
     
  724. Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P (2020). Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol, 72(6), 1088-1096.
     
  725. Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA (2020). Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B. Clin Infect Dis, (1), 1-10.
     
  726. Schmidt J, Buenger L, Krohn S, Kallies R, Zeller K, Schneider H, Ziebolz D, Berg T, Haak R (2020). Effect of a bioactive cement on the microbial community in carious dentin after selective caries removal - An in-vivo study. J Dent, 92(), 103264.
     
  727. Greverath LM, Leicht E, Wald de Chamorro N, Wilde AB, Steinhagen LM, Lieb C, Schmelzle M, Chopra S, Shibolet O, Fischer J, Berg T, Tacke F, Müller T (2020). Evaluation of muscarinic acetylcholine receptor type 3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Res, 50(3), 321-329.
     
  728. Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A (2020). GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol, 18(3), 728-735.
     
  729. Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM (2020). Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol, 30(1), 370-382.
     
  730. Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S (2020). Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int, 40(3), 539-548.
     
  731. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  732. Hofmann WP, Buggisch P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, Felten G, Heyne R, Ingiliz P, Schmidt A, Stein K, Wedemeyer H, Berg T, Wiegand J, Lammert F, Zeuzem S, Schattenberg JM (2020). The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. JHEP Rep, 2(6), 100168.
     
  733. Ricke J, Steffen IG, Bargellini I, Berg T, Bilbao Jaureguizar JI, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Seidensticker M (2020). Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep, 2(6), 100173.
     
  734. Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J (2020). Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). Eur J Gastroenterol Hepatol, 10(1), 1.
     
  735. Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ (2020). Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther, 1, 1.
     
  736. Glebe D, van Bömmel F, Dudareva S, Gärtner B, Monazahian M, Roß S, Rösler J, Slanina H, Spickhoff A, Thanheiser M, Schüttler CG (2020). Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige : Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e.?V. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 63(2), 218-225.
     
  737. Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L (2020). Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol, 1, 1.
     
  738. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  739. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  740. Cokan KB, Urlep ?, Lorbek G, Matz-Soja M, Skubic C, Per?e M, Jeruc J, Juvan P, Re?en T, Rozman D (2020). Chronic Disruption of the Late Cholesterol Synthesis Leads to Female-Prevalent Liver Cancer. Cancers (Basel), 12(11), 1.
     
  741. Herzer K, Sterneck M, Welker MW, Nadalin S, Kirchner G, Braun F, Malessa C, Herber A, Pratschke J, Weiss KH, Jaeckel E, Tacke F (2020). Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany. J Clin Med, 9(11), 1.
     
  742. Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A (2020). Current status of immunotherapy in gastrointestinal malignancies. Z Gastroenterol, 58(6), 542-555.
     
  743. Götze H, Friedrich M, Taubenheim S, Dietz A, Lordick F, Mehnert A (2020). Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Support Care Cancer, 28(1), 211-220.
     
  744. Prade VM, Kunzke T, Feuchtinger A, Rohm M, Luber B, Lordick F, Buck A, Walch A (2020). De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry. Mol Metab, 36(), 100953.
     
  745. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G (2020). Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol, 31(10), 1320-1335.
     
  746. Lorenzen S, Lordick F, Loosen SH, Tacke F, Trautwein C, Roderburg C, Ettrich TJ, Perkhofer L, Reinacher-Schick A, Stein A (2020). Current status of immunotherapy in gastrointestinal malignancies. Z Gastroenterol, 58(6), 542-555.
     
  747. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91(4), 319-328.
     
  748. Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, (2020). PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol, 1, 1.
     
  749. Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S (2020). Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z Gastroenterol, 58(11), 1110-1131.
     
  750. Blank V, Petroff D, Beer S, Böhlig A, Heni M, Berg T, Bausback Y, Dietrich A, Tönjes A, Hollenbach M, Blüher M, Keim V, Wiegand J, Karlas T (2020). Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep, 10(1), 18345.
     
  751. Demcsák A, Soós A, Kincses L, Capunge I, Minkov G, Kovacheva-Slavova M, Nakov R, Wu D, Huang W, Xia Q, Deng L, Hollenbach M, Schneider A, Hirth M, Ioannidis O, Vincze Á, Bajor J, Sarlós P, Czakó L, Illés D, Izbéki F, Gajdán L, Papp M, Hamvas J, Varga M, Kanizsai P, Bóna E, Mikó A, Váncsa S, Juhász MF, Ocskay K, Darvasi E, Miklós E, Er?ss B, Szentesi A, Párniczky A, Casadei R, Ricci C, Ingaldi C, Mastrangelo L, Jovine E, Cennamo V, Marino MV, Barauskas G, Ignatavicius P, Pelaez-Luna M, Rios AS, T (2020). Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis - An international cohort study. Pancreatology, 20(7), 1323-1331.
     
  752. Jaruvongvanich V, Vantanasiri K, Laoveeravat P, Matar RH, Vargas EJ, Maselli DB, Alkhatry M, Fayad L, Kumbhari V, Fittipaldi-Fernandez RJ, Hollenbach M, Watson RR, Gustavo de Quadros L, Galvao Neto M, Aepli P, Staudenmann D, Brunaldi VO, Storm AC, Martin JA, Gomez V, Abu Dayyeh BK (2020). Endoscopic full-thickness suturing plus argon plasma mucosal coagulation versus argon plasma mucosal coagulation alone for weight regain after gastric bypass: a systematic review and meta-analysis. Gastrointest Endosc, 92(6), 1164-1175.
     
  753. de-Madaria E, Sánchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Márta K, Kamal A, Lauret-Braña E, Barbu ST, Nunes V, Ruiz-Rebollo ML, García-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ (2020). Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut, 70(1), 139-147.
     
  754. Seltsam K, Pentner C, Weigl F, Sutedjo S, Zimmer C, Beer S, Bugert P, Ewers M, Ruffert C, Michl P, Laumen H, Witt H, Rosendahl J (2020). Sequencing of the complex CTRB1-CTRB2 locus in chronic pancreatitis. Pancreatology, 20(8), 1598-1603.
     
  755. Damm M, Weniger M, Kölsch AK, Lampert C, Ceyhan GO, Beer S, Schorn S, Moir J, Michl P, Rosendahl J (2020). The quality of pain management in pancreatic cancer: A prospective multi-center study. Pancreatology, 20(7), 1511-1518.
     
  756. Böhme R, Becker C, Keil B, Damm M, Rasch S, Beer S, Schneider R, Kovacs P, Bugert P, Riedel J, Griesmann H, Ruffert C, Kaune T, Michl P, Hesselbarth N, Rosendahl J (2020). Serum levels of advanced glycation end products and their receptors sRAGE and Galectin-3 in chronic pancreatitis. Pancreatology, 20(2), 187-192.
     
  757. Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J (2020). Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. Ultraschall Med, 34, 112-130.
     
  758. Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J (2020). Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. Ultraschall Med, 34, 112-120.
     
  759. Boehlig A, Blank V, Karlas T, Trawinski H, Hau HM, Lederer AA, Berg T (2020). A young woman from an Echinococcus-endemic area with progressive abdominal distension: a case report. J Med Case Rep, 14(1), 65.
     
  760. Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J (2020). Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol, 55(6), 706-711.
     
  761. Päth G, Mehana AE, Pilz IH, Alt M, Baumann J, Sommerer I, Hoffmeister A, Seufert J (2020). NUPR1 preserves insulin secretion of pancreatic ?-cells during inflammatory stress by multiple low-dose streptozotocin and high-fat diet. Am J Physiol Endocrinol Metab, 319(2), 338-344.
     
  762. Weismüller J, Thieme R, Hoffmeister A, Weismüller T, Gockel I (2020). [Barrett-Screening: Rational, current concepts and perspectives]. Laryngorhinootologie, 99(4), 214-223.
     
  763. Moulla Y, Lyros O, Mehdorn M, Lange U, Hamade H, Thieme R, Hoffmeister A, Feisthammel J, Blüher M, Jansen-Winkeln B, Gockel I, Dietrich A (2020). Correction to: Preoperative Upper-GI Endoscopy Prior to Bariatric Surgery: Essential or Optional? Obes Surg, 30(8), 3263.
     
  764. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Erratum to: Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91(4), 318-318.
     
  765. Moulla Y, Lyros O, Mehdorn M, Lange U, Hamade H, Thieme R, Hoffmeister A, Feisthammel J, Blüher M, Jansen-Winkeln B, Gockel I, Dietrich A (2020). Preoperative Upper-GI Endoscopy Prior to Bariatric Surgery: Essential or Optional? Obes Surg, 30(6), 2076-2084.
     
  766. Moulla Y, Reifenrath M, Rehmet K, Niebisch S, Jansen-Winkeln B, Sucher R, Hoffmeister A, Kreuser N, Köhler H, Gockel I (2020). [Hybrid esophagectomy with intraoperative hyperspectral imaging : Video article]. Chirurg, 91, 1-12.
     
  767. Moulla Y, Petersen TO, Maiwald B, Bailis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2020). [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 91, 319-328.
     
  768. Alvanos A, Rademacher S, Hoffmeister A, Seehofer D (2020). [Surgical approach to benign bile duct alterations]. Chirurg, 91(1), 11-17.
     
  769. Schuff-Werner P, Pönisch W, Berg T, Kaiser T (2020). Transient Howell-Jolly-body-like cytoplasmic inclusions in neutrophils after severe intoxication with alpha-lipoic acid. Scand J Clin Lab Invest, (), 1-4.
     
  770. Pfrepper C, Herber A, Weimann A, Siegemund R, Engelmann C, Aehling N, Seehofer D, Berg T, Petros S (2020). Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int, 1, 1-10.
     
  771. Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M (2020). Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS One, 15(12), 1-10.
     
  772. Schmidt J, Krohn S, Kallies R, Schneider H, Zeller K, Ziebolz D, Berg T, Haak R (2020). Antibacterial effect of a brominated self-etch adhesive on carious dentin-An in-vivo study. J Dent, (), 103555.
     
  773. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B (2020). PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). Clin Gastroenterol Hepatol, 1, 1-10.
     
  774. van Bömmel F, Berg T, Denecke T, Seehofer D, Schindler A, Veelken R (2020). Diagnostik und Therapie des hepatozellulären Karzinoms Der Onkologe, 26, 1175-1192.
     
  775. Metelmann IB, Seyfarth HJ, Schierle K, Kraemer S (2020). Utility of immunohistochemical staining for the diagnosis of Extra-adrenal mediastinal paraganglioma. Respir Med Case Rep, 31, 101278.
     
  776. Lange TJ, Borst M, Ewert R, Halank M, Klose H, Leuchte H, Meyer FJ, Seyfarth HJ, Skowasch D, Wilkens H, Held M (2020). [Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]. Pneumologie, 74(12), 847-863.
     
  777. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, IJzerman M, Solomon B (2020). Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 5(6), 109.
     
  778. Jenke R, Holzhäuser-Rein M, Mueller-Wilke S, Lordick F, Aigner A, Büch T (2020). SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. Int J Mol Sci, 22(1), 82.
     
  779. Hoeper MM, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberà JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, ?imková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Ghofrani HA (2020). Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respir Med, 177, 106241.
     
  780. Leuschner G, Klotsche J, Kreuter M, Prasse A, Wirtz H, Pittrow D, Frankenberger M, Behr J, Kneidinger N (2020). Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne), 7, 601279.
     
  781. Leuschner G, Klotsche J, Kreuter M, Prasse A, Wirtz H, Pittrow D, Frankenberger M, Behr J, Kneidinger N (2020). Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne), 7, 601279.
     
  782. Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Benjamin N, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Jureviciene E, Paleviciute E, Miliauskas S, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Wirtz H, Pfeuffer-Jovic E, Harbaum L, Scholtz W, Dumitrescu D, Bruch L, Coghlan G, Neurohr C, Tsangaris I, Gorenflo M, Scelsi L, Vonk-Noordegraaf A, Ulrich (2020). Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant, 39(12), 1435-1444.
     
  783. Trudzinski FC, Jörres RA, Alter P, Kahnert K, Waschki B, Herr C, Kellerer C, Omlor A, Vogelmeier CF, Fähndrich S, Watz H, Welte T, Jany B, Söhler S, Biertz F, Herth F, Kauczor HU, Bals R (2020). Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. Sci Rep, 10(1), 10544.
     
  784. Lutter JI, Jörres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, Schulz H, Vogelmeier CF, Holle R (2020). Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulm Med, 20(1), 148.
     
  785. Reuter-Oppermann M, Müller-Polyzou R, Wirtz H, Georgiadis A (2020). Influence of the pandemic dissemination of COVID-19 on radiotherapy practice: A flash survey in Germany, Austria and Switzerland. PLoS One, 15(5), 0233330.
     
  786. Kaemmerer H, Gorenflo M, Huscher D, Pittrow D, Apitz C, Baumgartner H, Berger F, Bruch L, Brunnemer E, Budts W, Claussen M, Coghlan G, Dähnert I, D'Alto M, Delcroix M, Distler O, Dittrich S, Dumitrescu D, Ewert R, Faehling M, Germund I, Ghofrani HA, Grohé C, Grossekreymborg K, Halank M, Hansmann G, Harzheim D, Nemes A, Havasi K, Held M, Hoeper MM, Hofbeck M, Hohenfrost-Schmidt W, Jurevi?ien? E, Gumbienè L, Kabitz HJ, Klose H, Köhler T, Konstantinides S, Köestenberger M, Kozlik-Feldmann R, Kramer (2020). Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. J Clin Med, 9(5), 1456.
     
  787. Schaudinn A, Hudak A, Linder N, Reinhardt M, Stocker G, Lordick F, Denecke T, Busse H (2020). Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. Obesity (Silver Spring), (), 25.
     
  788. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP (2020). Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol, 38(35), 4138-4148.
     
  789. Roy AC, Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T (2020). Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 20(4), 305-324.
     
  790. Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M (2020). Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology, 9(1), 180-182.
     
  791. Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S (2020). Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer, 135(), 1-7.
     
  792. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817-1828.
     
  793. Schopow N, Kallendrusch S, Gong S, Rapp F, Körfer J, Gericke M, Spindler N, Josten C, Langer S, Bechmann I (2020). Examination of ex-vivo viability of human adipose tissue slice culture. PLoS One, 15(5), 22-27.
     
  794. Voiosu T, Voiosu A, Bo?koski I, Arvanitakis M, Bronswijk M, Hollenbach M, Bengu? A, B?l?nescu P, Orlandini B, Blero D, Van der Merwe S, Mateescu RB, Devière J, Costamagna G (2020). Technical and clinical outcomes of endoscopic retrograde cholangiopancreatography (ERCP) procedures performed in patients with COVID-19. Therap Adv Gastroenterol, 13(), 1756284820980671.
     
  795. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C (2020). Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J Clin Virol, 129(), 104544.
     
  796. Wolf J, Kaiser T, Pehnke S, Nickel O, Lübbert C, Kalbitz S, Arnold B, Ermisch J, Berger L, Schroth S, Isermann B, Borte S, Biemann R (2020). Differences of SARS-CoV-2 serological test performance between hospitalized and outpatient COVID-19 cases. Clin Chim Acta, 511(), 352-359.
     
  797. Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, I Jzerman M, Solomon B (2020). Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 5(6), 1090.
     
  798. Ricke J, Steffen IG, Bargellini I, Berg T, Bilbao Jaureguizar JI, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Seidensticker M (2020). Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep, 2(6), 100173.
     
  799. Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M (2020). Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS One, 15(12), 1-10.
     
  800. Gloeckl R, Nell C, Schneeberger T, Jarosch I, Boensch M, Watz H, Wirtz H, Welte T, Kenn K, Koczulla AR (2020). Benefits of pulmonary rehabilitation in patients with advanced lymphangioleiomyomatosis (LAM) compared with COPD - a retrospective analysis. Orphanet J Rare Dis, 15(1), 255.
     
  801. Wedemeyer H, Sarrazin C, Keitel V, Denecke T, Lammert F, Müllhaupt B, Trebicka J, Fickert P, Wörns MA, Jonas S, Petrowsky H, Berg T (2020). Akute Hepatitiden und akutes Leberversagen In: xxx, Hepato Update 2020 (S. 1-10), Wiesbaden: med publico GmbH.
     
  802. Berg T (2020). Akute Hepatitiden und akutes Leberversagen In: Wedemeyer H, Sarrazin C, Keitel V, Denecke T, Lammert F, Müllhaupt B, Trebicka J, Fickert P, Wörns , Hepato Update 2020 (S. 1-10), Wiesbaden: med publico GmbH.
     
  803. Berg T (2020). Hepatologie I Hot Topic: Komplikationen/Kritische Fälle (CIRS) In: Miehlke S, Layer P, Strobel D, Berg T, Porschen R, Stallmach A, Weinke T, Langhorst J, Trautwein C, , Gastro Update 2020 (S. 1-10), Wiesbaden: med publico GmbH.
     
  804. Engelmann C, Bohlig A, Berg T (2020). Leberzirrhose und deren Komplikationen In: Andrea Tannapfel, Günter Klöppel , Pathologie (S. 345-375), Heidelberg: Springer.
     
  805. van Bömmel F, Berg T (2020). The stopping rules in hepatitis B virus therapy: can we provide any guidance? In: Graham R. Foster, K. Rajender R, Clinical Dilemmas in Viral Liver Disease (S. 175-181), Hoboken, New Jersey, Vereinigte Staaten: John Wiley & Sons Ltd..
     
  806. van Bömmel F, Berg T, Wiegand J, Böhling A (2020). Treatment of Hepatitis B Extrahepatic manifestations of chronic HCV In: Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer, Hepatology. A clinical Textbook (S. 1-10), Hamburg: Medizin Fokus Verlag.
     
  807. Matz-Soja M (2020). Bile Acids as Regulatory Signalling Molecules In: Damjana Rozman. Rolf Gebhardt, Mammalian Sterols : Novel Biological Roles of Cholesterol Synthesis Intermediates, Oxysterols and Bile Acids (S. 101-116), Heidelberg: Springer.
     
  808. Karlas T (2020). Role of Liver Stiffness in HematologicalDisorders: Assessment of Sinusoidal Obstruction Syndrome, Budd?Chiari Syndrome, and Treatment Complications. In: Mueller S, Liver Elastography (S. 169-176), Berlin: Springer Verlag.
     
  809. Karlas T (2020). Liver Stiffness in Patients with Wilson?s Disease. In: Mueller S, Liver Elastrography (S. 217-221), Berlin: Springer Verlag.
     
  810. Karlas T, Mueller S (2020). Liver Steatosis (CAP) as Modifier of Liver Stiffness. In: Mueller S, Liver Elastography (S. 459-467), Berlin: Springer Verlag.
     


    811. 2019


  811. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C (2019). High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother, 74(1), 135-138.
     
  812. Kreuter M, Wirtz H (2019). [Sirolimus for LAM - A New MILEStone Reached?] Pneumologie, 73(1), 22-23.
     
  813. Kreuter M, Wirtz H (2019). [Sirolimus for LAM - A New MILEStone Reached?] Pneumologie, 73(1), 22-23.
     
  814. Lordick F (2019). [Vitamin D and omega-3 fatty acid supplementation does not reduce the cancer and cardiovascular risk]. Strahlenther Onkol, 195, 693-694.
     
  815. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  816. Ben-Aharon I, Goshen-Lago T, Fontana E, Smyth E, Guren M, Caballero C, Lordick F (2019). Social networks for young patients with cancer: the time for system agility. Lancet Oncol, 20(6), 765.
     
  817. Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F (2019). EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 19(1), 494.
     
  818. Lordick F, Obermannova R, Vola D, Douillard JY, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes A (2019). Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 4(3), e000533-.
     
  819. Fries H, Hitzschke M, Lordick F (2019). A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations. Oncol Res Treat, 42(6), 350-353.
     
  820. Kuhn H, Zobel C, Vollert G, Gurcke M, Jenszowski C, Barina C, Frille A, Wirtz H (2019). High amplitude stretching of ATII cells and fibroblasts results in profibrotic effects. Exp Lung Res, 45(7), 167-174.
     
  821. Frille A, Tegelkamp S, Lerche M, Linder N, Rumpf JJ, Hesse S, Wirtz H (2019). Paraneoplastische neurologische Syndrome beim Lungenkarzinom Kompendium Pneumologie, 13, 42-48.
     
  822. Lerche M, Eichstaedt CA, Hinderhofer K, Grunig E, Tausche K, Ziemssen T, Halank M, Wirtz H, Seyfarth HJ (2019). Mutually reinforcing effects of genetic variants and interferon-? 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. Pulm Circ, 9(3), 2045894019872192-.
     
  823. Wiegand J, Buggisch P, Mauss S, Boeker KHW, Klinker H, Muller T, Gunther R, Serfert Y, Manns MP, Zeuzem S, Berg T, Hinrichsen H, C-Registry GH (2019). Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). Eur J Gastroenterol Hepatol, 31(11), 1424-1431.
     
  824. Kramer J, Wolffram I, Fruh U, Batz O, Berg T, Wiegand J (2019). Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. J Viral Hepat, 26(12), 1493-1495.
     
  825. Herta T, Petroff D, Engelmann C, Herber A, Aehling N, Scheuermann U, Bartels M, Seehofer D, Berg T, Wiegand J (2019). Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence. Ann Transplant, 24, 527-531.
     
  826. Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, Henker R, Berg T, Maidhof HP, Trauer H, Wiegand J (2019). Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality. Am J Gastroenterol, 114(8), 1358-1359.
     
  827. Karlas T, Weisse T, Petroff D, Beer S, Dohring C, Gnatzy F, Niederwieser D, Behre G, Mossner J, Fischer J, Troltzsch M, Wiegand J, Keim V, Franke GN (2019). Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. Bone Marrow Transplant, 54(11), 1738-1746.
     
  828. Karlas T, Wiegand J, Petroff D (2019). [Do NAFLD-patients require HCC screening?] Z Gastroenterol, 57(2), 160-161.
     
  829. Kao JH, Berg T (2019). Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut, 68(12), 2105-2106.
     
  830. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schonfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay (2019). Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 68(6), 1099-1107.
     
  831. Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, Konig B, Pangerl A, Niederau C (2019). Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther, 49(8), 1052-1059.
     
  832. Engelmann C, Schob S, Seehofer D, Berg T (2019). Editorial: moving towards a robust definition of sarcopenia in cirrhosis-authors' reply. Aliment Pharmacol Ther, 49(3), 341-342.
     
  833. Koukoulioti E, Fischer J, Schott E, Fulop B, Heyne R, Berg T, van Bommel F (2019). Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians. Liver Int, 39(4), 646-654.
     
  834. Olbrich A, Wardemann H, Bohm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J (2019). Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. J Infect Dis, 220(7), 1209-1218.
     
  835. Olbrich A, Wardemann H, Bohm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J (2019). Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. J Infect Dis, 220(7), 1209-1218.
     
  836. Kramer J, Wolffram I, Fruh U, Batz O, Berg T, Wiegand J (2019). Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. J Viral Hepat, 26(12), 1493-1495.
     
  837. Berg T, Tewarie L, Moza A, Zayat R, Autschbach R, Stoppe C, Goetzenich A, Benstoem C (2019). [Requirements for outpatient care after implantation of a ventricular assist device : Views of patients and their relatives]. Herz, 44(3), 257-264.
     
  838. Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung MC, Schott E, Fulop B, Schlosser B, Berg T, van Bommel F (2019). Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. Eur J Gastroenterol Hepatol, 31(7), 845-852.
     
  839. Schuldt AL, Kirsten H, Tuennemann J, Heindl M, van Bommel F, Feisthammel J, Hollenbach M, Hoffmeister A (2019). Necessity of transnasal gastroscopy in routine diagnostics: a patient-centred requirement analysis. BMJ Open Gastroenterol, 6(1), e000264.
     
  840. Weis S, Heindl M, Carvalho T, Jentho E, Lorenz J, Sommerer I, Mossner J, Hoffmeister A (2019). Azithromycin does not improve disease severity in acute experimental pancreatitis. PLoS One, 14(5), e0216614.
     
  841. Hollenbach M, Selig L, Lellwitz S, Beer S, Feisthammel J, Rosendahl J, Schaumburg T, Mossner J, Hoffmeister A (2019). Endoscopic full-thickness transoral outlet reduction with semicircumferential endoscopic submucosal dissection. Endoscopy, 51(7), 684-688.
     
  842. Hollenbach M, Tunnemann J, Struck MF, Feisthammel J, Schlosser T, Schaumburg T, Mossner J, Hoffmeister A (2019). Endoscopic findings and outcome in caustic ingestion of acidic and alkaline agents in adults: A retrospective analysis. Medicine (Baltimore), 98(35), e16729.
     
  843. Bucher JN, Hollenbach M, Strocka S, Gaebelein G, Moche M, Kaiser T, Bartels M, Hoffmeister A (2019). Segmental intrahepatic cholestasis as a technical complication of the transjugular intrahepatic porto-systemic shunt. World J Gastroenterol, 25(43), 6430-6439.
     
  844. Hollenbach M, Feisthammel J, Mossner J, Schlosser T, Kahn T, Sabri O, Hoffmeister A (2019). Transhepatic intraductal radiofrequency ablation of a biliary papillary mucinous neoplasm. Endoscopy, 51(9), 897-898.
     
  845. Schlosser T, Wiegand S, Dietz A, Hollenbach M, Lubbert C, Mossner J, Hoffmeister A (2019). Successful endoscopic recanalization of complete pharyngoesophageal obstruction after therapy of head and neck cancer. Z Gastroenterol, 57(8), 971-976.
     
  846. Henker R, Oltmanns A, Wald A, Tuennemann J, Opitz S, Hoffmeister A, Wirtz H, Mossner J, Jansen-Winkeln B, Karlas T (2019). Severe ileocecal inflammatory syndrome in adult patients with cystic fibrosis. Z Gastroenterol, 57(3), 312-316.
     
  847. Blank V, Wiegand J, Keim V, Karlas T (2019). Evaluation of a novel tomographic ultrasound device for abdominal examinations. PLoS One, 14(6), e0218754-.
     
  848. Blank V, Karlas T (2019). [Screening for patients at risk: value of transient elastography in NAFLD]. Z Gastroenterol, 57(9), 1122-1123.
     
  849. Karlas T, Reinhardt F, Blank V, Lippmann N, Seehofer D, Lubbert C (2019). Frequency and clinical presentation of alveolar and cystic echinococcosis in a tertiary medical center in Germany 2004-2018: lessons from a low-prevalence area. Z Gastroenterol, 57(11), 1281-1290.
     
  850. Schimmel T, Trawinski H, Karlas T, Wendt S, Lubbert C (2019). [Polymicrobial liver abscesses and pleural empyema in a 40-year-old male after tooth extraction and closed periodontal treatment: A case report]. Z Gastroenterol, 57(5), 600-605.
     
  851. Karlas T, Blank V, Pelz JO (2019). A Standardized Metrical 3D Ultrasound Approach for Limb Examination. Ultraschall Med, 40(4), 513-514.
     
  852. Wendt S, Trawinski H, Schubert S, Rodloff AC, Mossner J, Lubbert C (2019). The Diagnosis and Treatment of Pinworm Infection. Dtsch Arztebl Int, 116(13), 213-219.
     
  853. von Braun A, Trawinski H, Wendt S, Lubbert C (2019). Schistosoma and Other Relevant Helminth Infections in HIV-Positive Individuals-an Overview. Trop Med Infect Dis, 4(2), 65-78.
     
  854. Wendt S, Trawinski H, Lubbert C (2019). Furuncular Myiasis Caused by Mango Fly Larvae. Dtsch Arztebl Int, 116(42), 719.
     
  855. Krasselt M, Exner M, Lubbert C (2019). Ogilvie Syndrome in Disseminated Tuberculosis. Dtsch Arztebl Int, 116(9), 145.
     
  856. Krasselt M, Lubbert C, Trawinski H (2019). [31-Year-Old Woman with Fever, Arthralgia and Lymph Node Swelling]. Dtsch Med Wochenschr, 144(14), 941-942.
     
  857. Baumann A, Musaazi J, Kambugu A, Kalin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A (2019). Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. J Acquir Immune Defic Syndr, 80(4), 481-487.
     
  858. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C (2019). High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother, 74(1), 135-138.
     
  859. Engelmann C, Thomsen KL, Mookerjee RP (2019). Response to Intensive Care Is the Key to Prognosticate Patients With Severe Acute-on-Chronic Liver Failure. Crit Care Med, 47(4), e384-e385.
     
  860. Trawinski H, Karlas T, Seehofer D, Lubbert C, Halbritter J (2019). The Case | Atypical cysts in a patient with autosomal dominant polycystic kidney disease. Kidney Int, 96(4), 1043-1044.
     
  861. Wendt S, Trawinski H, Lubbert C (2019). Furuncular Myiasis Caused by Mango Fly Larvae. Dtsch Arztebl Int, 116(42), 719.
     
  862. Newsome PN, Berg T (2019). 2020 - A new decade of innovation for EASL. J Hepatol, 72(1), 8.
     
  863. Braunlich J, Dellweg D, Bastian A, Budweiser S, Randerath W, Triche D, Bachmann M, Kahler C, Bayarassou AH, Mader I, Geiseler J, Kohler N, Petroff D, Wirtz H (2019). Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD. Int J Chron Obstruct Pulmon Dis, 14, 1411-1421.
     
  864. Lerche M, Bailis N, Akritidou M, Meyer HJ, Surov A (2019). Pulmonary Vessel Obstruction Does Not Correlate with Severity of Pulmonary Embolism. J Clin Med, 8, 584.
     
  865. Lübbert C (2019). Fecal microbiota transplantation (FMT) ? an overview Adipositas, 13(04), 223-229.
     
  866. Lübbert C (2019). Gastrointestinale Infektionen: Steigende Hospitalisierungs- und Mortalitätsraten Dtsch Arztebl SUPPLEMENT: Perspektiven der Infektiologie, 116), 24-29.
     
  867. Lübbert C (2019). Antibiotika und der Gastrointestinaltrakt ? Update 2019 Gastroenterologie up2date, 15(1), 79-104.
     
  868. Schimmel T, Schwandt G, Trawinski H, Karlas T, Wendt S, Lübbert C (2019). Polymikrobielle Leberabszesse und Pleuraempyem bei einem 40-jährigen Mann nach Zahnextraktion und geschlossener Parodontitis-Behandlung: Ein Fallbericht Dtsch Zahnärztl Z, 74(5), 309-315.
     
  869. Trawinski H, Lübbert C (2019). Wichtige intestinale Parasitosen: Askariose (Spulwurm-Befall) Z Gastroenterol, 57(5), 568-569.
     
  870. von Braun A, Liebert UG, Lübbert C (2019). Wichtige Zoonosen: Frühsommer-Meningoenzephalitis (FSME) Z Gastroenterol, 57(7), 830-831.
     
  871. Wendt S, Thrum S, Lübbert C (2019). Wichtige Zoonosen: Leptospirose Z Gastroenterol, 57(10), 1177-1180.
     
  872. Wendt S, Trawinski H, von Braun A, Lübbert C (2019). Durch Zecken übertragbare Erkrankungen CME - Premiumfortbildung für die Medizinische Praxis, 16(5), 53-70.
     
  873. Wendt S, Lübbert C (2019). Wichtige strikt humanpathogene intestinale Parasitosen: Enterobiose Z Gastroenterol, 57(4), 470-471.
     
  874. Golombek T, Henker R, Rehak M, Quaschling U, Lordick F, Knodler M (2019). A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Oncol Res Treat, 42, 123-127.
     
  875. Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, Yahiaoui-Doktor M, Forstmeyer D, Lordick F, Knodler M (2019). The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. J Geriatr Oncol, 10, 937-943.
     
  876. Lordick F, Platzbecker U, Büch E, Köhl U (2019). Molekulare und zellbasierte Krebstherapie ? Quo vadis? Onkologe, 25, 61-67.
     
  877. Lordick F (2019). Adenokarzinome des ösophagogastralen Übergangs Onkologe, 25, 1046-1049.
     
  878. Lordick F, Gockel I (2019). Multimodale Therapie bei Adenokarzinomen des ösophagogastralen Übergangs. Onkologe, 25, 1086-1094.
     
  879. Smyth EC, Lordick F (2019). Nivolumab for previously treated squamous oesophageal carcinoma. Lancet Oncol, 20, 1468-1469.
     
  880. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F (2019). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcopenia Muscle, 0000, 0000.
     
  881. Wirtz H, Petroff D, Braunlich J (2019). Response to the letter to the editor "Nasal high-flow versus non-invasive ventilation in patients with chronic hypercapnic COPD" [Response to letter]. Int J Chron Obstruct Pulmon Dis, 14, 2119-2120.
     
  882. Kreuter M, Wirtz H (2019). Klinische Pneumologie Pneumologie, 73(05), 268-268.
     
  883. Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T (2019). Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res, 2019, 1-19.
     
  884. Schmidt J, Buenger L, Krohn S, Kallies R, Zeller K, Schneider H, Ziebolz D, Berg T, Haak R (2019). Effect of a bioactive cement on the microbial community in carious dentin after selective caries removal - An in-vivo study. J Dent, 2019, 1-7.
     
  885. Kaune T, Hollenbach M, Keil B, Chen JM, Masson E, Becker C, Damm M, Ruffert C, Grutzmann R, Hoffmeister A, Te Morsche RHM, Cavestro GM, Zuppardo RA, Saftoiu A, Malecka-Panas E, Gluszek S, Bugert P, Lerch MM, Weiss FU, Zou WB, Liao Z, Hegyi P, Drenth JP, Riedel J, Ferec C, Scholz M, Kirsten H, Toth A, Ewers M, Witt H, Griesmann H, Michl P, Rosendahl J (2019). Common variants in glyoxalase I do not increase chronic pancreatitis risk. PLoS One, 14(10), 1-14.
     
  886. Michel M, Hollenbach M, Pohl S, Ripoll C, Zipprich A (2019). Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. Front Oncol, 9, 1-14.
     
  887. Sternby H, Mahle M, Linder N, Erichson-Kirst L, Verdonk RC, Dimova A, Ignatavicius P, Ilzarbe L, Koiva P, Penttila A, Regner S, Bollen TL, Brill R, Stangl F, Wohlgemuth WA, Singh V, Busse H, Michl P, Beer S, Rosendahl J (2019). Mean muscle attenuation correlates with severe acute pancreatitis unlike visceral adipose tissue and subcutaneous adipose tissue. United European Gastroenterol J, 7(10), 1312-1320.
     
  888. Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, Henker R, Berg T, Maidhof HP, Trauer H, Wiegand J (2019). Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality. Am J Gastroenterol, 114(8), 1358-1359.
     
  889. Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F (2019). Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat, 000, 1-6.
     
  890. Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung MC, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F (2019). Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. Eur J Gastroenterol Hepatol, 31(7), 845-852.
     
  891. Wendt S, Trawinski H, von Braun A, Lübbert C (2019). Durch Zecken übertragbare Erkrankungen: Von der Lyme-Borreliose über das Q-Fieber bis zur FSME. CME (Berl), 16(5), 53-71.
     
  892. Wendt S, Trawinski H, Schubert S, Rodloff AC, Mössner J, Lübbert C (2019). The Diagnosis and Treatment of Pinworm Infection. Dtsch Arztebl Int, 116(13), 213-219.
     
  893. von Braun A, Trawinski H, Wendt S, Lübbert C (2019). Schistosoma and Other Relevant Helminth Infections in HIV-Positive Individuals-an Overview. Trop Med Infect Dis, 4(2), 65.
     
  894. Wendt S, Rodloff AC, Lübbert C (2019). In Reply. Dtsch Arztebl Int, 116(33-34), 561-562.
     
  895. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2019). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 10, 55-59.
     
  896. Kralisch S, Hoffmann A, Kloting N, Frille A, Kuhn H, Nowicki M, Paeschke S, Bachmann A, Bluher M, Zhang MZ, Harris RC, Stumvoll M, Fasshauer M, Ebert T (2019). The brown fat-secreted adipokine neuregulin 4 is decreased in human and murine chronic kidney disease. Eur J Endocrinol, 181, 151-159.
     
  897. Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Mohler M, Monig S, Obermannova R, Piessen G, Riddell A, Rocken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F (2019). The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer, 112, 1-8.
     
  898. Kuba K, Esser P, Mehnert A, Hinz A, Johansen C, Lordick F, Gotze H (2019). Risk for depression and anxiety in long-term survivors of hematologic cancer. Health Psychol, 38(3), 187-195.
     
  899. Zeynalova N, Schimpf S, Setter C, Yahiaoui-Doktor M, Zeynalova S, Lordick F, Loeffler M, Hinz A (2019). The association between an anxiety disorder and cancer in medical history. J Affect Disord, 246, 640-642.
     
  900. van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM (2019). SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers (Basel), 11(2), 187.
     
  901. Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, Frontini R, Gockel I (2019). [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. Chirurg, 90(2), 137-145.
     
  902. De Mello RA, Lordick F, Muro K, Janjigian YY (2019). Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book, 39, 237-247.
     
  903. Selby P, Popescu R, Lawler M, Butcher H, Costa A (2019). The Value and Future Developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book, 39, 332-340.
     
  904. Golombek T, Henker R, Rehak M, Quaschling U, Lordick F, Knodler M (2019). A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Oncol Res Treat, 42(3), 123-127.
     
  905. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2019). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 10(1), 55-59.
     
  906. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 30(1), 19-33.
     
  907. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 30(1), 34-43.
     
  908. De Mello RA, Lordick F, Muro K, Janjigian YY (2019). Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. Am Soc Clin Oncol Educ Book, 39, 237-247.
     
  909. Shah PH, Leibovich BC, Van Houten H, Lyon TD, Yao X, Knoedler M, Sangaralingham L, Kattah A, Thompson RH, Shah ND, Boorjian SA (2019). Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. J Urol, 202(1), 69-75.
     
  910. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  911. Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Mohler M, Vogel A (2019). Immunotherapy: New Options in Gastrointestinal Cancers? Visc Med, 35(1), 47-51.
     
  912. Hardavella G, Karampinis I, Frille A, Sreter K, Rousalova I (2019). Oxygen devices and delivery systems. Breathe (Sheff), 15(3), 108-116.
     
  913. Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Prols M, Manns MP, Fickert P, Trauner M (2019). Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol, 4(10), 781-793.
     
  914. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS (2019). Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol, 71(2), 397-408.
     
  915. Baumert TF, Berg T, Lim JK, Nelson DR (2019). Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology, 156(2), 431-445.
     
  916. Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM (2019). Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol, 30(1), 370-382.
     
  917. Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, Huo X, Aller R, Garcia-Monzon C, Teresa Arias-Loste M, Bugianesi E, Miele L, Gallego-Duran R, Fischer J, Berg T, Liddle C, Qiao L, George J, Eslam M (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. J Hepatol, 70(3), 494-500.
     
  918. Jalan R, Bataller R, Berg T, Lotersztajn S, Moreau R, Zucman-Rossi J, Walicki J (2019). Journal of Hepatology: The Home of Liver Research, 2015-2019. J Hepatol, 71(6), 1065-1069.
     
  919. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's Desk?: December 2019. J Hepatol, 71(6), 1061-1064.
     
  920. Huppe D, Serfert Y, Buggisch P, Mauss S, Boker KHW, Muller T, Klinker H, Gunther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H (2019). [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. Z Gastroenterol, 57(1), 27-36.
     
  921. Efe C, Tascilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli BT, Fischer J, Caliskan AR, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Onnerhag K, Gunsar F, Nilsson E, Heurgue-Berlot A, Guzelbulut F, Demir N, Gonen C, Semela D, Aladag M, Kiyici M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Wahlin S (2019). Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. Am J Gastroenterol, 114(7), 1101-1108.
     
  922. Wiltberger G, Wu Y, Lange U, Hau HM, Tapper E, Krenzien F, Atanasov G, Benzing C, Feldbrugge L, Csizmadia E, Broschewitz J, Bartels M, Seehofer D, Jonas S, Berg T, Hessel P, Ascherl R, Neumann UP, Pratschke J, Robson SC, Schmelzle M (2019). Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Aliment Pharmacol Ther, 49(6), 779-788.
     
  923. Muche M, Berg T, Rimpler S, Staedtler A, Bohm S, Nickel P, Baid-Agrawal S (2019). Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. Liver Int, 39(2), 263-270.
     
  924. Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Duran R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-?1 dependent mechanisms. Sci Rep, 9(1), 1439-1449.
     
  925. Wirtz TH, Fischer P, Backhaus C, Bergmann I, Brandt EF, Heinrichs D, Koenen MT, Schneider KM, Eggermann T, Kurth I, Stoppe C, Bernhagen J, Bruns T, Fischer J, Berg T, Trautwein C, Berres ML (2019). Genetic Variants in the Promoter Region of the Macrophage Migration Inhibitory Factor are Associated with the Severity of Hepatitis C Virus-Induced Liver Fibrosis. Int J Mol Sci, 20(15), 3753-3768.
     
  926. Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Mole A, Attali P, Le Boulicaut J, Vasseur B (2019). Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol, 4(6), 454-465.
     
  927. Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Gunther R, Hinrichsen H, Huppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M (2019). Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat, 26(2), 224-230.
     
  928. Schneider C, Remmler J, Netto J, Seehofer D, Engelmann C, Berg T, Thiery J, Kaiser T (2019). Copeptin - a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease. Clin Chem Lab Med, 57(12), 1897-1905.
     
  929. Nischalke HD, Lutz P, Bartok E, Kramer B, Langhans B, Frizler R, Berg T, Hampe J, Buch S, Datz C, Stickel F, Hartmann G, Strassburg CP, Nattermann J, Spengler U (2019). The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. J Mol Med (Berl), 97(11), 1589-1600.
     
  930. Schmidt J, Krohn S, Buenger L, Zeller K, Schneider H, Treuheit M, Kaiser T, Ziebolz D, Berg T, Haak R (2019). Molecular characterization of intact cell-derived and cell-free bacterial DNA from carious dentine samples. J Microbiol Methods, 158, 33-43.
     
  931. Fotopoulou C, Berg T, Hausen A, Hennig R, Jalan R, Malago M, Capel J, De Gottardi A, Stirnimann G (2019). Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites. BMC Palliat Care, 18(1), 109-118.
     
  932. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 394(10215), 2184-2196.
     
  933. Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Huppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J (2019). Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. J Clin Med, 8(12), 2101-2112.
     
  934. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F (2019). A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol, 4(7), 545-558.
     
  935. Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bommel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertoletti A, Lampertico P (2019). Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48?weeks in HDV-related compensated cirrhosis: A case report of 3 patients. J Hepatol, 71(4), 834-839.
     
  936. Eichler W, Lohrenz A, Simon KU, Krohn S, Lange J, Burger S, Liebscher I (2019). The role of ADGRE5/CD97 in human retinal pigment epithelial cell growth and survival. Ann N Y Acad Sci, 1456(1), 64-79.
     
  937. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH (2019). Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med, 380(8), 720-728.
     
  938. Weismuller J, Thieme R, Hoffmeister A, Weismuller T, Gockel I (2019). [Barrett-Screening: Rational, current concepts and perspectives]. Z Gastroenterol, 57(3), 317-326.
     
  939. Gotzel K, Chemnitzer O, Maurer L, Dietrich A, Eichfeld U, Lyros O, Moulla Y, Niebisch S, Mehdorn M, Jansen-Winkeln B, Vieth M, Hoffmeister A, Gockel I, Thieme R (2019). In-depth characterization of the Wnt-signaling/?-catenin pathway in an in vitro model of Barrett's sequence. BMC Gastroenterol, 19(1), 38-50.
     
  940. Kaune T, Hollenbach M, Keil B, Chen JM, Masson E, Becker C, Damm M, Ruffert C, Grutzmann R, Hoffmeister A, Te Morsche RHM, Cavestro GM, Zuppardo RA, Saftoiu A, Malecka-Panas E, Gluszek S, Bugert P, Lerch MM, Weiss FU, Zou WB, Liao Z, Hegyi P, Drenth JP, Riedel J, Ferec C, Scholz M, Kirsten H, Toth A, Ewers M, Witt H, Griesmann H, Michl P, Rosendahl J (2019). Common variants in glyoxalase I do not increase chronic pancreatitis risk. PLoS One, 14(10), 1-14.
     
  941. Phillip V, Pukitis A, Epstein A, Hapfelmeier A, Haf D, Schwab M, Demir IE, Rosendahl J, Hoffmeister A, Schmid RM, Weber A, Algul H (2019). Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial. Endosc Int Open, 7(7), 860-868.
     
  942. Herberg M, Siebert S, Quaas M, Thalheim T, Rother K, Hussong M, Altmuller J, Kerner C, Galle J, Schweiger MR, Aust G (2019). Loss of Msh2 and a single-radiation hit induce common, genome-wide, and persistent epigenetic changes in the intestine. Clin Epigenetics, 11(1), 65-77.
     
  943. Kuhnle A, Veelken R, Galuska CE, Saftenberger M, Verleih M, Schuppe HC, Rudloff S, Kunz C, Galuska SP (2019). Polysialic acid interacts with lactoferrin and supports its activity to inhibit the release of neutrophil extracellular traps. Carbohydr Polym, 208, 32-41.
     
  944. Sucher R, Hautz T, Mohr E, Mackowitz M, Mellitzer V, Steger C, Cardini B, Resch T, Margreiter C, Schneeberger S, Brandacher G, Fuchs D, Oberhuber R, Gostner JM (2019). Sodium Sulfite Exacerbates Allograft Vasculopathy and Affects Tryptophan Breakdown in Murine Heterotopic Aortic Transplantation. Oxid Med Cell Longev, 8461048, 1-11.
     
  945. Lam S, Nettel-Aguirre A, Van Biervliet S, Roeb E, Sadler MD, Friedrich-Rust M, Karlas T, Kitson MT, deBruyn JCC (2019). Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol, 2(2), 71-80.
     
  946. Trawinski H, Karlas T, Seehofer D, Lubbert C, Halbritter J (2019). The Case | Atypical cysts in a patient with autosomal dominant polycystic kidney disease. Kidney Int, 96(4), 1043-1044.
     
  947. Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gulberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A (2019). [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Z Gastroenterol, 57(5), 611-680.
     
  948. Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gulberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A (2019). [Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)]. Z Gastroenterol, 57(5), 611-680.
     
  949. Wolf B, Krasselt M, de Fallois J, von Braun A, Stepan H (2019). Tuberculosis in Pregnancy - a Summary. Geburtshilfe Frauenheilkd, 79(4), 358-365.
     
  950. Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M (2019). The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clin Pharmacol Ther, 106(2), 450-457.
     
  951. Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, Wanke K, Karrer U, Stiasny K, Heinz FX (2019). Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. NPJ Vaccines, 4, 38-49.
     
  952. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P (2019). Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? Antimicrob Agents Chemother, 63(6), 1-11.
     
  953. Bachmann N, von Braun A, Labhardt ND, Kadelka C, Gunthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Boni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J (2019). Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. J Antimicrob Chemother, 74(2), 468-472.
     
  954. Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B (2019). Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. AIDS Res Ther, 16(1), 39-44.
     
  955. Robinson SM, Rasch S, Beer S, Valantiene I, Mickevicius A, Schlaipfer E, Mann J, Maisonneuve P, Charnley RM, Rosendahl J (2019). Systemic inflammation contributes to impairment of quality of life in chronic pancreatitis. Sci Rep, 9(1), 7318-7326.
     
  956. Cwik S, Beer SMJ, Schmidt M, Gerhardt NC, de Los Arcos T, Rogalla D, Wessing J, Giner I, Hofmann M, Grundmeier G, Wieck AD, Devi A (2019). Luminescent Nd2S3 thin films: a new chemical vapour deposition route towards rare-earth sulphides. Dalton Trans, 48(9), 2926-2938.
     
  957. Sternby H, Mahle M, Linder N, Erichson-Kirst L, Verdonk RC, Dimova A, Ignatavicius P, Ilzarbe L, Koiva P, Penttila A, Regner S, Bollen TL, Brill R, Stangl F, Wohlgemuth WA, Singh V, Busse H, Michl P, Beer S, Rosendahl J (2019). Mean muscle attenuation correlates with severe acute pancreatitis unlike visceral adipose tissue and subcutaneous adipose tissue. United European Gastroenterol J, 7(10), 1312-1320.
     
  958. Eichler M, Hechtner M, Wehler B, Buhl R, Stratmann J, Sebastian M, Schmidberger H, Kortsik C, Nestle U, Wirtz H, Wehler T, Blettner M, Singer S (2019). Use of psychosocial services by lung cancer survivors in Germany : Results of a German multicenter study (LARIS). Strahlenther Onkol, 195(11), 1018-1027.
     
  959. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Glaser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J (2019). The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res, 20(1), 59.
     
  960. Henker R, Oltmanns A, Wald A, Tuennemann J, Opitz S, Hoffmeister A, Wirtz H, Mossner J, Jansen-Winkeln B, Karlas T (2019). Severe ileocecal inflammatory syndrome in adult patients with cystic fibrosis. Z Gastroenterol, 57(3), 312-316.
     
  961. Roick J, Danker H, Kersting A, Dietrich A, Dietz A, Papsdorf K, Meixensberger J, Stolzenburg JU, Wirtz H, Singer S (2019). The association of socioeconomic status with quality of life in cancer patients over a 6-month period using individual growth models. Support Care Cancer, 27(9), 3347-3355.
     
  962. Gottlieb J, Neurohr C, Muller-Quernheim J, Wirtz H, Sill B, Wilkens H, Bessa V, Knosalla C, Porstner M, Capusan C, Struber M (2019). A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation. Am J Transplant, 19(6), 1759-1769.
     
  963. Hechtner M, Eichler M, Wehler B, Buhl R, Sebastian M, Stratmann J, Schmidberger H, Gohrbandt B, Peuser J, Kortsik C, Nestle U, Wiesemann S, Wirtz H, Wehler T, Bals R, Blettner M, Singer S (2019). Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. J Thorac Oncol, 14(3), 420-435.
     
  964. Mischnik A, Lübbert C, Mutters NT (2019). Neue ??Laktam-Antibiotika und ??Laktamase-Inhibitoren gegen multiresistente Gram-negative Erreger Wien klin Mag, 22, 220-229.
     
  965. Gockel I, Lordick F, Lyros O, Kreuser N, Holscher AH, Wittekind C (2019). [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. Chirurg, 10, 4731-4742.
     
  966. Hinz A, Herzberg PY, Lordick F, Weis J, Faller H, Brahler E, Harter M, Wegscheider K, Geue K, Mehnert A (2019). Age and gender differences in anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care (Engl), 28, 13129.
     
  967. Kuon J, Vogt J, Mehnert A, Alt-Epping B, van Oorschot B, Sistermanns J, Ahlborn M, Ritterbusch U, Stevens S, Kahl C, Ruellan A, Matthias K, Kubin T, Stahlhut K, Heider A, Lordick F, Thomas M (2019). Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment. Oncol Res Treat, 42, 650-659.
     
  968. Tureci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol, 30, 1487-1495.
     
  969. Gotze H, Taubenheim S, Dietz A, Lordick F, Mehnert-Theuerkauf A (2019). Fear of cancer recurrence across the survivorship trajectory: Results from a survey of adult long-term cancer survivors. Psychooncology, 28, 2033-2041.
     
  970. Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Hocht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Monig S, Ott K, Quante M, Rocken C, Schlattmann P, Schmiegel WH, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S (2019). S3-Leitlinie Magenkarzinom ? Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs Z Gastroenterol, 57, 1517-1632.
     
  971. Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K, Wittekind C, Thieme R (2019). Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori, 0000, 0000.
     
  972. Lehmann-Laue A, Ernst J, Mehnert A, Taubenheim S, Lordick F, Gotze H (2019). [Supportive Care and Information Needs of Cancer Survivors: A Comparison of Two Cohorts of Longterm Cancers Survivors 5 and 10 Years after Primary Cancer Diagnosis]. Psychother Psychosom Med Psychol, 0000, 0000.
     
  973. Moulla Y, Petersen TO, Maiwald B, Balis N, Kreuser N, Lordick F, Seehofer D, Sucher R, Hecker M, Hoffmeister A, Jansen-Winkeln B, Gockel I (2019). [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. Chirurg, 0000, 0000.
     
  974. Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F (2019). Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat, 0000, 1-6.
     
  975. Gockel I, Lordick F, Lyros O, Kreuser N, Holscher AH, Wittekind C (2019). [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. Chirurg, 0000, 0000.
     
  976. Meier C, Taubenheim S, Lordick F, Mehnert-Theuerkauf A, Gotze H (2019). Depression and anxiety in older patients with hematological cancer (70+) - Geriatric, social, cancer- and treatment-related associations. J Geriatr Oncol, 0000, 0000.
     
  977. Zhang L, Rossi A, Lange L, Meumann N, Koitzsch U, Christie K, Nesbit MA, Moore CBT, Hacker UT, Morgan M, Hoffmann D, Zengel J, Carette JE, Schambach A, Salvetti A, Odenthal M, Buning H (2019). Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells. Hum Gene Ther, 30, 1284-1296.
     
  978. Klapdor R, Wang S, Morgan M, Dork T, Hacker U, Hillemanns P, Buning H, Schambach A (2019). Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. Int J Mol Sci, 20, 0000.
     
  979. Tannapfel A, Reinacher-Schick A, Hacker U, Lorenzen S, Mohler M, Vogel A (2019). Immunotherapy: New Options in Gastrointestinal Cancers? Visc Med, 35, 47-51.
     
  980. von Siemens SM, Perneczky R, Vogelmeier CF, Behr J, Kauffmann-Guerrero D, Alter P, Trudzinski FC, Bals R, Grohe C, Sohler S, Waschki B, Lutter JI, Welte T, Jorres RA, Kahnert K and the COSYCONET study group (2019). The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respir Res, 20(1), 257-.
     
  981. Ahnert P, Creutz P, Horn K, Schwarzenberger F, Kiehntopf M, Hossain H, Bauer M, Brunkhorst FM, Reinhart K, Volker U, Chakraborty T, Witzenrath M, Loffler M, Suttorp N, Scholz M and The PROGRESS Study Group (2019). Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia - results from the prospective observational PROGRESS study. Crit Care, 23(1), 110-.
     
  982. Kralisch S, Hoffmann A, Kloting N, Frille A, Kuhn H, Nowicki M, Paeschke S, Bachmann A, Bluher M, Zhang MZ, Harris RC, Stumvoll M, Fasshauer M, Ebert T (2019). The brown fat-secreted adipokine neuregulin 4 is decreased in human and murine chronic kidney disease. Eur J Endocrinol, 181(2), 151-159.
     
  983. Jentzsch M, Schwind S, Vucinic V, Wendt S, Stingu CS, Niederwieser D, Weidhase L (2019). [Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]. Med Klin Intensivmed Notfmed, 8, 1-3.
     
  984. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor?s Desk?: November 2019 J Hepatol, 71(5), 853-855.
     
  985. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor?s Desk?: October 2019 J Hepatol, 71(4), 641-644.
     
  986. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's Desk: September 2019 J Hepatol, 71(3), 449-452.
     
  987. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: August 2019 J Hepatol, 71(2), 231-234.
     
  988. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: July 2019 J Hepatol, 71(1), 1-4.
     
  989. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: June 2019 J Hepatol, 70(6), 1039-1042.
     
  990. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: May 2019 J Hepatol, 70(5), 819-821.
     
  991. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: April 2019 J Hepatol, 70(4), 583-586.
     
  992. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk...: March 2019 J Hepatol, 70(3), 335-338.
     
  993. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2019). From the Editor's desk: January 2019 J Hepatol, 70(1), 1-4.
     
  994. Marietta von Siemens S, Alter P, Lutter JI, Kauczor HU, Jobst B, Bals R, Trudzinski FC, Sohler S, Behr J, Watz H, Waschki B, Bewig B, Jones PW, Welte T, Vogelmeier CF, Jorres RA, Kahnert K (2019). CAT score single item analysis in patients with COPD: Results from COSYCONET. Respir Med, 159, 105810.
     
  995. Ahnert P, Creutz P, Horn K, Schwarzenberger F, Kiehntopf M, Hossain H, Bauer M, Brunkhorst FM, Reinhart K, Volker U, Chakraborty T, Witzenrath M, Loffler M, Suttorp N, Scholz M (2019). Sequential organ failure assessment score is an excellent operationalization of disease severity of adult patients with hospitalized community acquired pneumonia - results from the prospective observational PROGRESS study. Crit Care, 23(1), 110.
     
  996. Prill S, Rebstock J, Tennemann A, Korfer J, Sonnichsen R, Thieme R, Gockel I, Lyros O, Monecke A, Wittekind C, Weimann A, Grosser K, Wiechmann V, Kubick C, Bechmann I, Lordick F, Kallendrusch S (2019). Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer. Oncotarget, 10(46), 4731-4742.
     
  997. Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F (2019). High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. Eur J Cancer, 116, 107-113.
     
  998. Klinghammer K, Gauler T, Dietz A, Grunwald V, Stohlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Grosse-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U (2019). Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). Eur J Cancer, 122, 53-60.
     
  999. Ranacher C, Consani C, Tortschanoff A, Rauter L, Holzmann D, Fleury C, Stocker G, Fant A, Schaunig H, Irsigler P, Grille T, Jakoby B (2019). A CMOS Compatible Pyroelectric Mid-Infrared Detector Based on Aluminium Nitride. Sensors (Basel), 19(11), 1-10.
     
  1000. Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, Yahiaoui-Doktor M, Forstmeyer D, Lordick F, Knodler M (2019). The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. J Geriatr Oncol, 10(6), 937-943.
     
  1001. Richter D, Mehnert A, Forstmeyer D, Ernst J, Geue K (2019). Health Literacy in Adolescent and Young Adult Cancer Patients and Its Association with Health Outcomes. J Adolesc Young Adult Oncol, 8(4), 451-457.
     
  1002. Lübbert, C, Weinke T (2019). Reisediarrhö In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 499-503), Stuttgart: Thiene.
     
  1003. Lübbert C (2019). Zestoden-Infektionen In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 484-489), Stuttgart: Thieme.
     
  1004. Richter J, Lindner A, Lübbert C, Equihua-Martinez G (2019). Lambliasis In: Riemann JF, Fischbach W, Galle PR, Mössner J, Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 477-481), Stuttgart: Thieme.
     
  1005. Lübbert C (2019). Stuhlkultur In: Riemann JF, Fischbach W, Galle PR, Mössner J, Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 138-139), Stuttgart: Thieme.
     
  1006. Reinhardt F, Lübbert C (2019). Parasitosen des Gastrointestinaltrakts In: Lehnert H et al., SpringerReference Innere Medizin. Online-Lehrbuch (S. 1-16), Heidelberg: Springer.
     
  1007. Trawinski H (2019). Askariasis In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 489-493), Stuttgart: Thieme.
     
  1008. Trawinski H (2019). Trichuriasis In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie in Klinik und Praxis: Das komplette Referenzwerk für Klinik und Praxis (S. 493-495), Stuttgart: Thieme.
     
  1009. Pech O, Lordick F (2019). Ösophaguskarzinom In: Riemann JF, Fischbach W, Galle PR, Mössner J , Referenz Gastroenterologie (S. 295-301), Stuttgart: Georg Thieme Verlag.
     
  1010. Lordick F (2019). Chemotherapie In: Riemann JF, Fischbach W, Galle PR, Mössner J, Referenz Gastroenterologie (S. 1000-1006), Stuttgart: Georg Thieme Verlag .
     
  1011. Berg T (2019). Kapitel 7: Hepatologie In: Fischbach W, Layer P, Berg T, May A, Handbuch Gastroenterologie - GastroUpdate 2019 (S. 1-49), Wiesbaden: med publico GmbH.
     
  1012. Berg T (2019). Kapitel 8: Akute Hepatitiden und akutes Leberversagen In: Berg T, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2019 (S. 1-34), Wiesbaden : med publico GmbH.
     
  1013. Hollenbach M, Hoffmeister A (2019). Übelkeit In: Riemann, Fischbach, Galle, Mössner, Referenz Gastroenterologie. (S. 135-139), Stuttgart: Thieme Verlag.
     
  1014. Hollenbach M, Hoffmeister A (2019). Erbrechen In: Riemann, Fischbach, Galle, Mössner, Referenz Gastroenterologie (S. 140-143), Stuttgart: Thieme Verlag.
     
  1015. Hollenbach M, Hoffmeister A (2019). Photodynamische Therapie In: Riemann, Fischbach, Galle, Mössner, Referenz Gastroenterologie (S. 741-746), Stuttgart: Thieme Verlag.
     
  1016. Hollenbach M, Hoffmeister A (2019). Pankreasgangendoprothesen In: Riemann, Fischbach, Galle, Mössner, Referenz Gastroenterologie (S. 931-936), Stuttgart: Thieme Verlag.
     
  1017. Hollenbach M (2019). Dysphagie und Odynophagie In: Riemann, Fischbach, Galle, Mössner, Referenz Gastroenterologie (S. 255-261), Stuttgart: Thieme Verlag.
     
  1018. Aehling NF, Engelmann C, Berg T (2019). Die Leberzirrhose auf der Intensivstation In: Eckart J, Weigand MA, Briegel J , Intensivmedizin (S. 1-11), Landsberg am Lech: ecomed MEDIZIN .
     


    1019. 2018


  1019. Lippmann N, Wendt S, Lübbert C (2018). 44 year old femal africa traveller with `worm like` structure in the stool. Deutsche Medizinische Wochenzeitschrift , 143, 13-14.
     
  1020. Berg T (2018). Hepatitis C: Das können die neuen Medikamente. Ärztliches Journal Reise & Medizin , 42(1), 44-46.
     
  1021. Veelken R, Böhlig A, Berg T (2018). Leberkrebs: Screening ist Aufgabe des Hausarztes. Der Hausarzt, 55(17), 49-53.
     
  1022. Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS (2018). Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis, 67(5), 708-716.
     
  1023. von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Gunthard HF, Castelnuovo B, Fehr J, Kambugu A (2018). HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. J Acquir Immune Defic Syndr, 78(5), 566-573.
     
  1024. Wendt S, Lippmann N, Fahnert J, Rodloff AC, Lubbert C (2018). Brucella related myocarditis. Int J Infect Dis, 66, 126-127.
     
  1025. Bachmann N, von Braun A, Labhardt ND, Kadelka C, Gunthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Boni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J (2018). Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. J Antimicrob Chemother, 21, 1-5.
     
  1026. Lubbert C, Holler B (2018). Unexpected Findings in a Patient With Cancer of Unknown Primary Syndrome. Gastroenterology, 154(3), 491-492.
     
  1027. Trawinski H, Teich N, Lubbert C (2018). How a bite on the cheek of a 29-year-old female patient with Crohn's disease turned out to be tuberculosis. J Crohns Colitis, 12(6), 753-754.
     
  1028. Lübbert C, Reinhardt F, Karlas T, Schwarzer A, Riese F, Schmidt T, Bartels M (2018). Seronegative alveolar echinococcosis in a patient with multiple myeloma. International Journal of Infection Diseases, 69, 47-49.
     
  1029. von Braun A, Lubbert C (2018). [Treatment of acute and recurrent Clostridium difficile infections : What is new?] Internist (Berl), 59(5), 505-513.
     
  1030. Lubbert C, Lippmann N, von Braun A (2018). [New Guidelines and Data to Clostridium difficile - What's New?] Dtsch Med Wochenschr, 143(11), 787-792.
     
  1031. Lubbert C, Wendt S, Sander C, Beeskow A, Becker-Rux D (2018). Intracranial hypertension and vasculitic infarction in a patient with severe cerebral melioidosis. Lancet Infect Dis, 18(10), 1160.
     
  1032. Hollenbach M, Feisthammel J, Mossner J, Hoffmeister A (2018). [Dysphagia from a gastroenterologist's perspective]. Dtsch Med Wochenschr, 143(9), 660-671.
     
  1033. Schlosser T, Feisthammel J, Gockel I, Mossner J, Hoffmeister A (2018). Endoscopic suturing as a less invasive approach for the treatment of anastomotic leakage after esophagogastrostomy - a case report. Z Gastroenterol, 56(11), 1365-1368.
     
  1034. Hollenbach M, Feisthammel J, Mossner J, Hoffmeister A (2018). Analysis of Wire-Guided Hemostasis Introducer for Percutaneous Therapy of Bile Duct Stones. Digestion, 97(3), 267-274.
     
  1035. Hollenbach M, Prettin C, Gundling F, Schepp W, Seufert J, Stein J, Rosch T, Aberle J, Feisthammel J, Petroff D, Hoffmeister A (2018). Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterol, 18(1), 118.
     
  1036. Feisthammel J, Vu Trung K, Hollenbach M, Mossner J, Hoffmeister A (2018). Is CO2 insufflation an amelioration of routine colonoscopy? Minerva Gastroenterol Dietol, 64(3), 193-200.
     
  1037. Lordick F, Smyth EC (2018). Two steps forward and one step back. Nat Rev Clin Oncol, 0000, 0000.
     
  1038. Lordick F, Röcken C (2018). Molekulares Tumorboard. Magenkarzinom. Prädiktoren der Immuntherapie Forum, 6, 405-410.
     
  1039. Lubbert C, Reinhardt F, Karlas T, Schwarzer A, Riese F, Schmidt T, Bartels M (2018). Seronegative alveolar echinococcosis in a patient with multiple myeloma. Int J Infect Dis, 69, 47-49.
     
  1040. Karlas T (2018). Diagnose und Verlaufsbeurteilung von Fettlebererkrankungen. Der Gastroenterologe., 13(4), 272-283.
     
  1041. Wendt S, Lubbert C, Karlas T (2018). An Emerging Cause for Liver Abscesses With Poor Prognosis. Gastroenterology, 155(1), e18-e19.
     
  1042. Karlas T (2018). [Non-invasive quantification of liver fat]. Z Gastroenterol, 56(3), 303-304.
     
  1043. Karlas T (2018). [Elastography characteristics of liver lesions - a new diagnostic tool?] Z Gastroenterol, 56(10), 1283-1284.
     
  1044. Lindner F, Muhlberg R, Wiegand J, Troltzsch M, Hoffmeister A, Keim V, Karlas T (2018). Predictive value of liver and spleen stiffness in advanced alcoholic cirrhosis with refractory ascites. Z Gastroenterol, 56(6), 561-568.
     
  1045. Karlas T, Petroff D, Wiegand J (2018). Editorial: the impact of steatosis on liver stiffness quantification is minimal-Authors' reply. Aliment Pharmacol Ther, 47(10), 1417-1418.
     
  1046. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J (2018). Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther, 47(7), 989-1000.
     
  1047. Lordick F (2018). Towards risk-adapted perioperative treatment of gastroesophageal cancer. Ann Oncol, 0000, 0000.
     
  1048. Lordick F, Röcken C (2018). Molekulares Tumorboard. Magenkarzinom. Prädiktoren der Immuntherapie Forum, 0000, 12312-018-0501-5 .
     
  1049. Ilson D, Lordick F (2018). Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer? Lancet Oncol, 19, 1285-1286.
     
  1050. Lordick F (2018). More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. Eur J Cancer, 97, 25-26.
     
  1051. Adenis A, Lordick F (2018). Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. JAMA Oncol, 4, 887-888.
     
  1052. Lordick F (2018). Response-adapted treatment stratification in oesophago-gastric cancer Eur J Cancer, 92, 3.
     
  1053. Lordick F (2018). Changing paradigms in adjuvant treatment of colorectal cancer. Lancet Gastroenterol Hepatol, 3, 6-8.
     
  1054. Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, Lordick F, Mauer M (2018). Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. Eur J Cancer, 99, 49-57.
     
  1055. Knodler M, Korfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F (2018). Randomised phase II trial to investigate catumaxomab (anti-EpCAM?×?anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer, 119, 296-302.
     
  1056. Kerbert AJ, Engelmann C, Jalan R (2018). Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure. Semin Respir Crit Care Med, 39(5), 523-537.
     
  1057. Koukoulioti E, Fischer J, Schott E, Fulop B, Heyne R, Berg T, van Bommel F (2018). Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians. Liver Int, 1, 1-24.
     
  1058. Petroff D, Bluher M, Wiegand J (2018). Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society. Dig Liver Dis, 50(7), 731-733.
     
  1059. van Bommel F, Berg T (2018). Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int, 38, 90-96.
     
  1060. van Bommel F, van Bommel A, Krauel A, Wat C, Pavlovic V, Yang L, Deichsel D, Berg T, Bohm S (2018). Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis, 218(7), 1066-1074.
     
  1061. Lullau A, Petroff D, Batz O, Kramer J, Jedrysiak K, Tenckhoff H, Berg T, Wolffram I, Wiegand J (2018). Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. Eur J Gastroenterol Hepatol, 30(3), 280-283.
     
  1062. Lampertico P, Berg T (2018). Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology, 68(2), 397-400.
     
  1063. Fischer J, Koukoulioti E, Schott E, Fulop B, Heyne R, Berg T, van Bommel F (2018). Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population. Sci Rep, 8(1), 12737-12745.
     
  1064. Krohn S, Zeller K, Bohm S, Chatzinotas A, Harms H, Hartmann J, Heidtmann A, Herber A, Kaiser T, Treuheit M, Hoffmeister A, Berg T, Engelmann C (2018). Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis. PLoS One, 13(6), e0197319.
     
  1065. Engelmann C, Thomsen KL, Zakeri N, Sheikh M, Agarwal B, Jalan R, Mookerjee RP (2018). Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Crit Care, 22, 254.
     
  1066. Engelmann C, Schob S, Nonnenmacher I, Werlich L, Aehling N, Ullrich S, Kaiser T, Krohn S, Herber A, Sucher R, Bartels M, Surov A, Hasenclever D, Kahn T, Seehofer D, Moche M, Berg T (2018). Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Aliment Pharmacol Ther, 48, 1271-1281.
     
  1067. Berg T, Seehofer D, Kaiser T (2018). Reply Clin Gastroenterol Hepatol, 16(5), 783-784.
     
  1068. Engelmann C, Berg T (2018). Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. Visc Med, 34(4), 261-268.
     
  1069. Berg T, Petersen J (2018). Reply to: Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients J Hepatol, 68(5), 1104-1105.
     
  1070. Krasselt M, Baerwald C, Seifert O (2018). Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic. Z Rheumatol, 00, 00.
     
  1071. Lordick F (2018). Changing paradigms in adjuvant treatment of colorectal cancer. Lancet Gastroenterol Hepatol, 3(1), 6-8.
     
  1072. Borlak J, van Bommel F, Berg T (2018). N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int, 38(2), 365-376.
     
  1073. Kaiser T, Finstermeier K, Hantzsch M, Faucheux S, Kaase M, Eckmanns T, Bercker S, Kaisers UX, Lippmann N, Rodloff AC, Thiery J, Lubbert C (2018). Stalking a lethal superbug by whole-genome sequencing and phylogenetics: Influence on unraveling a major hospital outbreak of carbapenem-resistant Klebsiella pneumoniae. Am J Infect Control, 46(1), 54-59.
     
  1074. Hollenbach M, Hoffmeister A, Rosendahl J, Mossner J (2018). Importance of functional diagnostics in gastroenterology. Internist (Berl), 59(1), 25-37.
     
  1075. Mossner J, Reincke M (2018). [Functional testing in internal medicine]. Internist (Berl), 59(1), 1-2.
     
  1076. Kaiser T, Finstermeier K, Hantzsch M, Faucheux S, Kaase M, Eckmanns T, Bercker S, Kaisers UX, Lippmann N, Rodloff AC, Thiery J, Lubbert C (2018). Stalking a lethal superbug by whole-genome sequencing and phylogenetics: Influence on unraveling a major hospital outbreak of carbapenem-resistant Klebsiella pneumoniae. Am J Infect Control, 46(1), 54-59.
     
  1077. Wendt S, Lippmann N, Fahnert J, Rodloff AC, Lubbert C (2018). Brucella related myocarditis. Int J Infect Dis, 66, 126-127.
     
  1078. Kaiser T, Finstermeier K, Hantzsch M, Faucheux S, Kaase M, Eckmanns T, Bercker S, Kaisers UX, Lippmann N, Rodloff AC, Thiery J, Lubbert C (2018). Stalking a lethal superbug by whole-genome sequencing and phylogenetics: Influence on unraveling a major hospital outbreak of carbapenem-resistant Klebsiella pneumoniae. Am J Infect Control, 46(1), 54-59.
     
  1079. Wendt S, Lippmann N, Fahnert J, Rodloff AC, Lubbert C (2018). Brucella related myocarditis. Int J Infect Dis, 66, 126-127.
     
  1080. Krasselt M, Baerwald C (2018). Sex, Symptom Severity, and Quality of Life in Rheumatology. Clin Rev Allergy Immunol, 00, 00.
     
  1081. Gockel I, Hoffmeister A (2018). Endoscopic or Surgical Resection for Gastro-Esophageal Cancer. Dtsch Arztebl Int, 115, 513-519.
     
  1082. Hollenbach M, Kloting N, Sommerer I, Lorenz J, Heindl M, Kern M, Mossner J, Bluher M, Hoffmeister A (2018). p8 deficiency leads to elevated pancreatic beta cell mass but does not contribute to insulin resistance in mice fed with high-fat diet. PLoS One, 13, 0201159.
     
  1083. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schonfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay (2018). Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 00, 00.
     
  1084. van Campenhout MJH, van Bommel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA (2018). Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology, 68(3), 839-847.
     
  1085. Bräunlich J, Wirtz H (2018). Nasal high-flow in acute hypercapnic exacerbation of COPD. Int J Chron Obstruct Pulmon Dis, 13, 3895-3897.
     
  1086. Braunlich J, Mauersberger F, Wirtz H (2018). Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulm Med, 18(1), 14-.
     
  1087. Frille A, Leithner K, Olschewski A, Olschewski H, Wohlkonig C, Hrzenjak A (2018). No erythropoietin-induced growth is observed in non-small cell lung cancer cells. Int J Oncol, 52(2), 518-526.
     
  1088. Moeser A, Lerche M, Wirtz H, Stallmach A (2018). [Aspects of pulmonary involvement in inflammatory bowel disease]. Internist (Berl), 59(9), 876-885.
     
  1089. Schulze G, Seyfarth HJ (2018). A Rare Cause of Chronic Cough. Dtsch Arztebl Int, 115, 10.
     
  1090. Mühle A, Seyfarth HJ (2018). Frühdiagnostik der chronisch thromboembolischen pulmonalen Hypertonie durch Spiroergometrie Atemwegs- und Lungenkrankheiten, 44, 366-372.
     
  1091. Frille A, Hesse S, Linder N, SeyfarthHJ (2018). Nuklearmedizinische Diagnostik in der Pneumologie Der PNeumologe, 15, 279-294.
     
  1092. Wirtz H (2018). Sporadische Lymphangiolyomyomatose - Sirolimus hilft Patienten mit seltener Lungenerkrankung Therapie aktuell, 11, 1-3.
     
  1093. Bräunlich J (2018). Nasale High-Flow-Therapie bei respiratorischer Insuffizienz CME-Fortbildungen, 1, 1.
     
  1094. Kerbert AJ*, Engelmann C*, Jalan R (2018). Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure. Semin Respir Crit Care Med, 39(5), 523-537.
     
  1095. Knoedler MA, Jeffery MM, Philpot LM, Meier S, Almasri J, Shah ND, Borah BJ, Murad MH, Larson AN, Ebbert JO (2018). Risk Factors Associated With Health Care Utilization and Costs of Patients Undergoing Lower Extremity Joint Replacement. Mayo Clin Proc Innov Qual Outcomes, 2(3), 248-256.
     
  1096. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 12645.
     
  1097. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 12645.
     
  1098. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Mullhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Huppe D, Knecht G, Lutz T, Scho (2018). Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals. Gastroenterology, 00, 00.
     
  1099. Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grunbauer A, Neumann A (2018). Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol, 53(1), 76-82.
     
  1100. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 12645.
     
  1101. Fortea JI, Zipprich A, Fernandez-Mena C, Puerto M, Bosoi CR, Almagro J, Hollenbach M, Banares J, Rodriguez-Sanchez B, Cercenado E, Clement MA, Rose CF, Banares R, Vaquero J, Ripoll C (2018). Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver Int, 38(1), 102-112.
     
  1102. Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, Wolffram I, Petroff D, Aidelsburger P, Grunbauer A, Neumann A (2018). Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol, 53(1), 76-82.
     
  1103. Baumert TF, Berg T, Lim JK, Nelson DR (2018). Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges. Gastroenterology, 1, 1-40.
     
  1104. Beckebaum S, Herzer K, Bauhofer A, Gelson W, De Simone P, de Man R, Engelmann C, Mullhaupt B, Vionnet J, Salizzoni M, Volpes R, Ercolani G, De Carlis L, Angeli P, Burra P, Dufour JF, Rossi M, Cillo U, (2018). Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. Ann Transplant, 23, 789-801.
     
  1105. Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, Kirby P, Marcinak J, Ormarsdottir S, Schomaker SJ, Schuppe-Koistinen I, Wolen (2018). Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology, 1, 1-14.
     
  1106. Dultz G, Muller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Huppe D, Boker K, Wedemeyer H, Welzel TM (2018). Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging, 35(9), 843-857.
     
  1107. Efe C, Taii HA, Ytting H, Aehling N, Bhanji RA, Hagstrom H, Purnak T, Muratori L, Werner M, Muratori P, Klintman D, Schiano TD, Montano-Loza AJ, Berg T, Larsen FS, Alkhouri N, Ozaslan E, Heneghan MA, (2018). Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Dig Dis Sci, 63(5), 1348-1354.
     
  1108. El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, Loglio A, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Li (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther, 48(5), 564-573.
     
  1109. Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect Dis, 5(11), 1-7.
     
  1110. Grimaldi-Bensouda L, Wedemeyer H, Wiegand J, Lohse AW, Benichou J, Rossignol M, Larrey D, Abenhaim L, Poynard T, Schott E (2018). Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. Int J Cardiol, 266, 100-105.
     
  1111. Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hin (2018). Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS One, 13(6), 1-12.
     
  1112. Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H (2018). Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. J Hepatol, 69(4), 982-984.
     
  1113. Honer Zu Siederdissen C, Buggisch P, Boker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Huppe D, Manns MP, Mauss S (2018). Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J, 6(2), 213-224.
     
  1114. Kerbert AJ, Engelmann C, Jalan R (2018). Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure. Semin Respir Crit Care Med, 39(5), 523-537.
     
  1115. Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Gunther R, Hinrichsen H, Huppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M (2018). Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat, 1, 1-7.
     
  1116. Kuhn S, Splith K, Ballschuh C, Feldbrugge L, Krenzien F, Atanasov G, Benzing C, Hau HM, Engelmann C, Berg T, Schulte Am Esch J, Pratschke J, Robson SC, Schmelzle M (2018). Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent manner. Purinergic Signal, 1, 1-10.
     
  1117. Lange CM, Bechstein WO, Berg T, Engelmann C, Bruns T, Canbay A, Moreau R, Trebicka J (2018). Acute-on-Chronic Liver Failure. Visc Med, 34(4), 296-300.
     
  1118. Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, Huo X, Aller R, Garcia-Monzon C, Arias-Loste MT, Bugianesi E, Miele L, Gallego-Duran R, Fischer J, Berg T, Liddle C, LiangQiao, Georg (2018). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. J Hepatol, 1, 1-8.
     
  1119. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2018). From the Editor's desk... J Hepatol, 68(1), 1-4.
     
  1120. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2018). From the Editor's desk...: March 2018. J Hepatol, 68(3), 377-379.
     
  1121. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2018). From the Editor's desk....: April 2018. J Hepatol, 68(4), 631-634.
     
  1122. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2018). From the Editor's desk....: May 2018. J Hepatol, 68(5), 869-872.
     
  1123. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2018). From the Editor's desk...: June 2018. J Hepatol, 68(6), 1107-1109.
     
  1124. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2018). From the Editor's desk....: July 2018. J Hepatol, 69(1), 1-4.
     
  1125. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). From the Editor's desk....: August 2018. J Hepatol, 69(2), 265-268.
     
  1126. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268]. J Hepatol, 69(4), 987-.
     
  1127. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). From the Editor's desk....: September 2018. J Hepatol, 69(3), 559-561.
     
  1128. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). From the Editor's Desk?: October 2018. J Hepatol, 69(4), 759-761.
     
  1129. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). From the Editor's desk....: November 2018. J Hepatol, 69(5), 993-995.
     
  1130. Moreau R, Bataller R, Berg T, Lotersztajn S, Zucman-Rossi J, Jalan R (2018). From the Editor's desk.?: December 2018. J Hepatol, 69(6), 1209-1212.
     
  1131. Muche M, Berg T, Rimpler S, Staedtler A, Bohm S, Nickel P, Baid-Agrawal S (2018). Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. Liver Int, 1, 1-25.
     
  1132. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Lehretz M, Savvidou S, de la R (2018). Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol, 68(6), 1129-1136.
     
  1133. Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H, Spengler U, Timm J, Wedemeyer H, Wirth S, Zeuzem S (2018). Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012 Z Gastroenterol, 56(7), 756-838.
     
  1134. Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von F (2018). Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol, 113(10), 1475-1483.
     
  1135. Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von F (2018). Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis. Am J Gastroenterol, 113(7), 1099.
     
  1136. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Re (2018). Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 1, 1-9.
     
  1137. Pfirrmann D, Simon P, Mehdorn M, Hansig M, Stehr S, Selig L, Weimann A, Knodler M, Lordick F, Mehnert A, Gockel I (2018). [Preconditioning prior to visceral oncological surgery : A paradigm shift in visceral surgery?] Chirurg, 89, 896-902.
     
  1138. Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kolbl O, Hautmann MG, Strutz J, Schreiber F, Bockmuhl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehulsing M, Schroeder U, Woll (2018). Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol, 29, 2105-2114.
     
  1139. Sonnichsen R, Hennig L, Blaschke V, Winter K, Korfer J, Hahnel S, Monecke A, Wittekind C, Jansen-Winkeln B, Thieme R, Gockel I, Grosser K, Weimann A, Kubick C, Wiechmann V, Aigner A, Bechmann I, Lordi (2018). Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clin Colorectal Cancer, 17, 189-199.
     
  1140. Urban C, Buck A, Siveke JT, Lordick F, Luber B, Walch A, Aichler M (2018). PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. Biochim Biophys Acta Gen Subj, 1862, 51-60.
     
  1141. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S (2018). Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl), 27(1), 0.
     
  1142. Stahl M, Maderer A, Lordick F, Mihaljevic AL, Kanzler S, Hoehler T, Thuss-Patience P, Monig S, Kunzmann V, Schroll S, Sandermann A, Tannapfel A, Meyer HJ, Schuhmacher C, Wilke H, Moehler M (2018). Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). Eur J Cancer, 93, 119-126.
     
  1143. Lelorain S, Cattan S, Lordick F, Mehnert A, Mariette C, Christophe V, Cortot A (2018). In which context is physician empathy associated with cancer patient quality of life? Patient Educ Couns, 101, 1216-1222.
     
  1144. Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S (2018). Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer, 90, 26-33.
     
  1145. Polom K, Boger C, Smyth E, Marrelli D, Behrens HM, Marano L, Becker T, Lordick F, Rocken C, Roviello F (2018). Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur J Surg Oncol, 44, 626-631.
     
  1146. Berger AK, Lucke S, Abel U, Haag GM, Grullich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jager D (2018). Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. Br J Cancer, 119, 170-175.
     
  1147. Esser P, Kuba K, Mehnert A, Johansen C, Hinz A, Lordick F, Gotze H (2018). Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation. Eur J Haematol, 101, 340-348.
     
  1148. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli (2018). Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol, 36, 2796-2803.
     
  1149. Gotze H, Taubenheim S, Dietz A, Lordick F, Mehnert A (2018). Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics. J Cancer Surviv, 12, 712-720.
     
  1150. Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Hoblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Weise K, Schuller V, (2018). Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level. Cancer Med, 7, 5057-5065.
     
  1151. Gotze H, Kohler N, Taubenheim S, Lordick F, Mehnert A (2018). Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol, 18, 1879-4062.
     
  1152. Jansen-Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, Frontini R, Gockel I (2018). [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. Chirurg, 00000, 00104-018-0667-5.
     
  1153. Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C, Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B, Lovey J, Netikova (2018). ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol Hematol, 122, 179-193.
     
  1154. Rinke A, Wiedenmann B, Auernhammer C1, Bartenstein P2, Bartsch DK3, Begum N4, Faiss S5, Fottner C6, Gebauer B7, Goretzki P8, Lynen Jansen P9, Pöpperl G10, Scherübl H11, Weber MM6, Gress TM, Pavel M, A (2018). [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol, 56, 583-681.
     
  1155. Aggelis V, Cunningham D, Lordick F, Smyth EC (2018). Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. Ann Oncol, 29, 1377-1385.
     
  1156. Piegeler T, Stehr SN, Pfirrmann D, Knodler M, Lordick F, Mehnert A, Selig L, Weimann A, Mehdorn M, Gockel I, Simon P (2018). [Special situations of preconditioning and prehabilitation in oncological visceral surgery]. Chirurg, 89, 903-908.
     
  1157. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yosh (2018). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 0000, 0000.
     
  1158. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino (2018). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 0000, 0000.
     
  1159. Lubbert C, Reinhardt F, Karlas T, Schwarzer A, Riese F, Schmidt T, Bartels M (2018). Seronegative alveolar echinococcosis in a patient with multiple myeloma. Int J Infect Dis, 69, 47-49.
     
  1160. Lam S, Nettel-Aguirre A, Van Biervliet S, Roeb E, Sadler MD, Friedrich-Rust M, Karlas T, Kitson MT, deBruyn JC (2018). Transient Elastography in the Evaluation of Cystic Fibrosis?Associated Liver Disease: Systematic Review and Meta-analysis. ournal of the Canadian Association of Gastroenterology. , 1, 1.
     
  1161. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bha (2018). Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol, 0000, 0000.
     
  1162. Gockel I, Jansen-Winkeln B, Haase L, Rhode P, Mehdorn M, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K, Wittekind C, Thieme R (2018). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. J Gastric Cancer, 0000, 379-391.
     
  1163. Surov A, Paul L, Meyer HJ, Schob S, Engelmann C, Wienke A (2018). Apparent Diffusion Coefficient Is a Novel Imaging Biomarker of Myopathic Changes in Liver Cirrhosis. J Clin Med, 7(10), 1-9.
     
  1164. van Campenhout MJH, van Bommel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA (2018). Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology, 68(3), 839-847.
     
  1165. Rosendahl J, Kirsten H, Hegyi E, Kovacs P, Weiss FU, Laumen H, Lichtner P, Ruffert C, Chen JM, Masson E, Beer S, Zimmer C, Seltsam K, Algul H, Buhler F, Bruno MJ, Bugert P, Burkhardt R, Cavestro GM, C (2018). Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. Gut, 67(10), 1855-1863.
     
  1166. Weiss FU, Hesselbarth N, Parniczky A, Mosztbacher D, Lammerhirt F, Ruffert C, Kovacs P, Beer S, Seltsam K, Griesmann H, Bohme R, Kaune T, Hollenbach M, Schulz HU, Simon P, Mayerle J, Lerch MM, Cavestr (2018). Common variants in the CLDN2-MORC4 and PRSS1-PRSS2 loci confer susceptibility to acute pancreatitis. Pancreatology, 1, 1.
     
  1167. Pietsch C, Trawinski H, Lubbert C, Liebert UG (2018). Short Communication: West Nile fever imported from Austria to Germany. Transbound Emerg Dis, 21, 1-4.
     
  1168. Ny S, Kozlov R, Dumpis U, Edquist P, Grondahl-Yli-Hannuksela K, Kling AM, Lis DO, Lubbert C, Pomorska-Wesolowska M, Palagin I, Vilde A, Vuopio J, Walter J, Wisell KT (2018). Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis, 37(12), 2347-2354.
     
  1169. Mischnik A, Lubbert C, Mutters NT (2018). [New ??lactam antibiotics and ??lactamase inhibitors against multidrug-resistant Gram-negative bacteria]. Internist (Berl), 59(12), 1335-1343.
     
  1170. Wendt S, Lubbert C, Karlas T (2018). An Emerging Cause for Liver Abscesses With Poor Prognosis. Gastroenterology, 155(1), 18-19.
     
  1171. Lippmann N, Wendt S, Lubbert C (2018). [44 year old female africa traveller with 'worm-like' structure in the stool]. Dtsch Med Wochenschr, 143(1), 13-14.
     
  1172. Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B (2018). Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort. PLoS One, 13(11), 0206796.
     
  1173. Rudolph J, Just M, Trawinski H, Monecke A (2018). [A rare differential diagnosis of tonsillopharyngitis]. Laryngorhinootologie, 8, 1-3.
     
  1174. Bodmann KF, Lübbert C, et al (2018). S2k-Leitlinie der PEG für Chemotherapie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei erwachsenen- Update 2018. www.awmf.org, 0, 1-3.
     
  1175. Zeynalova N, Schimpf S, Setter C, Yahiaoui-Doktor M, Zeynalova S, Lordick F, Loeffler M, Hinz A (2018). The association between an anxiety disorder and cancer in medical history. J Affect Disord, 246, 640-642.
     
  1176. Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T, Reinicke D, Garcia M, Luc A, Baumann C, Ayav A, Laurent V, Hollenbach M, Ripoll C, Gueant-Rodrig (2018). Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine, 30, 138-147.
     
  1177. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Lehretz M, Savvidou S, de la R (2018). Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol, 68(6), 1129-1136.
     
  1178. Lobe M, Staubert S, Goldberg C, Haffner I, Winter A (2018). Towards Phenotyping of Clinical Trial Eligibility Criteria. Stud Health Technol Inform, 248, 293-299.
     
  1179. Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, Haffner I, Schierle K, Weirich G, Luber B (2018). Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol, 12(4), 441-462.
     
  1180. Eichler M, Hechtner M, Wehler B, Buhl R, Stratmann J, Sebastian M, Schmidberger H, Peuser J, Kortsik C, Nestle U, Wiesemann S, Wirtz H, Wehler T, Blettner M, Singer S (2018). Psychological distress in lung cancer survivors at least 1 year after diagnosis-Results of a German multicenter cross-sectional study. Psychooncology, 27(8), 2002-2008.
     
  1181. Hempel G, Schulze G, Wirtz H, Wrigge H (2018). Electrical Impedance Tomography for Confirmation of Lung Isolation during One-lung Ventilation. Anesthesiology, 129(3), 580-.
     
  1182. Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Walscher J, Wirtz H, Kirsten D (2018). [DGP Interstitial Lung Disease Patient Questionnaire]. Pneumologie, 72(6), 446-457.
     
  1183. Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jorres RA (2018). The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med, 134, 79-85.
     
  1184. Schupp JC, Freitag-Wolf S, Bargagli E, Mihailovic-Vucinic V, Rottoli P, Grubanovic A, Muller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J (2018). Phenotypes of organ involvement in sarcoidosis. Eur Respir J, 51(1), 1700991.
     
  1185. Lee DH, Isobe H, Wirtz H, Aleixo SB, Parente P, de Marinis F, Huang M, Arunachalam A, Kothari S, Cao X, Donnini N, Woodgate AM, de Castro J (2018). Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Serv Res, 18(1), 147.
     
  1186. Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, Grimminger F, Grimminger J, Grunig E, Guth S, Halank M, Heine A, Hoeper MM, Klose H, Lange TJ, Meyer K, Neurohr C, Nickolaus K, (2018). Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant, 37(10), 1235-1244.
     
  1187. Kovacs G, Dumitrescu D, Barner A, Greiner S, Grunig E, Hager A, Kohler T, Kozlik-Feldmann R, Kruck I, Lammers AE, Mereles D, Meyer A, Meyer J, Pabst S, Seyfarth HJ, Sinning C, Sorichter S, Stahler G, (2018). Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol, 272, 11-19.
     
  1188. Wilkens H, Konstantinides S, Lang IM, Bunck AC, Gerges M, Gerhardt F, Grgic A, Grohe C, Guth S, Held M, Hinrichs JB, Hoeper MM, Klepetko W, Kramm T, Kruger U, Lankeit M, Meyer BC, Olsson KM, Schafers (2018). Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol, 272, 69-78.
     
  1189. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra AM, Nagel C, Sablotzki A, Seyfarth HJ, Schranz D, Ulrich S, Hoeper MM, Lange TJ (2018). Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol, 272, 46-52.
     
  1190. Maciolek KA, Best SL, Lopez V, Posielski N, Knoedler M, Bushman WA, Jarrard DF, Downs TM, Abel EJ, Richards KA (2018). Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol, 36(8), 363-363.
     
  1191. Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect Dis, 5(11), 248-255.
     
  1192. S von Haeling, J Arends, D Blum, and U Hacker (2018). Kachexie bei Tumorerkrankungen. In: Hacker U, Erkennen und multimodal behandeln. (S. 20-28), München: Springer.
     
  1193. Golombek T, Lordick F (2018). Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung In: B Rau, P Piso, A Königsrainer, Peritoneale Tumoren und Metastasen (S. 245-260), Deutschland: Springer Verlag GmbH Deutschland .
     
  1194. Lordick F, Gockel I, Mössner J (2018). Ösophaguskarzinom beim alten und geriatrischen Patienten In: Ebert M, Härtel N, Wedding U, Geriatrische Onkologie (S. 313-324), Deutschland: Springer Nature .
     
  1195. Lordick F (2018). Immunonkologie der soliden Tumoren ? Neues In: Petrasch S, Ehninger G., Colloquium Onkologie 24. Update Hämatologie / Onkologie 2017 (S. 31-40), München: Lukon Verlag.
     
  1196. Berg T (2018). Hepatologie (II) In: Fischbach W, Layer P, Berg T, May A, Handbuch Gastroenterologie - GastroUpdate 2018 (S. 1-49), Wiesbaden : med publica GmbH.
     
  1197. Berg T (2018). Kapitel 8: Akute Hepatitiden und akutes Leberversagen In: Berg T, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2018 (S. 1-34), Wiesbaden: med publico GmbH.
     
  1198. Lübbert C (2018). Antiinfektiva- Leitfaden für eine empirische Therapie und Prophylaxe. In: Lübbert C, Antiinfektiva- Leitfaden für eine empirische Therapie und Prophylaxe. (S. 1-144), Leipzig: Universitätsklinikum Leipzig.
     
  1199. Lübbert C (2018). Sexuell übertragbare Krankheiten. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie (S. 344-357), Stuttgart: Thieme.
     
  1200. Fischbach W, Layer P, Berg T, May A (2018). Handbuch Gastroenterologie - GastroUpdate 2018 In: Fischbach W, Layer P, Berg T, May A, Handbuch Gastroenterologie - GastroUpdate 2018 (S. 1-380), Wiesbaden : med publico GmbH.
     
  1201. Hollenbach M, Hoffmeister A (2018). Übelkeit In: Riemann, Fischbach, Galle, Mössner, Gastroenterologie ? Das Referenzwerk für Klinik und Praxis (S. 56-60), Stuttgart: Thieme Verlag.
     
  1202. Hollenbach M, Hoffmeister A (2018). Erbrechen In: Riemann, Fischbach, Galle, Mössner, Gastroenterologie ? Das Referenzwerk für Klinik und Praxis (S. 59-63), Stuttgart: Thieme Verlag.
     
  1203. Hollenbach M, Hoffmeister A (2018). Photodynamische Therapie In: Riemann, Fischbach, Galle, Mössner, Gastroenterologie ? Das Referenzwerk für Klinik und Praxis (S. 458-465), Stuttgart: Thieme Verlag.
     
  1204. Hollenbach M, Hoffmeister A (2018). Pankreasgangendoprothesen In: Riemann, Fischbach, Galle, Mössner, Gastroenterologie ? Das Referenzwerk für Klinik und Praxis. (S. 876-884), Stuttgart: Thieme Verlag.
     
  1205. Hollenbach M (2018). Dysphagie und Odynophagie In: Riemann, Fischbach, Galle, Mössner, Gastroenterologie ? Das Referenzwerk für Klinik und Praxis (S. 135-143), Stuttgart: Thieme Verlag.
     
  1206. Hollenbach M (2018). The Role of Glyoxalase-I in Oxidant Stress of Liver Damage In: Patel V, Rajendram R, The Liver: Oxidative Stress and Dietary Antioxidants (S. 75-83), London: Elsevier.
     


    1207. 2017


  1207. Raulien N, Friedrich K, Strobel S, Rubner S, Baumann S, von Bergen M, Korner A, Krueger M, Rossol M, Wagner U (2017). Fatty Acid Oxidation Compensates for Lipopolysaccharide-Induced Warburg Effect in Glucose-Deprived Monocytes. Front Immunol, 8, 609.
     
  1208. Krasselt M, Ivanov JP, Baerwald C, Seifert O (2017). Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic. Rheumatol Int, 37(2), 229-237.
     
  1209. Fischer J, Weber AN, Bohm S, Dickhofer S, El Maadidi S, Deichsel D, Knop V, Klinker H, Moller B, Rasenack J, Wang L, Sharma M, Hinrichsen H, Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M, Probst-Muller E, Malinverni R, Bochud PY, Gardiner CM, O Farrelly C, Berg T (2017). Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut, 66(10), 1829-1837.
     
  1210. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wai-Sun Wong V, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Sik Jung K, Marcellin P, Filice C, Mahadeva S, Lai-Hung Wong G, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J (2017). Individual Patient Data Meta-Analysis of Controlled Attenuation Parameter (CAP) Technology for Assessing Steatosis. J Hepatol, 66(5), 1022-1030.
     
  1211. Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K (2017). Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. Hamostaseologie, 37(2), 127-130.
     
  1212. Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T (2017). Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol, 66(3), 657-659.
     
  1213. Hacker U (2017). Krebstherapie und Tumoransprechen. Forum, 32(3), 230-235.
     
  1214. Lordick F, Hacker U (2017). Gewichtsverlust aus onkologischer Sicht. Aktuelle Ernaehrungsmedizin, 42(2), 115-122.
     
  1215. Mehnert A, Lordick F (2017). [Cancer Throughout the Lifespan - Addressing the Psychosocial Needs of Diverse Populations]. Psychother Psychosom Med Psychol, 67(7), 277-278.
     
  1216. Lordick F (2017). Treatment of oesophageal cancer - Stressing the patient perspective. Editorial. Eur J Cancer, 84, 360-362.
     
  1217. Kataoka K, Deleersnijder A, Lordick F (2017). Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol, 43(10), 1835-1845.
     
  1218. Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F (2017). Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 20(5), 904-912.
     
  1219. Lordick F, Shitara K, Janjigian YY (2017). New agents on the horizon in gastric cancer. Ann Oncol, 28(8), 1767-1775.
     
  1220. Haag GM, Stocker G, Quidde J, Jaeger D, Lordick F (2017). Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study. BMC Cancer, 17(1), 509.
     
  1221. Obermannova R, Lordick F (2017). Management of Metastatic Gastric Cancer. Hematol Oncol Clin North Am, 31(3), 469-483.
     
  1222. Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Mohler M, Quaas A, Rocken C, Ruschoff J, Tannapfel A, Thuss-Patience P, Baretton G (2017). HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol, 143(5), 835-841.
     
  1223. Lordick F, Mossner J (2017). [Current Standard Diagnosis and Treatment of Colon Cancer]. Dtsch Med Wochenschr, 142(7), 487-490.
     
  1224. Lordick F (2017). Salvage chemotherapy for advanced gastric cancer: more than a false hope? Lancet Gastroenterol Hepatol, 2(4), 240-241.
     
  1225. Lordick F (2017). Anti-angiogenesis: disappointment in localised oesophagogastric cancer. Lancet Oncol, 18(3), 278-279.
     
  1226. Lordick F (2017). [Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe, 38(2), 87-92.
     
  1227. Keysselt K*, Kreutzmann T*, Rother K*, Kerner C, Krohn K, Przybilla J, Buske P, Loffler-Wirth H, Loeffler M, Galle J*, Aust G* (2017). Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency. Oncogene, 36(19), 2750-2761.
     
  1228. Engelmann C, Splith K, Krohn S, Herber A, Boehlig A, Boehm S, Pratschke J, Berg T, Schmelzle M (2017). Absolute quantification of microparticles by flow cytometry in ascites of patients with decompensated cirrhosis: a cohort study. J Transl Med, 15(1), 188.
     
  1229. Pfefferkorn M, Bohm S, Schott T, Deichsel D, Bremer CM, Schroder K, Gerlich WH, Glebe D, Berg T, van Bommel F (2017). Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut, 00, 00.
     
  1230. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J (2017). Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol, 67(5), 918-924.
     
  1231. Karlas T, Petroff D, Wiegand J (2017). Collaboration, Not Competition: The Role of Magnetic Resonance, Transient Elastography, and Liver Biopsy in the Diagnosis of Nonalcoholic Fatty Liver Disease. Editorial. Gastroenterology, 152(3), 479-481.
     
  1232. Berg T, Petersen J (2017). Reply to: Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication? J Hepatol, 00, 00.
     
  1233. Sonnichsen R, Hennig L, Blaschke V, Winter K, Korfer J, Hahnel S, Monecke A, Wittekind C, Jansen-Winkeln B, Thieme R, Gockel I, Grosser K, Weimann A, Kubick C, Wiechmann V, Aigner A, Bechmann I, Lordick F, Kallendrusch S (2017). Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clin Colorectal Cancer, 00, 00.
     
  1234. Mohr E, Sucher R, Seehofer D, Berg T (2017). Klatskin-Tumore: Die Rolle der Chemotherapie und Photodynamischen Therapie. Journal Onkologie, 3, 181-187.
     
  1235. Herta T, Fischer J, Berg T (2017). Genetik metabolischer und viraler Lebererkrankungen. Der Gastroenterologe, 12(1), 16-31.
     
  1236. Berg T (2017). Die Diagnose? Lila Beine. Stern, 48, 126.
     
  1237. Ebert T, Linder N, Schaudinn A, Busse H, Berger J, Lichtinghagen R, Keim V, Wiegand J, Karlas T (2017). Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. Endocrine, 58(2), 246-252.
     
  1238. Karlas T, Weise L, Kuhn S, Krenzien F, Mehdorn M, Petroff D, Linder N, Schaudinn A, Busse H, Keim V, Pratschke J, Wiegand J, Splith K, Schmelzle M (2017). Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. J Transl Med, 15(1), 106.
     
  1239. Karlas T, Beer S, Babel J, Busse H, Schaudinn A, Linder N, Wiegand J, Petroff D (2017). Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients? Hepatology, 65(6), 2126-2128.
     
  1240. Lubbert C, Baars C, Dayakar A, Lippmann N, Rodloff AC, Kinzig M, Sorgel F (2017). Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens. Infection, 45(4), 479-491.
     
  1241. Rosendahl J, Kirsten H, Hegyi E, Kovacs P, Weiss FU, Laumen H, Lichtner P, Ruffert C, Chen JM, Masson E, Beer S, Zimmer C, Seltsam K, Algul H, Buhler F, Bruno MJ, Bugert P, Burkhardt R, Cavestro GM, Cichoz-Lach H, Farre A, Frank J, Gambaro G, Gimpfl S, Grallert H, Griesmann H, Grutzmann R, Hellerbrand C, Hegyi P, Hollenbach M, Iordache S, Jurkowska G, Keim V, Kiefer F, Krug S, Landt O, Leo MD, Lerch MM, Levy P, Loffler M, Lohr M, Ludwig M, Macek M, Malats N, Malecka-Panas E, Malerba G, Mann K, M (2017). Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. Gut, 0, 1-9.
     
  1242. von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B (2017). Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. AIDS Res Ther, 14(1), 1.
     
  1243. Feisthammel J, Mossner J (2017). [Proctology for internists]. Internist (Berl), 58(10), 1053-1064.
     
  1244. Feisthammel J, Mossner J, Hoffmeister A (2017). Proctoscopy. Dtsch Med Wochenschr, 142(2), 135-138.
     
  1245. Karlas T (2017). [LI-RADS-CEUS for the classification of HCC risk in liver lesions]. Z Gastroenterol, 55(5), 507-508.
     
  1246. Lordick F, Mossner J (2017). [Current Standard Diagnosis and Treatment of Colon Cancer]. Dtsch Med Wochenschr, 142(7), 487-490.
     
  1247. Lubbert C, Nitschmann S (2017). [Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies]. Internist (Berl), 58(6), 639-642.
     
  1248. Lubbert C, Mutters R (2017). [Gastrointestinal infections]. Internist (Berl), 58(2), 149-169.
     
  1249. Lubbert C, Salzberger B, Mossner J (2017). [Fecal microbiota transplantation]. Internist (Berl), 58(5), 456-468.
     
  1250. Schlosser T, Feisthammel J, Moessner J, Hoffmeister A (2017). Endoscopic treatment of obesity and complications after bariatric surgery. Minerva Chir, 72(6), 530-537.
     
  1251. Beer S, Mossner J (2017). [Identical Variants Different Disease Course - Genetics of Chronic Pancreatitis]. Dtsch Med Wochenschr, 142(9), 673-677.
     
  1252. Blank V, Schierle K, Hacker U, Herta T, Vucinic V, Hoffmeister A, Mossner J, Jansen-Winkeln B, Keim V, Karlas T (2017). An unusual hypoechoic solid mass in the pancreatic head. Z Gastroenterol, 55(4), 375-378.
     
  1253. Henker R, Keim V, Karlas T (2017). Acute Infarction of the Spleen. Dtsch Arztebl Int, 114(21), 382.
     
  1254. Henker R, Schwind S, Dohring C, Heindl M, Beimler M, Hoffmeister A, Karlas T (2017). Giant duodenal hematoma after duodenal biopsy in a patient with suspected acute gastrointestinal graft-versus-host disease. Endoscopy, 49(01), 132-133.
     
  1255. Mossner J (2017). In Reply. Dtsch Arztebl Int, 114(6), 102-.
     
  1256. Mossner J (2017). [Diagnostic Procedures in Hereditary Diseases]. Editorial. Dtsch Med Wochenschr, 142(9), 633-634.
     
  1257. Salzberger B, Lehnert H, Mossner J (2017). [The human microbiome]. Internist (Berl), 58(5), 427-428.
     
  1258. Schuurmann M, Kunz M, Lubbert C (2017). Oriental Sore (Old-World Cutaneous Leishmaniasis). Dtsch Arztebl Int, 114(44), 754.
     
  1259. Hollenbach M, Thonig A, Pohl S, Ripoll C, Michel M, Zipprich A (2017). Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis. PLoS One, 12(2), e0171260.
     
  1260. Hollenbach M (2017). The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC). Int J Mol Sci, 18(11), E2466.
     
  1261. Hollenbach M (2017). Implication of advanced glycation endproducts (AGEs) related to their receptor RAGE and (Glo-I) in chronic liver disease and (HCC) Internal Medicine Review, 0, 0.
     
  1262. Hollenbach M, Feisthammel J, Mössner J, Hoffmeister A (2017). Analysis of wire-guided hemostasis introducer for percutaneous therapy of bile duct stones Digestion, 0, 0.
     
  1263. Berg T (2017). Chronische Virushepatitis - wann muss der Hausarzt daran denken? Aerztliches Journal Reise & Medizin, 2, 52-54.
     
  1264. Lubbert C, Kunz M (2017). Yellow Nail Syndrome. Dtsch Arztebl Int, 114(50), 874.
     
  1265. Braunlich J, Wirtz H (2017). Oral Versus Nasal High-Flow Bronchodilator Inhalation in Chronic Obstructive Pulmonary Disease. J Aerosol Med Pulm Drug Deliv, 000, 1432.
     
  1266. Braunlich J, Wirtz H (2017). NHF and hypercapnia: How brief can you look? Respirology, 22(6), 1049-1050.
     
  1267. Braunlich J, Goldner F, Wirtz H (2017). Nasal highflow eliminates CO2 from lower airways. Respir Physiol Neurobiol, 242, 86-88.
     
  1268. Bauer M, Fink B, Seyfarth HJ, Wirtz H, Frille A (2017). Tobacco-smoking induced GPR15-expressing T cells in blood do not indicate pulmonary damage. BMC Pulm Med, 17(1), 159.
     
  1269. Bosse-Henck A, Koch R, Wirtz H, Hinz A (2017). Fatigue and Excessive Daytime Sleepiness in Sarcoidosis: Prevalence, Predictors, and Relationships between the Two Symptoms. Respiration, 94(2), 186-197.
     
  1270. Kuhn H, Nieuwenhuijsen H, Karthe B, Wirtz H (2017). Stretch-induced apoptosis in rat alveolar epithelial cells is mediated by the intrinsic mitochondrial pathway. Exp Lung Res, 43(1), 49-56.
     
  1271. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S (2017). Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist, 22(5), 601-608.
     
  1272. Bräunlich, Jens (2017). Der nasale Highflow in der Intensiv- und Notfallmedizin. Intensiv und Notfallbehandlung, 42(2), 1-8.
     
  1273. Strobel S, Rossol M (2017). [Monocyte subpopulations in patients with rheumatoid arthritis]. Z Rheumatol, 76(7), 609-612.
     
  1274. Raulien N (2017). [Immunometabolism and inflammation: The cell is what it eats]. Z Rheumatol, 76(8), 705-707.
     
  1275. Thrum S (2017). [Obesity and autoimmunity: Adipose tissue as an immune organ?] Z Rheumatol, 76(4), 348-350.
     
  1276. Krasselt M, Pierer M, Amann K, Bachmann A, Lindner TH (2017). [Clinical Course of an Early Childhood-Onset Granulomatosis with Polyangiitis]. Dtsch Med Wochenschr, 142(12), 904-908.
     
  1277. Rothe K, Raulien N, Kohler G, Pierer M, Quandt D, Wagner U (2017). Autoimmune arthritis induces paired immunoglobulin-like receptor B expression on CD4+T cells from SKG mice. Eur J Immunol, 47(9), 1457-1467.
     
  1278. Gerdes S, Mrowietz U, Wagner U (2017). [Differential diagnostic spectrum of psoriasis vs. psoriatic arthritis in skin and joints]. Z Rheumatol, 76(6), 484-494.
     
  1279. Wendt S, Eder I, Wölfel R, Braun P, Lippmann N, Rodloff A (2017). [Botulism: Diagnosis and Therapy]. Dtsch Med Wochenschr, 142(17), 1304-1312.
     
  1280. Lübbert C, Mutters R (2017). [Gastrointestinal infections]. Internist (Berl), 58(2), 149-169.
     
  1281. Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkhardt H, Eby N, Fliedner G, Gauger B, Henkemeier U, Hofmann MW, Kleinert S, Kneitz C, Krueger K, Pohl C, Roske AE, Schett G, Schmalzing M, Tausche AK (2017). Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. Arthritis Care Res (Hoboken), 69(1), 58-66.
     
  1282. Griesser E, Vemula V, Raulien N, Wagner U, Reeg S, Grune T, Fedorova M (2017). Cross-talk between lipid and protein carbonylation in a dynamic cardiomyocyte model of mild nitroxidative stress. Redox Biol, 11, 438-455.
     
  1283. Thiele AG, Gausche R, Lindenberg C, Beger C, Arelin M, Rohde C, Mutze U, Weigel JF, Mohnike K, Baerwald C, Scholz M, Kiess W, Pfaffle R, Beblo S (2017). Growth and Final Height Among Children With Phenylketonuria. Pediatrics, 140(5), e20170015.
     
  1284. Weijers L, Baerwald C, Mennini FS, Rodriguez-Heredia JM, Bergman MJ, Choquette D, Herrmann KH, Attina G, Nappi C, Merino SJ, Patel C, Mtibaa M, Foo J (2017). Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Rheumatol Int, 37(7), 1111-1123.
     
  1285. Chen HH, Handel N, Ngeow J, Muller J, Huhn M, Yang HT, Heindl M, Berbers RM, Hegazy AN, Kionke J, Yehia L, Sack U, Blaser F, Rensing-Ehl A, Reifenberger J, Keith J, Travis S, Merkenschlager A, Kiess W (2017). Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol, 139(2), 607-620.
     
  1286. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Gortzen J, Puente A, Mullhaupt B, Navascues C, Nery F, Deltenre P, Turon F, Engelma (2017). Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int, 37(5), 694-699.
     
  1287. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydi (2017). Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol, 66(1), 11-18.
     
  1288. Herzer K, Welzel TM, Spengler U, Hinrichsen H, Klinker H, Berg T, Ferenci P, Peck-Radosavljevic M, Inderson A, Zhao Y, Jimenez-Exposito MJ, Zeuzem S (2017). Real-World Experience With Daclatasvir Plus Sofosbuvir ± Ribavirin for Post-Liver Transplant HCV Recurrence and Severe Liver Disease. Transpl Int, 30(3), 243-255.
     
  1289. Kharabian Masouleh S, Herzig S, Klose L, Roggenhofer E, Tenckhoff H, Kaiser T, Thone-Otto A, Wiese M, Berg T, Schroeter ML, Margulies DS, Villringer A (2017). Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study. J Viral Hepat, 24(3), 216-225.
     
  1290. Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan M (2017). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther, 45(5), 723-732.
     
  1291. Klapdor R, Wang S, Hacker U, Buning H, Morgan M, Dork T, Hillemanns P, Schambach A (2017). Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. Hum Gene Ther, 28(10), 886-896.
     
  1292. Blank V, Schierle K, Hacker U, Herta T, Vucinic V, Hoffmeister A, Mossner J, Jansen-Winkeln B, Keim V, Karlas T (2017). An unusual hypoechoic solid mass in the pancreatic head. Z Gastroenterol, 55(4), 375-378.
     
  1293. Hosel M, Huber A, Bohlen S, Lucifora J, Ronzitti G, Puzzo F, Boisgerault F, Hacker UT, Kwanten WJ, Kloting N, Bluher M, Gluschko A, Schramm M, Utermohlen O, Bloch W, Mingozzi F, Krut O, Buning H (2017). Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors. Hepatology, 66(1), 252-265.
     
  1294. Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O (2017). A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer, 116(5), 600-608.
     
  1295. Singer S, Danker H, Roick J, Einenkel J, Briest S, Spieker H, Dietz A, Hoffmann I, Papsdorf K, Meixensberger J, Mossner J, Schiefke F, Dietel A, Wirtz H, Niederwieser D, Berg T, Kersting A (2017). Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial. Psychooncology, 26(10), 1675-1683.
     
  1296. Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ (2017). Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther, 17(10), 951-964.
     
  1297. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol, 24(8), 2252-2258.
     
  1298. Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D (2017). Oesophageal cancer. Nat Rev Dis Primers, 3, 17048.
     
  1299. Kunzke T, Balluff B, Feuchtinger A, Buck A, Langer R, Luber B, Lordick F, Zitzelsberger H, Aichler M, Walch A (2017). Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget, 8(40), 68012-68025.
     
  1300. Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M (2017). What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol, 28(7), 1473-1483.
     
  1301. Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Buchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos (2017). 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer, 79, 41-49.
     
  1302. Pfirrmann D, Tug S, Brosteanu O, Mehdorn M, Busse M, Grimminger PP, Lordick F, Glatz T, Hoeppner J, Lang H, Simon P, Gockel I (2017). Internet-based perioperative exercise program in patients with Barretts carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial. BMC Cancer, 17(1), 413.
     
  1303. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D (2017). Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol, 3(5), 620-627.
     
  1304. Keck Chair T, Herrlinger Chair KR, Faiss S, Lordick F, Mansky T, Welsch T (2017). Arguments for and against Centralization in Oncologic Visceral Medicine. Visc Med, 33(2), 148-152.
     
  1305. Klar E, Buchler MW, Lang H, Lordick F, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN (2017). Oligometastases of Gastrointestinal Cancer Origin. Visc Med, 33(1), 76-81.
     
  1306. Kallendrusch S, Körfer J, Lordick F, Bechmann I (2017). Human tumor slice cultures for cancer research and drug testing. Integr Cancer Sci Therap, 4(4), 1000251.
     
  1307. Cornberg M, Petersen J, Schober A, Mauss S, Boker KH, Link R, Gunther R, Serfert Y, Pfeiffer-Vornkahl H, Manns MP, Sarrazin C, Huppe D, Berg T, Niederau C (2017). Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther, 45(5), 688-700.
     
  1308. Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zollner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, v (2017). Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis, 17(2), 215-222.
     
  1309. Hamidouche Z, Rother K, Przybilla J, Krinner A, Clay D, Hopp L, Fabian C, Stolzing A, Binder H, Charbord P, Galle J (2017). Bistable Epigenetic States Explain Age-Dependent Decline in Mesenchymal Stem Cell Heterogeneity. Stem Cells, 35(3), 694-704.
     
  1310. Becker S, Kinny-Koster B, Bartels M, Scholz M, Seehofer D, Berg T, Engelmann C, Thiery J, Ceglarek U, Kaiser T (2017). Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. PLoS One, 12(3), e0174424.
     
  1311. Kaiser T, Kinny-Koster B, Bartels M, Berg T, Scholz M, Engelmann C, Seehofer D, Becker S, Ceglarek U, Thiery J (2017). Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality. BMC Gastroenterol, 17(1), 57.
     
  1312. Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Gronbaek H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, (2017). IFN-?3, not IFN-?4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet, 49(5), 795-800.
     
  1313. Thabet K, Chan HLY, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Wong VW, Nazmy M, Fischer J, Liddle C, George J, Eslam M (2017). The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 65(6), 1840-1850.
     
  1314. Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang (2017). Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med, 376(22), 2134-2146.
     
  1315. Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, (2017). Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology, 153(1), 113-122.
     
  1316. Treutlein J, Frank J, Streit F, Reinbold CS, Juraeva D, Degenhardt F, Rietschel L, Witt SH, Forstner AJ, Ridinger M, Strohmaier J, Wodarz N, Dukal H, Foo JC, Hoffmann P, Herms S, Heilmann-Heimbach S, (2017). Genetic Contribution to Alcohol Dependence: Investigation of a Heterogeneous German Sample of Individuals with Alcohol Dependence, Chronic Alcoholic Pancreatitis, and Alcohol-Related Cirrhosis. Genes (Basel), 8(7), E183.
     
  1317. Schlegel V, Treuner-Kaueroff T, Seehofer D, Berg T, Becker S, Ceglarek U, Thiery J, Kaiser T (2017). Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease. PLoS One, 12(7), e0181540.
     
  1318. Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T (2017). Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. J Hepatol, 67(2), 237-245.
     
  1319. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 67(2), 370-398.
     
  1320. Remmler J, Schneider C, Treuner-Kaueroff T, Bartels M, Seehofer D, Scholz M, Berg T, Kaiser T (2017). Increased Level of Interleukin 6 Associates With Increased 90-Day and 1-Year Mortality in Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol, 00, 00.
     
  1321. Singer S, Danker H, Roick J, Einenkel J, Briest S, Spieker H, Dietz A, Hoffmann I, Papsdorf K, Meixensberger J, Mossner J, Schiefke F, Dietel A, Wirtz H, Niederwieser D, Berg T, Kersting A (2017). Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial. Psychooncology, 26(10), 1675-1683.
     
  1322. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Rev (2017). The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 66(5), 1444-1453.
     
  1323. Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Stallmach A, Engelmann C, Trepte C, Capel J, De Gottardi A (2017). Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther, 46(10), 981-991.
     
  1324. Efe C, Hagstrom H, Ytting H, Bhanji RA, Muller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, Gunsar F, Klintman D, Pares A, Heurgue-Berlot A, Schiano TD, Cengiz M, May-Sien Tan (2017). Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol, 15(12), 1950-1956.
     
  1325. Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hanel M, Salwender HJ, Weisel K, Durig J, Gorner M, Kirchner H, Peter N, Graeven U, Lor (2017). Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplant, 52(8), 1194-1198.
     
  1326. Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M (2017). ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol, 67(3), 585-602.
     
  1327. Gauthiez E, Habfast-Robertson I, Rueger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert (2017). A systematic review and meta-analysis of HCV clearance. Liver Int, 37(10), 1431-1445.
     
  1328. Linecker M, Krones T, Berg T, Niemann CU, Steadman RH, Dutkowski P, Clavien PA, Busuttil RW, Truog RD, Petrowsky H (2017). Potentially Inappropriate Liver Transplantation in the Era of the "Sickest-first" Policy - A Search for the Upper Limits. J Hepatol, 00, 1-37.
     
  1329. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk... J Hepatol, 66(1), 1-4.
     
  1330. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk.....: February 2017. J Hepatol, 66(2), 263-266.
     
  1331. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk...: March 2017. J Hepatol, 66(3), 469-472.
     
  1332. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk....: April 2017. J Hepatol, 66(4), 671-674.
     
  1333. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2017). From the Editors desk...: May 2017. J Hepatol, 66(5), 869-872.
     
  1334. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2017). From the Editors desk...: June 2017. J Hepatol, 66(6), 1107-1110.
     
  1335. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk...: May 2017. J Hepatol, 67(1), 1-4.
     
  1336. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2017). From the Editors desk...: August 2017. J Hepatol, 67(2), 207-210.
     
  1337. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2017). From the Editors desk...: September 2017. J Hepatol, 67(3), 437-440.
     
  1338. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk...: October 2017. J Hepatol, 67(4), 659-662.
     
  1339. Moreau R, Bataller R, Berg T, Zucmann-Rossi J, Jalan R (2017). From the Editors desk...: November 2017. J Hepatol, 67(5), 889-892.
     
  1340. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2017). From the Editors desk...: December 2017. J Hepatol, 67(6), 1125-1128.
     
  1341. Kolly P, Waidmann O, Vermehren J, Moreno C, Vogeli I, Berg T, Semela D, Zeuzem S, Dufour JF (2017). Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol, 67(4), 876-878.
     
  1342. John M, Metwally M, Mangia A, Romero-Gomez M, Berg T, Sheridan D, George J, Eslam M (2017). TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. Gastroenterology, 153(5), 1448-1449.
     
  1343. Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kummerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N (2017). First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. Eur J Cancer, 80, 14-25.
     
  1344. Jansen L, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann JC, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M (2017). S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol, 55(2), 167-206.
     
  1345. Chemnitzer O, Gotzel K, Maurer L, Dietrich A, Eichfeld U, Lyros O, Jansen-Winkeln B, Hoffmeister A, Gockel I, Thieme R (2017). Response to TNF-alpha Is Increasing Along with the Progression in Barretts Esophagus. Dig Dis Sci, 62(12), 3391-3401.
     
  1346. Diener MK, Huttner FJ, Kieser M, Knebel P, Dorr-Harim C, Distler M, Grutzmann R, Wittel UA, Schirren R, Hau HM, Kleespies A, Heidecke CD, Tomazic A, Halloran CM, Wilhelm TJ, Bahra M, Beckurts T, Borne (2017). Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. Lancet, 390(10099), 1027-1037.
     
  1347. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knegt R, de Ledinghen V, Piscaglia F, Procopet B, Saft (2017). EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall Med, 38(4), 377-394.
     
  1348. Jensen DM, Eklund S, Persson T, Ahlbom H, Stuart R, Barkun AN, Kuipers EJ, Mossner J, Lau JY, Sung JJ, Kilhamn J, Lind T (2017). Reassessment of Rebleeding Risk of Forrest IB (Oozing) Peptic Ulcer Bleeding in a Large International Randomized Trial. Am J Gastroenterol, 112(3), 441-446.
     
  1349. Pelz JO, Weinreich A, Karlas T, Saur D (2017). Evaluation of Freehand B-Mode and Power-Mode 3D Ultrasound for Visualisation and Grading of Internal Carotid Artery Stenosis. PLoS One, 12(1), e0167500.
     
  1350. Reuken PA, Torres D, Baier M, Loffler B, Lubbert C, Lippmann N, Stallmach A, Bruns T (2017). Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS One, 12(1), e0169900.
     
  1351. Reuken PA, Torres D, Baier M, Loffler B, Lubbert C, Lippmann N, Stallmach A, Bruns T (2017). Correction: Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS One, 12(2), e0172373.
     
  1352. Schmidt A, Pickartz T, Lerch MM, Fanelli F, Fiocca F, Lucatelli P, Cereatti F, Hoffmeister A, van Steenbergen W, Kraft M, Meier B, Caca K (2017). Effective treatment of benign biliary strictures with a removable, fully covered, self-expandable metal stent: A prospective, multicenter European study. United European Gastroenterol J, 5(3), 398-407.
     
  1353. Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A (2017). Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open, 7(9), e014679.
     
  1354. Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR (2017). Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother, 72(4), 1172-1177.
     
  1355. Singer S, Roick J, Meixensberger J, Schiefke F, Briest S, Dietz A, Papsdorf K, Mossner J, Berg T, Stolzenburg JU, Niederwieser D, Keller A, Kersting A, Danker H (2017). The effects of multi-disciplinary psycho-social care on socio-economic problems in cancer patients: a cluster-randomized trial. Support Care Cancer, 0, 0.
     
  1356. Beeskow A, Lubbert C, Voigt P (2017). [27-Year-Old Man with Indistinct Findings in FAST Sonography]. Dtsch Med Wochenschr, 142(6), 399-401.
     
  1357. Lyros O, Schickel S, Schierle K, Hoffmeister A, Gockel I (2017). [Gastric schwannoma: rare differenzial diagnosis of acute upper gastrointestinal (GI) bleeding]. Z Gastroenterol, 55(8), 761-765.
     
  1358. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Glaser S, Herth FJF, Welte (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res, 18(1), 139.
     
  1359. Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, Thabut D, Rudler M, Thibault V, Schuppe-Koistinen I, Bonnefont-Rousselot D, Hainque B, Imbert-Bismut F, (2017). Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS One, 12(12), e0189436.
     
  1360. Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S (2017). Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer, 90, 26-33.
     
  1361. Authors, Responsible in representation of the DGVS (2017). S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol, 55(2), 167-206.
     
  1362. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knegt R, de Ledinghen V, Piscaglia F, Procopet B, Saft (2017). EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med, 38(4), e16-47.
     
  1363. Hardavella G, Aamli-Gaagnat A, Frille A, Saad N, Niculescu A, Powell P (2017). Top tips to deal with challenging situations: doctor-patient interactions. Breathe (Sheff), 13(2), 129-135.
     
  1364. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knegt R, de Ledinghen V, Piscaglia F, Procopet B, Saft (2017). EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med, 38(4), 16-47.
     
  1365. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Magenkarzinom. (S. 134-145), München: Elsevier Verlag.
     
  1366. Behrens A, Lordick F (2017). Facharztwissen Gastroenterologie. In: Layer P, Rosien U, Ösophagustumoren. (S. 100-110), München: Elsevier Verlag.
     
  1367. Stocker G, Lordick F (2017). Gastroenterologische Infektiologie. In: Lübbert C, Vogelmann R , Infektionen und Entzündungsreaktionen als Folge der Tumorbehandlung. (S. 425-435), Berlin: De Gruyter Verlag.
     
  1368. Lordick F, Hacker U (2017). Zielgerichtete Therapie des kolorektalen Karzinoms. In: Hacker U, Zielgerichtete Therapie des kolorektalen Karzinoms. (S. 1-102), Bremen-London-Boston: UniMed Verlag AG.
     
  1369. Lorenzen S, Lordick F (2017). Nausea und Emesis in der Onkologie. In: Lordick F, Nausea und Emesis in der Onkologie. (S. 1-160), Bremen-London-Boston: UniMed Verlag AG.
     
  1370. Lordick F (2017). Elsevier Essentials Onkologie. In: Alt-Epping B, Fuxius S, Wedding U, Kapitel 16 Onkologische Tumortherapie in 20 Jahren. (S. 141-144), München: Elsevier GmbH.
     
  1371. Hacker U, Lordick F (2017). Tumor Angiogenesis. In: D. Marmé, Anti-Angiogenics in Gastroesophageal Cancer. (S. 1-19), Basel: Springer International Publishing AG.
     
  1372. Berg T (2017). Hepatologie (I) In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie - GastroUpdate 2017. (S. 1-71), Wiesbaden: med publica GmbH.
     
  1373. Berg T (2017). Kapitel 13: Akute Hepatitiden und akutes Leberversagen In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2017 (S. 1-31), Wiesbaden: med publico GmbH.
     
  1374. Böhlig A, Puchner KP, Berg T (2017). Extrahepatic Manifestations of Chronic HCV. Chapter 15. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology. A clinical Textbook. (S. 365-390), Hamburg: Medizin Fokus Verlag .
     
  1375. van Bömmel F, Wiegand J, Berg T (2017). Treatment of hepatitis B infections. Chapter 9 In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology. A clinical Textbook. (S. 161-205), Hamburg : Medizin Fokus Verlag.
     
  1376. Berg T (2017). Kapitel 10.2: Akute Virushepatitis. In: Layer P, Rosien U, Facharztwissen Gastroenterologie. (S. 326-341), Hamburg: Urban & Fischer in Elsevier.
     
  1377. Jung A, Frederkrug D, Rosien U, Layer P, Berg T (2017). Kapitel 10.3: Akutes Leberversagen. In: Layer P, Rosien U, Facharztwissen Gastroenterologie. (S. 341-346), Hamburg: Urban & Fischer in Elsevier.
     
  1378. Frederkrug D, Rose S, Rosien U, Berg T (2017). Kapitel 10.4: Chronische Hepatitis. In: Layer P, Rosien U, Facharztwissen Gastroenterologie. (S. 347-371), Hamburg: Urban & Fischer in Elsevier.
     
  1379. Teising S, Szuba J, Rosien U, Berg T (2017). Kapitel 10.9: Medikamentös induzierte und toxische Lebererkrankungen. In: Layer P, Rosien U, Facharztwissen Gastroenterologie. (S. 399-408), Hamburg: Urban & Fischer in Elsevier.
     
  1380. Frederkrug D, Berg T (2017). Kapitel 10.17: Lebertransplantation. In: Urban & Fischer in Elsevier, Facharztwissen Gastroenterologie. (S. 447-451), Hamburg: Urban & Fischer in Elsevier.
     
  1381. Engelmann C, Berg T (2017). Kapitel 4.4: Leberzirrhose. In: Ludwig M, Repetitorium für die Facharztprüfung Innere Medizin. (S. 220-237), Hamburg: Urban & Fischer in Elsevier.
     
  1382. Benckert J, Berg T (2017). Kapitel 4.5: Lebertransplantation. In: Ludwig M, Repetitorium für die Facharztprüfung Innere Medizin. (S. 237-242), Hamburg: Urban & Fischer in Elsevier.
     
  1383. Benckert J, Berg T (2017). Kapitel 4.6: Hepatozelluläres Karzinom. In: Ludwig M, Repetitorium für die Facharztprüfung Innere Medizin. (S. 242-250), Hamburg: Urban & Fischer in Elsevier.
     
  1384. Lübbert C, Vogelmann R (2017). Gastroenterologische Infektiologie. In: Lübbert C, Vogelmann R, Gastroenterologische Infektiologie. (S. 569), Beröom: De Gruyter.
     
  1385. Mössner, J (2017). Gensignaturen beim kolorektalen Karzinom und ihre therapeutischen Konsequenzen. In: Lordick F, Hacker, U T, Zielgerichtete Therapie des kolorektalen Karzinoms (S. 28-32), Bremen-London-Boston: UNI-MED Verlag AG.
     
  1386. Mossner J (2017). Leitsymptom Bauchschmerz. In: Lehnert, Hendrik, Referenzwerk Innere Medizin. (S. 7), Berlin, Heidelberg, New York: Springer.
     
  1387. Mossner J (2017). Magen-Darm-Mittel und Lebertherapeutika. In: hwabe U, Paffrath D, Ludwig W D, Tauber J, Arzneiverordnungs-Report 2017. (S. 539-561), Berlin, Heidelberg, New York: Springer.
     
  1388. Hollenbach M (2017). Impact of Glyoxalase-I (Glo-I) and Advanced Glycation End Products (AGEs) in Chronic Liver Disease. In: Georgios Tsoulfas, Liver Cirrhosis - Update and Current Challenges. (S. 211-232), Rijeka,Croatia: InTech.
     


    1389. 2016


  1389. Wald A, Deterding L, Maier M, Liebert UG, Berg T, Wirtz H, Wiegand J (2016). Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. Ann Transplant, 21, 368-372.
     
  1390. Lubbert C (2016). Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Rev Anti Infect Ther, 14(2), 193-206.
     
  1391. Karlas T, Benckert J, Beer S, Keim V, Berg T, Wiegand J (2016). Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy? Aliment Pharmacol Ther, 43(4), 543-544.
     
  1392. Deterding K, Gruner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Luth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J (2016). Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. Eur J Gastroenterol Hepatol, 28(2), 187-192.
     
  1393. Braunlich J, Kohler M, Wirtz H (2016). Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 11, 1077-1085.
     
  1394. Bosse-Henck A, Wirtz H, Hinz A (2016). [Organ Manifestation and Subjective Sleep Quality in Sarcoidosis]. Pneumologie, 70(8), 522-529.
     
  1395. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D (2016). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 27(Suppl.5), v50-57.
     
  1396. Lordick F, Terashima M (2016). Gastric cancer adjuvant therapy. Best Pract Res Clin Gastroenterol, 30(4), 581-591.
     
  1397. Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Rocken C, Ruschoff J, Tannapfel A (2016). [HER2 testing in gastric cancer - results of a German expert meeting]. Z Gastroenterol, 54(8), 791-796.
     
  1398. Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gassler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F (2016). Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med, 5(7), 1444-1453.
     
  1399. Obermannova R, Lordick F (2016). Insights into next developments in advanced gastric cancer. Curr Opin Oncol, 28(4), 367-375.
     
  1400. Lordick F, Janjigian YY (2016). Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol, 13(6), 348-360.
     
  1401. Lordick F, Hacker U (2016). [Weight loss in cancer patients]. Dtsch Med Wochenschr, 141(4), 247-252.
     
  1402. Alt-Epping B, Seidel W, Vogt J, Mehnert A, Thomas M, van Oorschot B, Wolff H, Schliephake H, Canis M, Droge LH, Nauck F, Lordick F (2016). Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study. Oncol Res Treat, 39(4), 186-191.
     
  1403. Ochsenreither S, Lordick F (2016). New concepts for clinical trial design in oncology. Forum , 31(3), 221-225.
     
  1404. van Oorschot B, Ruellan A, Lordick F (2016). Für die Arbeitsgemeinschaft Palliativmedizin der Deutschen Krebsgesellschaft (APM). Choosing wisely ? Klug entscheiden bei Tumorpatienten mit limitierter Prognose. Forum, 31(3), 237-240.
     
  1405. Lorenzen S, Lordick F (2016). Fortgeschrittenes Magenkarzinom Status quo der systemischen Therapie und Einfluss auf die Lebensqualität. Onkologe, 22(6), 406-412.
     
  1406. Kallendrusch S, Schopow N, Stadler SC, Buning H, Hacker UT (2016). Adeno-Associated Viral Vectors Transduce Mature Human Adipocytes in Three-Dimensional Slice Cultures. Hum Gene Ther Methods, 27(5), 171-173.
     
  1407. Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, Hedge P, Van Cutsem E, Coutelle O, Buning H (2016). Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. Br J Cancer, 114(8), 855-862.
     
  1408. Buning H, Hacker UT (2016). Inhibitors of Angiogenesis. Adv Exp Med Biol, 917, 261-285.
     
  1409. Hacker U (2016). Das Tumorstroma und seine Bedeutung für die Therapie solider Tumoren. Forum, 31(3), 216-220.
     
  1410. Baerwald C (2016). Update Rheumatologie. Arthrose, Schmerztherapie, Fibromyalgie. Z Rheumatol, 75(1), 2-3.
     
  1411. Krasselt M, Hauser W, Petzke F, Baerwald C (2016). [S3 guidelines on long-term opioid treatment in non-cancer pain. Recommendations for opioid use in clinical rheumatology]. Z Rheumatol, 75(2), 128-132.
     
  1412. Rothe K, Quandt D, Schubert K, Rossol M, Klingner M, Jasinski-Bergner S, Scholz R, Seliger B, Pierer M, Baerwald C, Wagner U (2016). Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells. Arthritis Rheumatol, 68(2), 337-346.
     
  1413. Krasselt M, Baerwald C (2016). [An update on glucocorticoid-induced osteoporosis]. Dtsch Med Wochenschr, 141(5), 352-357.
     
  1414. Krasselt M, Baerwald C (2016). Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther, 10, 1047-1058.
     
  1415. Seyfarth HJ, Wirtz H, Gille J, Gerlach S, Grachtrup S, Winkler J, Sablotzki A (2016). [Management and Outcome of Surgery in Patients with Severe Pulmonary Hypertension- A Single-Center Experience]. Pneumologie, 70(2), 117-122.
     
  1416. Costabel U, Wirtz H (2016). Seltene Lungenkrankheiten. Der Pneumologe, 13, 1-3.
     
  1417. Wirtz H (2016). LAM: Neue Therapien, neue Chancen. Der Pneumologe, 13, 13-19.
     
  1418. Fjeld K, Beer S, Johnstone M, Zimmer C, Mossner J, Ruffert C, Krehan M, Zapf C, Njolstad PR, Johansson S, Bugert P, Miyajima F, Liloglou T, Brown LJ, Winn SA, Davies K, Latawiec D, Gunson BK, Criddle DN, Pirmohamed M, Grutzmann R, Michl P, Greenhalf W, Molven A, Sutton R, Rosendahl J (2016). Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. PLoS One, 11(11), e0165567.
     
  1419. Petroff D, Hoffmeister A (2016). Excess weight loss should not be used to define success for bariatric endoscopy. Gastrointest Endosc, 83(6), 1306.
     
  1420. Feisthammel J, Bluher M, Mossner J, Hoffmeister A (2016). [Endoscopic treatment of obesity and complications following bariatric surgery]. Internist (Berl), 57(8), 748-754.
     
  1421. Feisthammel J, Jansen-Winkeln B (2016). [Rubber band ligation less painful than operation]. Dtsch Med Wochenschr, 141(21), 1518.
     
  1422. Mossner J (2016). The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int, 113(27-28), 477-483.
     
  1423. Karlas T, Petroff D (2016). Is Magnetic Resonance Imaging Really More Accurate for Classifying Steatosis Than Controlled Attenuation Parameter? Gastroenterology, 151(2), 374-375.
     
  1424. Frille A, Steinhoff KG, Hesse S, Grachtrup S, Wald A, Wirtz H, Sabri O, Seyfarth HJ (2016). Thoracic [18F]fluorodeoxyglucose uptake measured by positron emission tomography/computed tomography in pulmonary hypertension. Medicine (Baltimore), 95(25), e3976.
     
  1425. Mossner J (2016). Aufnahmeuntersuchungen bei Flüchtlingen. Dtsch Med Wochenschr, 141(14), 1006.
     
  1426. Mossner J (2016). Interventionelle Therapie in der Gastroenterologie Internist (Berl), 57(8), 737-739.
     
  1427. Mossner J (2016). [Question about weight loss is a must]. Dtsch Med Wochenschr, 141(4), 246.
     
  1428. Lubbert C, Wendt K, Feisthammel J, Moter A, Lippmann N, Busch T, Mossner J, Hoffmeister A, Rodloff AC (2016). Epidemiology and Resistance Patterns of Bacterial and Fungal Colonization of Biliary Plastic Stents: A Prospective Cohort Study. PLoS One, 11(5), e0155479.
     
  1429. Lubbert C, Zimmermann L, Borchert J, Horner B, Mutters R, Rodloff AC (2016). Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis. Infect Dis Ther, 5(4), 545-554.
     
  1430. Lubbert C, Schneitler S (2016). Parasitic and infectious diseases of the biliary tract in migrants and international travelers. Expert Rev Gastroenterol Hepatol, 10(11), 1211-1225.
     
  1431. Lübbert C (2016). Fäkale Mikrobiotatransplantation (FMT) Gesicherte Therapieindikationen und Zukunftsperspektiven. Der Diabetologe , 12(6), 409-416.
     
  1432. Lübbert C, Schneitler S (2016). Parasitäre und infektiöse Gallenwegserkrankungen. Relevante Aspekte nach Fernreise bzw. Migration. Der Gastroenterologe , 11, 303-316.
     
  1433. Lübbert C (2016). Epidemiologie und Therapie von Infektionen durch Carbapenem-resistente Enterobakterien (CRE) in Deutschland. Arzneiverordnung in der Praxis (AVP) , 43, 80-91.
     
  1434. Wollina U, Koch A, Nenoff P, Lübbert C (2016). Kutane Leishmaniasis? Risiko steigt auch in Deutschland. Der Deutsche Dermatologe , 64, 202-204.
     
  1435. Lubbert C, Vogelmann R, Salzberger B, Kern WV (2016). [Options for the optimized therapy of Helicobacter pylori infection]. Z Gastroenterol, 54(10), 1170-1171.
     
  1436. Trawinski H, Bruning JH, Baum P, Ziemer M, Schubert S, Lubbert C (2016). [Borderline leprosy as a rare differential diagnosis]. Dtsch Med Wochenschr, 141(11), 806-810.
     
  1437. Braunlich J, Nilius G (2016). [Nasal Highflow (NHF): A New Therapeutic Option for the Treatment of Respiratory Failure]. Pneumologie, 70(1), 49-54.
     
  1438. Engelmann C, Becker C, Boldt A, Herta T, Boehlig A, Splith K, Schmelzle M, Mueller N, Krohn S, Tautenhahn HM, Bartels M, Sack U, Berg T (2016). Ascites neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation. Sci Rep, 6, 37926.
     
  1439. Engelmann C, Splith K, Berg T, Schmelzle M (2016). Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure. Eur J Intern Med, 36, 37-39.
     
  1440. Engelmann C, Krohn S, Prywerek D, Hartmann J, Herber A, Boehlig A, Zeller K, Boehm S, Berg T (2016). Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. Eur J Gastroenterol Hepatol, 28(11), 1285-1292.
     
  1441. Fulop B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, Brodzinski A, Fischer J, Bohm S, van Bommel F, Sarrazin C, Berg T (2016). Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type. J Viral Hepat, 23(11), 866-872.
     
  1442. Kant J, Kratzsch J, Maier M, Liebert UG, Berg T, Wiegand J (2016). HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre. Z Gastroenterol, 54(3), 231-237.
     
  1443. Mueller T, Fischer J, Gessner R, Rosendahl J, Bohm S, van Bommel F, Knop V, Sarrazin C, Witt H, Marques AM, Kovacs P, Schleinitz D, Stumvoll M, Bluher M, Bugert P, Schott E, Berg T (2016). Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection. Liver Int, 36(9), 1267-1274.
     
  1444. Wald A, Deterding L, Maier M, Liebert UG, Berg T, Wirtz H, Wiegand J (2016). Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. Ann Transplant, 21, 368-372.
     
  1445. Fülöp B, Berg T (2016). Aktuelle Therapie der HCV Infection. TumorDiagn u Ther , 37(5), 245-249.
     
  1446. Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T (2016). Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther, 44(1), 16-34.
     
  1447. Wiegand J, van Bommel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T (2016). Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. J Hepatol, 64(6), 1428-1445.
     
  1448. Forns X, Berg T (2016). Hepatitis C virus - A teacher of clinical research, cell biology and immunology. Editorial. J Hepatol, 65(Suppl.1), S1.
     
  1449. Graf Einsiedel H, Christiansen H, Wiegand J (2016). Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection. Pediatr Infect Dis J, 35(12), 1373.
     
  1450. Lampertico P, Berg T (2016). Letter: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients - authors reply. Aliment Pharmacol Ther, 44(5), 538.
     
  1451. Herta T, Hecker M, van Boemmel F, Hoffmeister A, Karlas T (2016). Sonographic diagnosis of transhepatic placement of a percutaneous endoscopic gastrostomy (PEG) tube. Endoscopy, 47(Suppl1), E453-454.
     
  1452. Bräunlich J, Wirtz H (2016). Nasale High-flow-Therapie? Der nächste Schritt zur individuellen Atmungsunterstützung? Der Pneumologe, 13, 388-395.
     
  1453. Lübbert C (2016). Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Rev Anti Infect Ther, 14(2), 193-206.
     
  1454. Edelmann A, Wald A, Kaisers UX, Struck MF (2016). Delayed tracheobronchial rupture after caustic ingestion. Clin Respir J, 10(4), 540-541.
     
  1455. Kirsten H, Scholz M, Kovacs P, Grallert H, Peters A, Strauch K, Frank J, Rietschel M, Nothen MM, Witt H, Rosendahl J (2016). Genetic variants of lipase activity in chronic pancreatitis. Gut, 65(1), 184-185.
     
  1456. Konstantinides SV, Barco S, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grunig E, Halank M, Heydenreich N, Hoeper MM, Leuchte HH, Mayer E, Meyer F (2016). Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. J Thromb Thrombolysis, 42(4), 600-609.
     
  1457. Deppisch C, Herrmann G, Graepler-Mainka U, Wirtz H, Heyder S, Engel C, Marschal M, Miller CC, Riethmuller J (2016). Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection, 44(4), 513-520.
     
  1458. Kovacs G, Dumitrescu D, Barner A, Greiner S, Grunig E, Hager A, Kohler T, Kozlik-Feldmann R, Kruck I, Lammers A, Mereles D, Meyer A, Meyer FJ, Pabst S, Seyfarth HJ, Sinning C, Sorichter S, Stahler G, (2016). [Clinical classification and initial diagnosis of pulmonary hypertension: recommendations of the Cologne Consensus Conference 2016]. Dtsch Med Wochenschr, 141(S01), S10-S18.
     
  1459. van Grinsven J, van Brunschot S, Bakker OJ, Bollen TL, Boermeester MA, Bruno MJ, Dejong CH, Dijkgraaf MG, van Eijck CH, Fockens P, van Goor H, Gooszen HG, Horvath KD, van Lienden KP, van Santvoort HC, (2016). Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. HPB (Oxford), 18(1), 49-56.
     
  1460. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, Uiker S, Halank M, Olsson K, Seeger W, Gall H, Rosenkranz S, Wilkens H, Mertens D, Seyfarth HJ, Opitz C, Ulrich S, Egenlauf B, G (2016). Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J, 37(1), 35-44.
     
  1461. Song L, Wormann S, Ai J, Neuhofer P, Lesina M, Diakopoulos KN, Ruess D, Treiber M, Witt H, Bassermann F, Halangk W, Steiner JM, Esposito I, Rosendahl J, Schmid RM, Riemann M, Algul H (2016). BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues. Gastroenterology, 150(2), 499-512.
     
  1462. Wilkens H, Konstantinides S, Lang I, Bunck AC, Gerges M, Gerhardt F, Grgic A, Grohe C, Guth S, Held M, Hinrichs J, Hoeper MM, Klepetko W, Kramm T, Kruger U, Lankeit M, Meyer BC, Olsson KM, Schafers HJ (2016). [Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016]. Dtsch Med Wochenschr, 141(S01), S62-S69.
     
  1463. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechene A, Gerken G, Schlaak JF, Weinmann A, Worns MA, Galle P, (2016). Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol, 14(6), 875-886.
     
  1464. Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, De Francesco R, Fargion S, Colombo M, Datz C, Stick (2016). DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 63(2), 418-427.
     
  1465. Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Natterm (2016). FibroGENE: A gene-based model for staging liver fibrosis. J Hepatol, 64(2), 390-398.
     
  1466. Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46.
     
  1467. Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, Hartmann H, Wiese M, Boeker K, Loehr HF, John C, Leuschner M, Trautwein C, Felten G, Trein A, Krause W, Ruppert S, Warger T, Huepp (2016). Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Dig Dis Sci, 61(10), 3061-3071.
     
  1468. Ray Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Aguilar Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J, Buti M, Marcelli (2016). Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 64(4), 773-780.
     
  1469. Romeo S, Aghemo A, Berg T, Stickel F, Valenti L (2016). Reply. Hepatology, 63(3), 1052-1053.
     
  1470. Grunig E, Benjamin N, Lange TJ, Krueger U, Klose H, Neurohr C, Wilkens H, Halank M, Seyfarth HJ, Held M, Traube A, Pernow M, Grover ER, Egenlauf B, Gerhardt F, Viethen T, Rosenkranz S (2016). Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial. Respiration, 92(6), 362-370.
     
  1471. Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T (2016). The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis, 48(11), 1283-1289.
     
  1472. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F (2016). Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. Eur J Cancer, 68, 208-209.
     
  1473. Engelmann D, Scheffold K, Friedrich M, Hartung TJ, Schulz-Kindermann F, Lordick F, Schilling G, Lo C, Rodin G, Mehnert A (2016). Death-Related Anxiety in Patients With Advanced Cancer: Validation of the German Version of the Death and Dying Distress Scale. J Pain Symptom Manage, 52(4), 582-587.
     
  1474. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer, 63, 11-24.
     
  1475. Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Rothling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR (2016). ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 16, 503.
     
  1476. Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Rocken C, Ruschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R, Lorenzen S, Moehler M, Thuss-Patience P (2016). [HER2 testing in gastric cancer : Results of a meeting of German experts]. Pathologe, 37(4), 361-366.
     
  1477. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M (2016). Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer, 59, 160-170.
     
  1478. Janmaat VT, Bruno MJ, Polinder S, Lorenzen S, Lordick F, Peppelenbosch MP, Spaander MC (2016). Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. PLoS One, 11(4), e0153943.
     
  1479. Stadler SC, Hacker U, Burkhardt R (2016). Cholesterol metabolism and breast cancer. Curr Opin Lipidol, 27(2), 200-201.
     
  1480. Hofheinz RD, Ronellenfitsch U, Kubicka S, Falcone A, Burkholder I, Hacker UT (2016). Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterol Res Pract, 2016, 9189483.
     
  1481. Rubbert-Roth A, Zander T, Kneitz C, Baerwald C, Wirtz H, Witt C (2016). [Lung cancer and rheumatoid arthritis. An interdisciplinary challenge] Z Rheumatol, 75(1), 2-3.
     
  1482. Mutze U, Thiele AG, Baerwald C, Ceglarek U, Kiess W, Beblo S (2016). Ten years of specialized adult care for phenylketonuria - a single-centre experience. Orphanet J Rare Dis, 11, 27.
     
  1483. Riemekasten G, Aringer M, Baerwald CG, Meyer-Bahlburg A, Bergner R, Feuchtenberger M, Gebhardt C, Hellmich B, Keysser G, Lorenz HM, Kneitz C, Witte T, Muller-Ladner U, Schneider M, Braun J, Rautenstra (2016). [Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)]. Z Rheumatol, 75(5), 493-501.
     
  1484. Fitzcharles MA, Baerwald C, Ablin J, Hauser W (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz, 30(1), 47-61.
     
  1485. Olsson KM, Halank M, Egenlauf B, Fistera D, Gall H, Kaehler C, Kortmann K, Kramm T, Lichtblau M, Marra A, Nagel C, Sablotzki A, Seyfarth HJ, Schranz D, Ulrich S, Hoeper MM, Lange TJ (2016). [Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]. Dtsch Med Wochenschr, 141(S01), S42-S47.
     
  1486. Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann JC, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mossner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, (2016). [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol, 54(4), 327-363.
     
  1487. Linder N, Schaudinn A, Garnov N, Bluher M, Dietrich A, Schutz T, Lehmann S, Retschlag U, Karlas T, Kahn T, Busse H (2016). Age and gender specific estimation of visceral adipose tissue amounts from radiological images in morbidly obese patients. Sci Rep, 6, 22261.
     
  1488. Struck MF, Beilicke A, Hoffmeister A, Gockel I, Gries A, Wrigge H, Bernhard M (2016). Acute emergency care and airway management of caustic ingestion in adults: single center observational study. Scand J Trauma Resusc Emerg Med, 24, 45.
     
  1489. Rasch S, Valantiene I, Mickevicius A, Beer S, Rosendahl J, Charnley RM, Robinson SM (2016). Chronic pancreatitis: Do serum biomarkers provide an association with an inflammageing phenotype? Pancreatology, 16(5), 708-714.
     
  1490. Frille A, Braunlich J, Seyfarth HJ, Feisthammel J, Wirtz H (2016). Als der Polyp ging, kam Luft. Abstract. Pneumologie, 70(12), 826-830.
     
  1491. Greinert R, Ripoll C, Hollenbach M, Zipprich A (2016). Stepwise diagnosis in covert hepatic encephalopathy: critical flicker frequency and MELD-score as a first-step approach. Aliment Pharmacol Ther, 44(5), 514-521.
     
  1492. Hau HM, Thalmann F, Lubbert C, Morgul MH, Schmelzle M, Atanasov G, Benzing C, Lange U, Ascherl R, Ganzer R, Uhlmann D, Tautenhahn HM, Wiltberger G, Bartels M (2016). The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy. BMC Surg, 16(1), 49.
     
  1493. Hagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A, Link A, Demir M, Siebenhaar A, Storr M, Glueck T, Siegel E, Solbach P, Goeser F, Koelbel CB, Lohse A, Luebbert C, Kandzi U, Maier M, Schu (2016). Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. Dtsch Arztebl Int, 113(135-136), 583-589.
     
  1494. Burgers PT, Hoogendoorn M, Van Woensel EA, Poolman RW, Bhandari M, Patka P, Van Lieshout EM (2016). Total medical costs of treating femoral neck fracture patients with hemi- or total hip arthroplasty: a cost analysis of a multicenter prospective study. Osteoporos Int, 27(6), 1999-2008.
     
  1495. Chi H, Arends P, Reijnders JG, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zouli (2016). Flares during long-term entecavir therapy in chronic hepatitis B. J Gastroenterol Hepatol, 31(11), 1882-1887.
     
  1496. Koelsch S, Boehlig A, Hohenadel M, Nitsche I, Bauer K, Sack U (2016). The impact of acute stress on hormones and cytokines, and how their recovery is affected by music-evoked positive mood. Sci Rep, 6, 23008.
     
  1497. Schonemeier B, Metzger J, Klein J, Husi H, Bremer B, Armbrecht N, Dakna M, Schanstra JP, Rosendahl J, Wiegand J, Jager M, Mullen W, Breuil B, Plentz RR, Lichtinghagen R, Brand K, Kuhnel F, Mischak H, (2016). Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Pancreas, 45(7), 1018-1026.
     
  1498. Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Gronbaek H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengle (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun, 7, 12757.
     
  1499. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S (2016). Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut, 65(11), 1861-1870.
     
  1500. Zimmermann T, Beckebaum S, Berg C, Berg T, Braun F, Eurich D, Herzer K, Neumann U, Rupp C, Sterneck M, Strassburg C, Welker MW, Zachoval R, Gotthardt DN, Weigand K, Schmidt H, Wedemeyer H, Galle PR, Z (2016). [Expert recommendations: Hepatitis C and transplantation]. Z Gastroenterol, 54(7), 665-684.
     
  1501. Herzer K, Strassburg CP, Braun F, Engelmann C, Guba M, Lehner F, Nadalin S, Pascher A, Scherer MN, Schnitzbauer AA, Zimmermann T, Nashan B, Sterneck M (2016). Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clin Transplant, 30(5), 487-501.
     
  1502. Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P (2016). Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis, 16(5), 606-617.
     
  1503. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk....: January 2016 J Hepatol, 64(1), 1-4.
     
  1504. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: February 2016 J Hepatol, 64(2), 253-256.
     
  1505. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: March 2016 J Hepatol, 64(3), 527-531.
     
  1506. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: April 2016. J Hepatol, 64(4), 759-762.
     
  1507. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: May 2016. J Hepatol, 64(5), 991-994.
     
  1508. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: June 2016. J Hepatol, 64(6), 1199-1202.
     
  1509. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: July 2016. J Hepatol, 65(1), 1-4.
     
  1510. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: August 2016. J Hepatol, 65(2), 233-236.
     
  1511. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk: September 2016. J Hepatol, 65(3), 457-461.
     
  1512. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: October 2016. J Hepatol, 65(4), 657-660.
     
  1513. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk...: November 2016. J Hepatol, 65(5), 869-872.
     
  1514. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2016). From the Editors desk.... : December 2016. J Hepatol, 65(6), 1073-1076.
     
  1515. Bahmer T, Watz H, Waschki B, Gramm M, Magnussen H, Rabe KF, Wirtz H, Kirsten D, Kirsten A (2016). Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. Thorax, 71(7), 662-663.
     
  1516. Rubbert-Roth A, Zander T, Kneitz C, Baerwald C, Wirtz H, Witt C (2016). [Lung cancer and rheumatoid arthritis. An interdisciplinary challenge]. Z Rheumatol, 75(1), 47-53.
     
  1517. Lordick F (2016). Zielgerichtete medikamentöse Therapie. In: Mehnert A, Koch U, Handbuch Psychoonkologie. (S. 42-52), Göttingen: Holzgreve Verlag GmbH.
     
  1518. Mössner J, Kiehne K, Fölsch UR (2016). Entzündliche Pankreaserkrankungen internistische Therapie. In: Sauerbruch, T., Therapie-Handbuch Innere Medizin, 5. Auflage (S. 1-9), München: Elsevier, Urban und Fischer Verlag .
     
  1519. Mössner J (2016). Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe U, Paffrath D , Arzneiverordnungsreport 2016. (S. 531-552), Heidelberg: Springer.
     
  1520. Mössner J, Hoffmeister A, Mayerle J (2016). Chronic Pancreatitis. In: Podolsky DK, Yamadas Textbook of Gastroenterology. (S. 1702-1731), West Sussex: John Wiley & Sons.
     
  1521. Schaumburg F, Mischnik A, Lübbert C, Bekeredjian-Ding I (2016). MRSA- und VRE-Prävalenz in Afrika und Asien. In: Bundesamt für Verbraucherschutz und Lebensmittelsicherheit und die Paul-Ehrlich-Gesellschaft für Che, GERMAP 2015 ? Bericht über den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterinärmedizin in Deutschland. (S. 53-56), Rheinbach: Bundesamt für Verbraucherschutz und Lebensmittelsi.
     
  1522. Mischnik A, Bekeredjian-Ding I, Schaumburg F, Lübbert C (2016). ESBL-Prävalenz in Afrika und Asien. In: Bundesamt für Verbraucherschutz und Lebensmittelsicherheit und die Paul-Ehrlich-Gesellschaft für Che, GERMAP 2015? Bericht über den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterinärmedizin in Deutschland. (S. 67-71), Rheinbach: Bundesamt für Verbraucherschutz und Lebensmittelsi.
     
  1523. Berg T (2016). Kapitel 7: Hepatologie (I) In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie - GastroUpdate 2016 (S. 1-60), Wiesbaden: med publica GmbH.
     
  1524. Berg T (2016). Kapitel 13: Akute Hepatitiden und akutes Leberversagen. In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2016. (S. 1-30), Wiesbaden: med publico GmbH.
     
  1525. Böhlig A, Puchner KP, Berg T (2016). 15. Extrahepatic Manifestations of Chronic HCV. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2016 - A Clinical Textbook. (S. 355-378), Wuppertal: Flying Publisher.
     
  1526. van Bömmel F, Wiegand J, Berg T (2016). 9. Treatment of hepatitis B infections. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2016 - A Clinical Textbook. (S. 157-200), Wuppertal: Flying Publisher.
     
  1527. Hammerschmidt S, Wirtz H, Bein T (2016). Kapitel 7: Beatmungsinduzierte Lungenschädigung In: Bein T, Pfeifer M, Intensivbuch Lunge und Beatmung. Von der Pathophysiologie zur Strategie auf der Intensivstation (S. 141-157), Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft.
     
  1528. Berg T, Müller N, Kreisel W (2016). Autoimmunhepatitis. In: Miehlke S, Madisch A , Topische Steroide in der Gastroenterologie. (S. 32-50), Bremen: UniMed-Verlag AG.
     
  1529. Berg T, Engelmann C (2016). Automated low flow ascites pump. In: Miehlke S, Madisch A, Management of cirrhotic patients with ascites. (S. 62-71), Bremen: UniMed-Verlag AG.
     


    1530. 2015


  1530. Heindl M, Tuennemann J, Sommerer I, Mossner J, Hoffmeister A (2015). Loss of Bace1 in mice does not alter the severity of caerulein induced pancreatitis. PLoS One, 10(5), e0125556.
     
  1531. Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT (2015). Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalization without inducing empty basement membrane sleeves in xenograft tumors. Br J Cancer, 112(3), 495-503.
     
  1532. Hacker UT (2015). Cetuximab oder Bevacizumab in der Erstlinientherapie des metastasierten kolorektalen Karzinoms? Journalclub. Der Onkologe, 21(2), 161-162.
     
  1533. Derikx MH, Kovacs P, Scholz M, Masson E, Chen JM, Ruffert C, Lichtner P, Te Morsche RH, Cavestro GM, Algul H, Berg T, Bodeker H, Bluher M, Bruno MJ, Buch S, Bugert P, Cichoz-Lach H, Dabrowski A, Farre A, Frank J, Gasiorowska A, Geisz A, Goni E, Grothaus J, Grutzmann R, Haas S, Hampe J, Hellerbrand C, Hegyi P, Huster D, Ioana M, Iordache S, Jurkowska G, Keim V, Landt O, Di Leo M, Lerch MM, Levy P, Lohr MJ, Macek M, Malats N, Malecka-Panas E, Mariani A, Martorana D, Mayerle J, ... Rosendahl J (2015). Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study. Gut, 64(9), 1426-1433.
     
  1534. Karlas T, Kollmeier J, Bohm S, Muller J, Kovacs P, Troltzsch M, Weimann A, Bartels M, Rosendahl J, Mossner J, Berg T, Keim V, Wiegand J (2015). Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol, 50(2), 224-232.
     
  1535. Rygiel AM*, Beer S*, Simon P, Wertheim-Tysarowska K, Oracz G, Kucharzik T, Tysarowski A, Niepokoj K, Kierkus J, Jurek M, Gawlinski P, Poznanski J, Bal J, Lerch MM, Sahin-Toth M, Weiss FU (2015). Gene Conversion between Cationic Trypsinogen (PRSS1) and the Pseudogene Trypsinogen 6 (PRSS3P2) in Patients with Chronic Pancreatitis. Hum Mutat, 36(3), 350-356.
     
  1536. Weis S, Bielow T, Sommerer I, Iovanna J, Malicet C, Mossner J, Hoffmeister A (2015). P8 deficiency increases cellular ROS and induces HO-1. Arch Biochem Biophys, 565, 89-94.
     
  1537. Lubbert C, Straube L, Stein C, Makarewicz O, Schubert S, Mossner J, Pletz MW, Rodloff AC (2015). Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol, 305, 148-156.
     
  1538. Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, DeMasi R, Picchio G, Luo D, De Meyer S, Zeuzem S (2015). Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver Int, 35(2), 448-454.
     
  1539. van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, Edelmann A (2015). Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 61(1), 66-76.
     
  1540. Mössner J (2015). Editorial: Die anti-TNFalpha Therapie wird erwachsen. Kompakt Gastroenterologie, 1, 1-2.
     
  1541. Braunlich J, Seyfarth HJ, Frille A, Wirtz H (2015). Diffuse Interstitial Pulmonary Infiltrates in Malignant Melanoma. Respir Care, 60(7), e115-117.
     
  1542. Mössner J (2015). Editorial: Motilitätsstörungen Der Internist, 56, 613-614.
     
  1543. Mössner J (2015). Editorial: Die chronische Hepatitis C ist heilbar. Die Leitlinie der DGVS wird aber weiter aktualisiert werden müssen, um zu erfahren, welche Kombinationstherapie die Patienten mit oder ohne Zirrhose bei welchem Genotyp und nach welcher erfolglosen Vortherapie erhalten sollten. Kompakt Gastroenterologie, 5, 1-2.
     
  1544. Herber A, Berg T (2015). Aktuelle Empfehlungen zum Management der chronischen Hepatitis C. Ärztliches Journal Reise und Medizin, 0, 54-57.
     
  1545. Herber A, Berg T (2015). Kommende Therapieoptionen der chronischen Hepatitis C. HepNet Journal, 9, 16-19.
     
  1546. Hoffmeister A, Mayerle J, Beglinger C, Buchler MW, Bufler P, Dathe K, Folsch UR, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel WT, Layer P, Loehr M, Meier R, Riemann JF, Runzi M, Schmid RM, Schreyer A, Tribl B, Werner J, Witt H, Mossner J, Lerch MM (2015). Englischsprachige Version der S3-Leitlinie Chronische Pankreatitis. Z Gastroenterol, 53(12), 1447-1495.
     
  1547. Mössner J (2015). Editorial: Transorale Fundoplikatio: künftige Therapieoptionen bei PPI-refraktärer Refluxösophagitis? Kompakt Gastroenterologie, 3, 1-2.
     
  1548. Mössner J (2015). Editorial: Warum diagnostizieren wir in Deutschland im Gegensatz zu Japan das Magen-Frühkarzinom zu selten? Dtsch Med Wochenschr, 140, 716-717.
     
  1549. Karlas T, Dietrich A, Peter V, Wittekind C, Lichtinghagen R, Garnov N, Linder N, Schaudinn A, Busse H, Prettin C, Keim V, Troltzsch M, Schutz T, Wiegand J (2015). Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS One, 10(11), e0141649.
     
  1550. Gockel I, Hoffmeister A, Lordick F (2015). [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg, 86(11), 1014-1022.
     
  1551. Dietz A, Lordick F (2015). Update Skills in Head and Neck Surgery and Oncology 2015 : Aktuelles klinikrelevantes Wissen praxisnah präsentiert. HNO, 63(12), 880-881.
     
  1552. Hacker U, Lordick F (2015). [Current standards in the treatment of gastric cancer]. Dtsch Med Wochenschr, 140(16), 1202-1205.
     
  1553. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F (2015). Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer, 51(5), 569-576.
     
  1554. Lordick F (2015). Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis. Nat Rev Clin Oncol, 12(1), 7-8.
     
  1555. Lordick F (2015). [In Process Citation]. Oncol Res Treat, 38(5), 260-263.
     
  1556. Lordick F, Gockel I, Wittekind C (2015). Magenkarzinom: Neue molekulare Konzepte. Dtsch Arztebl , 112(20), 10.3238.
     
  1557. Behrens A, Ell C, Lordick F (2015). Perioperative and Palliative Chemotherapy for Esophageal Cancer. Viszeralmedizin , 31(5), 341-346.
     
  1558. Buning H, Huber A, Zhang L, Meumann N, Hacker U (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol, 24, 94-104.
     
  1559. Hoffmeister A, Mössner J (2015). Screening - Wo stehen wir: Darmkrebs Forum, 30, 38-41.
     
  1560. Berg T, Zeuzem S (2015). Einführung: Effektive Kontrolle der HBV-Infektion und Heilung der HCV-Infektion durch direkt antivirale Substanzen. Der Gastroenterologe, 10(4), 265-267.
     
  1561. Meusch U, Klingner M, Mathar C, Malysheva O, Baerwald C, Rossol M, Wagner U (2015). Brief Report: Autocrine Cytokine-Mediated Deficiency of TRAIL-Induced Monocyte Apoptosis in Rheumatoid Arthritis. Arthritis Rheumatol, 67(7), 1760-1765.
     
  1562. Meusch U, Krasselt M, Rossol M, Baerwald C, Klingner M, Wagner U (2015). In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis. J Transl Med, 13, 256.
     
  1563. Thrum S, H Trawinski, Ewens S, Baerwald C (2015). [Differential diagnosis of sternoclavicular arthritis]. Z Rheumatol, 74(10), 919-922.
     
  1564. Quandt D, Rothe K, Baerwald C, Rossol M (2015). GPRC6A mediates Alum-induced Nlrp3 inflammasome activation but limits Th2 type antibody responses. Sci Rep, 5, 16719.
     
  1565. Krasselt M, Baerwald C (2015). [Conservative Therapy of Osteoarthritis]. Dtsch Med Wochenschr, 140(24), 1839-1841.
     
  1566. Seyfarth HJ, Gille J, Sablotzki A, Gerlach S, Malcharek M, Gosse A, Gahr RH, Czeslick E (2015). Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations. GMS Interdiscip Plast Reconstr Surg DGPW, 4, 03.
     
  1567. Bräunlich J, Seyfarth HJ, Wirtz H (2015). Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. Multidiscip Respir Med, 10(1), 27.
     
  1568. Kolditz M, Seyfarth HJ, Wilkens H, Ewert R, Bollmann T, Dinter C, Hertel S, Klose H, Opitz C, Grunig E, Hoffken G, Halank M (2015). MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH. Lung, 193(6), 901-910.
     
  1569. Seyfarth HJ, Sack U, Gessner C, Wirtz H (2015). [Angiogenin, bFGF and VEGF: angiogenic markers in breath condensate of patients with pulmonary hypertension]. Pneumologie, 69(4), 207-211.
     
  1570. Braunlich J, Wirtz H (2015). [Nasal Highflow - Treatment option in severe hypoxaemia?]. Dtsch Med Wochenschr, 140(24), 1823-1826.
     
  1571. Bosse-Henck A, Wirtz H, Hinz A (2015). Subjective sleep quality in sarcoidosis. Sleep Med, 16(5), 570-576.
     
  1572. Olbrich S, Fischer MM, Sander C, Hegerl U, Wirtz H, Bosse-Henck A (2015). Objective markers for sleep propensity: comparison between the Multiple Sleep Latency Test and the Vigilance Algorithm Leipzig. J Sleep Res, 24(4), 450-457.
     
  1573. Sablotzki A, Seyfarth HJ, Gille J, Gerlach S, Malcharek M, Czeslick E (2015). Non-Cardiac General Surgery in Patients with Pulmonary Hypertension: Particularities of Perioperative Management. Clin Res Pulmonol, 3, 1-6.
     
  1574. Wirtz H, Kirsten D (2015). Lymphangioleiomyomatose (LAM) Atemwegs- und Lungenerkrankungen, 41(10), 451-458.
     
  1575. Bräunlich J (2015). Hypoxämie und Hyperkapnie während der COPD-Exazerbation: "Here to stay"? Pneumologie und HNO, 13, 16-17.
     
  1576. Fülöp B, Herber A, Berg T (2015). Therapie der chronischen HCV-Infektion. Kompendium Gastroenterologie, 11, 16-19.
     
  1577. Lordick F, Knödler M, Stocker G, Haffner I, Hacker U, Hoffmeister A, Mössner J (2015). Schwerpunkt Magen- und Pankreaskarzinom. Moderne pharmakologische Therapiekonzepte. Onkologie, 13, 22-26.
     
  1578. Karlas T, Berger J, Garnov N, Lindner F, Busse H, Linder N, Schaudinn A, Relke B, Chakaroun R, Troltzsch M, Wiegand J, Keim V (2015). Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques. World J Gastroenterol, 21(16), 4894-4902.
     
  1579. Weis S, Franke A, Berg T, Mossner J, Fleig WE, Schoppmeyer K (2015). Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev, 1, CD006745.
     
  1580. Mossner J (2015). [Endoscopic papillotomy doesn t increase cancer risk]. Dtsch Med Wochenschr, 140(22), 1650.
     
  1581. Mossner J (2015). [In Process Citation]. Grußwort. Z Gastroenterol, 53(8), 771-772.
     
  1582. Mossner J, Wolter AN (2015). [Career planning in medicine. Prof. Dr. Joachim Mössner interviewed by Anna Wolter]. Dtsch Med Wochenschr, 140(11), 856-857.
     
  1583. Mossner J (2015). [From dyspesia to gastric cancer-various causes, challenging diagnosis]. Dtsch Med Wochenschr, 140(10), 716-717.
     
  1584. Mossner J (2015). [Motility disorders of the gastrointestinal tract]. Internist (Berl), 56(6), 613-614.
     
  1585. Rosendahl J (2015). [Risk of pancreatic cancer in chronic pancreatitis - lower than previously supposed?]. Z Gastroenterol, 53(11), 1348-1349.
     
  1586. Rosendahl J (2015). [Early or late enteral nutrition in severe acute pancreatitis?]. Z Gastroenterol, 53(3), 244-245.
     
  1587. Herta T, Hecker M, van Boemmel F, Hoffmeister A, Karlas T (2015). Sonographic diagnosis of transhepatic placement of a percutaneous endoscopic gastrostomy (PEG) tube. Endoscopy, 47(Suppl1), 453-454.
     
  1588. Lubbert C, Hau HM, Rodloff A, Mossner J, Mischnik A, Bercker S, Bartels M, Kaisers UX (2015). [Clinical impact of infections with carbapenem-resistant enterobacteriaceae in liver transplant recipients]. Z Gastroenterol, 53(11), 1276-1287.
     
  1589. Trawinski H, Graber S, Leifels M, Schubert S, Lubbert C (2015). [Undulant fever and autoimmune hemolytic anemia in a 20-year-old exchange student from Jordan - the human brucellosis as an important differential diagnosis in migrants]. Dtsch Med Wochenschr, 140(24), 1848-1852.
     
  1590. Lubbert C, Rodloff AC, Hamed K (2015). Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE). Infect Dis Ther, 4(3), 259-271.
     
  1591. Berg T, Zeuzem S, Manns MP (2015). [In Process Citation]. Z Gastroenterol, 53(5), 519-523.
     
  1592. Fulop B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T (2015). Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. Liver Int, 35(10), 2275-2284.
     
  1593. Wolffram I, Petroff D, Batz O, Jedrysiak K, Kramer J, Tenckhoff H, Berg T, Wiegand J (2015). Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol, 62(6), 1256-1264.
     
  1594. Lubbert C, John E, von Muller L (2015). In reply. Dtsch Arztebl Int, 112(19), 346.
     
  1595. Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, Holscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer HJ, Palmqvist A, Rocken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wi (2015). International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 18(3), 550-563.
     
  1596. Boehm A, Lindner F, Wichmann G, Bauer U, Wittekind C, Knoedler M, Lordick F, Dietzsch S, Scholz M, Kortmann R, Dietz A (2015). Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol, 272(8), 2017-2025.
     
  1597. Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jager D, Buchler M, Bruckner T, Siewert J, Ott K (2015). Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer, 18(2), 314-325.
     
  1598. Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Schmidt M, Hacker UT, Alexander Shimabukuro A, Holtick U, Nokay B, Schroff M, Wittig B, Scheulen ME (2015). Phase I clinical study of the TLT9-agonist MGN1703 in patients with metastatic solid tumors. Eur J Cancer, 51(2), 146-156.
     
  1599. Mai M, Kovacs P, Stumvoll M, Rosendahl J, Tonjes A (2015). Association between genetic variants in PNPLA3 and serum adiponectin. Liver Int, 35(2), 679-680.
     
  1600. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bommel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti (2015). Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 64(8), 1289-1295.
     
  1601. Hoffmann FS, Schmidt A, Dittmann Chevillotte M, Wisskirchen C, Hellmuth J, Willms S, Gilmore RH, Glas J, Folwaczny M, Muller T, Berg T, Spengler U, Fitzmaurice K, Kelleher D, Reisch N, Rice CM, Endres (2015). Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology, 61(2), 460-470.
     
  1602. Balazs A, Ruffert C, Hegyi E, Hritz I, Czako L, Takacs T, Szepes Z, Nemeth BC, Gervain J, Izbeki F, Halasz A, Kelemen D, Szmola R, Novak J, Crai S, Illes A, Vincze A, Molnar Z, Varga M, Bod B, Farkas (2015). Genetic analysis of the bicarbonate secreting anion exchanger SLC26A6 in chronic pancreatitis. Pancreatology, 15(5), 508-513.
     
  1603. Rathmayer M, Scheffer H, Braun M, Heinlein W, Akoglu B, Brechmann T, Golder SK, Lankisch T, Messmann H, Schneider A, Wagner M, Flessa S, Meier A, Lewerenz B, Gossner L, Faiss S, Toermer T, Werner T, W (2015). [Improvement of cost allocation in gastroenterology by introduction of a novel service catalogue covering the complete spectrum of endoscopic procedures]. Z Gastroenterol, 53(3), 183-198.
     
  1604. Dietz A, Loeffler M, Rosolowski M, Kreuz M, Lordick F, Knodler M, Mozet C, Wichmann G (2015). [Gene expression analyses and their possible clinical benefit in head and neck cancer]. HNO, 63(11), 773-785.
     
  1605. Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Buchler MW, Ott K (2015). Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Eur J Surg Oncol, 41(10), 1340-1347.
     
  1606. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, T (2015). Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res, 21(24), 5469-5479.
     
  1607. Scheffold K, Philipp R, Engelmann D, Schulz-Kindermann F, Rosenberger C, Oechsle K, Harter M, Wegscheider K, Lordick F, Lo C, Hales S, Rodin G, Mehnert A (2015). Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial. BMC Cancer, 15, 592.
     
  1608. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R (2015). TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 532.
     
  1609. Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jager D, Grenacher L, Bruckner T, Buchler MW, Ott K (2015). Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol, 22 (Suppl 3), 905-914.
     
  1610. Fakhrian K, Ordu AD, Nieder C, Lordick F, Kup PG, Theisen J, Combs SE, Geinitz H (2015). Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. Tumori, 101(3), 263-267.
     
  1611. Schmidt T, Lordick F, Herrmann K, Ott K (2015). Value of functional imaging by PET in esophageal cancer. J Natl Compr Canc Netw, 13(2), 239-247.
     
  1612. Gockel I, Hoffmeister A, Lordick F (2015). [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg, 86(11), 1014-1022.
     
  1613. Strobel D, Bernatik T, Blank W, Will U, Reichel A, Wustner M, Keim V, Schacherer D, Barreiros AP, Kunze G, Nurnberg D, Ignee A, Burmester E, Bunk AA, Friedrich-Rust M, Froehlich E, Schuler A, Jenssen (2015). Incidence of bleeding in 8172 percutaneous ultrasound-guided intraabdominal diagnostic and therapeutic interventions - results of the prospective multicenter DEGUM interventional ultrasound study (PIUS study). Ultraschall Med, 36(2), 122-131.
     
  1614. Buch S, Stickel F, Trepo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Da (2015). A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet, 47(12), 1443-1448.
     
  1615. Malysheva O, Bedrich A, Kuipers JG, Kleine H, Wolff B, Baerwald CG (2015). Use of clinical scores to guide therapeutic decisions in patients with rheumatoid arthritis in daily care. Clin Exp Rheumatol, 33(2), 255-258.
     
  1616. Ewert R, Wilkens H, Skowasch D, Reppel M, Bollmann T, Halank M, Held M, Klose H, Gall H, Lange TJ, Opitz CF, Seyfarth HJ, Winkler J (2015). [Dyspnoea in Patients with Pulmonary Hypertension (PH) - a Survey in Spezialized German PH Centres]. Pneumologie, 69(6), 361-365.
     
  1617. Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, Lange TJ, Claussen M, Grohe C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JS (2015). Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One, 10(12), e0141911.
     
  1618. Behr J, Bonella F, Bonnet R, Glaser S, Grohe C, Gunther A, Koschel D, Kreuter M, Kirsten D, Krogel C, Markart P, Muller-Quernheim J, Neurohr C, Pfeifer M, Prasse A, Schonfeld N, Schreiber J, Wirtz H, (2015). [Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis]. Pneumologie, 69(8), 455-458.
     
  1619. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grunig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, (2015). Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med, 373(9), 834-844.
     
  1620. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyl (2015). Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med, 373(3), 220-231.
     
  1621. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Randerath W, Skowasch D, Meyer FJ, Kirschner J, Glaser S, Herth FJ, Welte T, Huber RM, Neurohr (2015). Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J, 46(1), 186-196.
     
  1622. Fjeld K, Weiss FU, Lasher D, Rosendahl J, Chen JM, Johansson BB, Kirsten H, Ruffert C, Masson E, Steine SJ, Bugert P, Cnop M, Grutzmann R, Mayerle J, Mossner J, Ringdal M, Schulz HU, Sendler M, Simon (2015). A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis. Nat Genet, 47(5), 518-522.
     
  1623. Schaudinn A, Linder N, Garnov N, Kerlikowsky F, Bluher M, Dietrich A, Schutz T, Karlas T, Kahn T, Busse H (2015). Predictive accuracy of single- and multi-slice MRI for the estimation of total visceral adipose tissue in overweight to severely obese patients. NMR Biomed, 28(5), 583-590.
     
  1624. Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rossle M, Panther E, Wiest R, Caca K, Hoffmeister A, Lutz H, Schoo R, Lorenzen H, Trebicka J, Appenrodt B, Schepke M, Fimmers R (2015). Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology, 149(3), 660-668.
     
  1625. Wiltberger G, Bucher JN, Schmelzle M, Hoffmeister A, Dietrich A (2015). Preoperative Endoscopy and Its Impact on Perioperative Management in Bariatric Surgery. Dig Surg, 32(4), 238-242.
     
  1626. Mischnik A, Kaase M, Lubbert C, Seifert H, Kern WV (2015). [Carbapenem-resistance in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii]. Dtsch Med Wochenschr, 140(3), 172-176.
     
  1627. Ducomble T, Faucheux S, Helbig U, Kaisers UX, Konig B, Knaust A, Lubbert C, Moller I, Rodloff AC, Schweickert B, Eckmanns T (2015). Large hospital outbreak of KPC-2-producing Klebsiella pneumoniae: investigating mortality and the impact of screening for KPC-2 with polymerase chain reaction. J Hosp Infect, 89(3), 179-185.
     
  1628. Casper M, Mengel M, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grunhage F, Lammert F (2015). The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. Trials, 16, 83.
     
  1629. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W (2015). Interferon-? rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun, 6, 6422.
     
  1630. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourliere M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, (2015). Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med, 373(27), 2608-2617.
     
  1631. Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P (2015). Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer, 121(20), 3631-3638.
     
  1632. Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D Ambrosio R, Maggioni M, De Francesco R, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L (2015). Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 62(1), 111-117.
     
  1633. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(1), 6-7.
     
  1634. Sarkar S, Sarkar R, Berg T, Schaefer M (2015). Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. Br J Psychiatry, 206(1), 45-51.
     
  1635. Sarrazin C, Berg T, Buggisch P, Dollinger MM, Hinrichsen H, Hofer H, Huppe D, Manns MP, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S (2015). [S3 guideline hepatitis C addendum]. Z Gastroenterol, 53(4), 320-334.
     
  1636. Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF (2015). Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. Hepatology, 62(3), 726-736.
     
  1637. Wang H, El Maadidi S, Fischer J, Grabski E, Dickhofer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Loffler MW, Wiese M, Pichulik T, Mullhaupt B, Semela D, Dufour JF, Bochud P (2015). A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology, 62(5), 1375-1387.
     
  1638. Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kinh N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Mer (2015). Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther, 42(7), 829-844.
     
  1639. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(2), 253-254.
     
  1640. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(3), 503-504.
     
  1641. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(4), 753-755.
     
  1642. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(5), 991-994.
     
  1643. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(6), 1221-1224.
     
  1644. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: December 2015. J Hepatol, 63(6), 1299-1302.
     
  1645. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: November 2015. J Hepatol, 63(5), 1057-1061.
     
  1646. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: July 2015. J Hepatol, 63(1), 1-4.
     
  1647. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: August 2015. J Hepatol, 63(2), 293-295.
     
  1648. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: September 2015. J Hepatol, 63(3), 537-539.
     
  1649. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the Editors desk...: October 2015. J Hepatol, 63(4), 775-777.
     
  1650. van Bömmel F, Berg T (2015). Langzeittherapie der HBV-Infektion mit oralen Polymeraseinhibitoren. Der Gastroenterologe, 10, 268-283.
     
  1651. Thiele AG, Rohde C, Mutze U, Arelin M, Ceglarek U, Thiery J, Baerwald C, Kiess W, Beblo S (2015). The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply. Mol Genet Metab Rep, 4, 62-67.
     
  1652. Moreau R, Bataller R, Berg T, Zucman-Rossi J, Jalan R (2015). From the editors desk ... J Hepatol, 62(1), 6-7.
     
  1653. Feisthammel J, Dietrich A (2015). Analprolaps und Rektumprolaps. In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-4), Heidelberg: Springer.
     
  1654. Ott K, Lordick F, Siewert JR (2015). Oesophageal Cancer: Treatment Strategies In: , Kuzdzal J. Textbook of Thoracic Surgery, Volume 2 (S. 591-600), Cracow : Medycyna Praktyczna.
     
  1655. Bahra M, Lordick F, Lutz M, Glanemann M, Neuhaus P (2015). Pankreaskarzinom In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 557-567), Berlin Heidelberg: Springer.
     
  1656. Lordick F (2015). Supportive Tumortherapien. In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 440-445), Berlin Heidelberg: Springer.
     
  1657. Feisthammel J (2015). Analfissur In: Lehnert H, Referenzwerk Innere Medizin (S. 1-4), Heidelberg: Springer.
     
  1658. Hammerschmidt S, Wirtz H, Bein T (2015). Beatmungsinduzierte Lungenschädigung. In: Bein T, Pfeifer M, Intensivbuch Lunge und Beatmung. (S. 141-151), Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft.
     
  1659. Wardemann H, Benckert J (2015). Kapitel 18: Immunologische Grundlagen entzündlicher Erkrankungen des Gastrointestinaltrakts. In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 185-189), Heidelberg: Springer.
     
  1660. Banasch M, Benckert J, Berg T, Kraus M, Pathil-Warth A, Pfersdorff M, Schmidt WE, Stremmel W, Trautwein C, Wasmuth HE, Wiegand J (2015). Kapitel 23: Entzündliche Lebererkrankungen. In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 303-349), Heidelberg: Springer.
     
  1661. Berg T (2015). Kapitel 7: Hepatologie (I) In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie - GastroUpdate 2015. (S. 1-57), Wiesbaden: med publico GmbH.
     
  1662. Berg T (2015). Kapitel 13: Akute Hepatitiden und akutes Leberversagen In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2015. (S. 1-33), Wiesbaden: med publico GmbH.
     
  1663. Böhlig A, Puchner KP, Berg T (2015). 15. Extrahepatic Manifestations of Chronic HCV In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2015 - A Clinical Textbook. (S. 321-341), Wuppertal: Flying Publisher.
     
  1664. van Bömmel F, Wiegand J, Berg T (2015). 9. Hepatitis B Treatment In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2015 - A Clinical Textbook. (S. 143-179), Wuppertal: Flying Publisher.
     
  1665. Feisthammel J (2015). Analvenenthrombose. In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-3), Heidelberg: Springer.
     
  1666. Feisthammel J (2015). Feigwarzen(Condyloma acuminata) In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-4), Heidelberg: Springer.
     
  1667. Feisthammel J (2015). Marisken In: Lehnert H, Referenzwerk Innere Medizin (S. 1-2), Heidelberg: Springer.
     
  1668. Fleig WE, Hoffmeister A, Lordick F (2015). Kapitel A4.7 Dünndarmneoplasien, Kolonpolypen und Gastrointestinale Polyposis-Syndrome. In: Meyer J, Jung N, Mayet WJ, Mertens P, Müller OA, Pfeifer M, Weiss N, Schellinger P, Wendtner CM, Rationelle Diagnostik und Therapie in der Inneren Medizin. (S. 1-7), München: Urban und Fischer in Elsevier.
     
  1669. Hoffmeister A, Hacker U (2015). Analkarzinom. In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-7), Heidelberg: Springer.
     
  1670. Berges W, Ell C, Hoffmeister A, Manner H, Moche M, Rünzi M (2015). Kapitel 4: Diagnostische und therapeutische Verfahren in der Viszeralmedizin In: Erckenbrecht JF, Jonas S, Viszeralmedizin. (S. 37-68), Heidelberg: Springer.
     
  1671. Mössner J, Rosendahl J (2015). Ätiologie, Pathogenese und Genetik der chronischen Pankreatitis. In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-7), Heidelberg: Springer.
     
  1672. Mössner J (2015). Nebenwirkungen von nichtsteroidalen Antiphlogistika (NSAR) im Gastrointestinaltrakt. In: Lehnert H, Referenzwerk Innere Medizin. (S. 1-4), Heidelberg: Springer.
     
  1673. Mössner J (2015). Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe U, Paffrath D, Arzneiverordnungs-Report 2015. (S. 757-788), Heidelberg: Springer.
     
  1674. Wiedmann M, Mössner J (2015). Esophageal Cancer: Molecular Mechanisms, Diagnosis and Treatment In: de Mello RA, Tavares A, Mountzios G, International Manual of Oncology Practice (S. 201-228), Switzerland: Springer International Publishing.
     


    1675. 2014


  1675. Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX (2014). Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection, 42(2), 309-16.
     
  1676. Beer S, Sahin-Toth M (2014). Exonic variants affecting pre-mRNA splicing add to genetic burden in chronic pancreatitis. Gut, 63(5), 860-861.
     
  1677. Lordick F, Hoffmeister A (2014). [Treatment of gastric cancer.] Internist (Berl), 55(1), 15-22.
     
  1678. Lordick F, Lorenzen S, Yamada Y, Ilson D (2014). Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer, 17(2), 213-225.
     
  1679. Stein C, Baerwald C (2014). Opioids for the treatment of arthritis pain. Expert Opin Pharmacother, 15(2), 193-202.
     
  1680. Weis S, John E, Lippmann N, Mossner J, Lubbert C (2014). [Clostridium difficile Infection (CDI) in the Course of Time - An Issue Only for the Internist?] Zentralbl Chir, 139(4), 460-8.
     
  1681. Lordick F, Hoffmeister A (2014). [Treatment of gastric cancer.] Internist (Berl), 55(1), 15-22.
     
  1682. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty Jr JF, McHutchison JG, Manns M (2014). Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol, 60(4), 715-722.
     
  1683. Wiegand J, Wedemeyer H, Franke A, Rossler S, Zeuzem S, Teuber G, Wachtler M, Rommele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns MP, Brosteanu O, Tillmann HL (2014). Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat, 21(10), 744-750.
     
  1684. Gomez-Martin C, Lopez-Rios F, Aparicio J, Barriuso J, Garcia-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vazquez-Sequeiros E, Lordick F (2014). A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett, 351(1), 30-40.
     
  1685. Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A (2014). Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev, 40(6), 692-700.
     
  1686. Lordick F (2014). Mistletoe treatment for cancer-promising or passé? Editorial. Dtsch Arztebl Int, 111(29-30), 491-492.
     
  1687. Lorenzen S, Sporl S, Lordick F (2014). [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer]. Z Gastroenterol, 52(8), 821-830.
     
  1688. Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Tredan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F (2014). Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol, 31(8), 76.
     
  1689. Lordick F (2014). Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol, 15(9), 914-916.
     
  1690. Lordick F, Knodler M, Hacker U, Bartels M (2014). [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. Chirurg, 85(1), 11-16.
     
  1691. Ahlhorn M, Lordick F (2014). Fortgeschrittenes Pankreaskarzinom. Möglicher Einfluss der Mistel auf das Überleben Der Onkologe, 20, 376-378.
     
  1692. Coutelle O, Büning H, Plütschow A, Fuchs M, Escalona-Espinosa L, Engert A, Hacker UT (2014). Prognostic Serum Cytokines in Classical Hodgkin Lymphoma? Letter. Clin Cancer Res, 20(24), 6633.
     
  1693. Lordick F, Ricke J, Mohnike K, Hacker U (2014). How to create evidence for the integration of locoregional treatments in future oncological treatment concepts? Viszeralmedizin, 30(4), 261-268.
     
  1694. Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Piekarek M, Brinkmann K, Seeger JM, Liwschitz M, Miwa S, Hallek M, Kronke M, Trifunovic A, Eming SA, Wiesner RJ, Hacker UT, Kashkar H (2014). Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol Med, 6(5), 624-639.
     
  1695. Quandt D, Rothe K, Scholz R, Baerwald CW, Wagner U (2014). Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis. PLoS One, 9(3), e93293.
     
  1696. Luttosch F, Baerwald C (2014). Pain management in elderly patients. Z Rheumatol, 73(3), 233-243.
     
  1697. Krasselt M, Baerwald C (2014). Pain treatment of inflammatory rheumatic diseases. Dtsch Med Wochenschr, 139(49), 2526-2528.
     
  1698. Krasselt M L, Wagner U (2014). Alterung und Immunität. Osteologie, 23(3), 195-201.
     
  1699. Krasselt M, Baerwald C (2014). The current relevance and use of prednisone in rheumatoid arthritis. Expert Rev Clin Immunol., 10(5), 557-571.
     
  1700. Schubert K, Meusch U, Scholz R, Rossol M, Wagner U (2014). To which lineage do tumor necrosis factor receptor type I-positive proinflammatory cells belong? Comment on the article by Schmidt et al. Arthritis Rheumatol., 66(7), 1961-1062.
     
  1701. Karlas T, Weber J, Nehring C, Kronenberger R, Tenckhoff H, Mossner J, Niederwieser D, Troltzsch M, Lange T, Keim V (2014). Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT. Bone Marrow Transplant, 49(6), 806-811.
     
  1702. Karlas T, Petroff D, Garnov N, Bohm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A, Busse H, Kahn T, Mossner J, Berg T, Troltzsch M, Keim V, Wiegand J (2014). Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One, 9(3), e91987.
     
  1703. Karlas T, Lindner F, Troltzsch M, Keim V (2014). Assessment of spleen stiffness using acoustic radiation force impulse imaging (ARFI): definition of examination standards and impact of breathing maneuvers. Ultraschall Med, 35(1), 38-43.
     
  1704. Schreyer AG, Jung M, Riemann JF, Niessen C, Pregler B, Grenacher L, Hoffmeister A (2014). S3 guideline for chronic pancreatitis - diagnosis, classification and therapy for the radiologist. Rofo, 186(11), 1002-1008.
     
  1705. Seyfarth HJ, Favreau N, Tennert C, Ruffert C, Halank M, Wirtz H, Mossner J, Rosendahl J, Kovacs P, Wittenburg H (2014). Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol, 13(6), 803-809.
     
  1706. Soares MP, Gozzelino R, Weis S (2014). Tissue damage control in disease tolerance. Trends Immunol, 35(10), 483-494.
     
  1707. Weis S, Schlaich TC, Dehghani F, Carvalho T, Sommerer I, Fricke S, Kahlenberg F, Mossner J, Hoffmeister A (2014). p8 Deficiency causes siderosis in spleens and lymphocyte apoptosis in acute pancreatitis. Pancreas, 43(8), 1277-1285.
     
  1708. Feisthammel J, Mössner J, Hoffmeister A (2014). Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. Viszeralmedizin, 30(4), 238-243.
     
  1709. Hoffmeister A, Mössner J (2014). Therapy of chronic pancreatitis - a guideline based review. Der Gastroenterologe, 9, 14-20.
     
  1710. Mossner J, Siegmund B (2014). [Chronic inflammatory bowel diseases]. Editorial. Internist (Berl), 55, 881-882.
     
  1711. Mossner J (2014). [Faecal calprotectin: less inappropriate endoscopies? - measurement of calprotectin mostly does not replace endoscopy]. Dtsch Med Wochenschr, 139(20), 1036.
     
  1712. Mossner J, Hiddemann W (2014). [Gastrointestinal tumors]. Einführung. Internist (Berl), 55(1), 5-6.
     
  1713. Rosendahl J, Mossner J (2014). [Intraductal papillary mucinous neoplasm of the pancreas]. Dtsch Med Wochenschr, 139(17), 894-897.
     
  1714. Tuennemann J, Mossner J, Beer S (2014). [Acute pancreatitis: guideline-based diagnosis and treatment]. Internist (Berl), 55(9), 1045-1056.
     
  1715. Lubbert C, Rodloff AC, Laudi S, Simon P, Busch T, Mossner J, Bartels M, Kaisers UX (2014). Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in liver transplant recipients. Liver Transpl, 20(6), 736-738.
     
  1716. Lubbert C, John E, von Muller L (2014). Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int, 111(43), 723-731.
     
  1717. Lubbert C, Schumacher U, Stareprawo S, Claus J, Heess-Erler G, Fiebig C, de With K, Wilhelms D, Kekule AS, Kloss T, Moritz S (2014). [Can the antibiotic prescription practice in a hospital be influenced by in-house guidelines?]. Dtsch Med Wochenschr, 139(50), 2578-2584.
     
  1718. Lubbert C, Lippmann N, Busch T, Kaisers UX, Ducomble T, Eckmanns T, Rodloff AC (2014). Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany. Am J Infect Control, 42(4), 376-380.
     
  1719. Lippmann N*, Lubbert C*, Kaiser T, Kaisers UX, Rodloff AC (2014). Clinical epidemiology of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis, 14(4), 271-272.
     
  1720. Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B, Frei U, Berg T (2014). Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol, 60(5), 928-933.
     
  1721. Krohn S, Bohm S, Engelmann C, Hartmann J, Brodzinski A, Chatzinotas A, Zeller K, Prywerek D, Fetzer I, Berg T (2014). Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites. J Clin Microbiol, 52(5), 1754-1757.
     
  1722. Marino Z, van Bommel F, Forns X, Berg T (2014). New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut, 63(2), 207-215.
     
  1723. van Bommel F, Berg T (2014). Antiviral therapy of chronic hepatitis B. Intervirology, 57(3-4), 171-180.
     
  1724. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H (2014). Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Aliment Pharmacol Ther, 39(11), 1342-1344.
     
  1725. Wiese M, Fischer J, Lobermann M, Gobel U, Grungreiff K, Guthoff W, Kullig U, Richter F, Schiefke I, Tenckhoff H, Zipprich A, Berg T, Muller T (2014). Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology, 59(1), 49-57.
     
  1726. Berg T (2014). Therapie der chronischen Hepatitis C mit Simeprevir, dem Proteasehemmer der nächsten Generation. Thieme Drug Report, 8, 1-16.
     
  1727. Baid-Agrawal S, Berg T (2014). Reply to: Underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients. J Hepatol, 61(5), 1185-1186.
     
  1728. Muller T, Wiese M, Berg T (2014). Reply to the Letter to the Editor by Claudio Puoti and Lia Bellis. Hepatology, 60(4), 1449-1450.
     
  1729. Deterding L, Braunlich J, Borte G, Seyfarth HJ, Wirtz H (2014). [Bilateral pneumothorax following acupuncture]. Pneumologie, 68(12), 799-801.
     
  1730. Kuhn H, Petzold K, Hammerschmidt S, Wirtz H (2014). Interaction of cyclic mechanical stretch and toll-like receptor 4-mediated innate immunity in rat alveolar type II cells. Respirology, 19(1), 67-73.
     
  1731. Fleischer M, Hinz A, Brahler E, Wirtz H, Bosse-Henck A (2014). Factors associated with fatigue in sarcoidosis. Respir Care, 59(7), 1086-1094.
     
  1732. Seyfarth HJ, Favreau N, Tennert C, Ruffert C, Halank M, Wirtz H, Mossner J, Rosendahl J, Kovacs P, Wittenburg H (2014). Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol, 13(6), 803-809.
     
  1733. Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Buchler M, Lordick F, Slotta-Huspenina J, Weichert W, Hofler H, Feith M, Ott K (2014). A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. Ann Surg Oncol, 21(3), 915-921.
     
  1734. Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Dietz A, Bechmann I (2014). Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer, 110(2), 479-488.
     
  1735. Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K (2014). Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer, 17(3), 478-88.
     
  1736. Albrecht K, Kruger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, et al. (2014). German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int, 34(1), 1-9.
     
  1737. Rohde C, von Teeffelen-Heithoff A, Thiele AG, Arelin M, Mutze U, Kiener C, Gerloff J, Baerwald C, Schultz S, Heller C, Muller AS, Kiess W, Beblo S (2014). PKU patients on a relaxed diet may be at risk for micronutrient deficiencies. Eur J Clin Nutr, 68(1), 119-124.
     
  1738. Halm U, Lamberts R, Knigge I, Mossner J, Zachaus M (2014). Esophageal intramural pseudodiverticulosis: endoscopic diagnosis and therapy. Dis Esophagus, 27(3), 230-234.
     
  1739. Strnad P, Nuraldeen R, Fischer J, Berg T, Trautwein C (2014). Hepcidin as a predictor of treatment response in chronic hepatitis C infection. Hepatology, 59(4), 1648.
     
  1740. Kabacam G, Wedemeyer H, Savas B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalcin K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydin C (2014). Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. Liver Int, 34(8), 1207-1215.
     
  1741. Toro P, Degen C, Pierer M, Gustafson D, Schroder J, Schonknecht P (2014). Cholesterol in mild cognitive impairment and Alzheimers disease in a birth cohort over 14 years. Eur Arch Psychiatry Clin Neurosci, 264(6), 485-92.
     
  1742. Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R (2014). Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol, 38(11), 1551-1556.
     
  1743. Aichler M, Luber B, Lordick F, Walch A (2014). Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol, 20(38), 13648-13657.
     
  1744. Fakhrian K, Ordu AD, Haller B, Theisen J, Lordick F, Bisof V, Molls M, Geinitz H (2014). Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus : A comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol, 190(11), 987-992.
     
  1745. Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A (2014). Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget, 5(16), 6620-6632.
     
  1746. Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Tureci O (2014). Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. Cancer Immunol Immunother, 63(12), 1273-1284.
     
  1747. Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Buchler M, Ott K (2014). Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol, 21(5), 1739-1748.
     
  1748. Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Buchler MW, Siewert JR, Lordick F, Ott K (2014). Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer, 110(7), 1712-1720.
     
  1749. Homayounfar K, Bleckmann A, Helms HJ, Lordick F, Ruschoff J, Conradi LC, Sprenger T, Ghadimi M, Liersch T (2014). Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases. Br J Surg, 101(5), 550-557.
     
  1750. Brucher BL, Lyman G, van Hillegersberg R, Pollock RE, Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D Ugo D, Roviello F, Steinau HU, et al. (2014). Imagine a world without cancer. BMC Cancer, 14, 186.
     
  1751. Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K (2014). A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer, 14, 58.
     
  1752. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R (2014). Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol, 25(1), 107-116.
     
  1753. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol, 25(5), 1018-1025.
     
  1754. Ott K, Schmidt T, Lordick F, Herrmann K (2014). [Importance of PET in surgery of esophageal cancer]. Chirurg, 85(6), 505-512.
     
  1755. Fakhrian K, Ordu AD, Lordick F, Theisen J, Haller B, Omrcen T, Molls M, Nieder C, Geinitz H (2014). Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU : More than 20 years experience at a single institution. Strahlenther Onkol, 190(12), 1133-1140.
     
  1756. Dietz A, Knödler M, Lordick F (2014). Primärtherapie der Kopf-Hals-Tumoren. Der Onkologe, 20(2), 144-151.
     
  1757. Homayounfar K, Lordick F, Ghadimi M (2014). Qualitätssicherung: Multidisziplinäre Tumorboards - trotz Problemen unverzichtbar. Dtsch Ärztebl, 111(22), A 998−1001.
     
  1758. Cella CA, Carlomagno C, Lordick F, Moretto R, De Stefano A, Raimondo L, D Armiento M, Camera L, Guadagno E, Attademo L, Feliciano S, Matano E (2014). Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4. Oncol Res Treat, 37(1-2), 55-58.
     
  1759. Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rubsam M, Huber A, Chiorini J, Almarza D, Eming SA, Ulus H, Nishimura S, Hacker UT, Hallek M, Niessen CM, Buning H (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther, 22(5), 929-939.
     
  1760. Steinhoff K, Pierer M, Siegert J, Pigla U, Laub R, Hesse S, Seidel W, Sorger D, Seese A, Kuenstler JU, Pietzsch HJ, Lincke T, Rullmann M, Emmrich F, Sabri O (2014). Visualizing inflammation activity in rheumatoid arthritis with Tc-99 m anti-CD4-mAb fragment scintigraphy. Nucl Med Biol, 41(4), 350-354.
     
  1761. Wiltberger G, Schmelzle M, Schubert S, Lubbert C, Brandmaier P, Berg T, Pfeiffer D, Rodloff A, Mohr FW, Jonas S (2014). Invasive cardiac aspergillosis after orthotopic liver transplantation. Z Gastroenterol, 52(8), 813-817.
     
  1762. Garnov N, Linder N, Schaudinn A, Bluher M, Karlas T, Schutz T, Dietrich A, Kahn T, Busse H (2014). Comparison of T1 relaxation times in adipose tissue of severely obese patients and healthy lean subjects measured by 1.5T MRI. NMR Biomed, 27(9), 1123-1128.
     
  1763. Hau HM, Fellmer P, Schoenberg MB, Schmelzle M, Morgul MH, Krenzien F, Wiltberger G, Hoffmeister A, Jonas S (2014). The collateral caval shunt as an alternative to classical shunt procedures in patients with recurrent duodenal varices and extrahepatic portal vein thrombosis. Eur J Med Res, 19, 36.
     
  1764. Nischalke HD, Lutz P, Kramer B, Sohne J, Muller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer HP, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U (2014). A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. J Hepatol, 61(5), 1073-1079.
     
  1765. Singer S, Danker H, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Kersting A (2014). Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials, 15, 482.
     
  1766. Benito de Valle M, Muller T, Bjornsson E, Otten M, Volkmann M, Guckelberger O, Wiedenmann B, Sadik R, Schott E, Andersson M, Berg T, Lindkvist B (2014). The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis, 46(10), 903-908.
     
  1767. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balik I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja J (2014). Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat, 21(Suppl.), 5-33.
     
  1768. de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Kraal G, Mulde (2014). Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology, 147(2), 443-452.
     
  1769. Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, Maieron A, Stern JO, Ozan M, Datsenko Y, Bocher WO, Steinmann G (2014). SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon ?-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. Antimicrob Agents Chemother, 58(6), 3429-3436.
     
  1770. Franke L, Therstappen E, Schlosser B, Biermer M, Berg T, Schafer M, Arck P, Uebelhack R, Friebe A (2014). A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. Depress Res Treat, 2014, 821381.
     
  1771. Glaser K, Kuppardt A, Krohn S, Heidtmann A, Harms H, Chatzinotas A (2014). Primer pairs for the specific environmental detection and T-RFLP analysis of the ubiquitous flagellate taxa Chrysophyceae and Kinetoplastea. J Microbiol Methods, 100, 8-16.
     
  1772. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg (2014). Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One, 9(2), e87974.
     
  1773. Grammatikos G, Farnik H, Bon D, Bohlig A, Bader T, Berg T, Zeuzem S, Herrmann E (2014). The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. J Viral Hepat, 21(8), 533-541.
     
  1774. Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP (2014). Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat, 21(9), 662-670.
     
  1775. Lipskoch M, Wiese M, Timm J, Roggendorf M, Viazov S (2014). Genetic heterogeneity of hepatitis C virus cell entry receptors seems to have no influence on selection of virus variants. Virol J, 11, 50.
     
  1776. Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP, Cornberg M, Herrmann E, Wedemeyer H (2014). PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic Hepatitis C. PLoS One, 9(4), 94512.
     
  1777. Mihm U, Welker MW, Teuber G, Wedemeyer H, Berg T, Sarrazin C, Bohm S, Alshuth U, Herrmann E, Zeuzem S (2014). Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J Viral Hepat, 21(1), 42-52.
     
  1778. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B (2014). ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med, 370(21), 1973-1982.
     
  1779. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hezode C, Lazaro P, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ ... et al. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with todays treatment paradigm. J Viral Hepat, 21(Suppl1), 34-59.
     
  1780. Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Huppe D, Manns M, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S (2014). Aktuelle Empfehlungen zur Therapie der chronischen Hepatitis C. Z Gastroenterol, 52(10), 1185-1197.
     
  1781. Stickel F, Buch S, Zoller H, Hultcrantz R, Gallati S, Osterreicher C, Finkenstedt A, Stadlmayr A, Aigner E, Sahinbegovic E, Sarrazin C, Schafmayer C, Braun F, Erhart W, Nothnagel M, Lerch MM, Mayerle (2014). Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet, 23(14), 3883-3890.
     
  1782. Susser S, Herrmann E, Lange C, Hamdi N, Muller T, Berg T, Perner D, Zeuzem S, Sarrazin C (2014). Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One, 9(11), e112592.
     
  1783. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Ormeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandao Mello CE, Bru (2014). Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat, 21(Suppl.1), 60-89.
     
  1784. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauv (2014). Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology, 146(2), 430-441.
     
  1785. Meier F, Oltmanns A, Brandmaier P, Wittekind C (2014). [Case report about a 35 year old patient with cystic fibrosis and metastatic pancreatic cancer]. Z Gastroenterol, 52(1), 55-57.
     
  1786. Singer S, Danker H, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mossner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Kersting A (2014). Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials, 15, 482.
     
  1787. Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D (2014). Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res, 1(1), 000010.
     
  1788. Riemekasten G, Kuebler WM, Schermuly R, Seyfarth HJ, Behr J, Grohe C, Hoeper MM, Olschewski A, Kwapiszewska G, Ulrich S, Voswinckel R, Weissmann N, Worth H, Viales RR, Pullamsetti SS, Grunig G (2014). [Pulmonary arterial hypertension - a disease of the immune system?]. Dtsch Med Wochenschr, 139(Suppl.4), S116-120.
     
  1789. Wilkens H, Lang I, Blankenburg T, Grohe C, Guth S, Held M, Klepetko W, Konstantinides S, Kramm T, Kruger U, Lankeit M, Schafers HJ, Seyfarth HJ, Mayer E (2014). [Chronic thromboembolic pulmonary hypertension - A position paper]. Dtsch Med Wochenschr, 139(Suppl.4), S155-165.
     
  1790. Wilkens H, Lang I, Blankenburg T, Grohe C, Guth S, Held M, Klepetko W, Konstantinides S, Kramm T, Kruger U, Lankeit M, Schafers HJ, Seyfarth HJ, Mayer E (2014). [Chronic thromboembolic pulmonary hypertension-a position paper]. Dtsch Med Wochenschr, 139(43), 2204-2206.
     
  1791. Keusch S, Hildenbrand FF, Bollmann T, Halank M, Held M, Kaiser R, Kovacs G, Lange TJ, Seyfarth HJ, Speich R, Ulrich S (2014). Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration, 88(1), 38-45.
     
  1792. Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Correa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Z (2014). Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatol Int, 8(4), 517-526.
     
  1793. Lordick F (2014). Nausea und Emesis in der Onkologie. 1.Auflage 2014 In: Lorenzen S, Nausea und Emesis in der Onkologie. (S. 1-157), Bremen: Uni-Med Verlag AG.
     
  1794. Mössner J (2014). Kapitel 31. Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe U, Paffrath D, Arzneiverordnungs-Report 2014. (S. 747-780), Berlin, Heidelberg: Springer Verlag.
     
  1795. Hoffmeister A (2014). Exkurs nicht-operative Verfahren - Endoskopische Adipositastherapie. In: Hellbardt M, Ernährung im Kontext der bariatrischen Chirurgie. (S. 77-80), Lengerich: Pabst Verlag.
     
  1796. Lübbert C (2014). Antiinfektiva - Leitfaden für die empirische Therapie und Prophylaxe. In: Lübbert C, Antiinfektiva - Leitfaden für die empirische Therapie und Prophylaxe. (S. 1-132), Leipzig: Merkur Druck und Kopierzentrum.
     
  1797. Berg T (2014). Kapitel 12: Akute Hepatitiden und akutes Leberversagen. In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie - HepatoUpdate 2014 (S. 1-30), Wiesbaden: med publico GmbH.
     
  1798. Berg T (2014). Kapitel 7: Hepatologie (I). In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie - GastroUpdate 2014. (S. 1-61), Wiesbaden: med publico GmbH.
     
  1799. Böhlig A, Puchner KP, Berg T (2014). 7. Extrahepatic Manifestations. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Short Guide to Hepatitis C. (S. 139-148), Wuppertal: Flying Publisher.
     
  1800. Böhlig A, Puchner KP, Berg T (2014). 15. Extrahepatic Manifestations of Chronic HCV. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2014 - A Clinical Textbook. (S. 307-327), Wuppertal: Flying Publisher.
     
  1801. van Bömmel F, Wiegand J, Berg T (2014). 9. Hepatitis B Treatment. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology 2014 - A Clinical Textbook. (S. 140-176), Wuppertal: Flying Publisher.
     
  1802. Wirtz H (2014). - Lymphangioleiomyomatose - Suche nach neuen Aufgaben - Ausblick In: WATL e.V., 50 Jahre WATL Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten e.V. (Hrsg.) (S. 18 Seiten), Leipzig: Merkur.
     


    1803. 2013


  1803. Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J (2013). ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients. J Cyst Fibros, 12(6), 826-827.
     
  1804. Lordick F, Holscher AH, Haustermans K, Wittekind C (2013). Multimodal treatment of esophageal cancer. Langenbecks Arch Surg, 398(2), 177-87.
     
  1805. Braunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H (2013). Effects of Nasal High Flow on Ventilation in Volunteers, COPD and Idiopathic Pulmonary Fibrosis Patients. Respiration, 85(4), 319-25.
     
  1806. Fischer J, Bohm S, George J, Sarrazin C, Berg T (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection. Hepatology, 57(1), 416-417.
     
  1807. Lordick F (2013). [Comments on the statement of the German Society of Pathology (DGP) on clinical studies from a clinical perspective]. Pathologe, 34(5), 476-478.
     
  1808. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 14(6), 490-499.
     
  1809. Lubbert C, Johann C, Kekule AS, Worlitzsch D, Weis S, Mossner J, Behl S, Seufferlein T (2013). [Immunosuppressive treatment as a risk factor for the occurrence of clostridium difficile infection (CDI)]. Z Gastroenterol, 51(11), 1251-1258.
     
  1810. Malysheva O, Esber A, Baerwald C (2013). Änderungen des autonomen Nervensystems bei rheumatoider Arthritis. Akt Rheumatol, 38(4), 241-246.
     
  1811. Mayerle J, Hoffmeister A, Werner J, Witt H, Lerch MM, Mossner J (2013). Chronic pancreatitis--definition, etiology, investigation and treatment. Dtsch Arztebl Int, 110(22), 387-393.
     
  1812. Oorschot BV, Rades D, Lordick F (2013). Connections are clearly more complexy. Dtsch Arztebl Int, 110(44), 753.
     
  1813. Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T, Gastmeier P, Eckmanns T, Rodloff AC, Kaisers UX (2013). Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents, 42(6), 565-570.
     
  1814. Lordick F, Rocken C (2013). The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Editorial. Ann Oncol, 24(5), 1135-1138.
     
  1815. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jager D, Buchler M, Siewert JR, Lordick F (2013). Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg, 398(2), 239-249.
     
  1816. Rosendahl J, Hoffmeister A, Schierle K, Maiwald B, Kahn T, Mossner J, Wittenburg H (2013). When in doubt, take it out? Cholestasis and obstructive gastric outlet syndrome in a patient with suspected chronic pancreatitis. Pancreatology, 13(4), 458-460.
     
  1817. Krasselt M, Baerwald C, Wagner U, Rossol M (2013). CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther, 15(5), 139-147.
     
  1818. Meusch U, Klingner M, Baerwald C, Rossol M, Wagner U (2013). Deficient spontaneous in-vitro apoptosis and increased tmTNF reverse signaling induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther, 15(6), 219-229.
     
  1819. Rossol M, Schubert K, Meusch U, Schulz A, Biedermann B, Grosche J, Pierer M, Scholz R, Baerwald C, Thiel A, Hagen S, Wagner U (2013). Tumor necrosis factor receptor type I expression of CD4+ T cells in rheumatoid arthritis enables them to follow tumor necrosis factor gradients into the rheumatoid synovium. Arthritis Rheum, 65(6), 1486-1476.
     
  1820. Wagner U, Schatz A, Baerwald C, Rossol M (2013). Brief report: deficient thymic output in rheumatoid arthritis despite abundance of prethymic progenitors. Arthritis Rheum, 65(10), 2567-2572.
     
  1821. Unger SI, Baerwald C (2013). Kutane leukozytoklastische Vaskulitis, Purpura Schönlein-Henoch und kryoglobulinämische Vaskulitis, Cutaneous Leukocytoclastic Vasculitis, Henoch-Schönlein Purpura and Cryoglobulinemic Vasculitis Akt Rheumatol , 38(5), 294-299.
     
  1822. Krasselt M, Baerwald C (2013). Soft tissue rheumatic syndromes and treatment of pain. Dtsch Med Wochenschr, 138(49), 2536-2538.
     
  1823. Baerwald C (2013). Interactions between Nervous and Immune Systems in Rheumatology. Editorial. Akt Rheumatol , 38(4), 217.
     
  1824. Lordick F, Forstmeyer D, Ahlborn M, Becker-Schiebe M, Hoffmann W, Schumacher G (2013). Medical Treatment of Peritoneal Carcinomatosis. Vizeralmedizin 2013, 29, 213-219.
     
  1825. Lordick F, Jähne J (2013). Evidence-Based Medicine oder Erfahrungsmedizin - Grenzentscheidungen in der Onkologie benötigen den erfahrenen Arzt. Viszeralmedizin, 29, 205-206.
     
  1826. Lorenzen S, Lordick F (2013). Therapie des fortgeschrittenen Magenkarzinoms. Onkologe 2013, 84, 389-394.
     
  1827. Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer, 109(6), 1408-1413.
     
  1828. Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U (2013). Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology, 84(5), 284-289.
     
  1829. Rosendahl J, Landt O, Bernadova J, Kovacs P, Teich N, Bodeker H, Keim V, Ruffert C, Mossner J, Kage A, Stumvoll M, Groneberg D, Kruger R, Luck W, Treiber M, Becker M, Witt H (2013). CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? Gut, 62(4), 582-592.
     
  1830. Beer S, Zhou J, Szabo A, Keiles S, Chandak GR, Witt H, Sahin-Toth M (2013). Comprehensive functional analysis of chymotrypsin C (CTRC) variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk. Gut, 62(11), 1616-1624.
     
  1831. Hoffmeister A, Tuennemann J, Sommerer I, Mossner J, Rittger A, Schleinitz D, Kratzsch J, Rosendahl J, Kloting N, Stahl T, Rossner S, Paroni F, Maedler K, Kovacs P, Bluher M (2013). Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. Obesity (Silver Spring), 21(12), 626-633.
     
  1832. Weis S, Franke A, Mossner J, Jakobsen JC, Schoppmeyer K (2013). Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev, 12, 003046.
     
  1833. Wiedmann MW, Mossner J (2013). New and emerging combination therapies for esophageal cancer. Cancer Manag Res, 5, 133-146.
     
  1834. Witt H, Beer S, Rosendahl J, Chen JM, Chandak GR, Masamune A, Bence M, Szmola R, Oracz G, Macek M Jr, Bhatia E, Steigenberger S, Lasher D, Buhler F, Delaporte C, Tebbing J, Ludwig M, Pilsak C, Saum K, Bugert P, Masson E, Paliwal S, Bhaskar S, Sobczynska-Tomaszewska A, Bak D, Balascak I, Choudhuri G, Nageshwar Reddy D, Rao GV, Thomas V, Kume K, Nakano E, Kakuta Y, Shimosegawa T, Durko L, Szabo A, Schnur A, Hegyi P, Rakonczay Z Jr, Pfutzer R, Schneider A, Groneberg DA, Braun M, Schmidt H, Witt U, (2013). Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet, 45(10), 1216-1220.
     
  1835. Working Group IAP/APA Acute Pancreatitis (2013). IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology, 13(4, Suppl.2), e1-15.
     
  1836. Feisthammel J, Jonas S, Mossner J, Hoffmeister A (2013). [The role of endoscopy in the therapy for perforations and leakages of the gastrointestinal tract]. Zentralbl Chir, 138(3), 295-300.
     
  1837. Lubbert C, Weis S (2013). [Drug therapy of infectious diarrhea: part 1: acute diarrhea]. Internist (Berl), 54(11), 1383-1392.
     
  1838. Lubbert C, Weis S (2013). [Drug therapy of infectious diarrhea : Part 2: chronic diarrhea]. Internist (Berl), 54(12), 1513-1519.
     
  1839. Lübbert C, Lippmann N, Rodloff AC (2013). Hochresistente Enterobakterien: Systematisches Screening ist notwendig. Deutsches Ärzteblatt, 110(46), 2206-2207.
     
  1840. Mossner J (2013). [Acute upper gastrointestinal bleeding outside regular working hours: do prognostic scores make sense?]. Dtsch Med Wochenschr, 138(21), 1095.
     
  1841. Mossner J (2013). [Precancerous conditions]. Internist (Berl), 54(6), 669-670.
     
  1842. Mossner J (2013). [Fascinating internal medicine. A personal viewpoint]. Dtsch Med Wochenschr, 138(14), 687-688.
     
  1843. Feisthammel J, Mossner J, Hoffmeister A (2013). [A quite usual pancreatitis?]. Dtsch Med Wochenschr, 138(36), 1765-1768.
     
  1844. Grimm M, Lubbert C, Mossner J, Weis S (2013). A young traveller presenting with typhoid fever after oral vaccination: a case report. J Med Case Rep, 7(1), 237.
     
  1845. Karlas T, Mossner J, Keim V (2013). A 44-year-old patient with fever, night sweats, and arthralgia. Gastroenterology, 145(1), 1-3.
     
  1846. Karlas T, Hoffmeister A, Fuchs J, Troltzsch M, Keim V (2013). Bile duct obstruction after transjugular intrahepatic portosystemic shunt implantation. Endoscopy, 45(Suppl.2), 47-48.
     
  1847. Lubbert C, Schubert S (2013). Phagocytosis of a mature schizont in severe falciparum malaria. Int J Infect Dis, 17(12), e1265.
     
  1848. Tuennemann J, Mossner J, Hoffmeister A (2013). Acute cerebrovascular incident as a complication of TIPS procedure. Z Gastroenterol, 51(4), 381-383.
     
  1849. Walldorf J, Lubbert C (2013). [Pitfalls in Diagnosis and Therapy for CMV Colitis in a 30-Year-Old HIV-Positive Patient]. Z Gastroenterol, 51(8), 740-743.
     
  1850. Wittenburg H, Keim V, Hoffmeister A (2013). Heap of stones: an unusual cause for biliary colic and elevated liver function tests. Ann Hepatol, 12(3), 493-494.
     
  1851. Wirtz H (2013). [In Process Citation]. Zentralbl Chir, 138(Suppl 1), S59-74.
     
  1852. Fischer J, Bohm S, Muller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fulop B, van Bommel F, George J, Berg T (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PLoS One, 8(10), e77530.
     
  1853. Kant J, Moller B, Heyne R, Herber A, Bohm S, Maier M, Liebert UG, Mossner J, Berg T, Wiegand J (2013). Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. Eur J Gastroenterol Hepatol, 25(4), 416-420.
     
  1854. Knop V, Teuber G, Klinker H, Moller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T (2013). Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Ann Hepatol, 12(2), 190-198.
     
  1855. Knop V, Bergk A, Schlosser B, Thieringer J, van Bommel F, Frost N, Kintscher U, Berg T (2013). Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. Eur J Gastroenterol Hepatol, 25(5), 594-600.
     
  1856. Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J (2013). Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS One, 8(6), e67481.
     
  1857. Muller T, Beutler C, Pico AH, Otten M, Durr A, Al-Abadi H, Guckelberger O, Meyer Zum Buschenfelde D, Johrens K, Volkmann M, Lankisch T, Voigtlander T, Anders M, Shibolet O, Jefferson DM, Podolsky DK, Fischer A, Veltzke-Schlieker W, Adler A, Baumgart DC, Sturm A, Wiedenmann B, Schott E, Berg T (2013). Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. Gastroenterology, 144(5), 1116-1128.
     
  1858. Berg T (2013). Update Intensivmedizin - Hepatologische Intensivmedizin. Med Klin Intensivmed Notfmed, 108, 180-181.
     
  1859. Böhlig A, Berg T (2013). Impfung bei Virushepatitis. Gastroenterologe, 8(1), 41-49.
     
  1860. Engelmann C, Berg T (2013). [Acute and acute-on chronic-liver failure]. Dtsch Med Wochenschr, 138(31), 1574-1577.
     
  1861. Karlas T, Wiegand J, Berg T (2013). Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab, 27(2), 195-208.
     
  1862. van Bommel F, Berg T (2013). Treatment of HBV related cirrhosis. Liver Int, 33(Suppl 1), 176-181.
     
  1863. Wiegand J, Berg T (2013). The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int, 110(6), 85-91.
     
  1864. Seyfarth HJ, Hammerschmidt S, Halank M, Neuhaus P, Wirtz HR (2013). Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulm Circ, 3(3), 632-638.
     
  1865. Fluhr G, Mayerle J, Weber E, Aghdassi A, Simon P, Gress T, Seufferlein T, Mossner J, Stallmach A, Rosch T, Muller M, Siegmund B, Buchner-Steudel P, Zuber-Jerger I, Kantowski M, Hoffmeister A, Rosendah (2013). Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol, 13, 11.
     
  1866. Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schroder M, Billing H, Fichtner A, Feneberg R, Sander A, Kopf-Shaki (2013). Epidemiology and morbidity of epstein-barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis, 56(1), 84-92.
     
  1867. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Grohe C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert (2013). Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol, 168(2), 871-880.
     
  1868. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, Winkler J, Seyfarth HJ, Glaser S, Blumberg F, Obst A, Dandel M, Hetzer R, Ewert R (2013). Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol, 167(4), 1193-1198.
     
  1869. Emmrich JV, Kamprad M, Sorge I, Hammerschmidt S, Gradistanac T, Schille R, Kiess W, Prenzel F (2013). Extensive fibrosis caused by Pleural Tuberculosis: A lesson from a case without post-exposure-prophylaxis. Pediatr Pulmonol, 48(2), 206-209.
     
  1870. Wilke H, Lordick F, Meyer HJ, Stahl M (2013). (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the west. Dig Surg, 30(2), 112-118.
     
  1871. Warneke VS, Behrens HM, Haag J, Balschun K, Boger C, Becker T, Ebert MP, Lordick F, Rocken C (2013). Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol, 22(3), 127-137.
     
  1872. Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N (2013). Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol, 24(8), 2068-2073.
     
  1873. Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Blaker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jager D, Buchler M, Siewert JR, Ott K (2013). A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol, 39(8), 823-830.
     
  1874. Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Dux M, Farkas S, Folprecht G, Galle P, Geissler M, Gerken G, Ha (2013). [Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol, 51(11), 1269-1326.
     
  1875. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buys (2013). Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst, 105(21), 1600-1607.
     
  1876. Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2013). Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol, 24(3), 725-733.
     
  1877. Harren K, Brandhoff B, Knodler M, Tudzynski B (2013). The High-Affinity Phosphodiesterase BcPde2 Has Impact on Growth, Differentiation and Virulence of the Phytopathogenic Ascomycete Botrytis cinerea. PLoS One, 8(11), e78525.
     
  1878. Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S (2013). Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany Clin Exp Rheumatol. , 31(3), 400-408.
     
  1879. Fischbach W, Baerwald C, Darius H, Gross M, Nickenig G, Nusslein H, Stichtenoth DO (2013). [Pain treatment with traditional NSAR and coxibs: an interdisciplinary assessment]. Dtsch Med Wochenschr, 138(3), 91-96.
     
  1880. Wigand R, Baerwald C, Krause A, Wollenhaupt J, Gaubitz M (2013). 12 Years of Celecoxib - an Inventory. Akt Rheumatol , 38(1), 38-44.
     
  1881. Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schull S, Andree M, Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebber U, Hacker UT, Kronke M, Mauch C, Hoppe T, Kashkar H (2013). Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep, 3(3), 881-891.
     
  1882. Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Kohne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol, 24(6), 1560-1567.
     
  1883. Huang H, Liu Y, Daniluk J, Gaiser S, Chu J, Wang H, Li ZS, Logsdon CD, Ji B (2013). Activation of nuclear factor-kappa B in acinar cells increases the severity of pancreatitis in mice. Gastroenterology, 144(1), 202-210.
     
  1884. Layer P, Dellinger EP, Forsmark CE, Levy P, Maravi-Poma E, Shimosegawa T, Siriwardena AK, Uomo G, Whitcomb DC, Windsor JA, Petrov MS (2013). [Determinant-based classification of acute pancreatitis severity. International multidisciplinary classification of acute pancreatitis severity: the 2013 German edition]. Z Gastroenterol, 51(6), 544-550.
     
  1885. Lohr JM, Dinter D, Diehl SJ, Haas SL, Veeser M, Pfutzer R, Retter J, Schonberg SO, Duber C, Keim V, Schadendorf D, Witt H (2013). Rapid progression of a splenic aneurysm due to segmental arterial mediolysis: a rare cause of acute pancreatitis. Pancreatology, 13(5), 553-556.
     
  1886. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, S (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 369(9), 809-818.
     
  1887. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C (2013). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 369(4), 319-329.
     
  1888. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med, 369(4), 330-340.
     
  1889. Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J (2013). ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients. J Cyst Fibros, 12(6), 826-827.
     
  1890. Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Glaser S, Gottlieb J, Grohe C, Kreuter M, Kroegel C, Markart P, Neurohr C, Pfeifer M, Prasse A, Schonfeld N, Schre (2013). [German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie, 67(2), 81-111.
     
  1891. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, Ghofrani A, Rosenkranz S, Seyfarth HJ, Halank M, Mayer E, Grunig E, Guth S (2013). Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res, 14, 104.
     
  1892. Grunig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E, D\'Andrea A, Naeije R, Olschewski H, Ulrich S, Nagel C, Halank M, Fischer C (2013). Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation, 128(18), 2005-2015.
     
  1893. Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, Meyer FJ, Grunig E, Seyfarth HJ, Kolditz M, Wieder G, Hoffken G, Kollner V (2013). Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung, 191(4), 337-343.
     
  1894. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, Preston IR, Barbera JA, Hassoun PM, Halank M, Jais X, Nickel N, Hoeper MM, Humbert M (2013). Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J, 41(4), 1302-1307.
     
  1895. Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Grosshennig A, Koch A, Diepolder H, Luth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Sc (2013). Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis, 13(6), 497-506.
     
  1896. Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Fuller C, Daumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T, Zeuzem S, Herrmann E, Sarrazin C (2013). Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol, 87(11), 6172-6181.
     
  1897. Jungst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F (2013). Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest, 43(10), 1069-1083.
     
  1898. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Mullhaupt B, Negro F, Semela D, Kutalik Z, Mull (2013). Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One, 8(5), e64053.
     
  1899. Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismuller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Ju (2013). Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet, 45(6), 670-675.
     
  1900. Marzioni M, Saccomanno S, Agostinelli L, Rychlicki C, De Minicis S, Pierantonelli I, Trauner M, Fickert P, Muller T, Shanmukhappa K, Trozzi L, Candelaresi C, Baroni GS, Benedetti A (2013). PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis. J Hepatol, 58(4), 750-756.
     
  1901. Nischalke HD, Berger C, Lutz P, Langhans B, Wolter F, Eisenhardt M, Kramer B, Kokordelis P, Glassner A, Muller T, Rosendahl J, Fischer J, Berg T, Grunhage F, Leifeld L, Soyka M, Nattermann J, Sauerbru (2013). Influence of the CXCL1 rs4074 A allele on alcohol induced cirrhosis and HCC in patients of European descent. PLoS One, 8(11), e80848.
     
  1902. Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK (2013). Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol, 58(3), 452-459.
     
  1903. Scaiewicz V, Nahmias A, Chung RT, Mueller T, Tirosh B, Shibolet O (2013). CCAAT/Enhancer-Binding Protein Homologous (CHOP) Protein Promotes Carcinogenesis in the DEN-Induced Hepatocellular Carcinoma Model. PLoS One, 8(12), e81065.
     
  1904. Schaefer M, Berg T, Sarkar S, Neumann K (2013). Escitalopram for the prevention of peginterferon-alpha 2a-associated depression. Ann Intern Med, 158(2), 140.
     
  1905. Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Gunther R, Zeuzem S, Gosseringer R, Ehrlich A, Neumann K, Wachtlin D, Sprinzl MF, Zimmermann T, Bocher WO, Galle PR (2013). No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. Dig Liver Dis, 45(4), 323-329.
     
  1906. Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlensti (2013). CCR5-delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes Immun, 14(5), 286-290.
     
  1907. Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F, Kitrinos KM (2013). Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat, 20(2), 131-140.
     
  1908. Uzi D, Barda L, Scaiewicz V, Mills M, Mueller T, Gonzalez-Rodriguez A, Valverde AM, Iwawaki T, Nahmias Y, Xavier R, Chung RT, Tirosh B, Shibolet O (2013). CHOP is a critical regulator of acetaminophen-induced hepatotoxicity. J Hepatol, 59(3), 495-503.
     
  1909. Ziegler S, Ruhl M, Tenckhoff H, Wiese M, Heinemann FM, Horn PA, Spengler U, Neumann-Haefelin C, Nattermann J, Timm J (2013). Susceptibility to chronic hepatitis C virus infection is influenced by sequence differences in immunodominant CD8+ T cell epitopes. J Hepatol, 58(1), 24-30.
     
  1910. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL (2013). Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 62(5), 760-765.
     
  1911. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM (2013). Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology, 57(3), 974-984.
     
  1912. Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J (2013). PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology, 58(2), 524-537.
     
  1913. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ (2013). Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med, 369(7), 630-639.
     
  1914. Lordick F, Hacker U (2013). Zielgerichtete Therapie des kolorektalen Karzinoms. 1. Auflage 2013. In: Hacker U, Zielgerichtete Therapie des kolorektalen Karzinoms. 1. Auflage 2013. (S. 1-45), Bremen: Uni-Med Verlag AG Bremen.
     
  1915. Karlas T, Feisthammel J, Mössner J (2013). Evidenz der laborchemischen Diagnostik des Pankreaskarzinoms. In: Beger HG, Büchler MW, Dralle H, Lerch M, Malfertheiner P, Mössner J, Riemann JF, Erkrankungen des Pankreas - Evidenz in Diagnostik, Therapie und Langzeitverlauf. (S. 360-362), Berlin, Heidelberg: Springer Verlag.
     
  1916. Mössner J, Rosendahl J (2013). Genetik entzündlicher Pankreaserkrankungen. In: Beger HG, Büchler MW, Dralle H, Lerch M, Malfertheiner P, Mössner J, Riemann JF, Erkrankungen des Pankreas - Evidenz in Diagnostik, Therapie und Langzeitverlauf. (S. 11-14), Berlin, Heidelberg: Springer Verlag.
     
  1917. Teich N, Mössner J (2013). Symptomatische und spezifische Therapie der akuten biliären, alkoholischen und idiopathischen Pankreatitis. In: Beger HG, Büchler MW, Dralle H, Lerch M, Malfertheiner P, Mössner J, Riemann JF, Erkrankungen des Pankreas - Evidenz in Diagnostik, Therapie und Langzeitverlauf. (S. 30-31), Berlin, Heidelberg: Springer Verlag.
     
  1918. Mössner J (2013). Kapitel 32. Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D, Arzneiverordnungs-Report 2013. (S. 703-732), Berlin, Heidelberg: Springer Verlag.
     
  1919. Lübbert C (2013). Kapitel 18. Infektionen des Herzens. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 248-253), Stuttgart: Thieme Verlag.
     
  1920. Lübbert C (2013). Kapitel 19. Infektionen des Verdauungstrakts. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 254-261), Stuttgart: Thieme Verlag.
     
  1921. Lübbert C (2013). Kapitel 20. Infektionen der Haut und der Weichteile. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 262-269), Stuttgart: Thieme Verlag.
     
  1922. Lübbert C (2013). Kapitel 22. Infektionen des zentralen Nervensystems (ZNS). In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 276-281), Stuttgart: Thieme Verlag.
     
  1923. Lübbert C (2013). Kapitel 23. Infektionen des Auges. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 282-285), Stuttgart: Thieme Verlag.
     
  1924. Lübbert C (2013). Kapitel 24. Infektionen des Ohrs. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 286-289), Stuttgart: Thieme Verlag.
     
  1925. Lübbert C (2013). Kapitel 25. Infektionen von Knochen und Gelenken. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 290-295), Stuttgart: Thieme Verlag.
     
  1926. Lübbert C (2013). Kapitel 29. Sexuell übertragbare Krankheiten. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 320-331), Stuttgart: Thieme Verlag.
     
  1927. Lübbert C (2013). Kapitel 30. Tropische und importierte Infektionskrankheiten. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 332-339), Stuttgart: Thieme Verlag.
     
  1928. Lübbert C (2013). Kapitel 31. Infektiologische Notfälle. In: Jassoy C, Schwarzkopf A, Hygiene, Infektiologie, Mikrobiologie. (S. 340-341), Stuttgart: Thieme Verlag.
     
  1929. Berg T (2013). Kapitel 13. Akutes Leberversagen und akute Hepatitis. In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie 2013 - HepatoUpdate 2013. (S. 32 S.), Wiesbaden: med publico GmbH.
     
  1930. Berg T (2013). Hepatologie (I). In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie 2013 - Gastro Update 2013. (S. 54 S.), Wiesbaden: med publico GmbH.
     
  1931. Böhlig A, Puchner KP, Berg T (2013). 15. Extrahepatic Manifestations of Chronic HCV. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 279-298), Wuppertal: Flying Publisher.
     
  1932. van Bömmel F, Wiegand J, Berg T (2013). 9. Hepatitis B Treatment. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 133-168), Wuppertal: Flying Publisher.
     


    1933. 2012


  1933. Pierer M, Rothe K, Quandt D, Schulz A, Rossol M, Scholz R, Baerwald C, Wagner U (2012). Reply. Arthritis Rheum, 64(8), 2804-5.
     
  1934. Lordick F (2012). Gastrointestinal cancer: Salvage chemotherapy in gastric cancer-more than a straw? Nat Rev Clin Oncol, 9(6), 312-313.
     
  1935. Lordick F (2012). [Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial]. Strahlenther Onkol, 188(7), 636-637.
     
  1936. Lordick F (2012). To resect or not resect in metastatic gastric cancer: that is the question! Gastric Cancer, 15(3), 229-231.
     
  1937. Lordick F (2012). Supportive treatment – an integral part of cancer Care. Editorial. Magazine of European Medical Oncology , 5(1), 1-2.
     
  1938. Lordick F (2012). Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res, 196, 201-211.
     
  1939. Ewert R, Glaser S, Winkler J, Schrader H, Trumper BG, Haase PU, Obst A, Hoheisel G (2012). [Cardiopulmonary Exercise Testing (CPET) in severe COPD--a multicentre comparison of two test protocols]. Pneumologie, 66(7), 402-407.
     
  1940. Seyfahrt HJ (2012). Pulmonale Hypertonie bei Lungenerkrankungen - Diagnose, Häufigkeit, prognostische Implikationen und therapeutische Überlegungen. Atemwegs- und Lungenerkrankungen, 38(5), 173-178.
     
  1941. Baerwald C, Kneitz C, Bach M, Licht M (2012). [Extra-articular manifestations of rheumatoid arthritis]. Z Rheumatol, 71(10), 841-849.
     
  1942. Malysheva O, Wagner U, Wahle M, Wagner U, Stalla GK, Baerwald CG (2012). Corticotropin releasing hormone (CRH) response in patients with early rheumatoid arthritis due to polymorphisms in the CRH gene. Clin Exp Rheumatologie, 30(3), 421-3.
     
  1943. Pierer M, Rothe K, Quandt D, Schulz A, Rossol M, Scholz R, Baerwald C, Wagner U (2012). Association of anticytomegalovirus seropositivity with more severe joint destruction and more frequent joint surgery in rheumatoid arthritis. Arthritis Rheum, 64(6), 1740-1749.
     
  1944. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U (2012). The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum, 64(3), 671-677.
     
  1945. Rossol M, Pierer M, Raulien N, Quandt D, Meusch U, Rothe K, Schubert K, Schoneberg T, Schaefer M, Krugel U, Smajilovic S, Brauner-Osborne H, Baerwald C, Wagner U (2012). Extracellular Ca(2+) is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun, 3, 1329.
     
  1946. Unger S, Baerwald CG (2012). [Soft tissue pain syndromes]. Dtsch Med Wochenschr, 137(49), 2574-2576.
     
  1947. Luttosch F, Baerwald C (2012). Pharmacological Treatment of Osteoarthritis. Akt Rheumatol , 37, 366-370.
     
  1948. Baerwald C (2012). Osteoarthritis - Pathophysiology and Therapy. Akt Rheumatol , 37, 357.
     
  1949. Baerwald C (2012). Osteoarthritis, pain management, fibromyalgia. Z Rheumatol , 71(11), 730-731.
     
  1950. Baerwald C (2012). Nicht-interventionelle Studie: Prednison MR bewegt Patienten. Deutsche Zeitschrift für Klinische Forschung. DZKF, 16, 63-64.
     
  1951. Grachtrup S, Brugel M, Pankau H, Halank M, Wirtz H, Seyfarth HJ (2012). Exercise dependence of N-terminal pro-brain natriuretic peptide in patients with precapillary pulmonary hypertension. Respiration, 84(6), 454-460.
     
  1952. Feisthammel J, Fritzsch D, Weis S, Mossner J, Hoffmeister A (2012). Endovascular coiling: an important technique in the management of gastrointestinal hemorrhage. Can J Gastroenterol, 26(10), 683.
     
  1953. Feisthammel J, Moche M, Mössner J, Hoffmeister A (2012). The use of a hemostasis introducer for percutaneus extraction of bile duct stones. Gastroenterology Research, 5(1), 6-9.
     
  1954. Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, Rensing-Ehl A, Ehl S, Reifenberger J, Loddenkemper C, Maul J, Hoffmeister A, Aretz S, Kiess W, Eng C, Uhlig HH (2012). Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology, 142(5), 1093-1096.
     
  1955. Hoffmeister A, Mayerle J, Dathe K, Mossner J, Lerch MM (2012). [Method report to the S3 guideline chronic pancreatitis: definition, etiology, diagnostics and conservative, interventional endoscopic and surgical therapy of the chronic pancreatitis]. Z Gastroenterol, 50(11), 1225-1236.
     
  1956. Hoffmeister A, Mayerle J, Beglinger C, Buchler MW, Bufler P, Dathe K, Folsch UR, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel WT, Layer P, Loehr M, Meier R, Riemann JF, Runzi M, Schmid RM, S (2012). [S3-Consensus guidelines on definition, etiology, diagnosis and medical, endoscopic and surgical management of chronic pancreatitis German Society of Digestive and Metabolic Diseases (DGVS)]. Z Gastroenterol, 50(11), 1176-1224.
     
  1957. Huster D, Kuhne A, Bhattacharjee A, Raines L, Jantsch V, Noe J, Schirrmeister W, Sommerer I, Sabri O, Berr F, Mossner J, Stieger B, Caca K, Lutsenko S (2012). Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology, 142(4), 947-956.
     
  1958. Karlas T, Hempel M, Troltzsch M, Huster D, Gunther P, Tenckhoff H, Mossner J, Berg T, Keim V, Wiegand J (2012). Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scand J Gastroenterol, 47(11), 1353-1361.
     
  1959. Karlas T, Neuschulz M, Oltmanns A, Guttler A, Petroff D, Wirtz H, Mainz JG, Mossner J, Berg T, Troltzsch M, Keim V, Wiegand J (2012). Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One, 7(7), e42139.
     
  1960. Lubbert C, Wilhelms D, Worlitzsch D, Ettrich TJ, Behl S, Seufferlein T (2012). [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)]. Z Gastroenterol, 50(4), 373-381.
     
  1961. Rosendahl J, Tonjes A, Schleinitz D, Kovacs P, Wiegand J, Ruffert C, Jesinghaus M, Schober R, Herms M, Grutzmann R, Schulz HU, Stickel F, Werner J, Bugert P, Bluher M, Stumvoll M, Bohm S, Berg T, Witt (2012). A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS One, 7(1), e29433.
     
  1962. Selig L, Reiche M, Ebert T, Krehl D, Kralisch S, Lossner U, Stach B, Bluher M, Stumvoll M, Bodeker H, Keim V, Mossner J, Fasshauer M (2012). Serum levels of adipocyte fatty acid-binding protein are decreased in chronic pancreatitis. Pancreas, 41(8), 1230-1234.
     
  1963. Weis S, Jesinghaus M, Kovacs P, Schleinitz D, Schober R, Ruffert C, Herms M, Wittenburg H, Stumvoll M, Bluher M, Grutzmann R, Schulz HU, Keim V, Mossner J, Bugert P, Witt H, Drenth JP, Krohn K, Rosend (2012). Genetic analyses of heme oxygenase 1 (HMOX1) in different forms of pancreatitis. PLoS One, 7(5), e37981.
     
  1964. Wiedmann MW, Mossner J (2012). Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol, 6, 381-393.
     
  1965. Feisthammel J, Schwalenberg T, Mössner J, Dietrich A (2012). Stuhlinkontinenz Sächsisches Ärzteblatt, 6, 245-248.
     
  1966. Mossner J (2012). [Interdisciplinary cooperation: prerequisite in clarification of pathogenesis as well as diagnostic and therapeutic strategies]. Dtsch Med Wochenschr, 137(22), 1149.
     
  1967. Mossner J (2012). [The wide focus of internal medicine]. Dtsch Med Wochenschr, 137(15), 773.
     
  1968. Mossner J (2012). [Genetically determined diseases. From clarification of the pathogenesis to consequences for therapy]. Internist (Berl), 53(4), 369-370.
     
  1969. Rosendahl J, Mossner J (2012). [Genetically determined pancreatic diseases]. Internist (Berl), 53(4), 386-390.
     
  1970. Mössner J (2012). Innere Medizin im Spiegel der Zeitgeschichte. Eröffnungsrede des 118. Internistenkongresses der Deutschen Gesellschaft für Innere Medizin am 15. April 2012 im Kurhaus Wiesbaden. Der Internist, 53(9), 1095-1098.
     
  1971. Lübbert C (2012). Sanierung eines MRSA-Dekubitus: Orale Antibiotika-Therapie? Consilium Infectiorum, 31, 17-18.
     
  1972. Lübbert C (2012). Antibiotika-Prophylaxe bei passagerem Schrittmacherkabel? Consilium Infectiorum, 33, 18-19.
     
  1973. Berg T, Buggisch P, Hueppe D, Mauss S, Wedemeyer H, Decker-Burgard S (2012). Telaprevir-based triple-therapy in patients with chronic hepatitis C in Germany: a 12-week interim analysis of real-life data. J Int AIDS Soc, 15(6), 18424.
     
  1974. Biermer M, Schlosser B, Fulop B, van Bommel F, Brodzinski A, Heyne R, Keller K, Sarrazin C, Berg T (2012). High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat, 19(8), 547-553.
     
  1975. Fischer J, Bohm S, Scholz M, Muller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bommel F, Brodzinski A, Fulop B, Migaud P, Berg T (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710.
     
  1976. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Disch (2012). Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med, 157(2), 94-103.
     
  1977. Tenckhoff S, Kaiser T, Bredeek F, Donfield S, Menius E, Lail A, Mossner J, Daar ES, Tillmann HL (2012). Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr, 61(2), 243-248.
     
  1978. Vermehren J, Schlosser B, Domke D, Elanjimattom S, Muller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N, Walcher F, Mockel M, Lehmann R, Zeuzem S, Sarrazin C, Berg T (2012). High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28.809 patients. PLoS One, 7(7), e41206.
     
  1979. van Bommel F, Trojan J, Deterding K, Wedemeyer H, Wasmuth HE, Huppe D, Moller B, Bock FJ, Feucht HH, Berg T (2012). Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther, 17(6), 1049-1058.
     
  1980. Wiegand J, Kuhne M, Pradat P, Mossner J, Trepo C, Tillmann HL (2012). Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Aliment Pharmacol Ther, 35(12), 1443-1450.
     
  1981. Benckert J, Berg T (2012). Therapie des Leberzellkarzinoms - aktueller Stand und Ausblick. Mitteilungsblatt der Sächsischen Krebsgesellschaft E.V., 17, 10-12.
     
  1982. Benckert J, Fuchs J, Berg T (2012). Diagnostik und Früherkennung des hepatozellulären Karzinoms. Der Gastroenterologe, 7(5), 390-397.
     
  1983. Berg T, Wiegand J (2012). Prediction of response to treatment in heaptitis B and hepatitis C. Syllabus of the Postgraduate Teaching Programme, 2012, 49-52.
     
  1984. Müller T, Berg T (2012). Immunglobulin G4 (IgG4)-assoziierte hepatobiliäre Erkrankungen. Aktuelle Rheumatologie, 37(5), 299-305.
     
  1985. Halbritter J, Wittenburg H, Schiefke I, Amann K, Lindner T, Rasche FM (2012). MPA: A treatment option for lymphocytic colitis and mesalamine-induced interstitial nephritis. Inflamm Bowel Dis, 18(3), E599-600.
     
  1986. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE (2012). Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. J Clin Gastroenterol, 46(4), 334-8.
     
  1987. Bruns T, Reuken PA, Fischer J, Berg T, Stallmach A (2012). Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. J Hepatol, 56(5), 1207-8.
     
  1988. Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, Wust P, Hamm B, Gebauer B (2012). Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol, 22(5), 1101-9.
     
  1989. Nischalke HD, Berger C, Luda C, Muller T, Berg T, Coenen M, Kramer B, Korner C, Trebicka J, Grunhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U (2012). The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. J Hepatol, 56(4), 758-64.
     
  1990. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Muller T, Berg T, Kramer B, Korner C, Odenthal M, Schulze F, Grunhage F, Nattermann J, Sauerbruch T, Spengler U (2012). The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer, 130(6), 1470-1475.
     
  1991. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P (2012). Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. J Hepatol, 56(3), 520-6.
     
  1992. Lowin T, Weidler C, Jenei-Lanzl Z, Capellino S, Baerwald CG, Buttgereit F, Straub RH (2012). Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum, 64(6), 1799-1808.
     
  1993. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K (2012). Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs, 30(3), 1138-1143.
     
  1994. Blank S, Blaker H, Schaible A, Lordick F, Grenacher L, Buechler M, Ott K (2012). Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg, 397(1), 45-55.
     
  1995. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Holscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, et al. (2012). Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer, 48(16), 2941-53.
     
  1996. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, et al. (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308(2), 147-156.
     
  1997. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sulberg H, Wittekind C, Potapov S, Staib L, Hess C, et al. (2012). Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol, 13(7), 679-687.
     
  1998. Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jager D, Luntz SP, Englert S, Rossion I, Koch M, Buchler MW, Kieser M, Weitz J (2012). Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS-a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer, 12, e142.
     
  1999. Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jager D (2012). A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. BMC Cancer, 12, e108.
     
  2000. Grenacher L, Schwarz M, Lordick F, Krause B, Roecken C, Moenig S, Ebert M, Jenssen C, Kauczor HU, Moehler M (2012). [S3 guideline - diagnosis and treatment of gastric carcinoma: relevance for radiologic imaging] Rofo, 184(8), 706-712.
     
  2001. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K (2012). Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol, 19(7), 2119-2127.
     
  2002. Meyer HJ, Holscher AH, Lordick F, Messmann H, Monig S, Schumacher C, Stahl M, Wilke H, Mohler M (2012). [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg, 83(1), 31-37.
     
  2003. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, Nischt R, Dienes HP, Odenthal M (2012). Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest, 92(7), 978-987.
     
  2004. Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, Weihrauch MR, von Bergwelt-Baildon M, Hacker UT (2012). Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest, 30(3), 225-230.
     
  2005. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B (2012). Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med, 367(6), 508-519.
     
  2006. Illes M, Luttosch F, Pierer M, Simon JC, Ziemer M (2012). Palpable purpura, gingival ulcerations and joint pain in a 24-year-old man. Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis). J Dtsch Dermatol Ges, 10(10), 767-769.
     
  2007. Kruger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Mange (2012). [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol, 71(7), 592-603.
     
  2008. Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Kruger DH, Berg T, Hofmann J (2012). Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol, 56(2), 500-502.
     
  2009. Begum N, Maasberg S, Plockinger U, Anlauf M, Rinke A, Popperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Burk CG, Hoffmann J, Goretzki P, Pape UF (2012). [Neuroendocrine Tumours of the GI Tract - Data from the German NET Registry]. Zentralbl Chir, 137(6), e1.
     
  2010. Dellinger EP, Forsmark CE, Layer P, Levy P, Maravi-Poma E, Petrov MS, Shimosegawa T, Siriwardena AK, Uomo G, Whitcomb DC, Windsor JA (2012). Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg, 256(6), 875-880.
     
  2011. Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Rossner S, Brase S, Lichtenthaler SF (2012). Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J, 31(14), 3157-3168.
     
  2012. Walther M, De Caul A, Aka P, Njie M, Amambua-Ngwa A, Walther B, Predazzi IM, Cunnington A, Deininger S, Takem EN, Ebonyi A, Weis S, Walton R, Rowland-Jones S, Sirugo G, Williams SM, Conway DJ (2012). HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. PLoS Pathog, 8(3), e1002579.
     
  2013. Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y (2012). Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. J Hepatol, 57(2), 260-266.
     
  2014. Hocker B, Bohm S, Fickenscher H, Kusters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schroder M, Feneberg R, Kopf-Shakib S, Tonshoff B (2012). (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int, 25(7), 723-731.
     
  2015. Ingiliz P, Krznaric I, Behrendt D, Baumgarten A, Berg T, Obermeier M (2012). Sexually transmitted infection with an immune-escape mutant hepatitis B virus (HBV) in an HBV-vaccinated individual with acute HIV-HCV infection. J Int AIDS Soc, 15(6), e18432.
     
  2016. Korner C, Riesner K, Kramer B, Eisenhardt M, Glassner A, Wolter F, Berg T, Muller T, Sauerbruch T, Nattermann J, Spengler U, Nischalke HD (2012). TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 12, 85.
     
  2017. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Muller T, Berg T, Bochud (2012). A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One, 7(7), 40159.
     
  2018. Lange J, Yafai Y, Noack A, Yang XM, Munk AB, Krohn S, Iandiev I, Wiedemann P, Reichenbach A, Eichler W (2012). The axon guidance molecule Netrin-4 is expressed by Mueller cells and contributes to angiogenesis in the retina. Glia, 60(10), 1567-1578.
     
  2019. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G (2012). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol, 56(6), 1247-1253.
     
  2020. Rifai K, Hadem J, Wiegand J, Potthoff A, Pischke S, Klempnauer J, Strassburg C, Wedemeyer H, Manns MP, Tillmann HL (2012). Gender differences in patient receiving liver transplantation for viral hepatitis. Z Gastroenterol, 50(8), 760-765.
     
  2021. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S (2012). [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol, 50(1), 57-72.
     
  2022. Stegmann KA, Bjorkstrom NK, Ciesek S, Lunemann S, Jaroszewicz J, Wiegand J, Malinski P, Dustin LB, Rice CM, Manns MP, Pietschmann T, Cornberg M, Ljunggren HG, Wedemeyer H (2012). Interferon alfa-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis, 205(9), 1351-1362.
     
  2023. von Hahn T, Schiene-Fischer C, Van ND, Pfaender S, Karavul B, Steinmann E, Potthoff A, Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Muller T, Berg T, Trepo E, Wedemeyer H, Manns MP, Pietschmann T, (2012). Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. Gastroenterology, 143(2), 439-447.
     
  2024. Deterding K, Heidelberger S, Wiebner B, Meining K, Cornberg M, P Manns M, Wedemeyer H (2012). [Knowledge and management of hepatitis B virus infected patients in Germany]. Dtsch Med Wochenschr, 137(15), 774-780.
     
  2025. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hir (2012). Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology, 143(5), 1244-1252.
     
  2026. Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yi (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. J Viral Hepat, 19(9), 623-634.
     
  2027. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, (2012). Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 143(3), 608-618.
     
  2028. Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D (2012). [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Dtsch Med Wochenschr, 137(49), 2586-2588.
     
  2029. Engeli S, Bluher M, Jumpertz R, Wiesner T, Wirtz H, Bosse-Henck A, Stumvoll M, Batkai S, Pacher P, Harvey-White J, Kunos G, Jordan J (2012). Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens, 30(12), 2345-2351.
     
  2030. Karlas T, Neuschulz M, Oltmanns A, Guttler A, Petroff D, Wirtz H, Mainz JG, Mossner J, Berg T, Troltzsch M, Keim V, Wiegand J (2012). Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One, 7(7), e42139.
     
  2031. Gille J, Seyfarth HJ, Gerlach S, Malcharek M, Czeslick E, Sablotzki A (2012). Perioperative anesthesiological management of patients with pulmonary hypertension. Anesthesiol Res Pract, 2012, e356982.
     
  2032. Nagel C, Prange F, Guth S, Herb J, Ehlken N, Fischer C, Reichenberger F, Rosenkranz S, Seyfarth HJ, Mayer E, Halank M, Grunig E (2012). Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One, 7(7), 41603-10.
     
  2033. Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, Fiehn C, Stockl F, Prange F, Staehler G, Reichenberger F, Tiede H, Halank M, Seyfarth HJ, Wagner S, Nagel C (2012). Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther, 14(3), 148-150.
     
  2034. Grunig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speic (2012). Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J, 40(1), 84-92.
     
  2035. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, Cruz-Monserrate Z, Wang H, Ji B, Logsdon CD (2012). An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest, 122(4), 1519-1528.
     
  2036. Unger S, Baerwald CG (2012). Pain in rheumatic diseases. In: Harrison A, Insights and Perspectives in Rheumatology. (S. 243-254), Rijeka: InTech.
     
  2037. Malysheva OA, Baerwald CG (2012). Interaction between stress and rheumatic diseases. In: Harrsion A, Insights and Perspectives in Rheumatology. (S. 215-240), Rijeka: Intech.
     
  2038. Mössner J (2012). Kapitel 32. Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D, Arzneiverordnungs-Report 2012. (S. 713-743), Berlin, Heidelberg: Springer Medizin Verlag.
     
  2039. Weis S, Benckert J, Mössner J, Moche M (2012). Interventionelle Behandlung von Lebertumoren. In: Zeller WJ, zur Hausen H, Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklung. (S. 1-13), Heidelberg: ecomed Medizin.
     
  2040. Wittenburg H (2012). 12. Hepatobiliary transport and gallstone formation. In: Häussinger D, Keitel V, Kubitz R, Hepatobiliary transport in health and disease. (S. 195-205), Berlin, Boston: Walter de Gruyter.
     
  2041. Berg T (2012). Kapitel 13: Hepatologie (II). In: Ell C, Fischbach W, Layer P, Zirngibl H, Handbuch Gastroenterologie - Gastro Update 2012. (S. 1-46), Wiesbaden: med publico GmbH.
     
  2042. Berg T (2012). Kapitel 13: Hepatologische Intensivmedizin. In: Welte T, Pohl J, Kluge S, Handbuch Intensivmedizin - Intensiv Update 2012. (S. 1-33), Wiesbaden: med publico GmbH.
     
  2043. Berg T (2012). Kapitel 13: Akute Hepatitis und akutes Leberversagen. In: Berg T, Bechstein WO, Jonas S, Lammert F, Handbuch Hepatologie - Hepato Update 2012 (S. 1-46), Wiesbaden: med publico GmbH.
     
  2044. Berg T, Mauss S, Hüppe D, Buggisch P (2012). Empfehlungen des bng zur Therapie der chronischen Hepatitis C - Update 2012 In: Berg T, Mauss S, Hüppe D, Buggisch P, Empfehlungen des bng zur Therapie der chronischen Hepatitis C - Update 2012 (S. 1-70), Ulm: bng, Berufsverband Niedergelassener Gastroenterolo.
     
  2045. Puchner KP, Böhlig A, Berg T (2012). 16. Extrahepatic manifestations of chronic HCV. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 272-290), Wuppertal: Bernd Kamps Steinhäuser Verlag.
     
  2046. Puchner KP, Böhlig A, Berg T (2012). 7. Extrahepatic Manifestations. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Short Guide to Hepatitis C 2012. (S. 91-99), Wuppertal: Bernd Kamps Steinhäuser Verlag.
     
  2047. van Bömmel F, Wiegand J, Berg T (2012). 9. Hepatitis B Treatment. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 128-159), Wuppertal: Bernd Kamps steinhäuser Verlag.
     
  2048. Sablotzki A, Seyfarth HJ (2012). 5.1.12.2 Perioperatives anästhesiologisches Management bei Patienten mit pulmonaler Hypertonie. In: Eckart Jaeger Möllhoff, Anästhesiologie. (S. 1-30), Landsberg Hamburg: ecomed Medizin .
     
  2049. Hammerschmidt S, Wirtz H (2012). Nichtkleinzelliges Lungenkarzinom - TKI, Antikörper, Chemotherapiesequenz, Erhaltung. In: Ehninger G, Dresdner Symposium Hämatologie und Onkologie 2011. (S. 17-31), München: Lukon.
     


    2050. 2011


  2050. Pierer M, Rossol M, Kaltenhauser S, Arnold S, Hantzschel H, Baerwald C, Wagner U (2011). Clonal expansions in selected TCR BV families of rheumatoid arthritis patients are reduced by treatment with the TNFalpha inhibitors etanercept and infliximab. Rheumatol Int, 31(8), 1023-9.
     
  2051. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T (2011). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol, 54(3), 415-421.
     
  2052. Schlosser B, Biermer M, Weich V, van Bommel F, Berg T (2011). Long-term evaluation of patients with sustained virologic remission by highly sensitive HCV RNA assays: No evidence for viral persistence. J Clin Virol, 50(1), 88-89.
     
  2053. Benckert J, Berg T (2011). [Diagnostik und Klinik der Infektion mit Hepatitis-A- und Hepatitis-E-Viren. Übertragung durch Trinkwasser und Lebensmittel] Pharm Unserer Zeit, 40(1), 25-29.
     
  2054. Berg T, Biermer M, Neumann U (2011). Silibinin in hepatitis C related liver transplantation. (Reply) J Hepatol, 54(3), 592.
     
  2055. Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mossner J, Berg T, Tillmann HL, Wiegand J (2011). Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis, 13(3), 299-302.
     
  2056. Malysheva O, Baerwald CG (2011). Low-dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis. Clin Exp Rheumatol, 29(5 ), 113-115.
     
  2057. Luttosch F, Baerwald C (2011). [Treatment of pain in rheumatic diseases]. Dtsch Med Wochenschr, 136(31-32), 1598-1600.
     
  2058. Malysheva O, Wagner U, Wahle M, Pierer M, Wagner U, Stalla GK, Baerwald CG (2011). Hypothalamic-pituitary-adrenal axis stress test in patients with early RA: role of corticotropin-releasing hormone promoter polymorphisms. Ann Rheum Dis, 70(11), 2058-2059.
     
  2059. Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, Hauschildt S (2011). LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol, 31(5), 379-446.
     
  2060. Gaiser S, Daniluk J, Liu Y, Tsou L, Chu J, Lee W, Longnecker DS, Logsdon CD, Ji B (2011). Intracellular activation of trypsinogen in transgenic mice induces acute but not chronic pancreatitis. Gut, 60(10), 1379-1388.
     
  2061. Karlas TF, Pfrepper C, Rosendahl J, Benckert C, Wittekind C, Jonas S, Moessner J, Troltzsch M, Tillmann HL, Berg T, Keim V, Wiegand J (2011). Acoustic radiation force impulse (ARFI) elastography in acute liver failure: necrosis mimics cirrhosis. Z Gastroenterol, 49(4), 443-448.
     
  2062. Karlas T, Pfrepper C, Wiegand J, Wittekind C, Neuschulz M, Mossner J, Berg T, Troltzsch M, Keim V (2011). Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scand J Gastroenterol, 46(12), 1458-1467.
     
  2063. Steiner B, Rosendahl J, Witt H, Teich N, Keim V, Schulz HU, Pfutzer R, Luhr M, Gress TM, Nickel R, Landt O, Koudova M, Macek M Jr, Farre A, Casals T, Desax MC, Gallati S, Gomez-Lira M, Audrezet MP, Fe (2011). Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat, 32(8), 912-920.
     
  2064. Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mossner J, Wiedmann M (2011). Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie, 34(8-9), 469-470.
     
  2065. Thrum S, Lorenz J, Mossner J, Wiedmann M (2011). Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma. Anticancer Res, 31(10), 3289-3299.
     
  2066. Wiedmann MW, Mossner J (2011). Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. Curr Cancer Drug Targets, 11(6), 714-733.
     
  2067. Mossner J (2011). Update lecture: benign diseases of the exocrine pancreas. Dig Dis, 29, 9-16.
     
  2068. Mossner J (2011). [Clinically relevant knowledge for short-on-time readers]. Dtsch Med Wochenschr, 136(31-32), 1565-1566.
     
  2069. Mossner J, Manns MP (2011). [Emergencies in gastroenterology]. Internist (Berl), 52(7), 793-794.
     
  2070. Weis S, Grimm M (2011). [Nosocomial diarrhea]. Internist (Berl), 52(2), 167-177.
     
  2071. Wittenburg H, Tennert U, Berg T (2011). [Complications of liver cirrhosis]. Internist (Berl), 52(9), 1061-1070.
     
  2072. Mössner J (2011). Editorial: Gastroösophageale Refluxkrankheit und ihre Komplikationen. Viszeralmedizin, 27(2), 103-104.
     
  2073. Wagner U, Wirtz H (2011). In Memoriam Prof. Dr. med. Hans-Ludwig Hahn. Pneumologie, 65(11), 705-706.
     
  2074. Frenzel J, Gessner C, Sandvoss T, Hammerschmidt S, Schellenberger W, Sack U, Eschrich K, Wirtz H (2011). Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry. PLoS One, 6(10), e25544.
     
  2075. Hinz A, Fleischer M, Brahler E, Wirtz H, Bosse-Henck A (2011). Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry, 33(5), 462-468.
     
  2076. Hamalainen N, Kohler D, Rabe K, Wirtz H (2011). [Institute of Lung Research - a new organ to support the further development in pneumology]. Dtsch Med Wochenschr, 136(13), 651-652.
     
  2077. Einenkel J, Holler B, Hoffmeister A (2011). Sonographic diagnosis and Endo-SPONGE assisted vacuum therapy of anastomotic leakage following posterior pelvic exenteration for ovarian cancer without using a protective stoma. J Gynecol Oncol, 22(2), 131-134.
     
  2078. Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, Wardemann H (2011). The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest, 121(5), 1946-1955.
     
  2079. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T (2011). Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology, 141(5), 1656-1664.
     
  2080. Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T (2011). The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol, 46(12), 1427-1436.
     
  2081. Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I (2011). Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort. Z Gastroenterol, 49(11), 1463-1469.
     
  2082. Wiegand J, Neumann K, Bohm S, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T (2011). Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis, 53(11), 1111-1114.
     
  2083. Berg T (2011). So klären Sie erhöhte Leberwerte ab! CME, 8(4), 47-54.
     
  2084. Biermer M, Berg T (2011). Chronische Virushepatitis - Adäquate Therapie senkt Zirrhose- und Karzinomrisiko. Hausarzt, 48(12), 32-37.
     
  2085. Herber A, Berg T (2011). Hepatitis C - neue Behandlungen. Med Welt, 62(3), 119-131.
     
  2086. Rosendahl J, Mössner J (2011). Genetics of chronic pancreatitis - new aspects? Postepy Nauk Med, 24(3), 186-192.
     
  2087. Baerwald C, Bolten W (2011). Editorial: Schmerztherapie bei muskuloskelettalen Erkrankungen. Arthritis + Rheuma, 31(2), 77.
     
  2088. Luttosch F, Baerwald C (2011). Biologika, ihre Anwendung, mögliche Kombinationen und die Frage nach Kontraindikationen. Schmerztherapie, 27(1), 3-4.
     
  2089. Malysheva O, Unger S, Luttosch F, Baerwald C (2011). Opioide bei der Schmerztherapie rheumatischer Erkrankungen. Arthritis und Rheuma, 31(2), 99-104.
     
  2090. Malysheva O, Unger S, Luttosch F, Baerwald C (2011). Opioide bei der Schmerztherapie rheumatischer Erkrankungen. Med Welt, 62(5), 240-243.
     
  2091. Baerwald C (2011). Rückenschmerzen - Welche Medikamente helfen? Ars Medici, 101(18), 728-730.
     
  2092. Malysheva O, Unger S, Luttosch F, Baerwald C (2011). Medikamentöse Therapie bei Rückenschmerzen. Der Allgemeinarzt, 33(4), 12-14.
     
  2093. Pierer M, Wagner U, Rossol M, Ibrahim S (2011). Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS One, 6(8), 23539.
     
  2094. Lordick F (2011). Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol, 7(2), 187-199.
     
  2095. Lorenzen S, Lordick F (2011). How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol, 23(4), 396-402.
     
  2096. Lordick F, Ott K, Krause BJ (2011). [Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas] Dtsch Med Wochenschr, 136(20), 1061-1066.
     
  2097. Lordick F (2011). The role of PET in predicting response to chemotherapy in oesophago-gastric cancer. Acta Gastroenterol Belg, 74(4), 530-535.
     
  2098. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Hofler H, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F (2011). Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 11, e509.
     
  2099. Lordick F, Ott K, Sendler A (2011). [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy] Chirurg, 82(11), 968-973.
     
  2100. Lordick F (2011). Current standard and trends in oesophageal cancer. Eur J Cancer, 47 (Suppl 3), S353-354.
     
  2101. Lordick F (2011). HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clin Transl Oncol, 13(9), 597-598.
     
  2102. Hacker U, Buning H (2011). Optimizing the adeno-associated viral vector system: a brief summary. Ther Deliv, 2(8), 967-970.
     
  2103. Hacker UT, Wolf J, Wendtner CM (2011). [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. Dtsch Med Wochenschr, 136(5), 179-181.
     
  2104. Frenzel J, Gessner C, Sandvoss T, Hammerschmidt S, Schellenberger W, Sack U, Eschrich K, Wirtz H (2011). Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry. PLoS One, 6(10), e25544.
     
  2105. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohe C, Gunther A, Halank M, Hammerl P, Held M, Kruger S, Lange TJ, ... Wirtz H et al. (2011). [Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010]. Pneumologie, 65(4), 208-218.
     
  2106. Kuipers EJ, Sung JJ, Barkun A, Mossner J, Jensen D, Stuart R, Lau JY, Ahlbom H, Lind T, Kilhamn J (2011). Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther, 28(2), 150-9.
     
  2107. Iwata R, Stieger B, Mertens JC, Muller T, Baur K, Frei P, Braun J, Vergopoulos A, Martin IV, Schmitt J, Goetze O, Bibert S, Bochud PY, Mullhaupt B, Berg T, Geier A (2011). The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. J Viral Hepat, 18(11), 768-778.
     
  2108. Lettow I, Berres ML, Schmitz P, Muller T, Berg T, Neumann UP, Trautwein C, Wasmuth HE (2011). A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. Hum Immunol, 72(3), 273-277.
     
  2109. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Sch (2011). Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology, 53(1), 62-72.
     
  2110. Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Boecher WO (2011). Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol, 54(6), 1114-22.
     
  2111. Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Boparai N, Griffe (2011). FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(3) program. J Hepatol, 54(2), 227-235.
     
  2112. Schupp CJ, Nitsche A, Bock-Hensley O, Bohm S, Flechtenmacher C, Kurth A, Saenger K, Hoferer M, Kusters U, Gunther P, Engelmann G, Schnitzler P (2011). A 14-year-old girl with a vesicle on her finger and lymphadenitis. J Clin Virol, 50(1), 1-3.
     
  2113. Stickel F, Buch S, Lau K, Zu Schwabedissen HM, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Gunther R, Arlt A, Seeger M, Muller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarra (2011). Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology, 53(1), 86-95.
     
  2114. Tillmann HL, Wiese M, Braun Y, Wiegand J, Tenckhoff S, Mossner J, Manns MP, Weissenborn K (2011). Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat, 18(4), 252-261.
     
  2115. Mutze U, Roth A, Weigel JF, Beblo S, Baerwald CG, Buhrdel P, Kiess W (2011). Transition of young adults with phenylketonuria from pediatric to adult care. J Inherit Metab Dis, 34(3), 701-709.
     
  2116. Koczulla R, Hattesohl A, Biller H, Hofbauer J, Hohlfeld J, Oeser C, Wirtz H, Jorres RA (2011). [Comparison of four identical electronic noses and three measurement set-ups]. Pneumologie, 65(8), 465-470.
     
  2117. Koczulla AR, Hattesohl A, Biller H, Hofbauer J, Hohlfeld J, Oeser C, Gessner C, Vogelmeier C, Baumbach JI, Wirtz H, Jorres RA (2011). [Smelling diseases? A short review on electronic noses]. Pneumologie, 65(7), 401-405.
     
  2118. Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoeper MM, Kramm T, Kruger U, Langer F, Rosenkranz S, Schafers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer E (2011). Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol, 154S1, 54-60.
     
  2119. Halank M, Knudsen L, Seyfarth HJ, Ewert R, Wiedemann B, Kolditz M, Hoffken G, Hoeper MM (2011). Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol, 49(9), 1258-1262.
     
  2120. Teich N, Klugmann T, Tiedemann A, Holler B, Mossner J, Liebetrau A, Schiefke I (2011). Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int, 108(7), 105-111.
     
  2121. Tonjes A, Wittenburg H, Halbritter J, Renner O, Harsch S, Stange EF, Lammert F, Stumvoll M, Kovacs P (2011). Effects of SLC10A2 variant rs9514089 on gallstone risk and serum cholesterol levels- meta-analysis of three independent cohorts. BMC Med Genet, 12, e149.
     
  2122. Benckert C, Quante M, Thelen A, Bartels M, Laudi S, Berg T, Kaisers U, Jonas S (2011). Impact of the MELD allocation after its implementation in liver transplantation. Scand J Gastroenterol, 46(7-8), 941-948.
     
  2123. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK (2011). Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology, 140(7), 1990-1999.
     
  2124. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP (2011). [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol, 49(7), 871-930.
     
  2125. Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Sarrazin C, Berg T, Muller T, Herrmann E, Geisslinger G, Lotsch J (2011). Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet Genomics, 21(5), 289-296.
     
  2126. Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, Neuhaus P, Neumann U (2011). Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant, 9(1), 1-6.
     
  2127. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M (2011). Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl, 17(3), 289-298.
     
  2128. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, Lenz O, Meyvisch P, Peeters M, Sekar V, Simmen K, Verloes R (2011). Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther, 16(7), 1021-1033.
     
  2129. Moller JF, Moller B, Wiedenmann B, Berg T, Schott E (2011). CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection. J Viral Hepat, 18(7), e341-349.
     
  2130. Mueller T, Beutler C, Pico AH, Shibolet O, Pratt DS, Pascher A, Neuhaus P, Wiedenmann B, Berg T, Podolsky DK (2011). Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int, 31(10), 1574-1588.
     
  2131. Muller T, Buch S, Berg T, Hampe J, Stickel F (2011). Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol, 55(3), 732-733.
     
  2132. Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, Berg T, Wedemeyer H, Tenckhoff H, Wiese M, Kullig U, Gobel U, Capka E, Schiefke I, Guthof W, Grungreiff K, Konig I, Roggendorf M, (2011). The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5^32 mutation. J Hepatol, 55(6), 1201-1206.
     
  2133. Nischalke HD, Berger C, Luda C, Berg T, Muller T, Grunhage F, Lammert F, Coenen M, Kramer B, Korner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U (2011). The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One, 6(11), e27087.
     
  2134. Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, Chang DI, Klein M, Heinemann FM, Tenckhoff H, Wiese M, Horn PA, Viazov S, Spengler U, Roggendorf M, Scherbaum N, Nattermann J, Hoffmann (2011). CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology, 140(7), 2064-2073.
     
  2135. Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med, 3(8), e57.
     
  2136. Suppiah V, Gaudieri S, Armstrong NJ, O\'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smed (2011). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med, 8(9), e1001092.
     
  2137. Wellge BE, Sterneck M, Teufel A, Rust C, Franke A, Schreiber S, Berg T, Gunther R, Kreisel W, Zu Eulenburg C, Braun F, Beuers U, Galle PR, Lohse AW, Schramm C (2011). Pregnancy in primary sclerosing cholangitis. Gut, 60(8), 1117-1121.
     
  2138. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bommel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Jan (2011). Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology, 54(2), 443-451.
     
  2139. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohe C, Gunther A, Halank M, Hammerl P, Held M, Kruger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, W (2011). Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol, 154(Suppl), 45-53.
     
  2140. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 377(9779), 1760-1769.
     
  2141. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011). Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med, 364(13), 1207-1217.
     
  2142. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtss (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 364(25), 2405-2416.
     
  2143. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 364(13), 1195-1206.
     
  2144. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP (2011). Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med, 364(4), 322-331.
     
  2145. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heesw (2011). Telaprevir for retreatment of HCV infection. N Engl J Med, 364(25), 2417-2428.
     
  2146. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N (2011). Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology, 54(5), 1538-1546.
     
  2147. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K (2011). Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Mol Imaging Biol, 13(1), 178-186.
     
  2148. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A (2011). Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol, 22(3), 524-535.
     
  2149. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rosler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickho (2011). Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant, 46(8), 1045-1052.
     
  2150. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S (2011). Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol, 22(6), 1358-1366.
     
  2151. Ott K, Lordick F, Blank S, Buchler M (2011). Gastric cancer: surgery in 2011. Langenbecks Arch Surg, 396(6), 743-758.
     
  2152. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R (2011). DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol, 18(9), 2688-2698.
     
  2153. Strohlein MA, Lordick F, Ruttinger D, Grutzner KU, Schemanski OC, Jager M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM (2011). Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie, 34(3), 101-108.
     
  2154. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Bohle E, Bokemeyer C, Bornschein J, et al. (2011). [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"] Z Gastroenterol, 49(4), 461-531.
     
  2155. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Buschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ (2011). Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol, 18(12), 3316-3323.
     
  2156. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR (2011). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer, 47(10), 1511-1520.
     
  2157. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, Budach V, Keilholz U (2011). Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 17(15), 5197-5204.
     
  2158. zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ (2011). (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med, 52(8), 1189-1196.
     
  2159. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jager D, Munter MW (2011). Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer, 11, e266.
     
  2160. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang Y (2011). The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol, 22 (Suppl 5), v1-9.
     
  2161. Coutelle O, Hallek M, Hacker UT (2011). Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer. memo - Magazine of European Medical Oncology, 4(2), 75-78.
     
  2162. Berg T (2011). Hepatologie. In: Ell C, Fischbach W, Layer H, Zirngibl H, Handbuch Gastroenterologie 2011 - Gastro Update 2011. Kapitel 7. (S. 1-67), Wiesbaden: med publico GmbH.
     
  2163. Berg T (2011). Hepatologische Intensivmedizin. In: Welte T, Werdan K, Pohl J, Handbuch Intensivmedizin 2011 - Intensiv Update 2011. Kapitel 6. (S. 1-28), Wiesbaden: med publico GmbH.
     
  2164. Wiegand J, Berg T (2011). Individually tailored treatment strategies in treatment-naive chronic hepatitis C genotype 1 patients. In: McCaughan GW, McHutchinson JG, Pawlotsky JM, Advanced Therapy for Hepatitis C. (S. 74-84), Oxford: Wiley-Blackwell.
     
  2165. Lordick F (2011). Biologie und zielgerichtete Therapie des Magenkarzinoms. In: Lordick F, Biologie und zielgerichtete Therapie des Magenkarzinoms. (S. ), Bremen – London – Boston : Uni-Med Verlag AG .
     
  2166. Lordick F, Peschel V (2011). Therapie-induzierte Nausea und Emesis in der Onkologie. In: Lordick F, Peschel V , Therapie-induzierte Nausea und Emesis in der Onkologie. (S. 1-93), Bremen – London – Boston: Uni-Med Verlag AG .
     


    2167. 2010


  2167. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht (2010). Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 51(1), 73-80.
     
  2168. Wolf S, Lorenz J, Mossner J, Wiedmann M (2010). Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol, 16(2), 156-166.
     
  2169. Petrasch F, Grothaus J, Mossner J, Schiefke I, Hoffmeister A (2010). Differences in bleeding behavior after endoscopic band ligation: a retrospective analysis. BMC Gastroenterol, 10, 5 ff.
     
  2170. Wiegand J, Meya S, Schlaphoff V, Manns MP, Mossner J, Wedemeyer H, Tillmann HL (2010). HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat, 17(9), 631-639.
     
  2171. Dietl P, Liss B, Felder E, Miklavc P, Wirtz H (2010). Lamellar body exocytosis by cell stretch or purinergic stimulation: possible physiological roles, messengers and mechanisms. Cell Physiol Biochem, 25(1), 1-12.
     
  2172. Gessner C, Rechner B, Hammerschmidt S, Kuhn H, Hoheisel G, Sack U, Ruschpler P, Wirtz H (2010). Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer, 68(2), 177-184.
     
  2173. Weis S, Mossner J, Schoppmeyer K (2010). A 79-Year-Old Patient With Yellow Sputum. Gastroenterology, 138(3), e1-e2.
     
  2174. Teich N, Aghdassi A, Fischer J, Walz B, Caca K, Wallochny T, von Aretin A, von Boyen G, Gopel S, Ockenga J, Leodolter A, Ruddel J, Weber E, Mayerle J, Lerch MM, Mossner J, Schiefke I (2010). Optimal timing of oral refeeding in mild acute pancreatitis: results of an open randomized multicenter trial. Pancreas, 39(7), 1088-1092.
     
  2175. Seyfarth HJ, Halank M, Wilkens H, Schafers HJ, Ewert R, Riedel M, Schuster E, Pankau H, Hammerschmidt S, Wirtz H (2010). Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol, 99(9), 553-556.
     
  2176. Kuhn H, Kruger S, Hammerschmidt S, Wirtz H (2010). High concentrations of vascular endothelial growth factor reduce stretch-induced apoptosis of alveolar type II cells. Respirology, 15(2), 343-348.
     
  2177. Grothaus J, Petrasch F, Zeynalova S, Mossner J, Schiefke I, Hoffmeister A (2010). Risk factors for bleeding complications after endoscopic variceal ligation therapy. Z Gastroenterol, 48(10), 1200-1206.
     
  2178. Rosendahl J, Teich N, Kovacs P, Szmola R, Bluher M, Gress TM, Hoffmeister A, Keim V, Lohr M, Mossner J, Nickel R, Ockenga J, Pfutzer R, Schulz HU, Stumvoll M, Wittenburg H, Sahin-Toth M, Witt H (2010). Complete analysis of the human mesotrypsinogen gene (PRSS3) in patients with chronic pancreatitis. Pancreatology, 10(2-3), 243-249.
     
  2179. Rosendahl J, Ronai Z, Kovacs P, Teich N, Wittenburg H, Bluher M, Stumvoll M, Mossner J, Keim V, Bradbury AR, Sahin-Toth M (2010). Sequence analysis of the human tyrosylprotein sulfotransferase-2 gene in subjects with chronic pancreatitis. Pancreatology, 10(2), 165-172.
     
  2180. Mossner J (2010). What's New in Therapy of Pancreatic Cancer? Dig Dis, 28(4-5), 679-683.
     
  2181. Mossner J, Riemann JF (2010). [Small intestine--new approaches in diagnostics and therapy]. Internist (Berl), 51(6), 693-694.
     
  2182. Teich N, Mossner J (2010). [Nutrition in acute pancreatitis]. Dtsch Med Wochenschr, 135(40), 1979-1981.
     
  2183. Wiedmann MW, Mossner J (2010). Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. Curr Drug Targets, 11(7), 834-850.
     
  2184. Wittenburg H, Tennert U, Mossner J (2010). [Hormonal and metabolic functions of the small intestine]. Internist (Berl), 51(6), 695-701.
     
  2185. Karlas T, Markuske M, Schierle K, Mossner J, Bartels M, Bodeker H (2010). [Jejunocolic fistulae after pylorus-preserving pancreatic head resection: an uncommon cause of chronic diarrhea]. Med Klin (Munich), 105(4), 253-257.
     
  2186. Tennert U, Schubert S, Troltzsch M, Ivanova Tchavdarova L, Mossner J, Schoppmeyer K (2010). Pitfall alveolar echinococcosis in non-endemic areas. Alveolar echinococcosis migrating northward. Ann Hepatol, 9(1), 99-103.
     
  2187. Wiegand J, Karlas T, Schiefke I, Krasselt U, Bock T, Mossner J, Tillmann HL (2010). Resistance management in chronic hepatitis B complicated by renal failure. Clin Nephrol, 74(1), 53-58.
     
  2188. Wittenburg H (2010). Hereditary liver disease: gallstones. Best Pract Res Clin Gastroenterol, 24(5), 747-756.
     
  2189. Mirzakhyl S, Wittenburg H (2010). Entstehung des Gallensteinleidens. Risikogruppen und Ansätze für Prävention. Die Medizinische Welt, 61(4), 213-218.
     
  2190. Hoffmeister A, Mössner J (2010). Palliative Therapie des fortgeschrittenen Pankreaskarzinoms. Der Onkologe, 16(6), 604-609.
     
  2191. Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL (2010). Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol, 82(11), 1850-1858.
     
  2192. Karlas T, Pfrepper C, Troeltzsch M, Wiegand J, Keim V (2010). Acoustic radiation force impulse liver stiffness measurement: interlobe differences demand standardized examination procedures. Eur J Gastroenterol Hepatol, 22(11), 1387.
     
  2193. Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J (2010). [ALT screening for chronic liver diseases: scrutinizing the evidence]. Z Gastroenterol, 48(1), 46-55.
     
  2194. Wiegand J, van Bommel F, Berg T (2010). Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis, 30(4), 361-377.
     
  2195. Luttosch F, Baerwald C (2010). [Rehabilitation in rheumatology]. Internist (Berl), 51(10), 1239-1245.
     
  2196. Pierer M, Wagner U (2010). [How do T-cells become activated in joints?]. Z Rheumatol, 69(8), 738ff.
     
  2197. Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T (2010). Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum, 62(12), 3635-3644.
     
  2198. Malysheva O, Pierer M, Wagner U, Baerwald CG (2010). [Stress and rheumatoid arthritis]. Z Rheumatol, 69(6), 539-543.
     
  2199. Lang LJ, Pierer M, Stein C, Baerwald C (2010). Opioids in rheumatic diseases. Ann N Y Acad Sci, 1193, 111-116.
     
  2200. Baerwald C (2010). Schmerz bei rheumatologischen Erkrankungen. Editorial. Akt Rheumatol, 35(3), 163.
     
  2201. Pierer M, Malysheva O, Wagner UG, Baerwald C (2010). Opioide bei muskuloskelettalen Schmerzen. Akt Rheumatol, 35(3), 184-8.
     
  2202. Unger S, Baerwald C (2010). Die leukozytoklastische Vaskulitis. Arthritis & Rheuma, 30(4), 205-210.
     
  2203. Unger S, Baerwald C (2010). Schmerztherapie mit selektiven und nichtselektiven Cyclooxygenaseinhibitoren in der Rheumatologie. Akt Rheumatol, 35(3), 178-83.
     
  2204. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F (2010). Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology, 139(4), 1207-1217.
     
  2205. Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N (2010). A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat, 17(9), 624-630.
     
  2206. Fischer J, Kappelmeyer U, Kästner M, Schauer F, Heipieper HJ (2010). The degradation of bisphenol A by the newly isolated bacterium Cupriavidus basilensis JF1 can be enhanced by biostimulation with phenol Int Biodeter Biodegr, 64(4), 324-330.
     
  2207. Fischer J, Schauer F, Heipieper HJ (2010). The trans/cis ratio of unsaturated fatty acids is not applicable as biomarker for environmental stress in case of long-term contaminated habitats. Appl Microbiol Biotechnol, 87(1), 365-371.
     
  2208. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, Zeuzem S, Hein J, Berg T (2010). High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 52(2), 472-479.
     
  2209. Sarrazin C*, Berg T*, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HH, Spengler U, Wirth S, Kessler HH, Peck-Radosavljevic M, Ferenci P, Vogel W, Moradpour D, Heim M, Cornberg M, Protzer U, (2010). [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol, 48(2), 289-351.
     
  2210. Brodzinski A, van Bömmel F (2010). Chronische Hepatitis B-Infektion bei Migranten. hepatitis & more, 2, 26-28.
     
  2211. Müller T, Rosendahl J, Berg T (2010). IL28B Update 2010. hepatitis & more, 1, 16-20.
     
  2212. van Bömmel F, Berg T (2010). HBV-Genotypen - ein zusätzlicher Parameter für die Indikationsstellung zur Therapie? Hepatitis & more, 2, 21-23.
     
  2213. Rosendahl J, Mössner J (2010). Chronische Pankreatitis. Die Medizinische Welt, 61(4), 219-223.
     
  2214. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T (2010). Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol, 52(6), 951-952.
     
  2215. Berg T (2010). Chronische Hepatitis B und C im Griff. Forschung & Praxis, 512(10), 14-17.
     
  2216. Wiegand J, van Bömmel F, Berg T (2010). Prophylaxe und Therapie der Hepatitis B und C. Kompendium Gastroenterologie, 6(1), 15-21.
     
  2217. Berg T (2010). Die Zukunft der Hepatitis B-Therapie - Welche Rolle werden Kombinationstherapien spielen? Arzneimittelforschung, 60(11), 702ff.
     
  2218. Mossner J, Keim V (2010). Pancreatic enzyme therapy. Dtsch Arztebl Int, 108(34-35), 578-582.
     
  2219. Mossner J (2010). New advances in cell physiology and pathophysiology of the exocrine pancreas. Dig Dis, 28(6), 722-728.
     
  2220. Hacker U, Hallek M, Kubicka S (2010). [Multimodality therapy of colorectal cancer]. Internist (Berl), 51(11), 1366-1373.
     
  2221. Hofheinz RD, Al-Batran SE, Ridwelski K, Gorg C, Wehle K, Birth M, Fetscher S, Scheiber H, Lukan N, Lordick F (2010). Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie, 33(10), 512-518.
     
  2222. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F, Peschel C (2010). Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer, 102(3), 500-505.
     
  2223. Lordick F, Lorenzen S (2010). System therapy of esophageal carcinoma and the value of targeted therapies. Onkologe, 16(5), 515-520.
     
  2224. Lordick F, Grenacher L, Rocken C, Ebert M, Moehler M, Schumacher G (2010). [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr, 135(34-35), 1671-82.
     
  2225. Lordick F, Ott K, Krause BJ (2010). New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol, 21(Suppl 7), 294-299.
     
  2226. Dagres N, Kottkamp H, Piorkowski C, Weis S, Arya A, Sommer P, Bode K, Gerds-Li JH, Kremastinos DT, Hindricks G (2010). Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation Implications for patient follow-up. Int J Cardiol, 139(3), 305-306.
     
  2227. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B et al. (2010). Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study. Gastroenterology, 138(4), 1338-1345.
     
  2228. Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, Wust P, Lopez-Hanninen E, Gademann G, Peters N, Berg T, Malfertheiner P, Ricke J (2010). Computed Tomography-Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. Int J Radiat Oncol Biol Phys, 78(1), 172-179.
     
  2229. Kamphues C, Lotz K, Rocken C, Berg T, Eurich D, Pratschke J, Neuhaus P, Neumann UP (2010). Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. Clin Transplant, 24(5), 652-659.
     
  2230. Bellecave P, Sarasin-Filipowicz M, Donze O, Kennel A, Gouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim MH (2010). Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology, 51(4), 1127-1136.
     
  2231. Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, Neuhaus P, Neumann U (2010). Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon. Dig Dis Sci, 55(7), 2063-2069.
     
  2232. Kok KF, van Soest H, van Herwaarden AE, van Oijen MG, Boland GJ, Halangk J, Berg T, de Vries RA, Drenth JP (2010). Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. Eur J Gastroenterol Hepatol, 22(7), 808-812.
     
  2233. Dintsios CM, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, Manns MP, Krauth C (2010). Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol, 22(3), 278-288.
     
  2234. Chase TH, Lyons BL, Bronson RT, Foreman O, Donahue LR, Burzenski LM, Gott B, Lane P, Harris B, Ceglarek U, Thiery J, Wittenburg H, Thon JN, Italiano JE Jr, Johnson KR, Shultz LD (2010). The mouse mutation "thrombocytopenia and cardiomyopathy" (trac) disrupts Abcg5: a spontaneous single gene model for human hereditary phytosterolemia/sitosterolemia. Blood, 115(6), 1267-1276.
     
  2235. Witt H, Rosendahl J, te Morsche RH, Santhosh S, Chacko A, Schulz HU, Landt O, Teich N, Keim V, Mössner J, Gress TM, Ockenga J, Schmidt H, Kovacs P, Blüher M, Stumvoll M, Kage A, Groneberg DA, Jansen J (2010). Mutational analysis of the gene encoding the zymogen granule membrane glycoprotein 2 (GP2) in patients with chronic pancreatitis. Pancreas, 39(2), 188-192.
     
  2236. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohe C, Gunther A, Halank M, Hammerl P, Held M, Kruger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, W (2010). [Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010]. Dtsch Med Wochenschr, 135, 115-124.
     
  2237. Jumpertz R, Wiesner T, Bluher M, Engeli S, Batkai S, Wirtz H, Bosse-Henck A, Stumvoll M (2010). Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea-specific role of oleoylethanolamide. Exp Clin Endocrinol Diabetes, 118(9), 591-595.
     
  2238. Bittner HB, Barten MJ, Binner C, Lehmann S, Garbade J, Hammerschmidt S, Wirtz H, Mohr FW (2010). Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation. Eur J Cardiothorac Surg, 38(3), 268-276.
     
  2239. Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoeper MM, Kramm T, Kruger U, Langer F, Schafers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer E (2010). [Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2010]. Dtsch Med Wochenschr, 135, 125-130.
     
  2240. Barkun AN, Adam V, Sung JJ, Kuipers EJ, Mossner J, Jensen D, Stuart R, Lau JY, Naucler E, Kilhamn J, Granstedt H, Liljas B, Lind T (2010). Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics, 28(3), 217-230.
     
  2241. Diener MK, Bruckner T, Contin P, Halloran C, Glanemann M, Schlitt HJ, Mossner J, Kieser M, Werner J, Buchler MW, Seiler CM (2010). ChroPac-trial: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial. Trials, 11, e47.
     
  2242. Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE (2010). Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer, 10, e457.
     
  2243. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mossner J, Bosch J (2010). Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med, 362(25), 2370-2379.
     
  2244. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzman CA, Ljung (2010). Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology, 138(5), 1885-1897.
     
  2245. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Gobel U, Capka E, Wiegand J, Schiefke I, Guthoff W, Grungreiff K, Konig I, Spengler U, McCarthy J, Shiann (2010). A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology, 139(5), 1586-1592.
     
  2246. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG (2010). Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology, 139(4), 1257-1266.
     
  2247. Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I (2010). Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. J Med Chem, 53(16), 6054-6063.
     
  2248. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R (2010). Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology, 52(4), 1201-1207.
     
  2249. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Al (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 376(9742), 705-716.
     
  2250. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM (2010). Telaprevir for previously treated chronic HCV infection. N Engl J Med, 362(14), 1292-1303.
     
  2251. Asbach P, Klatt D, Schlosser B, Biermer M, Muche M, Rieger A, Loddenkemper C, Somasundaram R, Berg T, Hamm B, Braun J, Sack I (2010). Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology, 257(1), 80-86.
     
  2252. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Berg T, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE (2010). Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest, 120(11), 4129-4140.
     
  2253. Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, Astani A, Jilg W, Zeier M, Schnitzler P (2010). Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol, 47(1), 89-92.
     
  2254. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF (2010). Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med, 16(6), 277-286.
     
  2255. Guttler T, Madl T, Neumann P, Deichsel D, Corsini L, Monecke T, Ficner R, Sattler M, Gorlich D (2010). NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat Struct Mol Biol, 17(11), 1367-1376.
     
  2256. Hofmann J, Frenzel K, Minh BQ, von Haeseler A, Edelmann A, Ross SR, Berg T, Kruger DH, Meisel H (2010). Quantitative detection and typing of hepatitis D virus in human serum by real-time polymerase chain reaction and melting curve analysis. Diagn Microbiol Infect Dis, 67(2), 172-179.
     
  2257. Lange CM, Roomp K, Dragan A, Nattermann J, Michalk M, Spengler U, Weich V, Lengauer T, Zeuzem S, Berg T, Sarrazin C (2010). HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. J Hepatol, 53(6), 1022-1028.
     
  2258. Lange CM, von Wagner M, Bojunga J, Berg T, Farnik H, Hassler A, Sarrazin C, Herrmann E, Zeuzem S (2010). Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol, 22(11), 1303-1307.
     
  2259. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bommel F, Hansen BE, Wedemeyer H, Janssen HL (2010). Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol, 52(4), 493-500.
     
  2260. Sixt S, Beer S, Bluher M, Korff N, Peschel T, Sonnabend M, Teupser D, Thiery J, Adams V, Schuler G, Niebauer J (2010). Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J, 31(1), 112-119.
     
  2261. Klinghammer K, Knodler M, Schmittel A, Budach V, Keilholz U, Tinhofer I (2010). Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 16(1), 304-310.
     
  2262. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT (2010). Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer, 103(9), 1407-1414.
     
  2263. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Va (2010). Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol, 28(35), 5210-5218.
     
  2264. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, Nekolla SG, Rummeny EJ, Wester HJ, Brix G, Schwaiger M, Beer AJ (2010). Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med, 51(11), 1691-1698.
     
  2265. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Ron (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 28(31), 4706-4713.
     
  2266. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687-697.
     
  2267. Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H (2010). High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol, 102(5), 503-508.
     
  2268. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther, 48(7), 473-475.
     
  2269. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi (2010). Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol, 11(1), 38-47.
     
  2270. Friederichs J, von Weyhern CW, Rosenberg R, Doll D, Busch R, Lordick F, Siewert JR, Sarbia M (2010). Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. Langenbecks Arch Surg, 395(4), 373-379.
     
  2271. Berg T (2010). Hepatologie. In: Ell C, Fischbach W, Layer P, Zirngibl H , GastroUpdate 2010. (S. 1-42), Berlin: Springer.
     
  2272. Berg T (2010). HBV induziertes akutes Leberversagen - Erläuterungen. In: Dancygier H, Wedemeyer H, Cronberg M, Zeuzem S, Manns MP, Hoffmann A, Wiebner B, Deutsche Leberstift, Das Leber-Buch. (S. 105-106), Hannover: Schluetersche GmbH & Co. KG Verlag und Druckerei.
     
  2273. Mössner J (2010). Pathogenese, Diagnose und konservative Therapie der akuten und chronischen Pankreatitis beim Menschen. In: Vervuert I, Aschenbach JR, Gäbel G, Daugschies A, Leipziger Blaue Hefte, LBH: Proceedings 5. Leipziger Tierärztekongress. (S. 173-176), Leipzig: Leipziger Universitätsverlag.
     
  2274. Berg T (2010). Hepatologische Intensivmedizin. In: Welte T, Werdan K, Ell C, IntensivUpdate 2010. (S. 1-30), Berlin: Springer.
     
  2275. Berg T, van Bömmel F (2010). Therapie der chronischen Hepatitis B Virus Monoinfektion. In: Rockstroh J, Mauss S, Jäger H, Koinfektion Hepatitis und HIV: Band 6. (S. 19-30), Stuttgart: Thieme.
     
  2276. Bergk A, Schott E, Büchsel R, Berg T (2010). Bösartige Tumoren des Gallenwegsystems – Epidemiologie, Ätiologie und Pathogenese. In: Birth M, Ittel TH, Pereira PL, Hepatobiliäre und Pankreastumoren. (S. 25-32), Berlin: Springer.
     
  2277. Hasper D, Berg T (2010). Hepatorenal Syndrome. In: Jörres A, Ronco C, Kellum JA, Management of Acute Kidney Problems. (S. 297-304), Berlin: Springer.
     
  2278. Heipieper HJ, Fischer J (2010). Bacterial solvent responses and tolerance: cis-trans isomerization. In: Timmis KN, Handbook of Hydrocarbon and Lipid Microbiology. (S. 4203-4211), Heidelberg: Springer.
     
  2279. Heipieper HJ, Fischer J, Meinhardt F (2010). Cis-trans isomerase of unsaturated fatty acids: An immediate bacterial adaptive mechanism to cope with emerging membrane perturbation caused by toxic hydrocarbons. In: Timmis KN, Handbook of Hydrocarbon and Lipid Microbiology. (S. 1605-1614), Heidelberg: Springer.
     
  2280. Puchner KP, Berg T (2010). Hepatitis C: Extrahepatic manifestations. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 239-255), Düsseldorf: Flying Publisher.
     
  2281. Schott E, Bergk A, Büchsel R, Berg T (2010). Hepatozelluläres Karzinom (HCC) – Epidemiologie, Ätiologie und Pathogenese. In: Birth M, Ittel TH, Pereira PL, Hepatobiliäre und Pankreastumoren. (S. 12-25), Berlin: Springer.
     
  2282. van Bömmel F, Wiegand J, Berg T (2010). Standard of care for hepatitis B virus infection. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Hepatology - A Clinical Textbook. (S. 101-129), Düsseldorf: Flying Publisher.
     
  2283. Mössner J (2010). 32. Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D, Arzneiverordnungs-Report 2010. (S. 653-681), Berlin, Heidelberg, New York: Springer .
     
  2284. Siewert JR, Lordick F (2010). Praxis der Viszeralchirurgie – Onkologische Chirurgie. In: Siewert JR , Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg Berlin New York: Springer Verlag.
     
  2285. Lordick F (2010). Biologisch zielgerichtete Therapie. In: Siewert JR, Lordick F, Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     
  2286. Lordick F, Beiglböck A, Jäger D, Siewert JR (2010). Multidisziplinarität im Cancer Center. In: Siewert JR, Lordick F, Praxis der Viszeralchirurgie – Onkologische Chirurgie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     
  2287. Lordick F, Hölscher AH (2010). Esophageal Cancer. In: Blanke, Roedel, Talamonti, Gastrointestinal Oncology, a Practical Guide. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     


    2288. 2009


  2288. Rossol M, Pierer M, Arnold S, Keyszer G, Burkhardt H, Baerwald C, Wagner U (2009). Homozygosity for DNASE2 single-nucleotide polymorphisms in the 5' regulatory region is associated with rheumatoid arthritis. Ann Rheum Dis, 68(9), 1498-1503.
     
  2289. Nast A, Malysheva O, Krause A, Wahle M, Baerwald CG (2009). Intracellular calcium responses to cholinergic stimulation of lymphocytes from healthy donors and patients with rheumatoid arthritis. Rheumatol Int, 29(5), 497-502.
     
  2290. Malysheva O , Pierer M, Wagner U, Baerwald C (2009). Indikationen und Wirksamkeit der Anti-TNF-Therapie. Arthritis und Rheuma , 29(4), 205-213.
     
  2291. Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U (2009). Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum, 60(9), 2612-2621.
     
  2292. Pierer M, Schulz A, Rossol M, Kendzia E, Kyburz D, Haentzschel H, Baerwald C, Wagner U (2009). Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol, 182(5), 3139-3145.
     
  2293. Wiegand J, Patel K, Tillmann HL (2009). Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response? Hepatology, 50(4), 1314.
     
  2294. Biermer M, Berg T (2009). Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology, 137(1), 390-391.
     
  2295. Wiegand J, Luz B, Mengelkamp AK, Moog R, Koscielny J, Halm-Heinrich I, Susemihl C, Bentzien F, Diekmann J, Wernet D, Karger R, Angert K, Schmitt-Thomssen A, Kiefel V, Lutter K, Hesse R, Katzel R, Opit (2009). Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. J Viral Hepat, 16(10), 743-748.
     
  2296. Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S (2009). Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology, 50(2), 369-377.
     
  2297. Weis S, Wittekind C, Benckert C, Mossner J, Wittenburg H (2009). Budd Chiari syndrome without evidence for thrombosis. Is it still a Budd Chiari ? Ann Hepatol, 8(4), 388-389.
     
  2298. Hoffmeister A, Dietz G, Zeitschel U, Mossner J, Rossner S, Stahl T (2009). BACE1 is a newly discovered protein secreted by the pancreas which cleaves enteropeptidase in vitro. JOP, 10(5), 501-506.
     
  2299. Wiedmann MW, Mossner J, Stumvoll M, Fuhrer D (2009). Case report: extreme CgA elevation under PPI confounding assessment of adrenal mass. Z Gastroenterol, 47(7), 671-673.
     
  2300. Schoppmeyer K, Weis S, Mossner J, Fleig WE (2009). Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev, 3, 1-5.
     
  2301. Wiedmann M, Heller F, Zeitz M, Mossner J (2009). Fracture of a covered self-expanding antireflux stent in two patients with distal esophageal carcinoma. Endoscopy, 41(Suppl 2), E129-E130.
     
  2302. Schoppmeyer K, Spieker H, Mossner J (2009). Failure of screening or failure to screen? The screening behavior of patients with colorectal cancer in the Leipzig area. Dtsch Arztebl Int, 106(12), 195-201.
     
  2303. Mossner J, Gross WL (2009). [Autoimmune diseases] Internist (Berl), 50(3), 265-266.
     
  2304. Teich N, Leinung S, Jonas S, Mossner J (2009). [Acute pancreatitis] Chirurg, 80(3), 245-252.
     
  2305. Karlas T, Schierle K, Mossner J (2009). [26-year-old woman with strong, partly crampy pains in upper abdomen] Dtsch Med Wochenschr, 134(1-2), 27-28.
     
  2306. Leonhardt K, Gebhardt R, Mossner J, Lutsenko S, Huster D (2009). Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem, 284(12), 7793-7802.
     
  2307. Puchner KP, Berg T (2009). [Extrahepatic manifestations of chronic hepatitis C virus infection] Z Gastroenterol, 47(5), 446-456.
     
  2308. Hammerschmidt S, Wirtz H (2009). Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int, 106(49), 809-18.
     
  2309. Braunlich J, Seyfarth HJ, Gessner C, Gradistanac T, Wirtz H (2009). [Lymphomatoid granulomatosis--a short description of an unusual case of the disease] Pneumologie, 63(12), 697-701.
     
  2310. Hoheisel G, Hagert-Winkler A, Winkler J, Kahn T, Rodloff AC, Wirtz H, Gillissen A (2009). [Pulmonary and pleural tuberculosis in the elderly] Med Klin (Munich), 104(10), 772-779.
     
  2311. Hoheisel G, Winkler J, Gessner C, Vogtmann M, Wirtz H (2009). [Professor Dr. med. habil. Joachim Schauer on the Occasion of his 70th Birthday] Pneumologie, 63(10), 594-595.
     
  2312. Hoheisel G, Vogtmann M, Gessner C, Winkler J, Rodloff AC, Wirtz H (2009). [Tuberculosis and travelling] Pneumologie, 63(9), 519-525.
     
  2313. Winkler J, Hagert-Winkler A, Wirtz H, Hoheisel G (2009). [Modern impulse oscillometry in the spectrum of pulmonary function testing methods] Pneumologie, 63(8), 461-469.
     
  2314. Kroegel C, Wirtz H (2009). History of guidelines for the diagnosis and management of asthma: from opinion to control. Drugs, 69(9), 1189-1204.
     
  2315. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ (2009). Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag, 5(1), 465-474.
     
  2316. Raaz U, Kuhn H, Wirtz H, Hammerschmidt S (2009). Rapamycin reduces high-amplitude, mechanical stretch-induced apoptosis in pulmonary microvascular endothelial cells. Microvasc Res, 77(3), 297-303.
     
  2317. Winkler J, Hagert-Winkler A, Wirtz H, Schauer J, Kahn T, Hoheisel G (2009). [Impulse oscillometry in the diagnosis of the severity of obstructive pulmonary disease] Pneumologie, 63(5), 266-275.
     
  2318. Engels K, Stauber R, Magnussen H, Kirsten D, Watz H, Wirtz H (2009). Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women. Eur Urol, 55(3), 755-756.
     
  2319. Baerwald C (2009). Schmerzen im höheren Alter. Mobil , 1, 25-27.
     
  2320. Rossol M, Pierer M, Arnold S, Keysser G, Burkhardt H, Baerwald C, Wagner U (2009). Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis. Arthritis Res Ther, 11(3), R91.
     
  2321. Pierer M, Baerwald C, Wagner U (2009). [Familial clustering, genetic roots and insights into the pathogenesis of autoimmune diseases] Z Rheumatol, 68(9), 758-762.
     
  2322. Wiedmann MW, Mossner J, Baerwald C, Pierer M (2009). TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets, 9(3), 295-314.
     
  2323. Heringlake S, Schutte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL (2009). Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol, 47(5), 417-423.
     
  2324. Pierer M, Baerwald C (2009). Biologika bei Rheuma: Was, wann, wie einsetzen? Extracta Orthopaedica , 6, 7-9.
     
  2325. Pierer M, Wagner U, Baerwald C: (2009). Schmerztherapie bei älteren Patienten. Allgemeinarzt , 5, 32-35.
     
  2326. Pierer M, Wagner U, Maleysheva O , Baerwald C (2009). Switch after Anti-TNF-alpha Failure: Is it an Adequate Strategy? Akt Rheumatol, 34(4), 220-225.
     
  2327. Unger S, Weigel JF, Stepan H, Baerwald CG (2009). A case of maternal PKU syndrome despite intensive patient counseling. Wien Med Wochenschr, 159(19-20), 507-510.
     
  2328. Schubert A, Grimm M (2009). Reisemedizin. Internist, 50(7), 841-51.
     
  2329. Kaiser T, Moessner J, Patel K, McHutchison JG, Tillmann HL (2009). Life threatening liver disease during treatment with monoclonal antibodies. BMJ, 338, e508.
     
  2330. Kendziorra K, Kluge R, Borte G, Kahn Th, Sabri O, Wirtz H (2009). PET/CT beim Lungenkarzinom Ärzteblatt Sachsen, 20(10), 544-547.
     
  2331. Hoheisel G, Winkler, J,Gessner C, Vogtmann M, Wirtz H (2009). Prof. Dr. med. habil. Joachim Schauer zum 70. Geburtstag Ärzteblatt Sachsen, 20(11), 587.
     
  2332. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Hofler H, Keller G (2009). CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer, 45(18), 3326-3335.
     
  2333. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Muller L, Rothling N, Peschel C, Langer R, Lordick F (2009). Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 20(10), 1667-1673.
     
  2334. Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F (2009). Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Onkologie, 32(1-2), 30-34.
     
  2335. Lordick F (2009). [Multidisciplinary treatment for adult soft tissue sarcoma]. Chirurg, 80(3), 209-215.
     
  2336. Lordick F, Ott K (2009). Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms. Der Gastroenterologe, 4(3), 224-231.
     
  2337. Ott K, Lordick F (2009). [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg, 80(11), 1028-1034.
     
  2338. Lordick F (2009). [Principles of neoadjuvant therapy]. Chirurg, 80(11), 1000-1005.
     
  2339. Czito B, Lordick F (2009). Accomplishments in 2008 in the adjuvant treatment of rectal cancer. Gastrointest Cancer Res, 5(Suppl 2), 8-14.
     
  2340. Apostolidis L, Kahlert C, Siegmund A, Thom R, Horstmann S, Jager D, Lordick F (2009). Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. Onkologie, 32(1-2), 50-53.
     
  2341. Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F (2009). Symptomatic hyponatraemia caused by cylophosphamide. Onkologie, 32(5), 280-282.
     
  2342. Fuchs B, Bondzio A, Wagner U, Schiller J (2009). Phospholipid compositions of sera and synovial fluids from dog, human and horse: a comparison by (31)P-NMR and MALDI-TOF MS. J Anim Physiol Anim Nutr (Berl), 93(4), 410-422.
     
  2343. Sattler A, Wagner U, Rossol M, Sieper J, Wu P, Krause A, Schmidt WA, Radmer S, Kohler S, Romagnani C, Thiel A (2009). Cytokine-induced human IFN{gamma} secreting effector-memory Th-cells in chronic autoimmune inflammation. Blood, 113(9), 1948-1956.
     
  2344. Teichert J, Sohr R, Hennig L, Baumann F, Schoppmeyer K, Patzak U, Preiss R (2009). Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos, 37(2), 292-301.
     
  2345. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, G (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 41(10), 1100-1104.
     
  2346. Potthoff A, Berg T, Wedemeyer H (2009). Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol, 44(12), 1487-1490.
     
  2347. Schmiegel W, Pox C, Arnold D, Porschen R, Rodel C, Reinacher-Schick A (2009). Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int, 106(51-52), 843-848.
     
  2348. Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Muller T, Gressner AM (2009). Elevated concentrations of 15-deoxy-Delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs. Liver Int, 29(5), 730-735.
     
  2349. Baid-Agrawal S, Frei U, Reinke P, Schindler R, Kopp MA, Martus P, Berg T, Juergensen JS, Anker SD, Doehner W (2009). Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant, 9(12), 2777-2784.
     
  2350. Schulte D, Vogel M, Langhans B, Kramer B, Korner C, Nischalke HD, Steinberg V, Michalk M, Berg T, Rockstroh JK, Sauerbruch T, Spengler U, Nattermann J (2009). The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. J Infect Dis, 200(9), 1397-1401.
     
  2351. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP (2009). Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat, 16(2), 75-90.
     
  2352. Halangk J, Berg T, Neumann K, Sarrazin C, Hinrichsen H, Fitz C, Puhl G, Mueller T, Neuhaus P, Wiedenmann B, Witt H (2009). Evaluation of angiotensinogen c.1-44G>A and p.M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies. Genet Test Mol Biomarkers, 13(3), 407-414.
     
  2353. Haas SL, Weiss C, Bugert P, Gundt J, Witt H, Singer MV, Berg T, Bocker U (2009). Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. J Clin Immunol, 29(5), 620-628.
     
  2354. Deterding K, Wiegand J, Gruner N, Hahn A, Jackel E, Jung MC, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H (2009). The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol, 47(6), 531-540.
     
  2355. Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Schott E, Weich V, Schlosser B, Wasmuth HE, Lammert F, Berg T, Schreier E (2009). Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infect Genet Evol, 9(5), 847-852.
     
  2356. Klade CS, Kubitschke A, Stauber RE, Meyer MF, Zinke S, Wiegand J, Zauner W, Aslan N, Lehmann M, Cornberg M, Manns MP, Reisner P, Wedemeyer H (2009). Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. Vaccine, 27, 3099-3108.
     
  2357. Vogel M, Deterding K, Wiegand J, Gruner NH, Baumgarten A, Jung MC, Manns MP, Wedemeyer H, Rockstroh JK (2009). Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis, 49(2), 317-9.
     
  2358. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, ... PROVE2 Study Te (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med, 360(18), 1839-1850.
     
  2359. Sung JJ, Barkun A, Kuipers EJ, Mossner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T (2009). Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med, 150(7), 455-464.
     
  2360. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL (2009). Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology, 137(1), 309-19.
     
  2361. Wasmuth HE, Tag CG, Van de Leur E, Hellerbrand C, Mueller T, Berg T, Puhl G, Neuhaus P, Samuel D, Trautwein C, Kanse SM, Weiskirchen R (2009). The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology, 49(3), 775-780.
     
  2362. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S (2009). Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology, 136(7), 2169-2179.
     
  2363. Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL, Ross S, Spangenberg HC, Garcia-Samaniego J, Fuchs M, Enriquez J, Wiegand J, Stern J, et al. (2009). Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther, 14(1), 23-32.
     
  2364. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS (2009). Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine, 27(37), 5142-5151.
     
  2365. Petrasek J, Hubacek JA, Stickel F, Sperl J, Berg T, Ruf E, Wichmann HE, Pfeufer A, Meitinger T, Trunecka P, Spicak J, Jirsa M (2009). Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis? Clin Chem Lab Med, 47(4), 398-404.
     
  2366. Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A, Wiederholt T, Berg T, Muller T, Trautwein C, Gressner AM, Weiskirchen R (2009). Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat, 16(9), 612-620.
     
  2367. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Gr (2009). Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa-ribavirin therapy. Gastroenterology, 136(5), 1618-1628.
     
  2368. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE (2009). A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol, 50(2), 370-376.
     
  2369. Hoeper MM, Gall H, Seyfarth HJ, Halank M, Ghofrani HA, Winkler J, Golpon H, Olsson KM, Nickel N, Opitz C, Ewert R (2009). Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J, 34(1), 132-137.
     
  2370. Borte S, Pan-Hammarstrom Q, Liu C, Sack U, Borte M, Wagner U, Graf D, Hammarstrom L (2009). Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood, 114(19), 4089-4098.
     
  2371. Kirsten H, Petit-Teixeira E, Scholz M, Hasenclever D, Hantmann H, Heider D, Wagner U, Sack U, Hugo Teixeira V, Prum B, Burkhardt J, Pierlot C, Emmrich F, Cornelis F, Ahnert P (2009). Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control study. Arthritis Res Ther, 11(3), R60.
     
  2372. Yu X, Wieczorek S, Franke A, Yin H, Pierer M, Sina C, Karlsen TH, Boberg KM, Bergquist A, Kunz M, Witte T, Gross WL, Epplen JT, Alarcon-Riquelme ME, Schreiber S, Ibrahim SM (2009). Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases. Genes Immun, 10(6), 601-605.
     
  2373. Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Braun J, Burkhardt H, Gaubitz M, Gromnica-Ihle E, Kellner H, Kuipers JG, Lorenz HM, Manger B, Müller-Ladner, Nüßlein HG, Pott HG, Rubbert-Roth A, Schnei (2009). Recommendations for the Treatment of Rheumatoid Arthritis. Akt Rheumatol, 34(4), 234-239.
     
  2374. Müller U, Winkler J, Seyfarth HJ, Haustein UF, Schauer J, Nenoff P (2009). In vitro susceptibility of aspergillus to antifungal agents. Act med bulgar, 36, 3-11.
     
  2375. Schneider R, Bercker S, Schubert S, Tillmann HL, Fangmann J, Hauss J, Bartels M (2009). Successful liver transplantation in antituberculosis therapy-induced acute fulminant hepatic failure. Transplant Proc, 41(9), 3934-3936.
     
  2376. Möbius C, Leinung S, Zabel-Langhennig A, Mössner J, Jonas S (2009). Diagnostik und Therapie der Refluxkrankheit Ärzteblatt Sachsen, 20(2), 72-75.
     
  2377. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K (2009). Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol, 22(12), 1555-1563.
     
  2378. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR (2009). Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol, 16(4), 1017-1025.
     
  2379. Ott K, Lordick F, Molls M, Bartels H, Biemer E, Siewert JR (2009). Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg, 96(3), 258-266.
     
  2380. Rosenberg R, Herrmann K, Gertler R, Kunzli B, Essler M, Lordick F, Becker K, Schuster T, Geinitz H, Maak M, Schwaiger M, Siewert JR, Krause B (2009). The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis, 24(2), 191-200.
     
  2381. Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW (2009). Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park), 23(2 Suppl1), 18-25.
     
  2382. Lordick F, Sendler A (2009). Magenkarzinom. In: Schmoll & Arnold, Therapiekonzepte bei gastrointestinalen Tumoren. (S. ), Bremen: Uni-Med Verlag.
     


    2383. 2008


  2383. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mossner J, Lammert F, Wittenburg H (2008). Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol, 48(1), 116-124.
     
  2384. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mossner J, Lammert F, Wittenburg H (2008). Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol, 48(1), 116-124.
     
  2385. Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ (2008). Acute Improved Hemodynamics following Inhaled Iloprost in Chronic Thromboembolic Pulmonary Hypertension. Respiration, 76(2), 154-159.
     
  2386. Teich N, Mossner J (2008). Hereditary chronic pancreatitis. Best Pract Res Clin Gastroenterol, 22(1), 115-130.
     
  2387. Rosendahl J, Witt H, Szmola R, Bhatia E, Ozsvari B, Landt O, Schulz HU, Gress TM, Pfutzer R, Lohr M, Kovacs P, Bluher M, Stumvoll M, Choudhuri G, Hegyi P, te Morsche RH, Drenth JP, Truninger K, Macek (2008). Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet, 40(1), 78-82.
     
  2388. Malysheva O, Pierer M, Wagner U, Wahle M, Wagner U, Baerwald CG (2008). Association between beta2 adrenergic receptor polymorphisms and rheumatoid arthritis in conjunction with human leukocyte antigen (HLA)-DRB1 shared epitope. Ann Rheum Dis, 67(12), 1759-1764.
     
  2389. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Hantzschel H, Baerwald CG (2008). Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol, 35(6), 979-985.
     
  2390. Mossner J, Teich N (2008). [Nutrition in acute pancreatitis] Z Gastroenterol, 46(8), 784-789.
     
  2391. Teich N, Lehmann I, Rosendahl J, Troltzsch M, Mossner J, Schiefke I (2008). The inverse starving test is not a suitable provocation test for Gilbert's syndrome. BMC Res Notes, 1, 35.
     
  2392. Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M (2008). Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol, 14(23), 3681-3692.
     
  2393. Wiegand J, Mossner J, Tillmann HL (2008). [Diagnostics and therapy of chronic hepatitis B and C] Internist (Berl), 49(7), 817-829.
     
  2394. Gundling F, Wittenburg H, Tannapfel A, Mossner J (2008). Neurological presentation of Whipple\'s disease after long-term antibiotic treatment: a case report. J Med Case Reports, 2, 191-.
     
  2395. Lobstein S, Kaiser T, Liebert U, Wojan M, Leichtle A, Mossner J, Wiegand J, Tillmann HL (2008). Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. Z Gastroenterol, 46(5), 415-420.
     
  2396. Wiedmann M, Zeh J, Schoppmeyer K, Moebius C, Niederhagen M, Wittekind C, Mossner J, Caca K (2008). Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma? J Chemother, 20(1), 112-118.
     
  2397. Petros S, Fischer J, Mossner J, Schiefke I, Teich N (2008). Treatment of massive cecal bleeding in a 28-Year-old patient with homozygous factor V deficiency with activated factor VII. Z Gastroenterol, 46(3), 271-273.
     
  2398. Hoffmeister A, Mossner J (2008). [Chronic pancreatitis] Dtsch Med Wochenschr, 133(9), 415-426.
     
  2399. Wiedmann M, Teich N, Ott R, Eichelkraut S, Mossner J (2008). A man with two pylori. Gut, 57(3), 305, 351.
     
  2400. Mossner J (2008). [Prevention in Internal Medicine.] Internist (Berl), 49(2), 145-145.
     
  2401. Hoffmeister A, Schiefke I, Teich N, Mossner J, Schoppmeyer K (2008). [Prevention of gastrointestinal malignancies.] Internist (Berl), 49(2), 178-184.
     
  2402. Tillmann HL, Thompson AJ (2008). Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterion. Digestion, 78(2-3), 120-122.
     
  2403. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL (2008). A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther, 13(4), 547-554.
     
  2404. Wiegand J, Hasenclever D, Tillmann HL (2008). Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther, 13(2), 211-220.
     
  2405. Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL (2008). [Acute hepatitis B: is antiviral therapy indicated? Two case reports] Dtsch Med Wochenschr, 133(22), 1178-1182.
     
  2406. Tillmann HL, Patel K, McHutchison JG (2008). GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality. Gastroenterology, 134(7), 2191-2191.
     
  2407. Kaiser T, Damerow HC, Tenckhoff S, Finger A, Bottcher I, Hafer C, Schwarz A, Luth JB, Schmidt Gurtler H, Colucci G, Manns MP, Wedemeyer H, Tillmann HL (2008). Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J Med Virol, 80(7), 1195-1201.
     
  2408. Tillmann HL, McHutchison JG (2008). Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 358(14), 1517.
     
  2409. Bodeker H, Leinung S, Wittenburg H, Fischer J, Schiefke I, Teich N (2008). The hole in the stomach. Diagn Ther Endosc, 2008, 257185-.
     
  2410. Keim V (2008). Role of genetic disorders in acute recurrent pancreatitis. World J Gastroenterol, 14(7), 1011-1015.
     
  2411. Kovacs P, Kurtz U, Wittenburg H (2008). Hepatic insulin resistance ties cholesterol gallstone formation and the metabolic syndrome. Ann Hepatol, 7(3), 262-264.
     
  2412. Weis S, Piorkowski C, Arya A, Bollmann A (2008). Septic vegetation at the left atrial appendage entrance after pulmonary vein ablation for atrial fibrillation. Europace, 10(2), 215-217.
     
  2413. Hoheisel G, Winkler J, Gessner C, Hammerschmidt S, Seyfarth HJ, Rodloff AC, Liebert UG, Wirtz H, Gillissen A (2008). [Clinical features and diagnosis of bronchopulmonary infections in the elderly] Pneumologie, 62(5), 297-304.
     
  2414. Gessner C, Dihazi H, Brettschneider S, Hammerschmidt S, Kuhn H, Eschrich K, Keller T, Engelmann L, Sack U, Wirtz H (2008). Presence of cytokeratins in exhaled breath condensate of mechanical ventilated patients. Respir Med, 102(2), 299-306.
     
  2415. Baerwald C, Graninger W (2008). [Algesiology of the musculoskeletal system.] Z Rheumatol, 67(8), 639.
     
  2416. Siegel L, Pierer M, Stein C, Baerwald C (2008). [Opioids in musculoskelettal pain.] Z Rheumatol, 67(8), 646-652.
     
  2417. Pierer M, Baerwald C (2008). [Biological therapy for the treatment of rheumatic diseases] Internist (Berl), 49(8), 938-946.
     
  2418. Baerwald C (2008). Wirksame Therapie auch älteren Patienten nicht vorenthalten MedReview, 10, 2-5.
     
  2419. Baerwald C, Ruf BR (2008). Lyme-Borreliose:Die wichtigsten Fakten Ärzteblatt Sachsen, 19(3), 101-104.
     
  2420. Gundling F, Harms RT, Schiefke I, Schepp W, Mössner J, Teich N (2008). Selbsteinschätzung von Warnsymptomen bei oberer gastrointestinaler Blutung Deutsches Ärzteblatt, 105(5), 73-77.
     
  2421. Huster D, Leonhardt K, Mössner J (2008). Wilson Disease – Update on Pathophysiology and Management Czech Slovak Gastroenterol Hepatol , 62(4), 220-228.
     
  2422. Mössner J (2008). Editorial – Das Spektrum der therapeutischen Möglichkeiten bei gastrointestinalen Neoplasien wird immer größer Kompakt Gastroenterologie, 1, 1-3.
     
  2423. Neubauer A, Mössner J (2008). Editorial: Antikörpertherapie Internist (Berl), 49(8), 917-918.
     
  2424. Teich N, Rosendahl J, Mössner J (2008). Angeborene Erkrankungen des exokrinen Pankreas Gastroenterologie up2date, 4(1), 35-50.
     
  2425. Teich N, Mössner J (2008). Pankreatitis: Schmerz trifft auf Gummibauch - Diagnose und Therapie der akuten Pankreatitis im Überblick CME, 5(12), 7-15.
     
  2426. Teich N (2008). Pancreatic cancer: cause and result of diabetes mellitus. Gastroenterology, 134(1), 344-345.
     
  2427. Weis S, Tröltzsch M, Mössner J (2008). Interventionelle nichtchirurgische Therapie von Lebermetastasen Chir Gastroenterol, 24(3), 200-206.
     
  2428. Wiedmann MW, Mössner J (2008). Aktuelle Diagnostik und Therapie der Gallenwegskarzinome Gastroenterologie up2date, 4(2), 171-192.
     
  2429. Tillmann HL (2008). Standard Therapie der Hepatitis C Med Review, 9(6), 17-18.
     
  2430. Tillmann HL (2008). Neue antivirale Ansaetze in der Behandlung viraler Hepatitiden MedReport, 32(41), 8.
     
  2431. Tillmann HL (2008). The treatment of chronic hepatitis B: Focus on adefovir-like antivirals Ther Clin Risk Manag, 4(4), 797-802.
     
  2432. Wiegand J (2008). Newly acquired hepatitis C--many hurdles from diagnosis until treatment initiation. J Gastroenterol Hepatol, 23(12), 1782-1784.
     
  2433. Wiegand J, Deterding K, Cornberg M, Wedemeyer H (2008). Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother, 62(5), 860-865.
     
  2434. Mössner J (2008). Interventionelle Endoskopie. Lehrbuch und Atlas Deutsches Ärzteblatt, 105(29), 1074.
     
  2435. Hoheisel G, Vogtmann M, Winkler J, Gessner C, Hammerschmidt S, Seyfarth HJ, Reimann S, Rodloff AC, Gillissen A, Wirtz H (2008). [Spectrum of Tuberculous Diseases in a Pulmonary Outpatient Clinic.] Med Klin (Munich), 103(11), 769-777.
     
  2436. Bold A, Wurth R, Keller T, Trahorsch U, Voigt P, Schubert S, Sack U (2008). Low-cost enumeration of CD4(+) T cells using a density-based negative selection method (Rosette Septrade mark) for the monitoring of HIV-infected individuals in non-OECD countries. Cytometry A, 73(1), 28-35.
     
  2437. Renner R, Fleck A, Schubert S, Baerwald RC, Beer J, Schober R, Holl-Ulrich K, Sticherling M (2008). Chronic Urticaria and Angioedema with Concomitant Eosinophilic Vasculitis due to Trichinella Infection. Acta Derm Venereol, 88(1), 78-79.
     
  2438. Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wolke G, Meese E, Sybrecht G, Kronenberg F, Cebulla M, Degen M, Drings P, Groschel A, Konietzko N, Kreymborg KG, Haussinger K, Hoffken G, Jilge B, (2008). Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer, 8, 60-69.
     
  2439. Busse F, Omidi L, Timper K, Leichtle A, Windgassen M, Kluge E, Stumvoll M (2008). Lead poisoning due to adulterated marijuana. N Engl J Med, 358(15), 1641-1642.
     
  2440. Mayer C, Muller A, Halbritter J, Wirtz H, Stumvoll M (2008). Isolated renal relapse of sarcoidosis under low-dose glucocorticoid therapy. J Gen Intern Med, 23(6), 879-882.
     
  2441. Watz H, Oltmanns A, Kimmel S, Magnussen H, Wirtz H, Kirsten D (2008). [Sporadic lymphangioleiomyomatosis. Clinical and lung functional characteristics of 32 female patients] Dtsch Med Wochenschr, 133(14), 705-708.
     
  2442. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S, Heinemann V (2008). Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol, 19(2), 340-347.
     
  2443. Konnopka A, Conrad K, Baerwald C, Konig HH (2008). Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. Ann Rheum Dis, 67(10), 1399-1405.
     
  2444. Mittelstrass K, Sauter W, Rosenberger A, Illig T, Timofeeva M, Klopp N, Dienemann H, Meese E, Sybrecht G, Woelke G, Cebulla M, Degen M, Morr H, Drings P, Groeschel A, Kreymborg KG, Haeussinger K, Hoef (2008). Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer, 8, 113-21.
     
  2445. Albert JG, Schulbe R, Hahn L, Heinig D, Schoppmeyer K, Porst H, Lorenz R, Plauth M, Dollinger MM, Mossner J, Caca K, Fleig WE (2008). Impact of capsule endoscopy on outcome in mid-intestinal bleeding: a multicentre cohort study in 285 patients. Eur J Gastroenterol Hepatol, 20(10), 971-977.
     
  2446. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rosch W, Mossner J, Stein JM (2008). Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol, 103(6), 1496-1504.
     
  2447. Mobius C, Aust G, Wiedmann M, Wittekind C, Mossner J, Hauss J, Witzigmann H (2008). Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma. Anticancer Res, 28(2A), 873-878.
     
  2448. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Muller GA, Mossner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt (2008). Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Brit J Cancer, 98(9), 1525-1532.
     
  2449. Sung JJ, Mossner J, Barkun A, Kuipers EJ, Lau J, Jensen D, Stuart R, Junghard O, Olsson G (2008). Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther, 27(8), 666-677.
     
  2450. Moenkemeyer M, Schmidt RE, Wedemeyer H, Tillmann HL, Heiken H (2008). GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J Med Virol, 80(11), 1933-1940.
     
  2451. Ciesek S, Helfritz FA, Lehmann U, Becker T, Strassburg CP, Neipp M, Ciner A, Fytili P, Tillmann HL, Manns MP, Wedemeyer H (2008). Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis, 197(3), 355-360.
     
  2452. Ciesek S, Liermann H, Hadem J, Greten T, Tillmann HL, Cornberg M, Aslan N, Manns MP, Wedemeyer H (2008). Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat, 15(3), 200-211.
     
  2453. Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Dra (2008). Prevalence of HBV genotypes in Central and Eastern Europe. J Med Virol, 80(10), 1707-1711.
     
  2454. Deterding K, Wiegand J, Gruner N, Wedemeyer H (2008). Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? J Hepatol, 48(6), 1019-1020.
     
  2455. Hadem J, Stiefel P, Bahr MJ, Tillmann HL, Rifai K, Klempnauer J, Wedemeyer H, Manns MP, Schneider AS (2008). Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol, 6(3), 339-345.
     
  2456. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, Klempnauer J, Tillmann HL, Manns MP, Rosenau J (2008). Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl, 14(4), 435-442.
     
  2457. Santantonio T, Wiegand J, Gerlach JT (2008). Acute hepatitis C: current status and remaining challenges. J Hepatol, 49(4), 625-633.
     
  2458. Lippert H, Mössner J, Ricke J (2008). Lebermetastasen. Editorial Chirurg Gastroenterol , 24(3), 191.
     
  2459. Scheid R, Teich N, Schroeter ML (2008). Aerophagia and belching after herpes simplex encephalitis. Cogn Behav Neurol, 21(1), 52-54.
     
  2460. Gillissen A, Gessner C, Hoheisel G, Juergens U (2008). [Friend or foe: combination therapy with inhaled corticosteroids and long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD)] Pneumologie, 62(7), 430-437.
     
  2461. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S (2008). Desferrithiocin analogues and nephrotoxicity. J Med Chem, 51(19), 5993-6004.
     
  2462. Lin QS, Weis S, Yang G, Zhuang T, Abate A, Dennery PA (2008). Catalytic inactive heme oxygenase-1 protein regulates its own expression in oxidative stress. Free Radic Biol Med, 44(5), 847-855.
     
  2463. Witzigmann H, Wiedmann M, Wittekind C, Mössner J, Hauss J (2008). Fortschritte in der chirurgischen und palliativen Therapie von Klatskin-Tumoren Deutsches Ärzteblatt, 105(9), 156-161.
     
  2464. Kassahun WT, Lamesch P, Wittekind Ch, Neid M, Schneider JP, Mössner J, Hauss J (2008). Signet-Ring Cell Carcinoma Arising in the Gastric Stump After Duodenopancreatectomy for Ductal Adenocarcinoma of the Pancreas: A Case Report Clinical Medicine: Oncology, 2, 111-114.
     
  2465. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008). Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res, 14(7), 2012-2018.
     
  2466. Baerwald C (2008). Schmerz bei rheumatologischen Erkrankungen. In: Wollenhaupt J, Pott HG, Fortschritte der klinischen Rheumatologie. 15. Workshop Deutscher Rheumatologen in Potsdam. (S. 8-11), Ratingen: Preuss.
     
  2467. Hoffmeister A, Mössner J, Teich N (2008). Übelkeit, Erbrechen, Malassimilation. In: Riemann J F, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 13-46), Stuttgart, New York : Thieme Verlag.
     
  2468. Huster D (2008). M. Wilson. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1369-1375), Stuttgart, New York : Thieme Verlag.
     
  2469. Keim V (2008). Arbeitskreis der Pankreatektomierten e.V. In: Riemann JF, Fischbach W, Galle PR, Mössner J, Gastroenterologie. (S. 1925-1926), Stuttgart, New York : Thieme Verlag.
     
  2470. Mayerle J, Bödeker H, Teich N, Witt H, Lerch MM (2008). Pathophysiologie der Pankreatitis. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1815-1819), Stuttgart, New York: Thieme Verlag.
     
  2471. Mössner J, Keim V (2008). Klinik, Diagnostik und konservative Therapie der chronischen Pankreatitis. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1844-1857), Stuttgart, New York : Thieme Verlag.
     
  2472. Schiefke I, Mössner J (2008). Bauchschmerzen. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 47-60), Stuttgart, New York : Thieme Verlag.
     
  2473. Schiefke I (2008). Cholangitis. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1719-1738), Stuttgart, New York : Thieme Verlag.
     
  2474. Teich N, Bödeker H, Mayerle J, Lerch MM, Witt H (2008). Ätiopathogenesen der Pankreatitis. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1807-1815), Stuttgart, New York : Thieme Verlag.
     
  2475. Tillmann HL (2008). Toxische Hepatitis. In: Riemann JF, Fischbach W, Galle PR, Mössner J, Gastroenterologie. (S. 1298-1302), Stuttgart, New York : Thieme Verlag.
     
  2476. Tillmann HL, Jassoy C (2008). Virale Erkrankungen der Leber im weiteren Sinne. In: Riemann JF, Fischbach W, Galle PR, Mössner J, Gastroenterologie. (S. 1331-1335), Stuttgart, New York : Thieme Verlag.
     
  2477. Wiedmann M, Schoppmeyer K, Caca K (2008). Gallenblasentumor, intrahepatisches Cholangiokarzinom (CCC), Hilustumoren (Klatskin) und distale Gallenwegstumoren. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1740-1755), Stuttgart, New York : Thieme Verlag.
     
  2478. Wittenburg H (2008). Gallensteine. In: Riemann JF, Fischbach W, Galle PR, Mössner J , Gastroenterologie. (S. 1687-1693), Stuttgart, New York: Thieme Verlag.
     
  2479. Mössner J (2008). Guidelines, Clinical Evaluation, Short Track. In: Beger HG, Matsuno S, Cameron JL, Diseases of the Pancreas – Current Surgical Therapy. (S. 119-128), Berlin, Heidelberg, New York : Springer Verlag .
     
  2480. Mössner, J (2008). Medical treatment of chronic pancreatitis: Pain management. In: Beger HG, Warshaw AL, Büchler ME, Kozarek RA, Lerch MM, Neoptolemos JP, Shiratori K, Whitcomb DC, The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery. (S. 504-511), Oxford: Blackwell, Publishing.
     
  2481. Mössner J (2008). Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D , Arzneiverordnungsreport 2008. (S. 661-690), Heidelberg: Springer Verlag.
     
  2482. Teich N, Keim V (2008). Hereditary pancreatitis: diagnostic and management. In: Beger HG, Matsumo S, Cameron JL, Diseases of the pancreas. Current surgical therapy Springer. (S. 361-372), Berlin: Springer Verlag.
     


    2483. 2007


  2483. Kaltenhauser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Hantzschel H, Wagner U (2007). Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford), 46(1), 100-104.
     
  2484. Rother K, Kirschner R, Sanger K, Bohlig L, Mossner J, Engeland K (2007). p53 downregulates expression of the G(1)/S cell cycle phosphatase Cdc25A. Oncogene, 26(13), 1949-1953.
     
  2485. Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H (2007). Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension. Respiration, 74(3), 287-292.
     
  2486. Tillmann HL, Thursz M (2007). Hepatitis C virus infection--its role in pathogenesis. J Infect Dis, 195(2), 168-170.
     
  2487. Tillmann HL (2007). Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol, 13(1), 125-140.
     
  2488. Wolkersdorfer GW, Miehlke S, Schneider R, Ehninger G, Schiefke I, Mossner J, Teich N (2007). Ileal perforation in a patient with Crohns disease while receiving recombinant human growth hormone therapy. Int J Colorectal Dis, 22(8), 983-984.
     
  2489. Wiegand J, Mossner J, Tillmann HL (2007). [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.] Internist (Berl), 48(2), 154-163.
     
  2490. Rosendahl J, Bodeker H, Mossner J, Teich N (2007). Hereditary chronic pancreatitis. Orphanet J Rare Dis, 2, 1-5.
     
  2491. Scheid R, Teich N (2007). Eine schwere neurologische Erkrankung bei einem Patienten mit Colitis ulcerosa und Proteinase-3-positiven atypischen ANCA Aktuel Neurol, 34(4), 240-242.
     
  2492. Huster D, Purnat TD, Burkhead JL, Ralle M, Fiehn O, Stuckert F, Olson NE, Teupser D, Lutsenko S (2007). High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem, 282(11), 8343-8355.
     
  2493. Krug S, Seyfarth HJ, Hagendorff A, Wirtz H (2007). Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur J Gastroenterol Hepatol, 19(12), 1140-1143.
     
  2494. Hammerschmidt S, Vogel T, Jockel S, Gessner C, Seyfarth HJ, Gillissen A, Wirtz H (2007). Protein kinase C inhibition attenuates hypochlorite-induced acute lung injury. Respir Med, 101(6), 1205-1211.
     
  2495. Seyfarth HJ, Wirtz H, Borte G, Gradistanac T, Gessner C, Hammerschmidt S (2007). [Ultrasound guided transthoracic biopsy - safety and efficaces] Pneumologie, 61(9), 563-567.
     
  2496. Hammerschmidt S, Kuhn H, Gessner C, Seyfarth HJ, Wirtz H (2007). Stretch-induced alveolar type II cell apoptosis: role of endogenous bradykinin and PI3K-Akt signaling. Am J Respir Cell Mol Biol, 37(6), 699-705.
     
  2497. Gessner C, Hammerschmidt S, Kuhn H, Hoheisel G, Gillissen A, Sack U, Wirtz H (2007). Breath condensate nitrite correlates with hyperinflation in chronic obstructive pulmonary disease. Respir Med, 101(11), 2271-2278.
     
  2498. Wirtz H, Grohe C (2007). [Section cell biology] Pneumologie, 61(8), 496-497.
     
  2499. Winkler J, Muller U, Nenoff P, Seyfarth HJ, Vogtmann M, Borte G, Ponisch W, Kahn T, Wirtz H, Schauer J, Hoheisel G (2007). Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation. Respiration, 74(6), 663-673.
     
  2500. Hantzschel H (2007). [Obituary for professor Werner Otto] Z Rheumatol, 66(6), 538-539.
     
  2501. Rossol M, Meusch U, Pierer M, Kaltenhauser S, Hantzschel H, Hauschildt S, Wagner U (2007). Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol, 179(6), 4239-4248.
     
  2502. Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE, Gay S, Kyburz D (2007). The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford), 46(7), 1063-1070.
     
  2503. Savkovic V, Gantzer H, Reiser U, Selig L, Gaiser S, Sack U, Kloppel G, Mossner J, Keim V, Horn F, Bodeker H (2007). Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem Biophys Res Commun, 356(2), 431-437.
     
  2504. Behrbohm J, Neid M, Stolzel U, Wittekind C, Hauss JP, Tillmann HL (2007). Improvement of multiple sclerosis on tacrolimus plus mycophenolate mofetil after liver transplantation. Clinical improvement of multiple sclerosis in a patient requiring liver transplantation for acute liver failure following interferon-beta therapy. Transpl Int, 20(12), 1077-1079.
     
  2505. Tillmann HL (2007). Does the presence of hepatic steatosis influence the efficacy of antiviral treatment in patients with hepatitis C? Nat Clin Pract Gastroenterol Hepatol, 4(10), 548-549.
     
  2506. Tillmann HL (2007). Screening for and treating hepatitis B virus in patients with HIV infection. Clin Infect Dis, 45(5), 633-636.
     
  2507. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL (2007). Longer survival of liver transplant recipients with hepatitis virus coinfections. Clin Transplant, 21(2), 258-264.
     
  2508. Busse FP, Mössner J, Stumvoll M, Kluge R, Schoppmeyer K (2007). Nichtoperative Therapiemöglichkeiten gastroenteropankreatischer neuroendokriner Tumoren Chir Gastroenterol, 23(2), 158-165.
     
  2509. Scheid R, Teich N (2007). Neurologic manifestations of ulcerative colitis. Eur J Neurol, 14(5), 483-493.
     
  2510. Neumann S, Schoppmeyer K, Lange T, Niederwieser D, Caca K (2007). Response:. Gastrointest Endosc, 66(5), 1068-1069.
     
  2511. Nieber K, Schoppmeyer K (2007). [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist] Pharm Unserer Zeit, 36(5), 373-380.
     
  2512. Feisthammel J, Schoppmeyer K, Mossner J, Schulze M, Caca K, Wiedmann M (2007). Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol, 30(3), 319-324.
     
  2513. Schoppmeyer K, Golsong J, Schiefke I, Mossner J, Caca K (2007). Antireflux stents for palliation of malignant esophagocardial stenosis. Dis Esophagus, 20(2), 89-93.
     
  2514. Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M (2007). Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol, 13(35), 4761-4770.
     
  2515. Rother K, Li YY, Tschop K, Kirschner R, Muller GA, Mossner J, Engeland K (2007). Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73. Cell Cycle, 6(7), 853-862.
     
  2516. Rother K, Dengl M, Lorenz J, Tschop K, Kirschner R, Mossner J, Engeland K (2007). Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. FEBS Lett, 581(6), 1166-1172.
     
  2517. Seidel W, Baerwald C (2007). Begeisterter akademischer Lehrer Prof. Dr. Holm Häntzschel zum 65. Geburtstag Journal der Universität Leipzig , 3, 35.
     
  2518. Schauer J (2007). Nachruf für Professor Dr. med. Werner Ries Journal der Universität Leipzig , 4, 40.
     
  2519. Mössner J (2007). Editorial: Infektionsprobleme bleiben ein wichtiges Thema. Kompakt Gastroenterologie, ??, 1-3.
     
  2520. Mössner J (2007). Editorial. Kompakt Gastroenterologie, ??, 1-3.
     
  2521. Mössner J (2007). Editorial: Viele, teils schon praxisrelevante neue Erkenntnisse in der gastroenterologischen Onkologie. Kompakt Gastroenterologie, ??, 1-3.
     
  2522. Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Grassler J (2007). [Molecular basis of primary renal hyperuricemia : Role of the human urate transporter hURAT1.] Z Rheumatol, 66(7), 556-561.
     
  2523. Hoheisel G, Luk WK, Winkler J, Wirtz H, Gillissen A, Hui DS, Liebert UG (2007). [Avian influenza and the Severe Acute Respiratory Syndrome (SARS) - experiences and perspectives] Pneumologie, 61(1), 41-45.
     
  2524. Baerwald, C (2007). Manifestationsformen von Rheuma Deut Z Klin Forsch, 11-12, 11-12.
     
  2525. Lehnert H, Mössner J (2007). Metabolisches Syndrom. Editorial Internist (Berl), 48(2), 115-116.
     
  2526. Wiedmann M, Kassahun W, Deckert F, Troltzsch M, Sturmvoll M, Fuhrer D (2007). [65-year old female patient with persistent hypercalcemia.] Internist (Berl), 48(12), 1436-1441.
     
  2527. Muller GA, Heissig F, Engeland K (2007). Chimpanzee, orangutan, mouse, and human cell cycle promoters exempt CCAAT boxes and CHR elements from interspecies differences. Mol Biol Evol, 24(3), 814-826.
     
  2528. Schoppmeyer K, Kreth F, Wiedmann M, Mossner J, Preiss R, Caca K (2007). A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs, 18(6), 697-702.
     
  2529. Wiegand J, Cornberg M, Aslan N, Schlaphoff V, Sarrazin C, Kubitschke A, Buggisch P, Ciner A, Jaeckel E, Manns MP, Wedemeyer H (2007). Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther, 12(3), 303-316.
     
  2530. Tillmann HL (2007). Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs, 8(8), 682-690.
     
  2531. Tschop K, Engeland K (2007). Cell cycle-dependent transcription of cyclin B2 is influenced by DNA methylation but is independent of methylation in the CDE and CHR elements. FEBS J, 274(20), 5235-5249.
     
  2532. Wittenburg H, Lammert F (2007). Genetic predisposition to gallbladder stones. Semin Liver Dis, 27(1), 109-121.
     
  2533. Schiefke I, Schoppmeyer K, Kluge R, Mössner J (2007). Epidemiologie, Klinik und Diagnostik von gastrointestinalen Stromatumoren (GIST) Verdauungskrankheiten, 25(6), 266-272.
     
  2534. Teich N, Mössner J (2007). Akute Pankreatitis Gastroenterologe , 2(5), 371-384.
     
  2535. Wiedmann M, Mössner J (2007). Das Hepaticusgabelkarzinom: Wie aufwendig muss die Diagnostik sein? Klinikarzt, 36(11), 620-625.
     
  2536. Mössner J (2007). Kommentiertes Referat: Therapie der distalen Pankreasgangstenose: weniger Schmerzen nach Operation als nach interventioneller Endoskopie. Dtsch Ärzteblatt , 104, 958.
     
  2537. Mössner J (2007). Kommentiertes Referat: Milde akute Pankreatitis – Wunschkost oder Wasser? Dtsch Ärzteblatt , 104, 3033.
     
  2538. Raczynski S, Mössner J, Teich N (2007). Welche Bedeutung hat die interventionelle Endoskopie in der Therapie der distalen Pankreasgangstenose? Med Klin (Munich), 102(6), 487-488.
     
  2539. Teich N, Ott R, Kahn T, Mössner J (2007). Akut stenosierender Morbus Crohn - Operation oder Immunsuppression? J Gastroenterol Hepatol Erkr, 5(3), 16-19.
     
  2540. Kuhn H, Hammerschmidt S, Wirtz H (2007). Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches. Curr Med Chem, 14(30), 3157-3165.
     
  2541. Kuhn H, Hammerschmidt S, Wirtz H (2007). Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches. Curr Med Chem, 14(30), 3157-3165.
     
  2542. Teichert J, Baumann F, Chao Q, Franklin C, Bailey B, Hennig L, Caca K, Schoppmeyer K, Patzak U, Preiss R (2007). Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol, 59(6), 759-770.
     
  2543. Trebst C, Wedemeyer H, Manns MP, Tillmann H, Windhagen A (2007). Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. Eur J Gastroenterol Hepatol, 19(1), 91-92.
     
  2544. Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, Greten T, Wiegand J, Manns MP, Wedemeyer H (2007). Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest, 37(1), 54-64.
     
  2545. Neumann S, Schoppmeyer K, Lange T, Wiedmann M, Golsong J, Tannapfel A, Mossner J, Niederwieser D, Caca K (2007). Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease. Gastrointest Endosc, 65(3), 403-409.
     
  2546. Gillissen A, Wirtz H, Hoheisel G (2007). [New perspectives in GINA Asthma Guideline 2006] Med Klin (Munich), 102(5), 399-403.
     
  2547. Mobius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mossner J, Hauss J, Witzigmann H (2007). Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol, 33(8), 1025-1029.
     
  2548. Kubitschke A, Bader C, Tillmann HL, Manns MP, Kuhn S, Wedemeyer H (2007). [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?] Internist (Berl), 48(10), 1165-1172.
     
  2549. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C (2007). Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat, 14(8), 556-563.
     
  2550. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C (2007). Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int, 27(3), 335-339.
     
  2551. Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP (2007). Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl, 13(3), 367-373.
     
  2552. Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, Finger A, Michel G, Nashan B, Kuse ER, Klempnauer J, Tillmann HL, Manns MP (2007). HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol, 46(4), 635-644.
     
  2553. Gundling F, Teich N, Strebel HM, Schepp W, Pehl C (2007). [Nutrition in liver cirrhosis.] Med Klin (Munich), 102(6), 435-444.
     
  2554. Mikhailova AG, Likhareva VV, Teich N, Rumsh LD (2007). The ways of realization of high specificity and efficiency of enteropeptidase. Protein Pept Lett, 14(3), 227-232.
     
  2555. Oxelmark L, Hilleras P, Dignass A, Mossner J, Schreiber S, Kruis W, Lofberg R (2007). Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis. Scand J Gastroenterol, 42(3), 406-407.
     
  2556. Willms H, Gutjahr K, Juergens UR, Hammerschmidt S, Gessner C, Hoheisel G, Wirtz H, Gillissen A (2007). [Diagnostics and therapy of idiopathic pulmonary hemosiderosis.] Med Klin (Munich), 102(6), 445-450.
     
  2557. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M (2007). Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J, 30(6), 1096-1102.
     
  2558. Halank M, Seyfarth HJ, Opitz C, Schmeisser A, Ewert R, Hoffken G (2007). [Pulmonary arterial hypertension in collagen disease: findings of the German Network for Systemic Scleroderma] Dtsch Med Wochenschr, 132(7), 337.
     
  2559. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Distler O, Jungel A (2007). Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum, 56(8), 2755-2764.
     
  2560. Maurer B, Distler JH, Moritz F, Gay S, Distler O (2007). [Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases] Z Rheumatol, 66(4), 304-310.
     
  2561. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A (2007). Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum, 56(4), 1087-1093.
     
  2562. Huber LC, Moritz F, Gay S (2007). Spondylarthritides and related entities: entheses and hypotheses. Arthritis Rheum, 56(1), 4-8.
     
  2563. Huber LC, Jungel A, Distler JH, Moritz F, Gay RE, Michel BA, Pisetsky DS, Gay S, Distler O (2007). The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis, 12(2), 363-374.
     
  2564. Hucl T, Kylanpaa-Back ML, Witt H, Kunzli B, Lempinen M, Schneider A, Kemppainen E, Lohr M, Friess H, Ockenga J, Rosendahl J, Schulz HU, Gress T, Singer MV, Pfutzer RH (2007). HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med, 9(7), 479-483.
     
  2565. Kiraly O, Boulling A, Witt H, Le Marechal C, Chen JM, Rosendahl J, Battaggia C, Wartmann T, Sahin-Toth M, Ferec C (2007). Signal peptide variants that impair secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause autosomal dominant hereditary pancreatitis. Hum Mutat, 28(5), 469-476.
     
  2566. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H (2007). Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J, 4, 58-.
     
  2567. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S (2007). Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl, 13(3), 349-360.
     
  2568. Witt H, Apte MV, Keim V, Wilson JS (2007). Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology, 132(4), 1557-1573.
     
  2569. Leinung S, Mössner J, Hauss J, Izbicki JR (2007). Endokrine und mesenchymale Tumoren des Gastrointestinaltraktes. Editorial. Chir Gastroenterol, 23(2), 106-107.
     
  2570. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U (2007). Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer, 55(1), 109-113.
     
  2571. Löffler G, Mössner J (2007). Gastrointestinaltrakt. In: Löffler G, Petrides PE, Heinrich PC, Biochemie & Pathobiochemie. (S. 1053-1102), Berlin, Heidelberg, New York: Springer.
     
  2572. Baerwald C (2007). Fibromyalgie. In: Peter H, Penzel T, Peter JH, Enzyklopädie der Schlafmedizin. (S. 416-419), Heidelberg: Springer Medizin Verlag.
     
  2573. Baerwald C (2007). Rheumatische Erkrankungen. In: Peter H, Penzel T, Peter JH, Enzyklopädie der Schlafmedizin. (S. 1034-1037), Heidelberg: Springer Medizin Verlag.
     
  2574. Hammerschmidt S, Wirtz H (2007). Beatmungsinduzierter Lungenschaden. In: Bein T, Pfeiffer M, Intensivbuch Lunge. (S. 127-142), Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft.
     
  2575. Keim V, Mössner J (2007). Akute und chronische Pankreatitis. In: Schölmerich J, Mössner J, Medizinische Therapie 2007/2008. (S. 969-976), Heidelberg: Springer Medizin Verlag .
     
  2576. Mössner J (2007). Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D , Arzneiverordnungsreport 2007. (S. 667-694), Berlin, Heidelberg, New York : Springer Verlag.
     
  2577. Wiedmann M, Mössner J (2007). Experimental strategies to treating biliary tract cancer. In: Whitten JT, Cancer of the Gallbladder: New Research (Horizons in Cancer Research). (S. 129-148), Hauppauge NY USA: Nova Publishers .
     
  2578. Siewert JR, Molls M, Zimmermann F, Lordick F (2007). Clinical Management. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, Gastrointestinal Oncology. Principles and Practice. (S. ), Philadelphia: Lippincott Williams & Wilkins.
     
  2579. Lordick F (2007). Therapiestrategien bei Patienten mit synchron metastasierten kolorektalen Karzinomen. In: Bokemeyer, Das kolorektale Karzinom – Grundlagen, Prävention und moderne Therapiekonzepte. (S. ), : SocioMed Verlag .
     
  2580. Sendler A, Lordick F, Tannapfel A (2007). Das Magenkarzinom. In: Hiddemann W, Onkologie. (S. ), Heidelberg, Berlin, New York: Springer Verlag.
     


    2581. 2006


  2581. Hoffmeister A, Wittenburg H, Teich N, Bachmann A, Borte G, Mossner J, Achenbach H (2006). [A 32-year-old patient with diarrhoe and acute kidney failure.] Internist (Berl), 47(10), 1063-1067.
     
  2582. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, Mossner J, Caca K (2006). Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs, 17(7), 783-795.
     
  2583. Raczynski S, Teich N, Borte G, Wittenburg H, Mossner J, Caca K (2006). Percutaneous transgastric irrigation drainage in combination with endoscopic necrosectomy in necrotizing pancreatitis (with videos). Gastrointest Endosc, 64(3), 420-424.
     
  2584. Uhlig HH, Galler A, Keim V, Mossner J, Kiess W, Caca K, Teich N (2006). Regression of pancreatic diabetes in chronic hereditary pancreatitis. Diabetes Care, 29(8), 1981-1982.
     
  2585. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, Tannapfel A, Wittekind C, Mossner J, Hauss J, Wiedmann M (2006). Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg, 244(2), 230-239.
     
  2586. Schiefke I, Schmaschke R, Ott R, Schiefke F, Mossner J, Schubert S (2006). [Indigenous helminthiasis] Internist (Berl), 47(8), 793-800.
     
  2587. Schiefke I, Schmaschke R, Ott R, Schiefke F, Mossner J, Schubert S (2006). [Tropical and subtropical helminthoses] Internist (Berl), 47(8), 801-809.
     
  2588. Teich N, Rosendahl J, Toth M, Mossner J, Sahin-Toth M (2006). Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat, 27(8), 721-730.
     
  2589. Battegay M, Mossner J (2006). [Parasitic diseases] Internist (Berl), 47(8), 785.
     
  2590. Feisthammel J, Troltzsch M, Witzigmann H, Mossner J, Caca K (2006). An unusual cause and treatment for ascites after liver transplantation. Gut, 55(6), 763, 884.
     
  2591. Wittenburg H, Lyons MA, Li R, Kurtz U, Wang X, Mossner J, Churchill GA, Carey MC, Paigen B (2006). QTL mapping for genetic determinants of lipoprotein cholesterol levels in combined crosses of inbred mouse strains. J Lipid Res, 47(8), 1780-1790.
     
  2592. Kamenz T, Caca K, Bluthner T, Tannapfel A, Mossner J, Wiedmann M (2006). Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol, 12(10), 1583-1590.
     
  2593. Mossner J (2006). [In Process Citation] Internist (Berl), 47(3), 223.
     
  2594. Wiegand J, Kaiser T, Lobstein S, Brand F, Wojan M, Stolzel U, Liebert UG, Mossner J, Tillmann HL (2006). Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany. Z Gastroenterol, 44(1), 11-14.
     
  2595. Tillmann HL (2006). Lamivudine-resistant hepatitis B virus infection post-liver transplantation from a hepatitis B core antibody donor. Am J Transplant, 6(8), 1980.
     
  2596. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP (2006). Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat, 13(4), 256-263.
     
  2597. Meier R, Ockenga J, Pertkiewicz M, Pap A, Milinic N, Macfie J, Loser C, Keim V (2006). ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin Nutr, 25(2), 275-284.
     
  2598. Lankisch PG, Weber-Dany B, Doobe C, Finger T, Maisonneuve P, Lowenfels AB, Keim V (2006). Pankrin: a new parameter for the diagnosis of acute pancreatitis in cases of late clinical presentation. Pancreas, 32(3), 330-331.
     
  2599. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology, 43(2), 250-256.
     
  2600. Selig L, Sack U, Gaiser S, Kloppel G, Savkovic V, Mossner J, Keim V, Bodeker H (2006). Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen. BMC Gastroenterol, 6(1), 30.
     
  2601. Huster D, Finegold MJ, Morgan CT, Burkhead JL, Nixon R, Vanderwerf SM, Gilliam CT, Lutsenko S (2006). Consequences of copper accumulation in the livers of the Atp7b-/- (Wilson disease gene) knockout mice. Am J Pathol, 168(2), 423-434.
     
  2602. Wiegand J, Neid M, Kaiser T, Wittekind C, Mossner J, Tillmann HL, Schiefke I (2006). Coexistence of autoimmune pancreatitis and primary biliary cirrhosis in a Caucasian patient - a rare cause of cholestasis. Z Gastroenterol, 44(12), 1227-1229.
     
  2603. Seyfarth HJ, Hammerschmidt S, Gessner C, Gradistanac T, Wirtz H (2006). [Pulmonary hamartoma--a rare cause of recurrent pneumonia in the course of immunosuppression] Pneumologie, 60(9), 537-538.
     
  2604. Kuhn H, Konrad J, Holtz S, Salameh A, Gessner C, Hammerschmidt S, Wirtz H (2006). Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer, 54(2), 149-153.
     
  2605. Hammerschmidt S (2006). [Early diagnosis of lung cancer: where do we stand?] MMW Fortschr Med, 148(22), 28, 30-31.
     
  2606. Kreymborg KG, Seyfarth HJ, Gessner C, Schutz A, Hammerschmidt S, Eichfeld U, Borte G, Wirtz H (2006). Diagnosis of aspergilloma in a pleural cavity (persistent pneumothorax) using classic imaging methods. Mycoses, 49(3), 210-215.
     
  2607. Gillissen A, Gessner C, Hammerschmidt S, Hoheisel G, Wirtz H (2006). [Acute bronchitis: when are antibiotics, and when is symptomatic treatment indicated?] MMW Fortschr Med, 148(1-2), 26-28.
     
  2608. Gillissen A, Gessner C, Hammerschmidt S, Hoheisel G, Wirtz H (2006). [Health significance of inhaled particles] Dtsch Med Wochenschr, 131(12), 639-644.
     
  2609. Sack U, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, Emmrich F, Hoheisel G, Wirtz H, Gessner C (2006). Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A, 69(3), 169-172.
     
  2610. Hoheisel G, Luk WK, Winkler J, Gillissen A, Wirtz H, Liebert UG, Hui DS (2006). [Severe Acute Respiratory Syndrome (SARS).] Med Klin (Munich), 101(12), 957-963.
     
  2611. Gessner C, Wirtz H (2006). Continuous exhaled breath condensate measurements in ventilated patients: I don t know what you guys are measuring, but you re certainly measuring it!. Respir Care, 51(10), 1118-1119.
     
  2612. Hammerschmidt S, Geßner C, Seyfarth HJ, Wirtz H (2006). Dehnungsabhängige pulmonale Freisetzung von Stickstoffmonoxid. Intensivmedizin und Notfallmedizin, 43(4), 260-269.
     
  2613. Gessner C, Hammerschmidt S, Kuhn H, Seyfarth HJ, Engelmann L, Sack U, Wirtz H (2006). Nitrit im Atemkondensat: Ein Marker für den mechanischen Stress unter Beatmung. Intensivmedizin und Notfallmedizin, 43(4), 270-278.
     
  2614. Tillmann HL, Kaiser T, Claes C, Schmidt RE, Manns MP, Stoll M (2006). Differential influence of different hepatitis viruses on quality of life in HIV positive patients. Eur J Med Res, 11(9), 381-385.
     
  2615. Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A (2006). Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci, 1073, 517-526.
     
  2616. Schoppmeyer K, Lange T, Wittekind C, Niederwieser D, Caca K (2006). TIPS for veno-occlusive disease following stem cell transplantation. Z Gastroenterol, 44(6), 483-486.
     
  2617. Schoppmeyer K, Miethe S, Wiedmann M, Liebmann A, Hauss J, Mossner J, Caca K, Witzigmann H, Hildebrandt G (2006). Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. Am J Clin Oncol, 29(6), 576-582.
     
  2618. Tschop K, Muller GA, Grosche J, Engeland K (2006). Human cyclin B3. mRNA expression during the cell cycle and identification of three novel nonclassical nuclear localization signals. FEBS J, 273(8), 1681-1695.
     
  2619. Lyons MA, Wittenburg H (2006). Susceptibility to cholesterol gallstone formation: evidence that LITH genes also encode immune-related factors. Biochim Biophys Acta, 1761(10), 1133-1147.
     
  2620. Lyons MA, Wittenburg H (2006). Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology, 131(6), 1943-1970.
     
  2621. Mössner J (2006). Editorial. Die „story“ der Cylcooxygenase-2-Inhibitoren geht weiter: Wem soll man glauben: Ergebnissen industrieunabhängiger Fall-Kontrollstudien, die einen niedrigeren Evidenzgrad haben oder dem Goldstandard, Ergebnissen (allerdings industriegesponserter) prospektiver randomisierter Studien? Kompakt Gastroenterologie, 1, 1-3.
     
  2622. Mössner J (2006). Chronische Pankreatitis: Klinik, Verlauf & Diagnostik. Der Gastroenterologe, 1(1), 18-26.
     
  2623. Mössner J (2006). Editorial. Kaffee schützt vor Leberzirrhose. Kompakt Gastroenterologie, 1, 1-3.
     
  2624. Teich N, Mössner J (2006). Mutationen im kationischen Trypsinogen und hereditäre chronische Pankreatitis. Klinikarzt, 35(7), 266-268.
     
  2625. Teich N, Engelmann L, Pfeiffer D (2006). Laienreanimation: schlechte Kenntnisse in Deutschland. Der Notarzt, 22(4), 114-118.
     
  2626. Wiedmann M, Hauss J, Witzigmann H, Mössner J (2006). Stellenwert spezieller palliativer Therapieverfahren: Gallengansstents, photodynamische Therapie, operative Umgehungsanastomosen. Onkologe, 12(12), 1237-1248.
     
  2627. Wiegand J, Mössner J, Tillmann HL (2006). Lebererkrankungen und Frakturrisiko. Gastro Liga Newsletter: Kompakt Gastroenterologie, 1, 2-3.
     
  2628. Wiegand J, Kaiser T, Tillmann HL (2006). Diagnostik und Therapie der chronischen Hepatitis B und C - State of the Art. Kompendium Gastroenterologie, (2)1, 1-3.
     
  2629. Wiegand J, Tillmann HL (2006). Beeinflussen Genotypen die Therapieentscheidung bei chronischer Hepatitis B – aktuelle Daten und ihre Einschränkungen. Lebenszeichen: Das Lebermagazin, 2, 1-3.
     
  2630. Rosendahl J, Teich N, Mossner J, Edelmann J, Koch CA (2006). Compound Heterozygous Mutations of the SBDS Gene in a Patient with Shwachman-Diamond Syndrome, Type 1 Diabetes Mellitus and Osteoporosis. Pancreatology, 6(6), 549-554.
     
  2631. Wiegand J, Peter A, Rosendahl J, Sommerer F, Mössner J, Caca K (2006). Polypoide Metastasen im gesamten Gastrointestinaltrakt – eine ungewöhnliche Manifestation eines großzelligen neuroendokrinen Karzinoms der Lunge. Coloproctology, 28(1), 9-12.
     
  2632. Mössner J (2006). Ernährung, Probiotika, Antibiotika,, antioxidative Therapie,Endoskopie bei chronischer Pankreatitis. Praxis (Schweizerische Rundschau für Medizin), 95(42), 1627-1635.
     
  2633. Seidel W, Baerwald C (2006). Prof. Dr. med. habil. Holm Häntzschel zum 65. Geburtstag Ärzteblatt Sachsen, 17(11), 577.
     
  2634. Malicet C, Hoffmeister A, Moreno S, Closa D, Dagorn JC, Vasseur S, Iovanna JL (2006). Interaction of the stress protein p8 with Jab1 is required for Jab1-dependent p27 nuclear-to-cytoplasm translocation. Biochem Biophys Res Commun, 339(1), 284-289.
     
  2635. Lange F, Hartl S, Ungethuem U, Kuban RJ, Hammerschmidt S, Faber S, Morawietz L, Wirtz H, Emmrich F, Krenn V, Sack U (2006). Anti-TNF effects on destructive fibroblasts depend on mechanical stress. Scand J Immunol, 64(5), 544-553.
     
  2636. Uhlmann D, Wiedmann M, Schmidt F, Kluge R, Tannapfel A, Berr F, Hauss J, Witzigmann H (2006). Management and outcome in patients with Klatskin-mimicking lesions of the biliary tree. J Gastrointest Surg, 10(8), 1144-1150.
     
  2637. Potthoff A, Tillmann HL, Bara C, Deterding K, Pethig K, Meyer S, Haverich A, Boker KH, Manns MP, Wedemeyer H (2006). Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat, 13(11), 734-741.
     
  2638. Deterding K, Tegtmeyer B, Cornberg M, Hadem J, Potthoff A, Boker KH, Tillmann HL, Manns MP, Wedemeyer H (2006). Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol, 45(6), 770-78.
     
  2639. Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H, Manns MP (2006). Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int, 19(10), 828-833.
     
  2640. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H (2006). Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat, 13(8), 505-514.
     
  2641. Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT (2006). Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med, 7(3), 173-180.
     
  2642. Witt H, Sahin-Toth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani (2006). A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet, 38(6), 668-673.
     
  2643. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H, Trebst C, Hecker H, Berding G (2006). Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut, 55(11), 1624-1630.
     
  2644. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein JM (2006). Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer, 119(11), 2651-2656.
     
  2645. Hoepffner N, Shastri YM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J (2006). Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther, 23(1), 145-154.
     
  2646. Treiber M, Schulz HU, Landt O, Drenth JP, Castellani C, Real FX, Akar N, Ammann RW, Bargetzi M, Bhatia E, Demaine AG, Battagia C, Kingsnorth A, O'reilly D, Truninger K, Koudova M, Spicak J, Cerny M, M (2006). Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med, 84(12), 1015-22.
     
  2647. Wedemeyer H, Cornberg M, Wiegand J, Jackel E, Manns MP (2006). Treatment of acute hepatitis C-how to explain the differences? Gastroenterology, 131(2), 682-3.
     
  2648. Kolschmann S, Ballin A, Juergens UR, Rohde G, Gessner C, Hammerschmidt S, Wirtz H, Gillissen A (2006). [Talc pleurodesis in malignant pleural effusions] Pneumologie, 60(2), 89-95.
     
  2649. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Barok (2006). Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol, 48(12), 2546-2552.
     
  2650. Halank M, Ewert R, Seyfarth HJ, Hoeffken G (2006). Portopulmonary hypertension. J Gastroenterol, 41(9), 837-847.
     
  2651. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J (2006). Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 28(4), 691-694.
     
  2652. Halank M, Ewert R, Opitz C, Seyfarth HJ, Hoffken G (2006). [Severe refractory pulmonary hypertension after liver transplantation for hepatitis C liver cirrhosis] Z Gastroenterol, 44(4), 346-7.
     
  2653. Gundling F, Teich N, Pehl C, Schepp W (2006). [Invasive and non-invasive diagnostic methods for evaluation of hypovolemia in acute pancreatitis] Z Gastroenterol, 44(12), 1247-1254.
     
  2654. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, Lahousse SA, Califano S, Maeda T, Ueno T, D Errico A, Trevisani F, Wands JR (2006). Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol, 44(5), 971-983.
     
  2655. Friedrich M, Grahnert A, Klein C, Tschop K, Engeland K, Hauschildt S (2006). Genomic organization and expression of the human mono-ADP-ribosyltransferase ART3 gene. Biochim Biophys Acta, 1759(6), 270-280.
     
  2656. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF (2006). Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect, 53(5), 337-349.
     
  2657. Mössner J (2006). Role of medical therapy in drug-induced bleeding. In: Malfertheiner P,Lundell L,Tytgat G, Update Gastroenterology 2006: Novel Developments in Gastroenterology. Combined EAGE, ASNEMGE, EDS, IDS, EAES Postgraduate Course. (S. 29-34), Paris: John Libbey Eurotext.
     
  2658. Mössner J (2006). Surveillance and Diagnostics of Chronic Pancreatitis. FALK-Symposium No. 150. In: Editors: PR Galle, G Gerken, WE Schmidt, B Wiedenmann, Disease Progression and Disease Prevention in the Gastrointestinal Tract. (S. 90-101), Lancaster, UK: Kluwer Academic Publishers.
     
  2659. Wedemeyer H, Tillmann HL (2006). Diagnostik. In: Manns MP, Wedemeyer H, In Handbuch Hepatitis C: Diagnostik der Virushepatitis C. (S. 46-54), Bremen: Uni-Med Verlag AG.
     
  2660. Wedemeyer H, Cornberg M, Hadem, J, Manns MP, Tillmann HL (2006). Problempatienten: Verlauf und Therapie. In: Manns MP, Wedemeyer H, Handbuch Hepatitis C: Diagnostik, Verlauf, Therapie. (S. 89-108), Bremen: Uni-Med Verlag AG.
     
  2661. Tillmann HL (2006). Hepatitis C und Transplantation. In: Manns MP, Wedemeyer H, Handbuch Hepatitis C: Diagnostik, Verlauf, Therapie. (S. 132-136), Bremen: Uni-Med Verlag AG.
     
  2662. Tillmann HL (2006). Hepatitis B Virus. Einführung und Virologie Diagnostik. In: Peck- Radosavljevic M, Leitfaden der chronischen Infektionskrankheiten der Leber. (S. 14-17), Bremen: Uni-Med Verlag AG.
     
  2663. Tillmann HL (2006). Hepatitis B Virus. Epidemiologie, Infektionswege, Pathogenese, Labordiagnostik, Titerbewegung und Klinik, Mutanten und Prophylaxe. In: Peck- Radosavljevic M, Leitfaden der chronischen Infektionskrankheiten der Leber. (S. 18-34), Bremen: Uni-Med Verlag AG.
     
  2664. Tillmann HL (2006). Hepatitis B Virus. Therapieoptionen der Zukunft. In: Peck- Radosavljevic M, Leitfaden der chronischen Infektionskrankheiten der Leber. (S. 58-61), Uni-Med Verlag AG: Peck-Radosavljevic M.
     
  2665. Mössner J (2006). Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D, Arzneiverordnungsreport. (S. 709-734), Berlin, Heidelberg, New York: Springer.
     
  2666. Mössner J (2006). NSAID induced lesions of the gastrointestinal tract (http://www.springerlink.com/content/x3j7173121627h28/fulltext.html) In: Schmidt RF, Willis WD, Encyclopedia of Pain. (S. 7 S.), Berlin, Heidelberg: Springer.
     
  2667. Wiedmann M, Mössner J (2006). Experimental strategies to treating biliary tract cancer. In: Whitten JT, Cancer of the Gallbladder: New Research (Horizons in Cancer Research). (S. 10 S.), New York: Nova Publishers.
     
  2668. Siewert JR, Lordick F (2006). Standards in der interdisziplinären Diagnostik und Therapie. In: Schmoll, Höffken, Possinger, Kompendium Internistische Onkologie. (S. 000), Heidelberg, Berlin, New York: Springer Verlag.
     
  2669. Zimmermann F, Meining A, Lordick F, Sarbia M (2006). Ösophagus-Plattenepithelkarzinom. In: Sendler A , Manual Gastrointestinale Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge (S. 1-18), München: Zuckschwerdt-Verlag.
     
  2670. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C, Zimmermann F (2006). Magenkarzinom. In: Sendler A , Manual Gastrointestinale Tumorendes Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. (S. 26-53), München: Zuckschwerdt-Verlag.
     
  2671. Nieder C, Lordick F (2006). Combination of platinum compounds and ionizing radiation. In: Brown JM, Mehta MP, Nieder C, Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy. (S. ), Berlin, Heidelberg, New York : Springer Verlag.
     
  2672. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher B (2006). Ösophagus-Plattenepithelkarzimom. In: Tumorzentrum München, Manual des Tumorzentrums München. (S. ), München Wien New York: Zuckschwerdt-Verlag.
     
  2673. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C, Zimmermann F (2006). Magenkarzinom. In: Tumorzentrum München, Manual des Tumorzentrums München. (S. ), München: Zuckschwerdt-Verlag.
     
  2674. Peschel C, Lordick F (2006). Therapie-induzierte Nausea und Emesis in der Onkologie. In: Lordick F, Therapie-induzierte Nausea und Emesis in der Onkologie. (S. ), Bremen, London, Boston.: Uni-Med Verlag.
     


    2675. 2005


  2675. Spiesbach K, Tannapfel A, Mossner J, Engeland K (2005). TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int J Cancer, 114(4), 555-562.
     
  2676. Teich N, Nemoda Z, Kohler H, Heinritz W, Mossner J, Keim V, Sahin-Toth M (2005). Gene conversion between functional trypsinogen genes PRSS1 and PRSS2 associated with chronic pancreatitis in a six-year-old girl. Hum Mutat, 25(4), 343-347.
     
  2677. Teich N, Keim V, Mossner J (2005). [Clinical implications of genetic risk factors of chronic pancreatitis] Internist (Berl), 46(2), 123-130.
     
  2678. Bohm K, Teich N, Hoffmeister A, Mossner J, Keim V, Bodeker H (2005). Transforming growth factor-beta-1 variants are not associated with chronic nonalcoholic pancreatitis. Pancreatology, 5(1), 75-80.
     
  2679. Muller D, Wiedmann M, Kluge R, Berr F, Mossner J, Sabri O, Caca K (2005). [Is 18F-FDG-PET suitable for therapy monitoring after palliative photodynamic therapy of non-resectable hilar cholangiocarcinoma?] Z Gastroenterol, 43(5), 439-443.
     
  2680. Kluge R, Barthel H, Pankau H, Seese A, Schauer J, Wirtz H, Seyfarth HJ, Steinbach J, Sabri O, Winkler J (2005). Different mechanisms for changes in glucose uptake of the right and left ventricular myocardium in pulmonary hypertension. J Nucl Med, 46(1), 25-31.
     
  2681. Wiedmann M, Hagendorff A, Bohm R, Schulz T, Mossner J, Caca K (2005). Malignant oesophago-pleuro-pericardial fistula in a patient with oesophageal carcinoma. Z Kardiol, 94(6), 411-414.
     
  2682. Wiedmann M, Wang X, Tang X, Han M, Li M, Mao Z (2005). PI3K/Akt-dependent regulation of the transcription factor myocyte enhancer factor-2 in insulin-like growth factor-1- and membrane depolarization-mediated survival of cerebellar granule neurons. J Neurosci Res, 81(2), 226-234.
     
  2683. Wiedmann MW, Caca K (2005). Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets, 5(3), 171-193.
     
  2684. Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mossner J, Caca K (2005). [Current diagnostics and therapy for carcinomas of the bilary tree and gallbladder.] Z Gastroenterol, 43(5), 473-475.
     
  2685. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J (2005). Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol, 11(12), 1843-1847.
     
  2686. Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mossner J, Caca K (2005). [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder] Z Gastroenterol, 43(3), 305-315.
     
  2687. Wittenburg H, Mossner J, Caca K (2005). Endoscopic treatment of duodenal obstruction due to a gallstone ("Bouveret's syndrome"). Ann Hepatol, 4(2), 132-134.
     
  2688. Huster D, Kuhn HJ, Mossner J, Caca K (2005). [Wilson disease.] Internist (Berl), 46(7), 731-740.
     
  2689. Schiefke I, Zabel-Langhennig A, Neumann S, Feisthammel J, Moessner J, Caca K (2005). Long term failure of endoscopic gastroplication (EndoCinch). Gut, 54(6), 752-758.
     
  2690. Schiefke I, Rogalski C, Zabel-Langhennig A, Witzigmann H, Mossner J, Hasenclever D, Caca K (2005). Are endoscopic antireflux therapies cost-effective compared with laparoscopic fundoplication? Endoscopy, 37(3), 217-222.
     
  2691. Schiefke I, Mossner J, Caca K (2005). [Reflux esophagitis] Internist (Berl), 46(3), 315-327.
     
  2692. Keim V (2005). [Chronic pancreatitis--pancreas cancer: influence of genetic factors] Schweiz Rundsch Med Prax, 94(20), 811-817.
     
  2693. Keim V (2005). [Diagnosis and treatment of acute pancreatitis] Z Gastroenterol, 43(5), 461-466.
     
  2694. Kaiser T, Tillmann HL (2005). GB virus C infection: is there a clinical relevance for patients infected with the human immunodeficiency virus? AIDS Rev, 7(1), 3-12.
     
  2695. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL (2005). Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol, 63(3), 232-235.
     
  2696. Tillmann HL, Manns MP, Rudolph KL (2005). Merging models of hepatitis C virus pathogenesis. Semin Liver Dis, 25(1), 84-92.
     
  2697. Tillmann HL, Wiegand J, Glomb I, Jelineck A, Picchio G, Wedemeyer H, Manns MP (2005). Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. Z Gastroenterol, 43(1), 11-16.
     
  2698. Schiefke I, Neumann S, Zabel-Langhennig A, Moessner J, Caca K (2005). Use of an Endoscopic Suturing Device (the "ESD") to Treat Patients with Gastroesophageal Reflux Disease, After Unsuccessful EndoCinch Endoluminal Gastroplication: Another Failure. Endoscopy, 37(8), 700-705.
     
  2699. Gaiser S, Ahler A, Gundling F, Kruse ML, Savkovic V, Selig L, Teich N, Tomasini R, Dagorn JC, Mossner J, Keim V, Bodeker H (2005). Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells. Biochem Biophys Res Commun, 334(2), 721-728.
     
  2700. Teich N, Kleeff J, Lochs H, Mossner J, Keim V, Friess H, Ockenga J (2005). The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol, 5(1), 20 (1-5).
     
  2701. Tillmann HL, Kaiser T, Fox Z, Staszewski S, Antunes F, Monforte A, Vernazza P, Hill A, Dragsted UB, Lundgren JD (2005). Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial. J Acquir Immune Defic Syndr, 40(3), 378-380.
     
  2702. Teich N, Engelmann L, Pfeiffer D (2005). [Resuscitation by laypersons: lack of knowledge of first-aid measures in Germany] Dtsch Med Wochenschr, 130(48), 2759-2762.
     
  2703. Zabel-Langhennig A, Caca K (2005). [Key symptom dysphagia] MMW Fortschr Med, 147(39), 63-64.
     
  2704. Schoppmeyer K, Kronberg J, Tannapfel A, Mossner J, Wittekind C, Caca K (2005). Predictive value of heparanase expression in the palliative therapy of pancreatic cancer. Pancreatology, 5(6), 570-575.
     
  2705. Mossner J, Caca K (2005). Developments in the inhibition of gastric acid secretion. Eur J Clin Invest, 35(8), 469-475.
     
  2706. Keim V (2005). Genetics of pancreatitis. Scand J Surg, 94(2), 103-107.
     
  2707. Keim V (2005). Mutations of the SPINK1 gene and their relation to chronic pancreatitis. Pancreatology, 5 (4-5), 311-311.
     
  2708. Gessner C, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, Engelmann L, Hoheisel G, Gillissen A, Sack U, Wirtz H (2005). Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med, 99(10), 1229-1240.
     
  2709. Wirtz HR, Kroegel C, Caffier P, Bittner H (2005). Bilateral lung transplantation for severe persistent and difficult asthma. J Heart Lung Transplant, 24(10), 1700-1703.
     
  2710. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J (2005). Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest, 128(2), 709-713.
     
  2711. Kuhn H, Weser L, Gessner C, Hammerschmidt S, Wirtz H (2005). Release of bFGF following apoptosis and necrosis in NSCLC cells: effects on chemosensitivity to cisplatin. Oncol Rep, 14(3), 759-762.
     
  2712. Hammerschmidt S, Kuhn H, Sack U, Schlenska A, Gessner C, Gillissen A, Wirtz H (2005). Mechanical stretch alters alveolar type II cell mediator release toward a proinflammatory pattern. Am J Respir Cell Mol Biol, 33(2), 203-210.
     
  2713. Moche M, Hui DS, Huse K, Chan KS, Choy DK, Scholz GH, Gosse H, Winkler J, Schauer J, Sack U, Hoheisel G (2005). [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion] Pneumologie, 59(8), 523-528.
     
  2714. Wittenburg H, Lyons MA, Li R, Kurtz U, Mossner J, Churchill GA, Carey MC, Paigen B (2005). Association of a lithogenic Abcg5/Abcg8 allele on Chromosome 17 (Lith9) with cholesterol gallstone formation in PERA/EiJ mice. Mamm Genome, 16(7), 495-504.
     
  2715. Gundling F, Mossner J (2005). [Management of erythropoetic and hepatic porphyrias] Dtsch Med Wochenschr, 130(7), 335-339.
     
  2716. Nitschmann S, Mossner J (2005). ASS oder Clopidogrel plus Esomeprazol bei Patienten nach Ulkusblutungen. Internist (Berl), 46(12), 1405-1408.
     
  2717. Mossner J (2005). [Acute abdomen] Internist (Berl), 46(9), 974-981.
     
  2718. Mossner J (2005). [Acute pancreatitis: diagnosis and conservative therapy] Schweiz Rundsch Med Prax, 94(20), 819-824.
     
  2719. Mossner J, Adler G (2005). Einführung zum Thema: Pankreaserkrankungen. Internist [Berl], 46(2), 121-122.
     
  2720. Mossner J, Manns M (2005). Einführung zum Thema: Genetische Erkrankungen in der Inneren Medizin. Internist [Berl], 46(7), 729-730.
     
  2721. Keim V (2005). Chronische Pankreatitis. Gastroenterologie up2date, 1(1), 33-47.
     
  2722. Keim V (2005). Chronische Pankreatitis (Fragebogen). Gastroenterologie up2date, 1(1), 48-50.
     
  2723. Keim V (2005). Chronische Pankreatitis (Antwortbogen). Gastroenterologie up2date, 1(1), 51-54.
     
  2724. Tillmann HL (2005). Akute Hepatitis B,ist eine Therapie sinnvoll? Bestehende Evidenz für geplante GAHB-Study (German Acute Hepatitis B Study) Z Klin Forsch, 7, 44-49.
     
  2725. Mössner J (2005). Acute Pancreatitis: Diagnosis and Conservative Therapy. Praxis (Schweizerische Rundschau für Medizin), 94, 819-824.
     
  2726. Mössner J (2005). Editorial: Wieder einen kleinen Schritt weiter. Kompakt Gastroenterologie, 1, 1-3.
     
  2727. Mössner J (2005). Treatment of chronic pancreatitis. Indian J Gastroenterol, 24, C3-C6.
     
  2728. Mössner J (2005). Editorial: Wissen auffrischen. Kompakt Gastroenterologie, 5, 1-3.
     
  2729. Tillmann HL (2005). Hepatitis B und Lebertransplantation Lebenszeichen. Das Lebermagazin. Sonderheft Hepatitis B, 1, 35-38.
     
  2730. Wiegand J, Kaiser T, Tillmann HL (2005). Virushepatitis. State of the Art Kompendium Gastroenterologie, 1, 32-35.
     
  2731. Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, Spengler U, Koletzko S, Jansen PL, Hochhaus G, Mollmann HW, Prols M, Manns MP (2005). Budesonide in previously untreated autoimmune hepatitis. Liver Int, 25(5), 927-934.
     
  2732. Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, Engelmann L, Schauer J, Emmrich F, Hoheisel G (2005). Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J, 25(4), 600-604.
     
  2733. Nemoda Z, Teich N, Hugenberg C, Sahin-Toth M (2005). Genetic and biochemical characterization of the E32del polymorphism in human mesotrypsinogen. Pancreatology, 5(2-3), 273-278.
     
  2734. Sack U, Hirth A, Funke B, Wiedemeyer K, Lange F, Troltzsch M, Tannapfel A, Gebhardt R, Emmrich F, Lehmann J (2005). A novel model of fibroblast-mediated cartilage destruction. Scand J Immunol, 61(1), 18-28.
     
  2735. Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, Caca K, Preiss R (2005). Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos, 33(7), 984-992.
     
  2736. Kassahun WT, Kahn T, Wittekind C, Mossner J, Caca K, Hauss J, Lamesch P (2005). Caroli's disease: Liver resection and liver transplantation. Experience in 33 patients. Surgery, 138(5), 888-898.
     
  2737. Kuhn AC, Teich N, Caca K, Limbach A, Hirsch W (2005). Chronic pancreatitis with pancreaticolithiasis and pseudocyst in a 5-year-old boy with homozygous SPINK1 mutation. Pediatr Radiol, 35(9), 902-905.
     
  2738. Winkler J, Seyfarth HJ, Hoheisel G, Halank M (2005). Möglichkeiten und Grenzen des ambulanten Managements von Patienten mit PAH. Intensiv- und Notfallbehandlung, 30(2), 45-52.
     
  2739. Menzel T, Peters K, Hammerschmidt S, Ritter O (2005). Metastatic signet ring cell gastric carcinoma presenting as an infrarenal aortic aneurysm. Gastric Cancer, 8(1), 47-49.
     
  2740. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J (2005). Bosentan therapy for portopulmonary hypertension. Eur Respir J, 25(3), 502-508.
     
  2741. Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C ... Vass G, Vogelberg C, Wi (2005). ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care Med, 171(8), 912-930.
     
  2742. Gundling F, Tillmann HL, Schmidt O, Brennenstuhl M, Nerlich A, Schepp W (2005). [Severe intrahepatic cholestasis in a 66-year old male patient with medically treated atrial fibrillation] Internist (Berl), 46(9), 1038-1042.
     
  2743. Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL (2005). Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol, 20(9), 1422-1428.
     
  2744. Nahor I, Abramovitch S, Engeland K, Werner H (2005). The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res, 15(6), 388-396.
     
  2745. Li R, Lyons MA, Wittenburg H, Paigen B, Churchill GA (2005). Combining data from multiple inbred line crosses improves the power and resolution of quantitative trait loci mapping. Genetics, 169(3), 1699-1709.
     
  2746. Grahnert A, Friedrich M, Engeland K, Hauschildt S (2005). Analysis of mono-ADP-ribosyltransferase 4 gene expression in human monocytes: splicing pattern and potential regulatory elements. Biochim Biophys Acta, 1730(3), 173-186.
     
  2747. Potthoff A, Sarhaddar J, Wiegand J, Lichtinghagen R, Sarrazin C, Ciner A, Hadem J, Trautwein C, Manns MP, Wedemeyer H (2005). Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. Hepatol Res, 31(1), 18-23.
     
  2748. Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mossner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Lofberg R (2005). Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol, 11(44), 7001-7006.
     
  2749. Uhlig HH, Schoppmeyer K, Schwerk C, Bühligen U, Bürk G, Kiess W (2005). Rolle der Kapselendoskopie in der pädiatrischen gastroenterologischen Diagnostik (Wireless capsule endoscopy as diagnostic tool in pediatric gastroenterology). Kinder- und Jugendmedizin, 5(6), 321-323.
     
  2750. Rifai K, Tillmann HL, Manns MP (2005). Treatment of fulminant hepatitis. In: Thomas HC, Lemon S, Zuckermann A, Virus Hepatitis. (S. 666-681), Oxford: Blackwell.
     
  2751. Mössner J (2005). What is the epidemiological impact in pancreatic cancer. In: Dominguez-Munes E, Clinical pancreatology for practicing gastroenterologists and surgeons. (S. 331-350), Malden, Mass.: Blackwell.
     
  2752. Mössner J (2005). Chronic pancreatitis: controversies in pain therapy, medical therapeutic options. In: Ammann RW, Adler G, Büchler M, DiMagio EP, Sarner, Pancreatitis: Advances in Pathobiology, Diagnosis and Treatment. Series: Falk Symposium, Vol. 143 (S. 176-189), Berlin: Springer Netherland.
     
  2753. Siewert JR, Stein HJ, Lordick F (2005). Ösophaguskarzinom. In: Siewert JR, Rothmund M, Schumpelick V , Praxis der Viszeralchirurgie: Onkologische Chirurgie. (S. 445-481), Berlin, Heidelberg, New York: Springer Verlag.
     
  2754. Siewert JR, Sendler A, Lordick F (2005). Magenkarzinom. In: Siewert JR, Rothmund M, Schumpelick V , Praxis der Viszeralchirurgie: Onkologische Chirurgie (S. 403-433), Berlin, Heidelberg, New York: Springer Verlag.
     


    2755. 2004


  2755. Haugwitz U, Tschop K, Engeland K (2004). SIRF--a novel regulator element controlling transcription from the p55Cdc/Fizzy promoter during the cell cycle. Biochem Biophys Res Commun, 320(3), 951-960.
     
  2756. Wiedmann M, Berr F, Schiefke I, Witzigmann H, Kohlhaw K, Mossner J, Caca K (2004). Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc, 60(1), 68-75.
     
  2757. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J, Engeland K (2004). Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene, 23(19), 3376-3384.
     
  2758. Schiefke I, Klecker C, Maier M, Oesen U, Etzrodt G, Tannapfel A, Liebert UG, Berr F (2004). Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int, 24(2), 98-104.
     
  2759. Teich N, Le Marechal C, Kukor Z, Caca K, Witzigmann H, Chen JM, Toth M, Mossner J, Keim V, Ferec C, Sahin-Toth M (2004). Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat, 23(1), 22-31.
     
  2760. Teich N, Mossner J (2004). Genetic aspects of chronic pancreatitis. Med Sci Monit, 10(12), 325-328.
     
  2761. Teich N, Keim V, Mossner J, Cotton RG, Horaitis O (2004). The WayStation: the novel way for the collection of pancreatitis-associated mutations. Pancreatology, 4, 249-250.
     
  2762. Teich N, Mossner J, Keim V (2004). How effective is published medical education? Lancet, 363(9417), 1326.
     
  2763. Tillmann HL, Manns MP, Claes C, Heiken H, Schmidt RE, Stoll M (2004). GB virus C infection and quality of life in HIV-positive patients. AIDS Care, 16(6), 736-743.
     
  2764. Mattner F, Tillmann HL (2004). Proof of alleged transmission of hepatitis C virus by a conjunctival blood splash. Am J Infect Control, 32(6), 375-376.
     
  2765. Tillmann HL (2004). Hepatitis C virus infection and the brain. Metab Brain Dis, 19, 351-356.
     
  2766. Mossner J, Manns MP (2004). [Diagnosis and therapy of biliary tract diseases. An assessment of the current status] Internist (Berl), 45(1), 7.
     
  2767. Schoppmeyer K, Wiedmann M, Mossner J, Caca K (2004). [Conservative and interventional endoscopic therapy of biliary tract carcinoma] Internist (Berl), 45(1), 49-55.
     
  2768. Schoppmeyer K, Mossner J (2004). [Best supportive care of pancreatic carcinoma] Internist (Berl), 45, 769-776.
     
  2769. Wiedmann M, Dietrich A, Mossner J, Witzigmann H, Caca K (2004). Combined percutaneous transhepatic biliary drainage with port implantation for management of patients with malignant biliary obstruction. Gastrointest Endosc, 60(1), 117-120.
     
  2770. Feisthammel J, Caca K, Mossner J, Kahn T, Kluge R (2004). An important pitfall in diagnosing gall bladder cancer. Gut, 53(11), 1651.
     
  2771. Gundling F, Secknus R, Abele-Horn M, Mossner J (2004). [Pyogenic liver abscess. State-of-the-art situation for diagnosis and therapy] Dtsch Med Wochenschr, 129(31-32), 1685-1688.
     
  2772. Kreth F, Neumann S, Hegenbart U, Mossner J, Caca K (2004). [26-year-old patient with ulcerative colitis and anemia] Internist (Berl), 45(2), 217-220.
     
  2773. Neumann S, Caca K, Mossner J (2004). [Pancreatico-pleural fistula in chronic pancreatitis with necrosis of the pancreatic tail] Dtsch Med Wochenschr, 129(34-35), 1802-1805.
     
  2774. Wiedmann M, Seidel W, Mende L, Petros S, Engelmann L (2004). A severe case of systemic lupus erythematosus with cerebral involvement. Vasa, 33(4), 242-246.
     
  2775. Wiegand J, Tischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P, Rohde P, Manns MP, Trautwein C, Tillmann HL (2004). Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol, 42(1), 15-18.
     
  2776. Schiefke I, Soeder H, Zabel-Langhennig A, Teich N, Neumann S, Borte G, Mossner J, Caca K (2004). Endoluminal gastroplication: What are the predictors of outcome? Scand J Gastroenterol, 39(12), 1296-1303.
     
  2777. Klar E, Mossner J (2004). Tumoren der Gallenblase und Gallenwege Chir Gastroenterol, 20(4), 241.
     
  2778. Mossner J (2004). Evidenzbasierte Therapie in der gastroenterologischen Onkologie Chir Gastroenterol, 20(1), 5.
     
  2779. Riemann JF, Mossner J (2004). Palliative Tumortherapie im Verdauungstrakt Der Internist, 45, 755.
     
  2780. Mossner J (2004). Neue Entwicklungen bei Erkrankungen des oberen Gastrointestinaltraktes 5. Gesprächsforum des Berufsverbandes Niedergelassener Gastroenterologen Deutschlands e.V. Gastro Nachrichten, 42, 17-19.
     
  2781. Wiedmann MW, Caca K (2004). General principles of photodynamic therapy (PDT) and gastrointestinal applications. Curr Pharm Biotechnol, 5(4), 397-408.
     
  2782. Wiedmann M, Schoppmeyer K, Mössner J, Caca K (2004). Palliative Therapie des Gallengangkarzinoms. Chir Gastroenterol, 20(4), 286-292.
     
  2783. Schiefke I, Mossner J, Caca K (2004). Do biliary stents cause or prevent cholangitis in malignant disease? Gastroint Endosc, 59, 598-599.
     
  2784. Huster D, Weizenegger M, Kress S, Mossner J, Caca K (2004). Rapid detection of mutations in Wilson disease gene ATP7B by DNA strip technology. Clin Chem Lab Med, 42(5), 507-510.
     
  2785. Keim V (2004). [Pancreatitis: from chronic inflammation to cancer] Dtsch Med Wochenschr, 129 Suppl 2, S94-S95.
     
  2786. Mossner J (2004). Inflammatory Pancreatic Diseases: an Update. Dig Dis, 22(3), 233-234.
     
  2787. Savcovic V, Gaiser S, Iovanna JL, Bödecker H (2004). The stress response of the exocrine panreas. Dig Dis, 22(3), 239-246.
     
  2788. Teich N, Mössner J (2004). Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis, 22(3), 235-238.
     
  2789. Gundling F, Secknus R, Troltzsch M, Borte G, Mossner J (2004). [Pyogenic liver abscess in chronic alcoholic pancreatitis] Dtsch Med Wochenschr, 129(31-32), 1679-1682.
     
  2790. Teich N, Mössner J (2004). Alpha-1-Antitrypsinmangel und asymptomatische Erhöhung der Pankreasenzyme: eine zufällige Assoziation. Tägl Praxis, 45, 83-84.
     
  2791. Gundling F, Kreth F, Troltzsch M, Tannapfel A, Bodeker H, Mossner J (2004). [Unclear liver fibrosis in a 42-year-old patient with polycythemia vera] Internist (Berl), 45(11), 1293-1298.
     
  2792. Gundling F, Reitmeier F, Tannapfel A, Schutz A, Weber A, Ussmuller J, Keim V, Mossner J, Teich N (2004). Chronic parotitis: not another SPINKosis. Dig Dis, 22(3), 292-295.
     
  2793. Mössner J (2004). Akute Pankreatitis: Diagnostik und internistische Therapie. journalMED, 3, 1-2.
     
  2794. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H (2004). High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol, 73(3), 387-391.
     
  2795. Tribl B, Filipp D, Bodeker H, Yu P, Hammerrmuller I, McKerlie C, Keim V, Sibbald WJ (2004). Pseudomonas pneumonia-mediated sepsis induces expression of pancreatitis-associated protein-I in rat pancreas. Pancreas, 29(1), 33-40.
     
  2796. Walker JM, Huster D, Ralle M, Morgan CT, Blackburn NJ, Lutsenko S (2004). The N-terminal metal-binding site 2 of the Wilson's Disease Protein plays a key role in the transfer of copper from Atox1. J Biol Chem, 279(15), 15376-15384.
     
  2797. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J (2004). [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study] Dtsch Med Wochenschr, 129(34-35), 1806-1807.
     
  2798. Schön MR, Tillmann HL, Hauss J (2004). Therapiemöglichkeiten bei Leberversagen Viszeralchirurgie, 39(2), 122-128.
     
  2799. Pradat P, Maynard M, Buti M, Berthillon P, Picchio G, Tillmann HL, Wiegand J, Voirin N, Manns MP, Esteban JI, Martinot M, Marcellin P, Trepo C (2004). The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. J Med Virol, 73(3), 392-396.
     
  2800. Wedemeyer H, Cornberg M, Tegtmeyer B, Frank H, Tillmann HL, Manns MP (2004). Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect, 10(1), 70-72.
     
  2801. Blum HE, Berg T, Tillmann HL, Von Weizsacker F (2004). [Procedures for problematic situations with hepatitis B] Z Gastroenterol, 42(8), 692-697.
     
  2802. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mossner J, Junghard O (2004). The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther, 20(4), 413-421.
     
  2803. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H (2004). Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology, 40(1), 98-107.
     
  2804. Lyons MA, Wittenburg H, Li R, Walsh KA, Korstanje R, Churchill GA, Carey MC, Paigen B (2004). Quantitative trait loci that determine lipoprotein cholesterol levels in an intercross of 129S1/SvImJ and CAST/Ei inbred mice. Physiol Genomics, 17(1), 60-68.
     
  2805. Miehle K, Tannapfel A, Lamesch P, Borte G, Schenker E, Kluge R, Ott RA, Wiechmann V, Koch M, Kassahun W, Paschke R, Koch CA (2004). Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production upon second recurrence. J Clin Endocrinol Metab, 89(8), 3731-3736.
     
  2806. Bernhard MK, Ohlenbusch T, Bödeker H, Pfäffle R (2004). Akute Ulkusblutung bei parasuizidaler Intoxikation mit Bromhexin-Saft – ein Fallbericht. Kinder- und Jugendmedizin, 4(1), 12-14.
     
  2807. Mössner J (2004). Chronische Pankreatitis. In: . Caspary WF, Mössner J, Stein J, Therapie gastroenterologischer Krankheiten. (S. 404-414), Berlin, Heidelberg, New York: Springer Verlag.
     
  2808. Secknus R, Mössner, J (2004). Prophylaxe in der Endoskopie. In: Ganten TM, Geiss HK, Stremmel W, Infektionen in der Gastroenterologie. (S. 270-278), Bremen, London, Boston: UNI-MED Verlag AG.
     
  2809. Mössner J (2004). Nichtrefluxbedingte Ösophagititiden. In: Caspary WF, Mössner J, Stein J, Therapie gastroenterologischer Krankheiten. (S. 15-23), Berlin, Heidelbeg, New York: Springer Verlag.
     
  2810. Mössner J (2004). Akute Pankreatitis – Diagnostik und internistische Therapie. In: Maier K-P, Blum HE, X. Gastroenterologie Seminarwoche Titisee. (S. 134-139), xxx: Falk-Foundation.
     
  2811. Mössner J (2004). Gastroösophageale Refluxkrankheit. In: Caspary WF, Mössner J, Stein J, Therapie gastroenterologischer Krankheiten. (S. 3-14), Berlin, Heidelbeg, New York: Springer Verlag.
     
  2812. Mössner J, Holtermüller KH (2004). Magen-Darm-Mittel und Laxantien. In: Schwabe U, Paffrath D, Arzneiverordnungsreport 2004. (S. 659-684), Berlin, Heidelberg, New York: Springer Verlag.